{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.13789"}, {"@name": "filename", "#text": "19909_TESE_Identifica%c3%a7%c3%a3oProte%c3%adnasAssociadas.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "KARINA TACIANA SANTOS SILVA \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nIDENTIFICA\u00c7\u00c3O DE PROTE\u00cdNAS ASSOCIADAS \u00c0 CARCINOG\u00caNESE \n\nINDUZIDA POR DIBENZOTIOFENO E DIBENZOTIOFENO SULFONA EM \n\nRATOS WISTAR \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nOURO PRETO \u2013 MG, ABRIL DE 2015 \n\n\n\n \n\nUNIVERSIDADE FEDERAL DE OURO PRETO \n\nN\u00daCLEO DE PESQUISAS EM CI\u00caNCIAS \n\nBIOL\u00d3GICAS \u2013 NUPEB \n\nP\u00d3S-GRADUA\u00c7\u00c3O EM CI\u00caNCIAS BIOL\u00d3GICAS \n\n \n\n \n\n \n\n \n\n \n\nIDENTIFICA\u00c7\u00c3O DE PROTE\u00cdNAS ASSOCIADAS \u00c0 CARCINOG\u00caNESE \n\nINDUZIDA POR DIBENZOTIOFENO E DIBENZOTIOFENO SULFONA EM \n\nRATOS WISTAR \n\n \n\n \n\n \n\n \n\nAutora: Karina Taciana Santos Silva \n\nOrientador: Prof. Dr. Milton H\u00e9rcules Guerra de Andrade \n\nCoorientador: Prof. Dr. William de Castro Borges \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nOuro Preto \u2013 MG, abril de 2015\n\nTese submetida ao programa de P\u00f3s-\n\nGradua\u00e7\u00e3o do N\u00facleo de Pesquisas em \n\nCi\u00eancias Biol\u00f3gicas da Universidade Federal \n\nde Ouro Preto, como parte integrante dos \n\nrequisitos para obten\u00e7\u00e3o do t\u00edtulo de Doutor \n\nem Ci\u00eancias Biol\u00f3gicas, \u00e1rea de \n\nconcentra\u00e7\u00e3o: Bioqu\u00edmica Estrutural e \n\nBiologia Molecular. \n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nS381i Silva, Karina Taciana Santos. \nIdentifica\u00e7\u00e3o de prote\u00ednas associadas \u00e0 carcinog\u00eanese induzida por \n\nDibenzotiofeno e Dibenzotiofeno Sulfona em ratos Wistar [manuscrito]  / \nKarina Taciana Santos Silva. - 2015. \n\nxxii, 172pf.: il.: color; grafs; tabs. \n \n\nOrientador: Prof. Dr. Milton H\u00e9rcules Guerra de Andrade. \nCoorientador: Prof. Dr. William Castro-Borges. \n\n \nTese (Doutorado) - Universidade Federal de Ouro Preto. N\u00facleo de \n\nPesquisas em Ci\u00eancias Biol\u00f3gicas. Programa de P\u00f3s-gradua\u00e7\u00e3o em Ci\u00eancias \nBiol\u00f3gicas. \n\n\u00c1rea de Concentra\u00e7\u00e3o: Bioqu\u00edmica Estrutural e Biologia Molecular. \n \n\n1. C\u00e2ncer. 2. Dibenzotiofeno. 3. Prote\u00f4mica. I. Andrade, Milton H\u00e9rcules \nGuerra de. II. Castro-Borges, William. III. Universidade Federal de Ouro Preto. \nIV. Titulo. \n\n                                                                                      \n\n                               CDU: 616-006.6:577.122                                                                                                 \n \n\n \nCataloga\u00e7\u00e3o: www.sisbin.ufop.br \n\n \n\nhttp://www.sisbin.ufop.br/\n\n\nSilva, K.T.S.                                                                                           Ata Defesa \n\ni \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                             Colaboradores \n\nii \n\nCOLABORADORES \n\n \n\nProf. Dr. Wanderson Geraldo de Lima - UFOP \n\nProf\u00aa. Dr\u00aa. Yara Cristina de Paiva Maia - UFU \n\nProf. Dr. Luiz Ricardo Goulart Filho \u2013 UFU \n\nDr. Fausto Em\u00edlio Capparelli - UFU \n\nMsc. Renata Alves de Oliveira e Castro \n\nMsc. Vin\u00edcius Corr\u00eaa Rodrigues \n\nAline Dias de Almeida \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                             Aux\u00edlio \n\niii \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nEste trabalho foi realizado no LABORAT\u00d3RIO DE ENZIMOLOGIA E \n\nPROTE\u00d4MICA \u2013 NUPEB/UFOP, com aux\u00edlio da Coordenadoria de \n\naperfei\u00e7oamento de Pessoal de N\u00edvel Superior (CAPES) e Universidade \n\nFederal de Ouro Preto (UFOP).\n\n\n\nSilva, K.T.S.                                                                                                                    Dedicat\u00f3ria \n\niv \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDedico este trabalho \u00e0 \n\nminha fam\u00edlia e ao Allan, \n\nminhas fontes de for\u00e7a, amor \n\ne apoio incondicionais. \n\n\n\nSilva, K.T.S.                                                                                                                           Ep\u00edgrafe \n\nv \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\u201cO homem interior se renova \n\nsempre. A luta enriquece-o de \n\nexperi\u00eancia, a dor aprimora-lhe as \n\nemo\u00e7\u00f5es e o sacrif\u00edcio tempera-lhe \n\no car\u00e1ter.\u201d \n\n(Chico Xavier) \n\n\n\nSilva, K.T.S.                                                                                                         Agradecimentos \n\nvi \n\nAGRADECIMENTOS \n \n \n\n\u00c0s ag\u00eancias de fomento FAPEMIG e CNPq pelo apoio financeiro. \n\nAo Prof. Dr. William de Castro Borges, pela disponibilidade e \n\naprendizado. Obrigada pela coorienta\u00e7\u00e3o e por compartilhar os problemas, \n\nalegrias e enfrentar comigo as dificuldades encontradas.  \n\nAo Prof. Dr. Milton H\u00e9rcules Guerra de Andrade, pela orienta\u00e7\u00e3o.  \n\nAo T\u00e9cnico Jos\u00e9 Henrique Braga Fortes, muito obrigada por toda a ajuda, \n\npela amizade, risadas e por compartilhar as alegrias, ang\u00fastias e d\u00favidas \n\nsurgidas durante esses anos de conviv\u00eancia. \n\nAo Prof. Marcos Aur\u00e9lio de Santana, pelo apoio e colabora\u00e7\u00e3o. \n\nAo Prof. Dr. Wanderson Geraldo de Lima, pelo aprendizado e \n\ncolabora\u00e7\u00e3o. \n\nAos laborat\u00f3rios LIMP, LIP e LBBM por permitirem o uso de equipamentos \n\ne depend\u00eancias para realiza\u00e7\u00e3o de parte deste trabalho. \n\nAos professores do NUPEB que contribu\u00edram de maneira construtiva para \n\na realiza\u00e7\u00e3o deste trabalho. \n\n\u00c0 Renata, pela colabora\u00e7\u00e3o e disponibilidade dedicadas a este trabalho. \n\nPela amizade e apoio que recebi durante esses anos de estudo. \n\nAos alunos de inicia\u00e7\u00e3o cient\u00edfica Aline, Vin\u00edcius e Pablo, que \n\nparticiparam diretamente da realiza\u00e7\u00e3o deste trabalho, obrigada pela ajuda \n\ninestim\u00e1vel. Sem voc\u00eas, a conclus\u00e3o deste trabalho teria sido imposs\u00edvel. \n\nAos amigos que fiz no LEP durante esses 6 anos de p\u00f3s-gradua\u00e7\u00e3o, muito \n\nobrigada pelas risadas, conversas e pela ajuda, principalmente nos momentos \n\nfinais do desenvolvimento deste trabalho. \n\nAos meus pais, pelo amor, carinho e apoio incondicionais. Obrigada por \n\nacreditarem nos meus sonhos e muitas vezes abrirem m\u00e3o dos seus para que \n\nessa conquista se tornasse poss\u00edvel. \n\nA minha irm\u00e3, pela amizade e companheirismo mesmo \u00e0 dist\u00e2ncia. \n\nAo Allan, por transformar qualquer dia em um dia especial, pelo amor, \n\ncarinho e apoio. \n\nEnfim, agrade\u00e7o a todos que de maneira direta ou indireta contribu\u00edram \n\npara a realiza\u00e7\u00e3o deste trabalho. \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                               \u00cdndice \n\nvii \n\n\u00cdNDICE \n\n \n\n \n\nRESUMO .........................................................................................................................x \n\nLISTA DE ABREVIATURAS ....................................................................................xiii \n\nLISTA DE FIGURAS ..................................................................................................xvi \n\nLISTA DE TABELAS ...................................................................................................xx \n\n1. INTRODU\u00c7\u00c3O ...........................................................................................................2 \n\n 1.1. Epidemiologia ................................................................................................2 \n\n1.2. Aspectos Gerais da Oncog\u00eanese .....................................................................3 \n\n 1.3. Trato Gastrointestinal Inferior ........................................................................4 \n\n  1.3.1. Caracter\u00edsticas Gerais ......................................................................4 \n\n  1.3.2. C\u00e2ncer Intestinal ..............................................................................6 \n\n  1.3.3. Fatores de Risco e Gen\u00e9ticos ...........................................................8 \n\n 1.4. Vis\u00e3o Geral de Vias de Sinaliza\u00e7\u00e3o Atuantes no CCR ...................................9 \n\n  1.4.1. Via Wnt/?-catenina ..........................................................................9 \n\n  1.4.2. Via Notch .......................................................................................11 \n\n  1.4.3. Via Hedgehog ................................................................................12 \n\n  1.4.4. Via PI3K/Akt ..................................................................................14 \n\n 1.5. Carcinog\u00eanese Qu\u00edmica ................................................................................16 \n\n  1.5.1. Dibenzotiofeno e Dibenzotiofeno Sulfona .....................................18 \n\n  1.5.2. 1,2-Dimetilhidrazina ......................................................................21 \n\n 1.6. Biomarcadores e C\u00e2ncer ...............................................................................21 \n\n  1.6.1. Prote\u00f4mica e Phage Display ..........................................................23 \n\n2. JUSTIFICATIVA ......................................................................................................25 \n\n3. OBJETIVOS ..............................................................................................................27 \n\n 3.1. Objetivo Geral ..............................................................................................27 \n\n  3.1.1. Objetivos Espec\u00edficos ....................................................................27 \n\n4. MATERIAL E M\u00c9TODOS ......................................................................................29 \n\n 4.1. Material Biol\u00f3gico ........................................................................................29 \n\n  4.1.1. Indu\u00e7\u00e3o de C\u00e2ncer em Ratos Wistar Tratados com DMH, DBT e \n\nDBTO2 ............................................................................................................................29 \n\n  4.1.2. Necropsia .......................................................................................30 \n\n 4.2. An\u00e1lise Histol\u00f3gica .......................................................................................30 \n\n  4.2.1. Imunohistoqu\u00edmica: CEA e CD44 .................................................31 \n\n\n\nSilva, K.T.S.                                                                                                                               \u00cdndice \n\nviii \n\n 4.3. Extra\u00e7\u00e3o de Prote\u00ednas e An\u00e1lise Prote\u00f4mica .................................................31 \n\n  4.3.1. Eletroforese Uni e Bidimensional (1D/2D SDS-PAGE) ................32 \n\n  4.3.2. Digest\u00e3o in gel ...............................................................................33 \n\n  4.3.3. An\u00e1lise de Prote\u00ednas por Espectrometria de Massas .......................34 \n\n  4.3.4. Categoriza\u00e7\u00e3o Funcional e Mapa de Intera\u00e7\u00e3o Proteica .................34 \n\n 4.4. Western bloting \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.35 \n\n 4.5. Biopanning (Phage Display)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.35 \n\n  4.5.1. Extra\u00e7\u00e3o de Prote\u00ednas para Phage Display .....................................35 \n\n  4.5.2. Ciclos de Sele\u00e7\u00e3o de Phage Display ...............................................36 \n\n  4.5.3. Titula\u00e7\u00e3o de Clones Obtidos no Phage Display ............................37 \n\n  4.5.4. Extra\u00e7\u00e3o de DNA de Fagos e Sequenciamento .............................37 \n\n  4.5.5. An\u00e1lise in silico dos Pept\u00eddeos Obtidos .........................................39 \n\n 4.6. S\u00edntese de Pept\u00eddeos ......................................................................................40 \n\n  4.6.1. An\u00e1lise de Pureza e Confirma\u00e7\u00e3o de Identidade ............................41 \n\n 4.7. S\u00edntese de Colunas de Afinidade ...................................................................42 \n\n  4.7.1. Identifica\u00e7\u00e3o de Prote\u00ednas Ligantes ................................................43 \n\n  4.7.2. An\u00e1lise in silico da Intera\u00e7\u00e3o Prote\u00edna/Pept\u00eddeo ............................44 \n\n 4.8. An\u00e1lise Estat\u00edstica .........................................................................................44 \n\n5. RESULTADOS E DISCUSS\u00c3O ...............................................................................46 \n\n 5.1. Efeitos Biol\u00f3gicos do Tratamento com DMH, DBT e DBTO2 ......................46 \n\n  5.1.1. Hemogramas e Dosagens S\u00e9ricas de ALT, AST e Amilase ............47 \n\n  5.1.2. Avalia\u00e7\u00f5es Morfol\u00f3gicas Macro e Microsc\u00f3picas de Tecidos \n\nExtra\u00eddos Durante a Necropsia ........................................................................................48 \n\n  5.1.3. Marca\u00e7\u00e3o Imunohistoqu\u00edmica: CEA e CD44 .................................54 \n\n 5.2. An\u00e1lise Prote\u00f4mica .......................................................................................57 \n\n 5.3. Identifica\u00e7\u00e3o de Pept\u00eddeos Ligantes \u00e0 Tecidos Neopl\u00e1sicos Intestinais de \n\nAnimais Tratados com DMH, DBT e DBTO2 .................................................................71 \n\n  5.3.1. Biopanning de Tecido Intestinal ....................................................72 \n\n  5.3.2. An\u00e1lise in silico de Pept\u00eddeos Selecionados ..................................73 \n\n  5.3.3. S\u00edntese de Pept\u00eddeos .......................................................................75 \n\n  5.3.4. Isolamento de Prote\u00ednas por Afinidade aos Pept\u00eddeos Selecionados \n\npor Phage Display ...........................................................................................................77 \n\n6. CONCLUS\u00d5ES .........................................................................................................82 \n\n7. PERSPECTIVAS ......................................................................................................84 \n\n\n\nSilva, K.T.S.                                                                                                                               \u00cdndice \n\nix \n\n8. REFER\u00caNCIAS BIBLIOGR\u00c1FICAS ....................................................................86 \n\n9. AP\u00caNDICES ..............................................................................................................99 \n\n 9.1. Ap\u00eandice A \u2013 Contagens Global e Diferencial de Leuc\u00f3citos para Todos os \n\nAnimais Tratados ............................................................................................................99 \n\n 9.2. Ap\u00eandice B \u2013 Dosagens s\u00e9ricas de AST, ALT e Amilase ............................100 \n\n 9.3. Ap\u00eandice C \u2013 An\u00e1lise Estat\u00edstica Referente a Avalia\u00e7\u00e3o Histol\u00f3gica de \n\nIntestinos Delgado e Grosso Entre Grupos Controle .....................................................101 \n\n 9.4. Ap\u00eandice D \u2013 Dados Obtidos por Espectrometria de Massas para 2D SDS-\n\nPAGE e Cromatografia de Afinidade ............................................................................102 \n\n 9.5. Ap\u00eandice E \u2013 Western bloting .....................................................................155 \n\n 9.6. Ap\u00eandice F \u2013 Alinhamento Entre Sequ\u00eancias Pept\u00eddicas e Banco de Dados de \n\nProte\u00ednas para Rattus norvegicus ...................................................................................156 \n\n 9.7. Ap\u00eandice G \u2013 Artigo Publicado ..................................................................161 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                           Resumo \n\nx \n\nRESUMO \n\n \n\nO alto conte\u00fado de compostos organossulfurados nos derivados de petr\u00f3leo compromete \n\nsua qualidade; assim, sua remo\u00e7\u00e3o ou convers\u00e3o a subst\u00e2ncias menos t\u00f3xicas s\u00e3o \n\nimportantes etapas durante o processo de refino. Os limites de concentra\u00e7\u00e3o para esses \n\ncompostos est\u00e3o sob r\u00edgido controle em diversos pa\u00edses com o objetivo de minimizar seu \n\nimpacto negativo sobre a sa\u00fade animal e o ambiente. Dentre eles, o dibenzotiofeno (DBT) \n\n\u00e9 um hidrocarboneto polic\u00edclico arom\u00e1tico que cont\u00e9m um \u00e1tomo de enxofre em \n\nsubstitui\u00e7\u00e3o em sua estrutura. Devido \u00e0 import\u00e2ncia dessas mol\u00e9culas na oncog\u00eanese, e a \n\nescassez de investiga\u00e7\u00f5es toxicol\u00f3gicas relacionadas ao DBT, este trabalho prop\u00f4s \n\nrealizar uma avalia\u00e7\u00e3o dos efeitos t\u00f3xicos e moleculares promovidos por um tratamento \n\ncr\u00f4nico de ratos Wistar com dose sub-letal (30 mg/kg) de DBT e seu derivado oxidado \n\nDBTO2 (dibenzotiofeno sulfona), ambos administrados durante 10 semanas. Em paralelo, \n\nseus efeitos t\u00f3xicos foram comparados com aqueles provocados pelo tratamento com o \n\nagente mutag\u00eanico cl\u00e1ssico, 1,2-dimetilhidrazina (DMH), administrado na mesma dose \n\ndurante o mesmo per\u00edodo. Na 14\u00aa semana ap\u00f3s a \u00faltima dose, os animais foram \n\nsacrificados para uma avalia\u00e7\u00e3o inicial da contagem de c\u00e9lulas sangu\u00edneas e das fun\u00e7\u00f5es \n\nhep\u00e1ticas e pancre\u00e1ticas.  N\u00e3o foram observadas altera\u00e7\u00f5es nesses par\u00e2metros. Entretanto, \n\nan\u00e1lises histopatol\u00f3gicas revelaram les\u00f5es de car\u00e1ter pr\u00e9-neopl\u00e1sico nos intestinos dos \n\nanimais tratados com DBT e DBTO2 que mostraram-se compar\u00e1veis em intensidade e \n\naltera\u00e7\u00f5es morfol\u00f3gicas com aquelas encontradas no c\u00f3lon de animais tratados com \n\nDMH.  Em concord\u00e2ncia com esse achado, os marcadores tumorais CD44 e CEA \n\n(ant\u00edgeno carcinoembrion\u00e1rio), utilizados em ensaios de imunohistoqu\u00edmica \n\ndemonstraram aumento de express\u00e3o de aproximadamente tr\u00eas vezes para os animais dos \n\ngrupos Testes em rela\u00e7\u00e3o aos animais dos grupos Controle.  An\u00e1lises prote\u00f4micas \n\nrealizadas por eletroforese bidimensional (2D SDS-PAGE) demonstraram padr\u00f5es de \n\nexpress\u00e3o proteica diferenciados entre os diferentes grupos. Al\u00e9m da an\u00e1lise prote\u00f4mica, \n\nfoi realizado ensaio de sele\u00e7\u00e3o de pept\u00eddeos ligantes de prote\u00ednas especificamente \n\nrelacionados \u00e0s altera\u00e7\u00f5es promovidas pelos indutores qu\u00edmicos utilizados, empregando \n\na t\u00e9cnica de Phage Dislay. Tal metodologia permitiu a pr\u00e9-sele\u00e7\u00e3o de seis pept\u00eddeos \n\nespec\u00edficos e relacionados aos mecanismos de desenvolvimento/manuten\u00e7\u00e3o de c\u00e2ncer. \n\nA identifica\u00e7\u00e3o das prote\u00ednas diferencialmente expressas observadas por 2D SDS-PAGE \n\ne, das prote\u00ednas alvo que interagem com pept\u00eddeos espec\u00edficos relacionados \u00e0s altera\u00e7\u00f5es \n\npromovidas por esses agentes qu\u00edmicos, auxilia no avan\u00e7o do entendimento acerca dos \n\n\n\nSilva, K.T.S.                                                                                                                           Resumo \n\nxi \n\nmecanismos envolvidos no estabelecimento das les\u00f5es encontradas nos animais tratados \n\ncom DBT e DBTO2. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                          Abstract \n\nxii \n\nABSTRACT \n\n \n\nThe high content of organosulfur compounds in petroleum derivatives compromises their \n\nquality and, therefore, their removal or conversion to less toxic substances are important \n\nsteps during oil refining. The concentration limits of such compounds in fuels are under \n\nstrict control worldwide with the aim to minimize their negative impact upon animal \n\nhealth and the environment. Among them, dibenzothiophene (DBT) is a polycyclic \n\naromatic hydrocarbon containing a sulfur atom replacing a carbon in the main structure. \n\nGiven the importance of such molecules during oncogenesis and the scarcity of \n\ntoxicological investigations related to DBT, this work proposes an evaluation of the toxic \n\neffects promoted by a chronic treatment of Wistar rats with a sub-lethal dose (30 mg/kg) \n\nof DBT and its oxidized derivative DBTO2 (dibenzothiophene sulfone), both \n\nadministered during 10 weeks. In parallel, their toxicological effects were compared to \n\nthose inflicted by treatment with the classic mutagenic compound, 1,2-dimethylhydrazine \n\n(DMH), given at 30 mg/kg for the same period. At the 14th week after the last dose, the \n\nanimals were sacrificed for the initial evaluation of blood cell counts and assessment of \n\nhepatic and pancreatic functions. We have observed no alterations in either blood cell \n\nparameters or indication of liver and spleen injuries. However, pre-neoplastic lesions in \n\nthe small intestine of DBT and DBTO2 treated animals were comparable in intensity and \n\nmorphology to those found in the colon of DMH-treated animals. In agreement with this \n\nfinding two tumor markers CD44 and CEA (carcinoembrionic antigen), were detected by \n\nimmunohistochemistry and demonstrate approximately three fold higher for treated \n\nanimals when compared to control groups.  Proteomic analyses by 2D electrophoresis \n\n(2D SDS-PAGE) reveal different expression patterns for Test groups when compared to \n\nControl groups. In addition to the proteomic analysis, we also performed a selection of \n\ntest specifically protein binding peptides related to changes produced by chemical \n\ninducers used employing the Phage Display technique. This methodology allowed the \n\npre-selection of six specific peptides related to the mechanisms of \n\ndevelopment/maintenance of cancer. The identification of differentially expressed \n\nproteins observed by 2D SDS-PAGE, and of proteins that interact with specific peptides \n\nrelated to alterations caused by such agents, assists in advancing understanding of \n\nmechanisms involved in the establishment of lesions found in animals treated DBT and \n\nDBTO2.\n\n\n\nSilva, K.T.S.                                                                              Lista de Abreviaturas \n\nxiii \n\nLISTA DE ABREVIATURAS \n\n \n\n\u00b5g- micro gramas \n\n\u00b5L- micro litros \n\n\u00b5m- micro metros \n\n2D SDS-PAGE- Eletroforese bidimensional em \n\ngel de poliacrilamida \n\nACF- Focos de criptas aberrantes \n\nACN- Acetonitrila \n\nACTB- Actina subunidade beta \n\nADH- \u00c1lcool dehidrogenase \n\nAHR- Receptor aril hidrocarbono \n\nAKR1B1- Aldose redutase \n\nAkt- Prote\u00edna quinase B \n\nALDOA- Aldolase A \n\nALT- Alanina amino transferase \n\nANOVA- An\u00e1lise de vari\u00e2ncia \n\nANXA2- Anexina 2 \n\nANXA5- Anexina 5 \n\nAOM- Azoximetanol \n\nAPC- Adenomatous polyposis coli \n\nARHGDIA- Inibidor de dissocia\u00e7\u00e3o Rho-GDP \n\nAST- Aspartato amino trasnferase \n\nATIC- Bioss\u00edntese de purina bifuncional  \n\nBAX- Prote\u00edna associada a BCL2 \n\nBcl2- B-cell CLL/lymphoma 2 \n\nBmi- BMI polycomb ring finger oncogene \n\nCA- Carbohydrate antigen \n\nCALR- Calreticulina \n\nCANX- Calnexina \n\nCCA- Centro de Ci\u00eancia Animal \n\nCCR- C\u00e2ncer colorretal \n\nCCT6- Prote\u00edna complexo T1 sub. zeta \n\nCD44- Cluster of differentiation 44 \n\nCEA- Carcinoembrionic antigen \n\nCEUA- Comiss\u00e3o de \u00e9tica no uso de animais \n\nCFL- Cofilina \n\nc-Jun- Protooncogene jun \n\nCK1- Case\u00edna quinase 1 \n\nCKB- Creatina quinase B \n\nCMPK- Citidina monofosfato quinase  \n\nc-Myc- Protooncogene myc \n\nCORO1A- Coronina 1A \n\nCOX2- Ciclooxigenase \n\nCYP450- Citocromo P450 \n\nDBT- Dibenzotiofeno \n\nDBTO2- Dibenzotiofeno sulfona \n\nDCC- Diciclohexilcarbodiimida \n\nDCM- Diclorometano \n\nDL50- Dose Letal 50% \n\nDLD- Dihidrolipoil dehidrogenase \n\nDMF- Dimetilformamida \n\nDMH- 1,2-Dimetilhidrazina \n\nDNA- \u00c1cido desoxiribonucleico \n\nDPP7- Dipeptidil peptidase \n\nDvl- Dishevelled \n\nDyrk1-Dual-specificity tyrosine-(Y)-\n\nphosphorylation regulated kinase 1A \n\nE1A- Fator de transcri\u00e7\u00e3o E1A \n\nE2F- Fator de transcri\u00e7\u00e3o E2F \n\nEEF2- Fator de elonga\u00e7\u00e3o EEF2 \n\nEGFR- Receptor de fator de crescimento \n\nepidermal \n\nENO1- Enolase alfa \n\nEZR- Ezrina \n\nFAK- Quinase de ades\u00e3o focal \n\nFDR- False Discovery rate \n\nFITC- Isotiocianato de Fluoresce\u00edna \n\nFz- Frizzled \n\nGAPDH- Gliceralde\u00eddo 3-fosfato dehidrogenase \n\nGLI- Fator de transcri\u00e7\u00e3o GLI \n\nGLUT- Receptor de glicose \n\nGNB2L1- Prote\u00edna ligante de nucleot\u00eddeo guanina \n\nGSK3- Glicog\u00eanio sintase quinase 3 \n\nHBP- 2-Hidr\u00f3xibifenil \n\nHDAC- Histona deacetilase \n\nHE- Hematoxilina/Eosina \n\nHh- Hedgehog \n\nHPA- Hidrocarbonetos polic\u00edclicos arom\u00e1ticos \n\nHPAS- Hidrocarbonetos polic\u00edclicos arom\u00e1ticos \n\nsulfurados \n\nHPLC- Cromatografia L\u00edquida de Alta Press\u00e3o \n\nHRP- Horseradish peroxidase \n\nHSP70- Heat shock protein 70 \n\nHSP90B1- Endoplasmina \n\nHSPA2- Heat shock protein HSPA2 \n\nHSPA5- Heat shock protein HSPA5 \n\nIARC- Ag\u00eancia internacional para pesquisa em \n\nc\u00e2ncer \n\nIGF-IIR- Receptor de fator de crescimento tipo \n\ninsulina 2 \n\nIGG2A- Imunoglobulina gama 2A \nINCA- Instituto Nacional do C\u00e2ncer \n\nkDa- kilo Dalton \n\nK-ras- Kirsten rat sarcoma viral oncogene \n\nhomolog \n\nKRT8- Queratina 8 \n\nLDHA- Lactato dehidrogenase A \n\nLEF- Fator potenciador linf\u00f3ide \n\nLGALS3- Galectina 3 \n\n\n\nSilva, K.T.S.                                                                              Lista de Abreviaturas \n\nxiv \n\nLRP6- Lipoprotein receptor related protein 6 \n\nLUM- Lumican \n\nM- Molar \n\nMAM- Metil azoximetanol \n\nMCPT1-  Protease de mast\u00f3citos \n\nmM- mili molar \n\nmm- mil\u00edmetro \n\nMS- Espectrometria de Massas \n\nmTORC1- \n\nMYL- Miosina cadeia leve \n\nng- nanogramas \n\nNHS- N-hidroxisuccinimida \n\nNICD- Por\u00e7\u00e3o terminal do receptor Notch \n\nNL- N\u00e3o linear \n\nNuA4- Histona acetiltransferase \n\nOPAS- Organiza\u00e7\u00e3o Pan-Americana de Sa\u00fade \n\np/v- peso/volume \n\np53- Prote\u00edna tumoral p53 \n\nPAF- Polipose adenomatosa familiar \n\nPBSS- Tamp\u00e3o Fosfato de S\u00f3dio com Salina \n\nPGAM1- Fosfoglicerato mutase 1 \n\nPGK1- Fosfoglicerato quinase \n\npH- potencial hidrogeni\u00f4nico \n\nPIC- Coquetel de inibidores de protease \n\nPIP- Fosfatidil inositol fosfato \n\nPKM2- Piruvato quinase \n\nPNLIP- Triacilglicerol lipase \n\nppm- Partes por milh\u00e3o \n\nPRDX1- Peroxiredoxina 1 \n\nPtch- Prote\u00edna Patched \n\nPTEN- Phosphatase and tensin homolog \n\nPVDF- Polyvinylidene fluoride \n\nRac- Rho-GTPase \n\nRaf- Quinase Raf \n\nRas- GTPase \n\nRBBP4- Prote\u00edna ligante de histona RBBP4 \n\nRBP-JK- Recombining binding protein supressor \n\nof hairless \n\nRFESD- Prote\u00edna Rieske Fe-S \n\nRNA- \u00c1cido ribonucleico \n\nSAGA- Histona acetiltransferase \n\nSDS- Duodecil sulfato de s\u00f3dio \n\nSELENBP- Prote\u00edna ligante de sel\u00eanio 1 \n\nSOD- Super\u00f3xido dismutase \n\nSTAGA- Histona acetiltransferase \n\nTAGLN- Transgelina \n\nTBST- Tamp\u00e3o Tris-HCL com Tween 20 \n\nTCF- Fator T celular \n\nTF- Transferrina \n\nTFA- \u00c1c. Trifluoroac\u00e9tico \n\nTFTC- TAT-binding protein free TAF-containing \n\ncomplex \n\nTGF?- Fator de crescimento transformador \n\nTIMP-1- Tissue inhibitor of metalloproteinases \n\nTIP60- Histona acetiltransferase \n\nTKT- Transcetolase \n\nTNM- Estadiamento tumoral \n\nTPM- Tropomiosina \n\nTRA1- Prote\u00edna associada a transcri\u00e7\u00e3o 1 \n\nUI- Unidades internacionais \n\nUICC- Union for International Cancer Control \n\nv/v- volume/volume \n\nVDAC2- Canal ani\u00f4nico voltagem dependente \n\nVEGF- Fator de crescimento vascular endotelial \n\nWDR1- Repeti\u00e7\u00e3o WD \n\nWHO- World Health Organization \n\nYWHAE- 14-3-3 ?\n\n\n\nSilva, K.T.S.                                                                              Lista de Abreviaturas \n\nxv \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                    Lista de Figuras \n\nxvi \n\nLISTA DE FIGURAS \n\n \n\nFigura 01: Distribui\u00e7\u00e3o proporcional de \u00f3bitos no Brasil por tipo de c\u00e2ncer em 2014 por \n\nsexo....................................................................................................................................2 \n\n \n\nFigura 02: Corte histol\u00f3gico de se\u00e7\u00e3o do duodeno no intestino delgado mostrando as \n\ncamadas que comp\u00f5em o mesmo.......................................................................................5  \n\n \n\nFigura 03: Corte histol\u00f3gico de se\u00e7\u00e3o de intestino grosso mostrando as camadas Mucosa, \n\nSubmucosa, T\u00fanica Muscular e Serosa al\u00e9m de componentes caracter\u00edsticos..................5  \n\n \n\nFigura 04: Sequ\u00eancia adenoma-carcinoma em c\u00e2ncer colorretal......................................6 \n\n \n\nFigura 05: Eventos gen\u00e9ticos envolvidos no desenvolvimento do c\u00e2ncer colorretal.........7 \n\n \n\nFigura 06: Via Wnt/?-catenina........................................................................................10 \n\n \n\nFigura 07: Diagrama simplificado da via de sinaliza\u00e7\u00e3o Notch e seus poss\u00edveis alvos....12  \n\n \n\nFigura 08: Via de sinaliza\u00e7\u00e3o Hedgehog em vertebrados................................................13 \n\n \n\nFigura 09:  Via de sinaliza\u00e7\u00e3o PI3K/Akt e vias associadas..............................................15  \n\n \n\nFigura 10: Vias de sinaliza\u00e7\u00e3o Notch, Wnt, e Hedgehog regulando o destino celular.....16  \n\n \n\nFigura 11: Estruturas qu\u00edmicas dos principais compostos contendo enxofre encontrados \n\nno petr\u00f3leo.......................................................................................................................19 \n\n \n\nFigura 12: \u201cVia de metabolismo 4S para DBT\u201d..............................................................20  \n\n \n\nFigura 13: Esquema representativo do tempo de tratamento e espera para o \n\ndesenvolvimento de altera\u00e7\u00f5es patol\u00f3gicas nos animais tratados com DMH, DBT e \n\nDBTO2.............................................................................................................................30 \n\n\n\nSilva, K.T.S.                                                                                    Lista de Figuras \n\nxvii \n\nFigura 14: Biopanning com a biblioteca de pept\u00eddeos Ph.D. Sele\u00e7\u00e3o de ligantes \n\nespec\u00edficos.......................................................................................................................37 \n\n \n\nFigura 15: Gr\u00e1fico de acompanhamento de peso dos animais pertencentes aos grupos \n\ncontroles e testes ao longo de 24 semanas de tratamento/lat\u00eancia.....................................46 \n\n \n\nFigura 16: A) Fotografia de parte do intestino grosso de animal pertencente ao Grupo III \n\n(Teste DMH 30 mg/kg) onde podem ser observadas as forma\u00e7\u00f5es de p\u00f3lipos. B) \n\nFotografia de parte do intestino delgado de animais pertencentes aos Grupos IV e V \n\n(Testes DBT 30 mg/kg e DBTO2 30 mg/kg respectivamente) onde podem ser observados \n\np\u00f3lipos.............................................................................................................................49  \n\n \n\nFigura 17: Fotomicrografias de cortes histol\u00f3gicos de intestino delgado e grosso corados \n\npela t\u00e9cnica de HE............................................................................................................53  \n\n \n\nFigura 18: Fotomicrografias de cortes histol\u00f3gicos de intestino delgado e grosso corados \n\npela t\u00e9cnica de imunohistoqu\u00edmica com anti-CEA e anti CD44 e contra corados com \n\nhematoxilina....................................................................................................................56  \n\n \n\nFigura 19: G\u00e9is 2D SDS-PAGE 10% representativos da extra\u00e7\u00e3o de prote\u00ednas sol\u00faveis \n\nde intestinos delgados dos A) Grupo Controle \u00d3leo (III) e B) Teste DBT (IV)................58  \n\n \n\nFigura 20: G\u00e9is 2D SDS-PAGE 10% representativos da extra\u00e7\u00e3o de prote\u00ednas sol\u00faveis \n\nde intestinos delgados dos A) Grupo Controle \u00d3leo (III) e B) Teste DBTO2 (V)..............58  \n\n \n\nFigura 21: G\u00e9is 2D SDS-PAGE 10% representativos da extra\u00e7\u00e3o de prote\u00ednas sol\u00faveis \n\nde intestinos delgados dos A) Grupo Controle Salina (I) e B) Teste DMH (II).................59  \n\n \n\nFigura 22:  Diferen\u00e7as nos n\u00edveis de express\u00e3o proteica dos grupos Teste DBT IV (barras \n\nbrancas) e Teste DBTO2 V (barras pretas) em rela\u00e7\u00e3o ao grupo Controle \u00d3leo III...........63  \n\n \n\nFigura 23: Mapa de intera\u00e7\u00e3o proteica para prote\u00ednas diferencialmente expressas entre \n\ngrupos Teste IV e V e Controle III....................................................................................66  \n\n\n\nSilva, K.T.S.                                                                                    Lista de Figuras \n\nxviii \n\nFigura 24:  Diferen\u00e7a nos n\u00edveis de express\u00e3o proteica entre o grupo Teste DMH (II) e o \n\ngrupo Controle Salina (I). Os resultados representam a m\u00e9dia \u00b1 SEM de triplicatas \n\nbiol\u00f3gicas independentes.................................................................................................67 \n\n \n\nFigura 25: Mapa de intera\u00e7\u00e3o prote\u00edna-metab\u00f3lito para prote\u00ednas diferencialmente \n\nexpressas entre grupos Teste II e Controle I.....................................................................70  \n\n \n\nFigura 26: Perfis eletrofor\u00e9ticos representativos em 1D SDS-PAGE 12% de prote\u00ednas de \n\nIntestino Delgado (Controle DBT; Teste DBT (D)) e de Intestino Grosso (Teste DBT (G); \n\nControle DMH; Teste DMH) para a verifica\u00e7\u00e3o da qualidade da extra\u00e7\u00e3o proteica.........71  \n\n \n\nFigura 27: Fotografias representativas da titula\u00e7\u00e3o dos fagos obtidos no \u00faltimo ciclo de \n\nsele\u00e7\u00e3o de cada grupo para isolamento das col\u00f4nias de ER2738 e consequente \n\namplifica\u00e7\u00e3o e sequenciamento do DNA.........................................................................73  \n\n \n\nFigura 28: Alinhamento das sequ\u00eancias pept\u00eddicas obtidas ap\u00f3s sequenciamento do DNA \n\ndos fagos selecionados randomicamente ao fim do terceiro ciclo de biopanning para os \n\ntr\u00eas grupos avaliados........................................................................................................74  \n\n \n\nFigura 29: Perfis cromatogr\u00e1ficos em sistema HPLC dos pept\u00eddeos obtidos em fase \n\nreversa..............................................................................................................................76  \n\n \n\nFigura 30: Perfis eletrofor\u00e9ticos de 1D SDS-PAGE de extratos proteicos referentes a \n\ngrupos Controle e Testes ap\u00f3s cromatografia de afinidade...............................................77  \n\n \n\nFigura 01.A: Contagens global e diferencial de leuc\u00f3citos provenientes dos grupos \n\nControles (I e III) e Testes (II, IV e V) ao final do per\u00edodo de tratamento/lat\u00eancia............99 \n\n \n\nFigura 01.B: Dosagens enzim\u00e1ticas s\u00e9ricas: A) Raz\u00e3o AST/ALT; B) Amilase \n\nprovenientes dos grupos Controles (I e III) e Testes (II, IV e V) ao final do per\u00edodo de \n\ntratamento/lat\u00eancia.........................................................................................................100 \n\n \n\nFigura 01.E: Valida\u00e7\u00e3o dos experimentos de imunohistoqu\u00edmica e an\u00e1lise prote\u00f4mica. \n\nA) SDS-PAGE 1D de extratos de prote\u00edna total de intestino delgado dos animais \n\n\n\nSilva, K.T.S.                                                                                    Lista de Figuras \n\nxix \n\npertencentes aos grupos III, IV e V. B) Western blotting para detec\u00e7\u00e3o de CEA, Calnexina \n\ne ?-actina........................................................................................................................155 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                   Lista de Tabelas \n\nxx \n\nLISTA DE TABELAS \n\n \n\nTabela 01: Pept\u00eddeos selecionados por Phage display para s\u00edntese em fase s\u00f3lida..........40 \n\n \n\nTabela 02: Frequ\u00eancia de les\u00f5es observadas no intest. grosso dos animais pertencentes \n\naos Grupos I-V.................................................................................................................51 \n\n \n\nTabela 03: Frequ\u00eancia de les\u00f5es observadas no intest. delgado dos animais pertencentes \n\naos Grupos I-V.................................................................................................................51 \n\n \n\nTabela 04: Prote\u00ednas identificadas por spot nos g\u00e9is referentes aos grupos Teste IV e V \n\nque apresentaram altera\u00e7\u00e3o na express\u00e3o ? 1,5 vezes em rela\u00e7\u00e3o ao grupo Controle III..60 \n\n \n\nTabela 05: Prote\u00ednas identificadas por spot nos g\u00e9is referentes ao grupo Teste II que \n\napresentaram altera\u00e7\u00e3o na express\u00e3o ? 1,5 vezes em rela\u00e7\u00e3o ao grupo Controle I............61 \n\n \n\nTabela 06: Massas moleculares preditas e observadas para cada pept\u00eddeo sintetizado....75 \n\n \n\nTabela 01.C: Compara\u00e7\u00e3o de frequ\u00eancia das les\u00f5es observadas no intestino delgado para \n\nos Grupos Controle \u00d3leo e Controle Salina....................................................................101 \n\n \n\nTabela 02.C: Compara\u00e7\u00e3o de frequ\u00eancia das les\u00f5es observadas no intestino grosso para \n\nos Grupos Controle \u00d3leo e Controle Salina....................................................................101 \n\n \n\nTabela 01.D: Pept\u00eddeos sequenciados por prote\u00edna identificada atrav\u00e9s de espectrometria \n\nde massas para os grupos Teste IV e V em rela\u00e7\u00e3o ao grupo Controle III no experimento \n\nempregando 2D SDS-PAGE..........................................................................................102 \n\n \n\nTabela 02.D: Pept\u00eddeos sequenciados por prote\u00edna identificada atrav\u00e9s de espectrometria \n\nde massas para o grupo Teste III em rela\u00e7\u00e3o ao grupo Controle I no experimento \n\nempregando 2D SDS-PAGE..........................................................................................114 \n\n\n\nSilva, K.T.S.                                                                                   Lista de Tabelas \n\nxxi \n\nTabela 03.D: Pept\u00eddeos sequenciados por prote\u00edna identificada atrav\u00e9s de espectrometria \n\nde massas para as bandas isoladas por cromatografia de afinidade e selecionadas em 1D \n\nSDS-PAGE....................................................................................................................149 \n\n \n\nTabela 01. F: Rela\u00e7\u00e3o de prote\u00ednas que apresentaram regi\u00e3o de similaridade com os \n\npept\u00eddeos selecionados por Phage display atrav\u00e9s do alinhamento de sequ\u00eancias realizado \n\npor BLASTp..................................................................................................................156 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                                            Introdu\u00e7\u00e3o\n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n2 \n\n1- INTRODU\u00c7\u00c3O \n\n \n\n1.1. Epidemiologia \n\n \n\nApesar dos avan\u00e7os tecnol\u00f3gicos, a incid\u00eancia e a mortalidade por c\u00e2ncer t\u00eam \n\naumentado nas \u00faltimas d\u00e9cadas. Em 2008, a Ag\u00eancia Internacional para Pesquisa em \n\nC\u00e2ncer (IARC)/Organiza\u00e7\u00e3o Mundial de Sa\u00fade (WHO) estimou que ocorreriam 12,4 \n\nmilh\u00f5es de novos casos e 7,6 milh\u00f5es de \u00f3bitos por c\u00e2ncer, doen\u00e7a esta que em 2030 ser\u00e1 \n\nrespons\u00e1vel por mais de 11 milh\u00f5es de \u00f3bitos em todo o mundo (UICC 2005; WHO 2007, \n\n2008). No ano de 2014 mais de 220 mil pessoas vieram a \u00f3bito no Brasil v\u00edtimas desta \n\npatologia (Fig. 05) (WHO, 2015). \n\n \n\n \n\nFigura 01: Distribui\u00e7\u00e3o proporcional de \u00f3bitos no Brasil por tipo de c\u00e2ncer em 2014 por sexo. \n\nFonte: (WHO, 2015). \n\n \n\nSegundo o Instituto Nacional do C\u00e2ncer (INCA) o c\u00e2ncer \u00e9 uma importante causa \n\nde doen\u00e7a e morte no Brasil e desde 2003 as neoplasias malignas representam quase 17% \n\ndos \u00f3bitos de causa conhecida notificados no Sistema de Informa\u00e7\u00f5es sobre Mortalidade. \n\nAs estimativas para o ano de 2014 apontaram a ocorr\u00eancia de 32.600 novos casos de \n\nc\u00e2ncer colorretal sendo 15.070 homens e 17.530 mulheres. Al\u00e9m disso, ocorreram mais \n\nde 14 mil \u00f3bitos por essa neoplasia em 2011 (INCA, 2015). \n\nO c\u00e2ncer colorretal constitui atualmente uma neoplasia de ocorr\u00eancia universal e \n\nde import\u00e2ncia crescente como problema de sa\u00fade p\u00fablica. Sua incid\u00eancia varia de \n\nmaneira importante entre os diferentes pa\u00edses, representando a terceira causa de c\u00e2ncer \n\nno mundo entre ambos os sexos e a segunda em pa\u00edses desenvolvidos (Lopez and Monafo, \n\n1993; Jemal et al., 2005). A soma de casos novos diagnosticados a cada ano atinge 50% \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n3 \n\ndo total observado nos cinco continentes, como registrou em 2002 a Organiza\u00e7\u00e3o Pan-\n\nAmericana da Sa\u00fade (OPAS) (INCA, 2006).  \n\nDiante deste cen\u00e1rio, fica clara a necessidade da continuidade em investimentos \n\nno desenvolvimento de a\u00e7\u00f5es para o controle do c\u00e2ncer nos diferentes n\u00edveis de atua\u00e7\u00e3o, \n\ncomo na promo\u00e7\u00e3o da sa\u00fade, na detec\u00e7\u00e3o precoce, na assist\u00eancia aos pacientes, e na \n\nforma\u00e7\u00e3o de recursos humanos. \n\n \n\n1.2. Aspectos Gerais da Oncog\u00eanese \n\n \n\nNeoplasia (gr. \u201cneo\u201d + \u201cplasis\u201d = neoforma\u00e7\u00e3o) \u00e9 o termo utilizado para \n\ncaracterizar a prolifera\u00e7\u00e3o local de clones celulares at\u00edpicos, sem causa aparente, de \n\ncrescimento excessivo, progressivo, ilimitado, n\u00e3o coordenado, aut\u00f4nomo, irrevers\u00edvel, e \n\ncom tend\u00eancia a perda de diferencia\u00e7\u00e3o celular (Robbins and Cotran, 2010). No entanto, \n\na persist\u00eancia do crescimento \u00e9 resultado de altera\u00e7\u00f5es gen\u00e9ticas que permitem a \n\nprolifera\u00e7\u00e3o excessiva e desregulada de forma aut\u00f4noma; apesar de os tumores \n\ngeralmente dependerem do organismo hospedeiro para nutri\u00e7\u00e3o e suprimento sangu\u00edneo. \n\nAs anomalias gen\u00e9ticas encontradas no c\u00e2ncer afetam tipicamente tr\u00eas classes \n\ngerais de genes (Croce, 2008). Os genes promotores, ou oncogenes (1), os genes \n\nsupressores de tumor (2) e, os genes envolvidos no reparo do DNA (3). Quando algum \n\ndesses sofre muta\u00e7\u00e3o, os controles gen\u00e9ticos pelos quais eles s\u00e3o respons\u00e1veis s\u00e3o \n\nperdidos e o processo carcinog\u00eanico pode ser iniciado (Vogelstein and Kinzler, 2004; Lea \n\net al., 2007; Croce, 2008).  \n\nDesta forma, o c\u00e2ncer \u00e9 uma doen\u00e7a complexa e multicausal que ocorre como \n\nconsequ\u00eancia do ac\u00famulo progressivo de muta\u00e7\u00f5es nos genes onde os produtos prot\u00e9icos \n\ndesempenham importantes pap\u00e9is no controle da prolifera\u00e7\u00e3o e diferencia\u00e7\u00e3o celular e na \n\napoptose. Usualmente, diversos fatores promotores atuam anteriormente ao \n\ndesenvolvimento neopl\u00e1sico e com poucas exce\u00e7\u00f5es, uma muta\u00e7\u00e3o \u00fanica n\u00e3o \u00e9 suficiente \n\npara o estabelecimento da doen\u00e7a.  \n\nTodos os tumores, benignos ou malignos, apresentam dois componentes b\u00e1sicos: \n\nc\u00e9lulas neopl\u00e1sicas clonais que constituem seu par\u00eanquima, e estroma reativo, constitu\u00eddo \n\nde tecido conjuntivo, vasos sangu\u00edneos e quantidade vari\u00e1vel de macr\u00f3fagos e linf\u00f3citos. \n\nSabe-se que os tumores malignos induzem resposta inflamat\u00f3ria celular cr\u00f4nica n\u00e3o \n\nrelacionada com necrose ou infec\u00e7\u00e3o do tumor, e o infiltrado \u00e9 composto principalmente \n\nde c\u00e9lulas T e macr\u00f3fagos. Assim, a defesa imunol\u00f3gica responde a ant\u00edgenos tumorais \n\nhttp://pt.wikipedia.org/wiki/Oncogene\nhttp://pt.wikipedia.org/wiki/Gene_supressor_de_tumor\nhttp://pt.wikipedia.org/wiki/Gene_supressor_de_tumor\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n4 \n\npresentes na superf\u00edcie das c\u00e9lulas malignas expressos diferencialmente daqueles das \n\nc\u00e9lulas normais e, em alguns casos, pode ser respons\u00e1vel pelo retardo do crescimento \n\ntumoral e de sua progress\u00e3o (Zbar, 2004).  \n\nIn vitro, c\u00e9lulas isoladas do sistema imune t\u00eam mostrado serem efetivas contra \n\ntumores atrav\u00e9s de mecanismos como lise osm\u00f3tica ou apoptose e citotoxicidade celular.  \n\nIn vivo, contudo, os tumores parecem desenvolver mecanismos de escape ao sistema \n\nimune. As c\u00e9lulas neopl\u00e1sicas podem evadir ao sistema imune por diversas vias, sendo a \n\ncapacidade de interfer\u00eancia na fun\u00e7\u00e3o das c\u00e9lulas imunes o principal motivo de falha no \n\ncontrole da progress\u00e3o tumoral (Dunn et al., 2004; Bellati et al., 2009). Al\u00e9m disso, o \n\npapel do microambiente tumoral no reconhecimento e progress\u00e3o do c\u00e2ncer tem sido cada \n\nvez mais estudado, e as intera\u00e7\u00f5es entre as c\u00e9lulas imunes, as c\u00e9lulas tumorais e os \n\ncomponentes moleculares do tumor exercem influ\u00eancia significativa na progress\u00e3o da \n\ndoen\u00e7a (Rosenberg et al., 2004). \n\n \n\n1.3. Trato Gastrointestinal Inferior \n\n \n\n1.3.1. Caracter\u00edsticas Gerais \n\n \n\nO trato gastrointestinal inferior est\u00e1 morfologicamente divido em regi\u00f5es \n\ndistintas: intestino delgado (duodeno, jejuno e \u00edleo) e intestino grosso (ceco, c\u00f3lon, reto, \n\ncanal anal e ap\u00eandice). \u00c9 constitu\u00eddo de v\u00e1rias camadas histol\u00f3gicas dispostas \n\nconcentricamente e similares em toda a extens\u00e3o com pequenas modifica\u00e7\u00f5es e \n\nespecifica\u00e7\u00f5es regionais. \n\nO intestino delgado apresenta modifica\u00e7\u00f5es estruturais que aumentam a \u00e1rea total \n\nda sua superf\u00edcie e que promovem a absor\u00e7\u00e3o de nutrientes vindos da alimenta\u00e7\u00e3o. Possui \n\nquatro t\u00fanicas que comp\u00f5em a parede intestinal: (1) mucosa; (2) submucosa; (3) t\u00fanica \n\nmuscular e (4) serosa, sendo as duas primeiras, os principais s\u00edtios de altera\u00e7\u00f5es \n\nhistol\u00f3gicas observadas em est\u00e1gios iniciais de transforma\u00e7\u00f5es neopl\u00e1sicas (Fig. 01). \n\nTumores na regi\u00e3o do intestino delgado s\u00e3o geralmente raros, correspondendo a cerca de \n\n1 a 6% de todas as neoplasias do trato gastrointestinal (Rangel et al., 2000). \n\nAs pregas e vilos encontrados no intestino delgado n\u00e3o s\u00e3o encontrados no \n\nintestino grosso, por\u00e9m, as mesmas camadas constituem este segmento. As c\u00e9lulas \n\nepiteliais s\u00e3o mais planas e a mucosa \u00e9 mais espessa, possuindo longas Gl\u00e2ndulas de \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n5 \n\nLieberkuhn e grande abund\u00e2ncia de c\u00e9lulas caliciformes quando comparado com o \n\nintestino delgado (Fig. 02) (Vries et al., 2010).  \n\n \n\n \nFigura 02: Corte histol\u00f3gico de se\u00e7\u00e3o do duodeno no intestino delgado mostrando as camadas que \n\ncomp\u00f5em o mesmo: Mucosa; Submucosa; T\u00fanica Muscular e Serosa al\u00e9m de Tecido Conjuntivo, C\u00e9lulas \n\nCaliciformes e Gl\u00e2ndulas de Lieberkhunn.  \n\nFonte: Atlas Virtual de histologia UFSM \n\n \n\n \n\nFigura 03: Corte histol\u00f3gico de se\u00e7\u00e3o de intestino grosso mostrando as camadas Mucosa, Submucosa, \n\nT\u00fanica Muscular e Serosa al\u00e9m de componentes caracter\u00edsticos: Gl\u00e2ndulas de Lieberkhunn e C\u00e9lulas \n\nCaliciformes.  \n\nFonte: Atlas Virtual de histologia UFSM \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n6 \n\n1.3.2. C\u00e2ncer Intestinal \n\n \n\nOs adenomas constituem os tipos de p\u00f3lipos mais frequentemente encontrados no \n\nintestino delgado, possuindo predile\u00e7\u00e3o pelo duodeno distal embora possam ser \n\nencontrados em toda a sua extens\u00e3o. Histologicamente, eles s\u00e3o similares aos adenomas \n\nencontrados na regi\u00e3o colorretal tendendo a apresentar uma arquitetura de vilos mais \n\npronunciada. Assim como para a regi\u00e3o colorretal, o risco de progress\u00e3o maligna de um \n\nadenoma \u00e9 maior quanto maior for o p\u00f3lipo (Brosens et al., 2007). \n\nA transforma\u00e7\u00e3o de c\u00e9lulas epiteliais normais em adenomas e carcinomas segue, \n\nusualmente, um modelo de progress\u00e3o de est\u00e1gios histol\u00f3gicos e altera\u00e7\u00f5es gen\u00e9ticas e \n\nepigen\u00e9ticas simult\u00e2neas (Fearon and Vogelstein, 1990) (Fig. 03). Tais altera\u00e7\u00f5es \n\nfornecem \u00e0s c\u00e9lulas neopl\u00e1sicas vantagens sob sua expans\u00e3o clonal e levam \u00e0 perda da \n\ninibi\u00e7\u00e3o por contato celular, evas\u00e3o de mecanismos apopt\u00f3ticos e de interrup\u00e7\u00e3o do ciclo \n\ncelular, aquisi\u00e7\u00e3o de caracter\u00edsticas do tipo c\u00e9lula tronco, entre outros (Cardoso et al., \n\n2007). \n\n \n\n \n\nFigura 04: Sequ\u00eancia adenoma-carcinoma em c\u00e2ncer colorretal. A inicia\u00e7\u00e3o e progress\u00e3o da tumorog\u00eanese \n\nde uma mucosa normal em carcinoma e met\u00e1stase \u00e9 geralmente associada a caracter\u00edsticas morfol\u00f3gicas e \n\nhistopatol\u00f3gicas. \nFonte: Adaptado de Cardoso et al., 2007 e Perse and Cerar, 2011. \n\n \n\n \n\nA sequ\u00eancia adenoma-carcinoma-met\u00e1stase \u00e9 iniciada quando surgem pequenas \n\nles\u00f5es na arquitetura glandular do epit\u00e9lio intestinal chamadas focos de criptas aberrantes \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n7 \n\n(ACF). Os ACF s\u00e3o agregados de criptas anormais caracterizados por hiperprolifera\u00e7\u00e3o, \n\ntamanho aumentado, zonas pericr\u00edpticas expandidas e fendas alongadas (Rosenberg and \n\nLiu, 1995; Papanikolaou et al., 1998; Papanikolaou et al., 2000). \n\nAlgumas muta\u00e7\u00f5es est\u00e1gio-espec\u00edficas que ocorrem no modelo de progress\u00e3o \n\nadenoma-carcinoma-met\u00e1stase s\u00e3o conhecidas, e incluem altera\u00e7\u00f5es no gene supressor \n\nde tumor APC (Adenomatous polyposis coli) (Epit\u00e9lio Normal ? Adenoma), no proto-\n\noncogene K-ras (presente em adenomas) e no gene supressor de tumor p53 (na transi\u00e7\u00e3o \n\nAdenoma ? Carcinoma) (Nambiar et al., 2010). Al\u00e9m disso, outros genes est\u00e3o \n\nsignificativamente alterados em diferentes classes de tumores e envolvidos na \n\ncarcinog\u00eanese colorretal, no entanto, m\u00e9todos de classifica\u00e7\u00e3o e estadiamento do tumor \n\ne realiza\u00e7\u00e3o de progn\u00f3sticos mais robustos e menos invasivos continuam sendo \n\nnecessidades m\u00e9dicas ainda n\u00e3o atendidas (Fig. 04) (Hoops and Traber, 1997; Nambiar \n\net al., 2010). \n\n \n\n \n\nFigura 05: Eventos gen\u00e9ticos envolvidos no desenvolvimento do c\u00e2ncer colorretal. A acumula\u00e7\u00e3o \n\ngradativa de muta\u00e7\u00f5es afeta o controle de crescimento, diferencia\u00e7\u00e3o e sobreviv\u00eancia celular. Para o CCR \n\nos genes cruciais envolvidos no desenvolvimento de p\u00f3lipos e c\u00e2ncer para cada etapa s\u00e3o mostrados nas \n\ncaixas brancas. \n\nFonte: Adaptado de Simpson and Dorow, 2001. \n\n \n\nOs recentes progressos da prote\u00f4mica t\u00eam contribu\u00eddo para o entendimento da \n\npatofisiologia das neoplasias, propiciando novas perspectivas para diagn\u00f3sticos e \n\ndescoberta de novas drogas anti-c\u00e2ncer. A avalia\u00e7\u00e3o sistem\u00e1tica do proteoma, de forma a \n\ncomparar a express\u00e3o proteica de duas c\u00e9lulas, tecidos ou organismos em diferentes \n\ncondi\u00e7\u00f5es fisiol\u00f3gicas possibilita a obten\u00e7\u00e3o de informa\u00e7\u00f5es para identifica\u00e7\u00e3o, \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n8 \n\nquantifica\u00e7\u00e3o e caracteriza\u00e7\u00e3o de modifica\u00e7\u00f5es p\u00f3s-traducionais presentes em prote\u00ednas \n\ne que influenciam diretamente o funcionamento celular (Wilkins et al., 1996; Cho, 2007). \n\nNesse sentido, a prote\u00f4mica tem sido utilizada tamb\u00e9m como nova ferramenta na \n\nbusca por biomarcadores moleculares para o c\u00e2ncer colorretal (CCR). As altera\u00e7\u00f5es na \n\nexpress\u00e3o proteica envolvidas na transforma\u00e7\u00e3o maligna podem ser monitoradas de \n\nmaneira quantitativa e qualitativa e fornecem valiosas informa\u00e7\u00f5es que podem ser \n\nutilizadas para a obten\u00e7\u00e3o de diagn\u00f3sticos e progn\u00f3sticos mais efetivos. Al\u00e9m disso, \n\nrepresentam um grande impacto na oncologia cl\u00ednica, especialmente se o biomarcador \n\npode ser detectado antes dos sintomas cl\u00ednicos ou se permite um acompanhamento da \n\nresposta ao tratamento (Cho, 2007; Alhquist, 2010).  \n\nEmbora as altera\u00e7\u00f5es moleculares relacionadas ao CCR tenham sido \n\nextensivamente investigadas, poucos pesquisadores t\u00eam descrito as aplica\u00e7\u00f5es desses \n\nbiomarcadores na detec\u00e7\u00e3o de est\u00e1gios prim\u00e1rios de diagn\u00f3stico e preven\u00e7\u00e3o do c\u00e2ncer. \n\nConsiderando que o CCR pode ser prevenido se o adenoma for diagnosticado e removido, \n\ntorna-se necess\u00e1ria a identifica\u00e7\u00e3o de marcadores capazes de diagnosticar de maneira \n\ntecido-espec\u00edfica e precoce as altera\u00e7\u00f5es iniciais que ocorrem durante o desenvolvimento \n\ndesta doen\u00e7a (Chang et al., 2005).  \n\n \n\n1.3.3. Fatores de Risco e Gen\u00e9ticos \n\n \n\nA explica\u00e7\u00e3o para os altos \u00edndices encontrados para o CCR est\u00e1 na maior \n\nexposi\u00e7\u00e3o dos indiv\u00edduos a fatores de risco cancer\u00edgenos. A redefini\u00e7\u00e3o dos padr\u00f5es de \n\nvida, a partir da uniformiza\u00e7\u00e3o das condi\u00e7\u00f5es de trabalho, nutri\u00e7\u00e3o e consumo \n\ndesencadeados pelo processo global de industrializa\u00e7\u00e3o refletem-se no perfil \n\nepidemiol\u00f3gico das popula\u00e7\u00f5es (Montesano and Hall, 2001). \n\nFatores de risco heredit\u00e1rios e ambientais (diet\u00e9ticos ou n\u00e3o) est\u00e3o envolvidos no \n\ndesenvolvimento do CCR. As altera\u00e7\u00f5es gen\u00e9ticas que levam a esta doen\u00e7a podem ser \n\nadquiridas, gerando o chamado c\u00e2ncer espor\u00e1dico, respons\u00e1vel por 75 a 85% dos casos. \n\nNele, existe uma a\u00e7\u00e3o cumulativa de agentes carcin\u00f3genos ambientais e diet\u00e9ticos sobre \n\na mucosa, levando a modifica\u00e7\u00f5es espec\u00edficas no DNA das c\u00e9lulas do epit\u00e9lio intestinal \n\n(Cecconello, 2008). Em outras circunst\u00e2ncias, o indiv\u00edduo j\u00e1 apresenta ao nascimento ou \n\nadquire precocemente muta\u00e7\u00f5es espec\u00edficas que desencadeiam as formas heredit\u00e1rias do \n\nCCR, representadas principalmente pela polipose adenomatosa familiar (PAF) e pelo \n\nc\u00e2ncer colorretal heredit\u00e1rio n\u00e3o associado \u00e0 polipose (Hoops and Traber, 1997).  \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n9 \n\nQuanto \u00e0 influ\u00eancia da alimenta\u00e7\u00e3o, \u00e9 sabido que a dieta ocidental caracterizada \n\npelo alto teor de gordura saturada, juntamente com a ingest\u00e3o excessiva de prote\u00edna de \n\norigem animal e baixo teor de fibras, est\u00e1 associada a maior potencial carcinog\u00eanico. \n\nTamb\u00e9m s\u00e3o considerados nocivos, os fatores relacionados ao estilo de vida como fumo, \n\nsedentarismo, obesidade, consumo excessivo de \u00e1lcool e ingest\u00e3o de aminas \n\nheteroc\u00edclicas e hidrocarbonetos arom\u00e1ticos (Marques-Vidal et al., 2006). \n\n \n\n1.4. Vis\u00e3o Geral de Vias de Sinaliza\u00e7\u00e3o Atuantes no CCR \n\n \n\n No c\u00f3lon humano, cerca de 10 bilh\u00f5es de novas c\u00e9lulas s\u00e3o geradas diariamente \n\npor progenitoras localizadas na base das criptas. O destino desse novo epit\u00e9lio \u00e9 \n\ndeterminado por sinais extracelulares gerados a n\u00edvel populacional. Tal sinaliza\u00e7\u00e3o \n\nextr\u00ednseca \u00e9 realizada por morf\u00f3genos, prote\u00ednas sol\u00faveis que formam gradientes de \n\nconcentra\u00e7\u00e3o e atuam de maneira dose dependente induzindo respostas celulares distintas \n\nem suas c\u00e9lulas alvo (Tabata and Takei, 2004). \n\n \n\n 1.4.1. Via Wnt/?-catenina \n\n \n\nA via de sinaliza\u00e7\u00e3o Wnt/?-catenina \u00e9 altamente conservada em eucariotos e \n\nparticipa de diversos acontecimentos ligados ao desenvolvimento celular. Ela \n\ndesempenha pap\u00e9is na prolifera\u00e7\u00e3o, movimento, estabelecimento da polaridade e decis\u00e3o \n\ndo destino celular e manuten\u00e7\u00e3o de c\u00e9lulas tronco. Um dos caminhos mais bem estudados \n\npara essa via \u00e9 caracterizado pela estabiliza\u00e7\u00e3o e ac\u00famulo de ?-catenina no citosol, que \n\nent\u00e3o migra para o n\u00facleo onde participa da ativa\u00e7\u00e3o da transcri\u00e7\u00e3o de prote\u00ednas chave na \n\ncarcinog\u00eanese como c-Myc, VEGF, ciclina D1, entre outras (via can\u00f4nica) (Krauzova \n\nand Korinek, 2014; Markowska et al., 2014; Klimczak, 2015). \n\nNa aus\u00eancia de Wnt, a prote\u00edna ?-catenina \u00e9 constantemente degradada pela a\u00e7\u00e3o \n\ndo complexo proteico formado por Axina, APC, CK1 (case\u00edna quinase 1) e GSK3 \n\n(glicog\u00eanio sintase quinase 3). As prote\u00ednas CK1 e GSK3 fosforilam continuamente a \n\nregi\u00e3o N terminal de ?-catenina que resultam no reconhecimento do produto fosforilado \n\npor ?-Trcp, uma subunidade de E3 ubiquitina ligase. A ubiquitina\u00e7\u00e3o de ?-catenina leva \n\na sua degrada\u00e7\u00e3o proteassomal prevenindo assim que esta prote\u00edna migre para o n\u00facleo e \n\native a transcri\u00e7\u00e3o de genes reprimidos pelo complexo TCF/LEF ligado ao DNA (Fator \n\nT celular/Fator Potenciador Linf\u00f3ide) (Fig. 06, A). A via \u00e9 ativada quando um ligante \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n10 \n\nWnt se liga ao receptor transmembrana Fz (Frizzled) e seu co-receptor LRP6 (Lipoprotein \n\nreceptor related protein 6). Ocorre a forma\u00e7\u00e3o de um complexo transmembrana Wnt-Fz-\n\nLRP6 e recrutamento de uma terceira prote\u00edna chamada Dvl (Dishevelled), que por \n\nfosforila\u00e7\u00e3o resulta no sequestro do complexo de degrada\u00e7\u00e3o, inibindo-o (Fig. 06, B) \n\n(MacDonald et al., 2009; White et al., 2012). \n\n \n\n \n\nFigura 06: Via Wnt/?-catenina.  A) Na aus\u00eancia de Wnt, ?-catenina \u00e9 fosforilada pelo complexo formado \n\npor Axina, CK1, GSK3 e APC sendo posteriormente reconhecida e ubiquitinada por ?-Trcp e direcionada \n\npara degrada\u00e7\u00e3o proteassomal. B) Na presen\u00e7a de ligante Wnt, ocorre a forma\u00e7\u00e3o de um complexo receptor \n\nFz-LRP6 que sequestra o complexo de degrada\u00e7\u00e3o inibindo-o e estabilizando a ?-catenina presente no \n\ncitosol que ent\u00e3o migra para o n\u00facleo onde co-ativa TCF levando \u00e0 transcri\u00e7\u00e3o dos regulados por esta \n\nprote\u00edna. \n\nFonte: MacDonald et al., 2009. \n\n  \n\nOs mam\u00edferos apresentam 19 formas de prote\u00ednas Wnt ricas em ciste\u00edna e com \n\npept\u00eddeo sinal N-terminal para secre\u00e7\u00e3o. Tais prote\u00ednas sofrem glicosila\u00e7\u00e3o e lipida\u00e7\u00e3o \n\nantes da excre\u00e7\u00e3o e tais modifica\u00e7\u00f5es t\u00eam papel direto na ativa\u00e7\u00e3o da via. No CCR cerca \n\nde 90% dos tumores apresentam alguma muta\u00e7\u00e3o em fatores regulat\u00f3rios da via sendo as \n\nmais comuns aquelas que afetam o gene APC ou CTNNB1 (?-catenina). Tais muta\u00e7\u00f5es \n\nconferem diferentes n\u00edveis de ativa\u00e7\u00e3o da via e requerem diferentes subconjuntos de \n\neventos cooperativos (p. ex. silenciamento epigen\u00e9tico, sinais do microambiente ou \n\naltera\u00e7\u00f5es em outras vias) para levar \u00e0 progress\u00e3o tumoral por diferentes mecanismos \n\n(Brabletz et al., 1998; Vermeulen et al., 2010; White et al., 2012). \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n11 \n\nO crosstalk entre a via Wnt/?-catenina e outras vias de sinaliza\u00e7\u00e3o ligadas ao \n\ndesenvolvimento podem modular a via ?-catenina no CCR. A prote\u00edna de membrana \n\nNotch1 pode se ligar \u00e0 ?-catenina ativa e regular negativamente sua fun\u00e7\u00e3o em c\u00e9lulas \n\ntronco e tumorais.  A via Hedgehog tamb\u00e9m pode regular a via Wnt/?-catenina. Arimura \n\ne colaboradores demonstraram correla\u00e7\u00e3o entre a presen\u00e7a do mediador de Hedgehog, \n\nSmoothened (Smo), e aumento da atividade de Wnt/?-catenina em camundongos \n\nmutantes para APC (Arimura et al., 2009). \n\n Por fim, deve-se ressaltar que embora a via Wnt/?-catenina seja essencial na \n\nreprograma\u00e7\u00e3o celular relacionada ao CCR atrav\u00e9s do est\u00edmulo da express\u00e3o g\u00eanica de \n\nfatores chave, ela possui um efeito transit\u00f3rio e ativo somente nos est\u00e1gios iniciais da \n\ntransforma\u00e7\u00e3o n\u00e3o sendo necess\u00e1ria para a manuten\u00e7\u00e3o celular de pluripot\u00eancia \n\n(Klimczak, 2015). \n\n \n\n1.4.2. Via Notch \n\n \n\nA via Notch \u00e9 essencial na diferencia\u00e7\u00e3o de c\u00e9lulas caliciformes e c\u00e9lulas \n\nprogenitoras, participando da regula\u00e7\u00e3o do desenvolvimento e homeostase intestinal. Em \n\nhumanos e camundongos os ligantes Notch (Jagged1, Jagged2, DLL1, DLL3 e DLL4) \n\nativam os receptores Notch (Notch1-4) levando \u00e0 transcri\u00e7\u00e3o de diversos genes alvo (p21, \n\nHes-1, Dellex, etc) (Fre et al., 2005). \n\nUm ligante Notch presente na membrana de uma c\u00e9lula adjacente liga-se a um \n\nreceptor presente na c\u00e9lula receptora. A intera\u00e7\u00e3o receptor-ligante leva \u00e0 ativa\u00e7\u00e3o do \n\ncomplexo enzim\u00e1tico ?-secretase que cliva a regi\u00e3o transmembrana do pr\u00f3prio receptor \n\nNotch (NICD) ativando-o. A por\u00e7\u00e3o NICD migra para o n\u00facleo celular onde liga-se a um \n\nregulador transcricional (CBP ou RBP-JK em vertebrados). O complexo formado desloca \n\nco-repressores ligados aos fatores de transcri\u00e7\u00e3o e recruta co-ativadores transcricionais \n\nque induzem a express\u00e3o g\u00eanica (Fig. 07). Diversas vias de sinaliza\u00e7\u00e3o podem ser super \n\nreguladas atrav\u00e9s da ativa\u00e7\u00e3o da via Notch, como por exemplo a via PI3K/AKT por \n\ninativa\u00e7\u00e3o de PTEN (hom\u00f3logo de fosfatase e tensina deletado no cromossomo 10) e as \n\nvias c-Myc e EGFR (receptor de fator de crescimento epidermal). A ativa\u00e7\u00e3o da via \n\nparece estar associada com o desenvolvimento prim\u00e1rio do CCR indicando que este \u00e9 um \n\nevento inicial na carcinog\u00eanese colorretal (Qiao and Wong, 2009; Miyamoto and \n\nRosenberg, 2011; Xie et al., 2014). \n\n \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n12 \n\n \n\nFigura 07: Diagrama simplificado da via de sinaliza\u00e7\u00e3o Notch e seus poss\u00edveis alvos. Setas para cima \n\nindicam aumento de express\u00e3o regulada por Notch e setas para baixo indicam diminui\u00e7\u00e3o de express\u00e3o \n\nregulada por Notch. \n\nFonte: Qiao and Wong, 2009. \n\n \n\n 1.4.3. Via Hedgehog \n\n \n\nHedgehog s\u00e3o mol\u00e9culas sinalizadoras secretadas que em mam\u00edferos englobam \n\ntr\u00eas prote\u00ednas hom\u00f3logas com diferentes distribui\u00e7\u00f5es temporais e espaciais: Sonic \n\nhedgehog (Shh); Indian hedgehog (Ihh); Desert hedgehog (Dhh) referidas em conjunto \n\ncomo Hhs (Ingham and McMahon, 2001). Essas prote\u00ednas atuam via receptores de \n\nmembrana Patched (Ptch), cuja express\u00e3o \u00e9 super regulada pela sinaliza\u00e7\u00e3o de Hh, e \n\nSmoothened (Smo). Na aus\u00eancia de Hh, Ptch inibe cataliticamente a atividade de Smo \n\nafetando sua localiza\u00e7\u00e3o na membrana celular. Uma mol\u00e9cula end\u00f3gena que atua como \n\nagonista de Smo \u00e9 transportada para fora da c\u00e9lula por Ptch prevenindo sua liga\u00e7\u00e3o a \n\nSmo. Quando presente Hh liga-se a Patch inativando-a e consequentemente ativando Smo \n\nque traduz o sinal ao citoplasma via GLI (fam\u00edlia de fatores de transcri\u00e7\u00e3o com motivo \n\ndedo de zinco) (Fig. 08) (Bale and Yu,2001; van den Brink and Hardwick, 2006; \n\nMazumdar et al., 2011). \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n13 \n\n \n\n \n\nFigura 08: Via de sinaliza\u00e7\u00e3o Hedgehog em vertebrados. A cascata de Hh \u00e9 iniciada quando Hh liga-se a \n\nPatch ativando uma segunda prote\u00edna transmembrana chamada Smo. Os fatores de transcri\u00e7\u00e3o GLI \n\nlocalizados downstream na via de sinaliza\u00e7\u00e3o ativam a transcri\u00e7\u00e3o de genes alvo (GLI A). Na aus\u00eancia de \n\nHh Ptch inibe a atividade de Smo afetando sua localiza\u00e7\u00e3o na membrana e levando ao processamento \n\nproteol\u00edtico de prote\u00ednas GLI reprimindo a transcri\u00e7\u00e3o de genes alvo (GLI R). \n\nFonte: Adaptado de Gupta et al., 2010. \n\n \n\nOs fatores GLI existem como tr\u00eas prote\u00ednas separadas: GLI1 e GLI2 que atuam \n\ncomo ativadores transcricionais e GLI3 que atua como repressor transcricional. A \n\nexpress\u00e3o de GLI1 \u00e9 altamente dependente da ativa\u00e7\u00e3o da sinaliza\u00e7\u00e3o por Hh. Na \n\naus\u00eancia de Hh, Ptch bloqueia a atividade de Smo e as prote\u00ednas GLI s\u00e3o \n\nproteoliticamente processadas para gerar o repressor GLIR, largamente derivado de GLI3 \n\nque reprime a transcri\u00e7\u00e3o. A liga\u00e7\u00e3o de Hh a Ptch interrompe a inibi\u00e7\u00e3o de Smo gerando \n\no ativador GLIA constitu\u00eddo principalmente por GLI2 e ativando a express\u00e3o de genes \n\nalvo (GLI1, Ptch1, prote\u00edna de intera\u00e7\u00e3o com Hh, Ciclina D, Myc, Bmi1, Bcl2, VEGF, \n\netc).  A ativa\u00e7\u00e3o de GLI \u00e9 regulada em diferentes n\u00edveis via fosforila\u00e7\u00e3o por inibidores \n\ncomo Ren, PKA, GSK3 e ativadores como Dyrk1, Akt e Ras (Gupta et al.,2010). \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n14 \n\n1.4.4. Via PI3K/Akt \n\n \n\nA ativa\u00e7\u00e3o da via PI3K/Akt (fosfatidilinositol-3 quinase) ocorre atrav\u00e9s da liga\u00e7\u00e3o \n\nde fatores de crescimento, citocinas ou insulina a um receptor de membrana tirosina \n\nquinase, levando \u00e0 autofosforila\u00e7\u00e3o de um dom\u00ednio intracelular do mesmo. Tal \n\nfosforila\u00e7\u00e3o permite que ocorram altera\u00e7\u00f5es na conforma\u00e7\u00e3o e subsequente ativa\u00e7\u00e3o de \n\nPI3K (composta por uma subunidade catal\u00edtica \u2013 p110 e uma subunidade regulat\u00f3ria \u2013 \n\np85). PI3K promove a transforma\u00e7\u00e3o de fosfatidilinositol 4,5-bisfosfato (PIP2) em \n\nfosfatidilinositol 3,4,5-trifosfato (PIP3) que, por sua vez, medeia a fosforila\u00e7\u00e3o e ativa\u00e7\u00e3o \n\nde Akt. PIP2 e PIP3 s\u00e3o lip\u00eddeos chave respons\u00e1veis por mediar respostas celulares ao \n\nest\u00edmulo por fatores de crescimento ou citocinas, liga\u00e7\u00e3o de integrinas, e sinaliza\u00e7\u00e3o via \n\nintegrina quinase ou quinase de ades\u00e3o focal (FAK) (Markowska et al., 2014). \n\nAkt, tamb\u00e9m conhecida como prote\u00edna quinase B (PKB), pode ser ativada tamb\u00e9m \n\nem condi\u00e7\u00f5es de hip\u00f3xia, hipoglicemia, a\u00e7\u00e3o de radicais livres entre outras. Um dos \n\nprincipais pap\u00e9is de Akt \u00e9 a promo\u00e7\u00e3o da prolifera\u00e7\u00e3o celular e inibi\u00e7\u00e3o da apoptose por \n\nfosforila\u00e7\u00e3o de caspase 9 e intera\u00e7\u00e3o com o antagonista de morte celular BCL2. A \n\nfosforila\u00e7\u00e3o e inativa\u00e7\u00e3o de GSK3 por Akt leva \u00e0 inibi\u00e7\u00e3o da liga\u00e7\u00e3o de GSK3 \u00e0s ciclinas \n\nD e E, e aos fatores de transcri\u00e7\u00e3o c-Myc e c-Jun, protegendo-os da degrada\u00e7\u00e3o \n\nproteol\u00edtica e favorecendo a entrada da c\u00e9lula na fase S. Quando ativada, Akt promove a \n\ns\u00edntese proteica e crescimento celular por ativa\u00e7\u00e3o do complexo mTORC1 que ativa a \n\nquinase p70 S6, promovendo aumento na tradu\u00e7\u00e3o de RNA mensageiro e ativando a \n\nprote\u00edna ribossomal S6 e o fator de elonga\u00e7\u00e3o 2 (EEF2) (Fig. 09). Al\u00e9m disso, Akt \n\ntamb\u00e9m regula o balan\u00e7o de carboidratos por aumento de express\u00e3o dos transportadores \n\nde glicose GLUT1 e GLUT3, e facilitando a transloca\u00e7\u00e3o de GLUT4 \u00e0 membrana celular, \n\ncontribuindo para um aumento de influxo de glicose na c\u00e9lula (Brown and Toker, 2015; \n\nSimpson et al., 2015). \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n15 \n\n \n\nFigura 09:  Via de sinaliza\u00e7\u00e3o PI3K/Akt e vias associadas. PTEN: Hom\u00f3logo de fosfatase e tensina \n\ndeletado no cromossomo 10; PI3K: fosfoinositol 3-quinase; EGFR: receptor de fator de crescimento \n\nepidermal; ERK \u00bd: quinase regulada por sinal extracelular \u00bd; FGFR: receptor de fator de crescimento de \n\nfobroblasto; HER2: fator de crescimento epidermal humano; IRS-1: substrato para receptor de insulina 1; \n\nMEK \u00bd: proteinaquinase \u00bd ativada por mit\u00f3geno; VEGFR: fator de crescimento vascular endotelial. \n\nFonte:  Simpson et al., 2015. \n\n \n\nComo descrito anteriormente, as vias de sinaliza\u00e7\u00e3o relacionadas ao \n\ndesenvolvimento celular est\u00e3o interligadas em um complexo n\u00edvel de regula\u00e7\u00e3o celular. \n\nNa Figura 10 podemos observar os pontos de regula\u00e7\u00e3o cruzada exercidos pelas tr\u00eas vias \n\ndescritas neste t\u00f3pico. \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n16 \n\n \n\nFigura 10: Vias de sinaliza\u00e7\u00e3o Notch, Wnt, e Hedgehog regulando o destino celular. A) Via Notch: a \n\nintera\u00e7\u00e3o ligante-receptor promove a clivagem do dom\u00ednio NICD por ?-secretase e sua transloca\u00e7\u00e3o para o \n\nn\u00facleo com consequente indu\u00e7\u00e3o da transcri\u00e7\u00e3o de genes alvo. B) Via Wnt: estabiliza\u00e7\u00e3o e ac\u00famulo nuclear \n\nde ?-catenina que se associa com os fatores de transcri\u00e7\u00e3o LCF/LEF e co-ativadores (CBP) ativando a \n\nexpress\u00e3o de genes alvo. C) Via Hedgehog: o ligante Hh ativa o receptor Ptch que por sua vez libera o \n\nreceptor Smo. Smo ent\u00e3o passa a inibir a fosforila\u00e7\u00e3o e clivagem de GLI por GSK3, CK1 e PKA \n\npromovendo a forma\u00e7\u00e3o de GLIA que ativa a transcri\u00e7\u00e3o. Notar que a transcri\u00e7\u00e3o de genes por Hedgehog \n\nativa a via Notch e a presen\u00e7a de GSK3 3 CK1 do complexo de degrada\u00e7\u00e3o de Wnt s\u00e3o tamb\u00e9m \n\nrespons\u00e1veis por inibir a via Hedgehog por fosforila\u00e7\u00e3o de GLI. \n\nFonte: Malhotra et al., 2011 \n\n \n\n1.5. Carcinog\u00eanese Qu\u00edmica \n\n \n\nOs c\u00e2nceres causados por agentes ambientais frequentemente ocorrem em tecidos \n\ncomo pulm\u00e3o, trato gastrointestinal e pele, porque esses \u00f3rg\u00e3os est\u00e3o expostos ao \n\nambiente (Shubik and Sice,1956). Recentemente, o estudo da carcinog\u00eanese qu\u00edmica tem \n\nsido mesclado com estudos de altera\u00e7\u00f5es celulares em c\u00e9lulas cancer\u00edgenas, \n\npossibilitando assim a busca por marcadores biol\u00f3gicos e vias metab\u00f3licas alteradas.  \n\nA carcinog\u00eanese qu\u00edmica causa altera\u00e7\u00f5es gen\u00e9ticas e epigen\u00e9ticas em c\u00e9lulas \n\nsuscept\u00edveis que podem transmitir vantagem seletiva para o crescimento e sofrer \n\nexpans\u00e3o clonal. Sendo assim, elas se tornam geneticamente inst\u00e1veis e transformadas \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n17 \n\nem c\u00e9lulas neopl\u00e1sicas. O primeiro est\u00e1gio da carcinog\u00eanese, o de inicia\u00e7\u00e3o tumoral, \n\nenvolve a exposi\u00e7\u00e3o de c\u00e9lulas normais a carcin\u00f3genos f\u00edsicos e qu\u00edmicos. Estes \n\ncarcin\u00f3genos causam danos ao DNA e a outras macromol\u00e9culas fornecendo \u00e0s c\u00e9lulas \n\niniciadas responsividade alterada ao microambiente e vantagem proliferativa. No segundo \n\nest\u00e1gio, a promo\u00e7\u00e3o tumoral resulta na prolifera\u00e7\u00e3o excessiva das c\u00e9lulas iniciadas e \n\naumenta a probabilidade de ocorr\u00eancia de danos gen\u00e9ticos adicionais, incluindo muta\u00e7\u00f5es \n\nend\u00f3genas que acumulam na popula\u00e7\u00e3o em expans\u00e3o. No est\u00e1gio de progress\u00e3o tumoral \n\nou terceiro est\u00e1gio ocorre a aquisi\u00e7\u00e3o de m\u00faltiplas altera\u00e7\u00f5es gen\u00e9ticas e multiplica\u00e7\u00e3o \n\ndescontrolada e irrevers\u00edvel das c\u00e9lulas alteradas (Loeb and Harris, 2008; Irigaray and \n\nBelpomme, 2010). \n\nO campo de estudos sobre a carcinog\u00eanese qu\u00edmica provavelmente teve in\u00edcio \n\ncom as associa\u00e7\u00f5es epidemiol\u00f3gicas de ocorr\u00eancia de tumores com a exposi\u00e7\u00e3o \u00e0 fuma\u00e7a \n\nde tabaco realizadas por Hill e Pott no in\u00edcio do s\u00e9culo 18. A partir da\u00ed, seguiram-se \n\nobserva\u00e7\u00f5es de tumores no trato urin\u00e1rio de trabalhadores que mantinham contato com \n\narilaminas nas f\u00e1bricas europ\u00e9ias no final do s\u00e9culo 19. Al\u00e9m destes, trabalhos com \n\nanimais experimentais envolvendo hidrocarbonetos polic\u00edclicos arom\u00e1ticos (HPA) \n\nderivados de \u00f3leos crus serviram desde ent\u00e3o como importantes prot\u00f3tipos para o estudo \n\nde HPA (Guengerich,2001).  \n\nOs HPA representam uma importante classe de poluentes ambientais os quais t\u00eam \n\nrecebido aten\u00e7\u00e3o especial pelo fato de alguns de seus componentes demonstrarem forte \n\npotencial mutag\u00eanico e carcinog\u00eanico, al\u00e9m de desempenharem pap\u00e9is cruciais em tr\u00eas \n\nproblemas ambientais importantes: polui\u00e7\u00e3o do ar, chuva \u00e1cida e mudan\u00e7a clim\u00e1tica \n\nglobal. Esses compostos est\u00e3o presentes nos combust\u00edveis f\u00f3sseis e s\u00e3o formados durante \n\na combust\u00e3o incompleta e pir\u00f3lise de mat\u00e9ria org\u00e2nica. Eles podem, por exemplo, ser \n\ngerados durante inc\u00eandios florestais e erup\u00e7\u00f5es vulc\u00e2nicas al\u00e9m de serem constituintes \n\nnaturais dos \u00f3leos crus, alguns tipos de alimentos e produtos petroqu\u00edmicos. Al\u00e9m disso, \n\npodem ser formados pelo g\u00e1s de cozinha e no tr\u00e1fego, sendo tamb\u00e9m uma das diversas \n\nclasses de carcinog\u00eanicos qu\u00edmicos presentes na fuma\u00e7a de cigarro (Honer, 2001).  \n\nA ampla distribui\u00e7\u00e3o dos HPA provenientes de fontes naturais e antropog\u00eanicas \n\njuntamente com processos de distribui\u00e7\u00e3o e transporte explica sua ocorr\u00eancia ub\u00edqua. Os \n\nseres humanos s\u00e3o expostos a HPA ambientais, ocupacionais, medicinais e provenientes \n\nda dieta. A absor\u00e7\u00e3o atrav\u00e9s do trato pulmonar, gastrointestinal e da pele ocorre de \n\nmaneira dependente do tipo de HPA, do tamanho das part\u00edculas onde est\u00e3o adsorvidos, \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n18 \n\nda composi\u00e7\u00e3o do adsorvente, e da sua afinidade por gordura (Jacob and Grimmer, 1996; \n\nAngerer et al., 1997; Schoket, 1999; Strickland and Kang, 1999).  \n\nO metabolismo desempenha um importante papel na convers\u00e3o de carcin\u00f3genos \n\nqu\u00edmicos em esp\u00e9cies reativas que danificam macromol\u00e9culas celulares, interferem com \n\nvias de sinaliza\u00e7\u00e3o e que podem causar c\u00e2ncer. C\u00e9lulas de c\u00f3lon humano sabidamente \n\nmetabolizam HPA. Os n\u00edveis induz\u00edveis das enzimas do complexo citocromo P450 \n\n(CYP450) podem influenciar no desenvolvimento de tumores nos intestinos grosso e \n\ndelgado como consequ\u00eancia da ingest\u00e3o de HPA (Diggs et al., 2011). Em roedores, a \n\nabsor\u00e7\u00e3o no trato gastrointestinal ocorre rapidamente e picos destes compostos podem ser \n\nidentificados no sangue 1-2 horas ap\u00f3s a administra\u00e7\u00e3o (Lipniak et al., 1993).  \n\n \n\n1.5.1. Dibenzotiofeno e Dibenzotiofeno Sulfona \n\n \n\nO petr\u00f3leo e o carv\u00e3o s\u00e3o importantes combust\u00edveis f\u00f3sseis de composi\u00e7\u00e3o \n\ncomplexa da qual se distinguem quatro fam\u00edlias de compostos: hidrocarbonetos alif\u00e1ticos, \n\nc\u00edclicos, arom\u00e1ticos e heteromol\u00e9culas contendo \u00e1tomos de nitrog\u00eanio (N), enxofre (S) \n\nou oxig\u00eanio (O) na estrutura. Os compostos sulfurados constituem a terceira popula\u00e7\u00e3o \n\npresente nesses combust\u00edveis e, devido \u00e0 sua dif\u00edcil biodegradabilidade, s\u00e3o considerados \n\ncompostos recalcitrantes podendo servir como marcadores da polui\u00e7\u00e3o gerada por \u00f3leo. \n\nO dibenzotiofeno (DBT) e seus derivados s\u00e3o os maiores representantes desta classe (Fig. \n\n11) (Kropp et al., 1997; Heilmann et al., 2004).  \n\nO conte\u00fado elevado de hidrocarbonetos arom\u00e1ticos polic\u00edclicos sulfurados \n\n(HPAS) em produtos do petr\u00f3leo compromete a qualidade dos mesmos e sua remo\u00e7\u00e3o ou \n\nconvers\u00e3o em estruturas menos t\u00f3xicas \u00e9 uma importante etapa no processo de refino \n\n(Zhang et al., 2005). Os limites de concentra\u00e7\u00e3o desses compostos em combust\u00edveis \n\nobedecem \u00e0s legisla\u00e7\u00f5es espec\u00edficas de cada pa\u00eds com o objetivo de minimizar os efeitos \n\nnegativos \u00e0 sa\u00fade e ao ambiente. A gasolina e o diesel comercializados na comunidade \n\nEurop\u00e9ia e nos EUA devem apresentar, respectivamente, os limites m\u00e1ximos de 30 e 50 \n\nppm de HPAS. A Alemanha limitou o conte\u00fado de enxofre presente no diesel e na \n\ngasolina a 10 ppm em 2001 (Babich and Moulijn, 2003).  \n\n \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n19 \n\n \n\nFigura 11: Estruturas qu\u00edmicas dos principais compostos contendo enxofre encontrados no petr\u00f3leo. \n\nFonte: Adaptado de Speight, 2002. \n\n \n\nVisando uma redu\u00e7\u00e3o da queima e consequente emiss\u00e3o de compostos sulfurados \n\nno ambiente, diversos estudos buscam o desenvolvimento de tecnologias para a \n\nremedia\u00e7\u00e3o do enxofre de combust\u00edveis. A redu\u00e7\u00e3o dessas subst\u00e2ncias por parte das \n\nrefinarias revela a preocupa\u00e7\u00e3o do setor em oferecer combust\u00edveis menos t\u00f3xicos e menos \n\npoluentes. Neste contexto, o dibenzotiofeno \u00e9 utilizado na verifica\u00e7\u00e3o da efici\u00eancia de \n\nprocessos de dessulfuriza\u00e7\u00e3o em derivados do petr\u00f3leo e, apesar disso, poucos relatos \n\nsobre sua a\u00e7\u00e3o t\u00f3xica em mam\u00edferos t\u00eam sido apresentados (Leighton, 1989; Kobayashi \n\net al., 2000; Madeira et al., 2008; Scherer et al., 2009).  \n\nTrabalhos da d\u00e9cada de 80 foram realizados em animais experimentais \n\nempregando doses maci\u00e7as de DBT e derivados por via oral e subcut\u00e2nea na expectativa \n\nde demonstrar efeitos t\u00f3xicos. Tais trabalhos estabeleceram a dose letal (DL50) de 470 \n\nmg/kg e graves les\u00f5es no p\u00e2ncreas e f\u00edgado, congest\u00e3o pulmonar, edema, e hemorragia \n\nintestinal com doses de 335 mg/kg observadas nos ratos que sobreviveram a um tempo \n\nmaior que 24 horas ap\u00f3s a ingest\u00e3o do DBT. Outros estudos onde foram administrados o \n\nDBT e outros an\u00e1logos ativos de petr\u00f3leo demonstraram, al\u00e9m dos efeitos citados acima, \n\naltera\u00e7\u00f5es nos linfonodos mesent\u00e9ricos e necrose das c\u00e9lulas do timo (Leighton, 1989).  \n\nA toxicidade individual dos HPA de maneira geral est\u00e1 relacionada com a ativa\u00e7\u00e3o \n\nmetab\u00f3lica e a forma\u00e7\u00e3o de metab\u00f3litos carcinog\u00eanicos respons\u00e1veis pela alquila\u00e7\u00e3o do \n\nDNA e do est\u00e1gio de inicia\u00e7\u00e3o atrav\u00e9s de mecanismos complexos associados \u00e0 \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n20 \n\ncarcinog\u00eanese qu\u00edmica (Aas et al., 2000). Os metab\u00f3litos ativos formados a partir de HPA \n\ns\u00e3o produtos de rea\u00e7\u00f5es catalisadas por enzimas CYP450 em particular, pela isoenzima \n\nP4501A1 e, embora os n\u00edveis basais dessa isoforma sejam baixos em diversos tecidos, \n\nocorre uma indu\u00e7\u00e3o da sua express\u00e3o ap\u00f3s a exposi\u00e7\u00e3o a diversos tipos de HPA \n\n(Soontjens et al., 1997; Jones et al., 2000).  \n\nUma das vias de metaboliza\u00e7\u00e3o do DBT inicialmente descrita em esp\u00e9cies de \n\nRhodococcus sp. IGTS8 \u00e9 chamada de via sulf\u00f3xido-sulfona-sulfonato-sulfato ou \u201cVia \n\n4S\u201d. Durante o metabolismo, o DBT sofre a a\u00e7\u00e3o de um sistema multienzim\u00e1tico com \n\ntr\u00eas diferentes atividades, que promovem um ataque oxidativo progressivo no grupo \n\ntiof\u00eanico. A primeira enzima da via \u00e9 uma monooxigenase que oxida o DBT a 5,5\u2019-\n\ndi\u00f3xido de DBT (DBTO2) em dois passos; a segunda enzima apresenta atividade similar \n\n\u00e0 uma monoxigenase e converte o 5,5\u2019-di\u00f3xido de DBT a 2\u2019- hidroxibifenil-2-sulfinato. \n\nFinalmente, a quebra da liga\u00e7\u00e3o C-S transforma o 2\u2019-hidroxibifenil-2-sulfinato em dois \n\nprodutos finais, 2-hidroxibifenil (HBP) e sulfito (Fig. 12) (Gray et al., 1996). \n\n \n\n \n\nFigura 12: \u201cVia 4S\u201d. O enxofre \u00e9 removido na forma de sulfito, permanecendo intacta a estrutura \n\nhidroxilada. \n\nFonte:  Silva, 2007. \n \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n21 \n\nSabe-se que exposi\u00e7\u00f5es ao DBT presente em ambientes aqu\u00e1ticos podem exercer \n\nefeitos em embri\u00f5es de zebrafish, como por exemplo, promovendo uma curvatura dorsal \n\ndo tronco e cauda, redu\u00e7\u00e3o do crescimento, e edemas severos do peric\u00e1rdio e saco \n\nvitel\u00ednico. Deformidades similares comumente chamadas de s\u00edndrome do saco azul e \n\nredu\u00e7\u00f5es no n\u00edvel de incuba\u00e7\u00e3o concentra\u00e7\u00e3o-dependentes tamb\u00e9m foram observadas \n\n(Wozny et al., 2010).  \n\nComo a dieta \u00e9 uma das principais fontes de exposi\u00e7\u00e3o humana e animal a HPA, \n\nas c\u00e9lulas epiteliais intestinais constituem os alvos prim\u00e1rios a entrarem em contato com \n\nos contaminantes. O metabolismo de HPA pelos citocromos P450 \u00e9 bem caracterizado e, \n\nembora exista evid\u00eancia consider\u00e1vel de que o f\u00edgado de mam\u00edferos pode metabolizar tais \n\nsubst\u00e2ncias, o metabolismo em tecidos extra-hep\u00e1ticos como o intestino pode ser de \n\ngrande import\u00e2ncia (Cavret and Feidt, 2005).  \n\nO fato de agentes qu\u00edmicos promoverem altera\u00e7\u00f5es rand\u00f4micas no genoma \n\njustifica o direcionamento de esfor\u00e7os para a quantifica\u00e7\u00e3o dessas mudan\u00e7as, diminui\u00e7\u00e3o \n\nda exposi\u00e7\u00e3o a esses agentes e desenvolvimento de alternativas para a quimiopreven\u00e7\u00e3o.  \n\n \n\n1.5.2. 1,2-Dimetilhidrazina \n\n \n\nO modelo de indu\u00e7\u00e3o de CCR utilizando DMH \u00e9 largamente aplicado por \n\ncompartilhar similaridades histol\u00f3gicas, morfol\u00f3gicas e moleculares com o c\u00e2ncer \n\nespor\u00e1dico observado em humanos (Chen and Huang, 2009; Rosenberg et al., 2009). Tal \n\nsubst\u00e2ncia \u00e9 metabolizada pelo f\u00edgado por diversas rea\u00e7\u00f5es e intermedi\u00e1rios (AOM \u2013 \n\nazoxymethanol e MAM \u2013 methylazoxumethanol), levando \u00e0 forma\u00e7\u00e3o do produto final \n\naltamente reativo: \u00edon metildiaz\u00f4nio. O intermedi\u00e1rio MAM pode ser excretado junto \u00e0 \n\nbile e transportado ao c\u00f3lon a partir do intestino delgado, ou seguir diretamente \u00e0s c\u00e9lulas \n\nepiteliais do c\u00f3lon via circula\u00e7\u00e3o na corrente sangu\u00ednea. Este metab\u00f3lito \u00e9 respons\u00e1vel \n\npela metila\u00e7\u00e3o de bases do DNA do tecido epitelial resultando em apoptose, aumento na \n\nprolifera\u00e7\u00e3o e surgimento de muta\u00e7\u00f5es nesse tecido (Chang, 1984; Perse and Cerar, \n\n2011). \n\n \n\n1.6. Biomarcadores e C\u00e2ncer \n\n  \n\nComo importantes indicadores biol\u00f3gicos do estado de progress\u00e3o tumoral e \n\ncondi\u00e7\u00e3o fisiol\u00f3gica das c\u00e9lulas, os biomarcadores representam ferramentas poderosas no \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n22 \n\nmonitoramento do c\u00e2ncer e aferi\u00e7\u00e3o da efic\u00e1cia e seguran\u00e7a de agentes quimioter\u00e1picos \n\n(Duffy et al., 2003; Cho, 2007). Tais mol\u00e9culas podem ser divididas pela habilidade de \n\nauxiliar na preven\u00e7\u00e3o, promover detec\u00e7\u00e3o precoce, estabelecer progn\u00f3stico e predizer a \n\nresposta do paciente a terapias espec\u00edficas (McLeod and Murray, 1999; Kulasingam and \n\nDiamandis, 2008). A descoberta de biomarcadores tamb\u00e9m auxilia no entendimento de \n\nmecanismos biol\u00f3gicos que ocorrem durante o desenvolvimento e progress\u00e3o da doen\u00e7a. \n\nA a\u00e7\u00e3o de circuitos regulat\u00f3rios e a ocorr\u00eancia de rea\u00e7\u00f5es cruzadas entre as vias \n\nenvolvidas no processo bioqu\u00edmico de estabelecimento do c\u00e2ncer dificulta o \n\nentendimento e predi\u00e7\u00e3o do funcionamento intracelular. Como nas c\u00e9lulas normais, a \n\nmaioria das c\u00e9lulas tumorais utiliza vias de sinaliza\u00e7\u00e3o redundantes para assegurar a \n\nmanuten\u00e7\u00e3o e viabilidade das fun\u00e7\u00f5es cr\u00edticas \u00e0 sobreviv\u00eancia (Cho, 2007). \n\nO estadiamento convencional para o CCR n\u00e3o leva em conta a grande \n\nvariabilidade existente entre os pacientes e, alguns est\u00e1gios de progress\u00e3o n\u00e3o podem ser \n\npreditos utilizando o crit\u00e9rio histopatol\u00f3gico comum (Kahlenberg et al., 2003). Com o \n\navan\u00e7o das t\u00e9cnicas de an\u00e1lise molecular e uma melhor compreens\u00e3o dos mecanismos \n\nenvolvidos na tumorog\u00eanese, diversos fatores progn\u00f3sticos moleculares t\u00eam sido \n\nidentificados. \n\nEntre os marcadores proteicos conhecidos, o ant\u00edgeno carcinoembrion\u00e1rio (CEA) \n\n\u00e9 utilizado atualmente na cl\u00ednica para progn\u00f3stico molecular em c\u00e2ncer colorretal. A \n\nconcentra\u00e7\u00e3o s\u00e9rica desta mol\u00e9cula acima de 5 ng/mL est\u00e1 associada com a recorr\u00eancia \n\nda doen\u00e7a e met\u00e1stase. O CEA \u00e9 uma glicoprote\u00edna de membrana de alta massa molecular \n\npertencente \u00e0 superfam\u00edlia das imunoglobulinas. Esta mol\u00e9cula desempenha pap\u00e9is na \n\nades\u00e3o celular, imunidade e apoptose estando implicada na ocorr\u00eancia de met\u00e1stase \n\n(Duffy et al., 2003; Kahlenberg et al., 2003).  \n\nEmbora o CEA seja o biomarcador mais utilizado no CCR, sua detec\u00e7\u00e3o somente \n\ntorna-se poss\u00edvel em pacientes em est\u00e1gio de desenvolvimento avan\u00e7ado, o que impede \n\nque ele seja \u00fatil na detec\u00e7\u00e3o precoce deste tipo de c\u00e2ncer. Outros ant\u00edgenos tumorais t\u00eam \n\nsido estudados como potenciais biomarcadores para o CCR. Entre eles destacam-se o \n\nCA19-9 (ant\u00edgeno carboidrato 19-9), CA 242, CA-195, CA 50, CA 74-2, CD44 (Cluster \n\ndifferentiation 44) e o TIMP-1 (inibidor tecidual de metaloproteinase-1). Entretanto, \n\nassim como o CEA, esses marcadores possuem baixa sensibilidade e especificidade n\u00e3o \n\nsendo adequados para prop\u00f3sitos de triagem ou diagn\u00f3stico precoce para o CCR (Cho et \n\nal., 1997; Coppola et al., 1998; Li et al., 2001; Qiu et al., 2008).  \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n23 \n\nSendo assim, o entendimento das bases bioqu\u00edmicas e altera\u00e7\u00f5es moleculares \n\nenvolvidas na carcinog\u00eanese pode facilitar a detec\u00e7\u00e3o de tumores em est\u00e1gios iniciais e \n\nles\u00f5es pr\u00e9-cancerosas que apresentam risco de sofrer transforma\u00e7\u00f5es malignas. A \n\ndetec\u00e7\u00e3o pr\u00e9-sintom\u00e1tica desses est\u00e1gios iniciais traz grande benef\u00edcio na redu\u00e7\u00e3o dos \n\nn\u00edveis de mortalidade (Alquist, 2010).  \n\n \n\n1.6.1. Prote\u00f4mica e Phage Display \n\n \n\nAs aberra\u00e7\u00f5es relacionadas aos tumores afetam os n\u00edveis gen\u00f4micos, \n\ntranscricionais e p\u00f3s-transcricionais (Hassaneim et al., 2011). Desde o sequenciamento \n\ndo genoma humano, v\u00e1rios esfor\u00e7os na aplica\u00e7\u00e3o das an\u00e1lises de express\u00e3o g\u00eanica na \n\npesquisa m\u00e9dica, especialmente em c\u00e2ncer, t\u00eam sido realizados. Estudos no n\u00edvel de \n\nexpress\u00e3o g\u00eanica resultam em melhor entendimento do comportamento celular tanto nas \n\nc\u00e9lulas normais quanto nas c\u00e9lulas tumorais (Wulfkuhle et al., 2003). Entretanto, \n\ngeralmente n\u00e3o h\u00e1 rela\u00e7\u00e3o direta entre altera\u00e7\u00f5es na express\u00e3o g\u00eanica e n\u00edveis de \n\nexpress\u00e3o proteica.  \n\nAs prote\u00ednas s\u00e3o os maiores elementos funcionais das c\u00e9lulas e os estudos de seus \n\nperfis de express\u00e3o em processos regulat\u00f3rios podem auxiliar no entendimento das \n\naltera\u00e7\u00f5es moleculares presentes no c\u00e2ncer. Os estudos de intera\u00e7\u00e3o de prote\u00ednas com \n\noutras mol\u00e9culas, indu\u00e7\u00e3o e controle de vias metab\u00f3licas, prolifera\u00e7\u00e3o celular, \n\ncrescimento, apoptose e senesc\u00eancia, oferecem uma vis\u00e3o \u00fanica de sistemas biol\u00f3gicos \n\ncomplexos (Chuthapisith et al., 2007).  \n\nM\u00e9todos prote\u00f4micos utilizados na identifica\u00e7\u00e3o de marcadores tumorais tem \n\ncomo objetivo buscar modifica\u00e7\u00f5es espec\u00edficas nas prote\u00ednas de tecidos tumorais para \n\npermitir a realiza\u00e7\u00e3o de tratamentos individualizados para certos tipos de c\u00e2ncer \n\n(Simpson and Dorow, 2001). Tradicionalmente, a an\u00e1lise do perfil prote\u00f4mico de \n\nmisturas complexas como lisados celulares ou fra\u00e7\u00f5es sub celulares enriquecidas, envolve \n\na combina\u00e7\u00e3o de diversas t\u00e9cnicas de fracionamento com a espectrometria de massas \n\n(MS) para a identifica\u00e7\u00e3o das prote\u00ednas que comp\u00f5em a amostra (Cecconi and Zam\u00f2, \n\n2011).  \n\nAl\u00e9m da identifica\u00e7\u00e3o e an\u00e1lise dos n\u00edveis de express\u00e3o proteicos, h\u00e1 um grande \n\ninteresse na elucida\u00e7\u00e3o das redes de intera\u00e7\u00e3o de prote\u00ednas relacionadas ao c\u00e2ncer. A \n\nhabilidade de utilizar bibliotecas sint\u00e9ticas de pept\u00eddeos para obter ligantes espec\u00edficos de \n\n\n\nSilva, K.T.S.                                                                                                                     Introdu\u00e7\u00e3o \n\n24 \n\nprote\u00ednas e entender suas intera\u00e7\u00f5es permite uma maior compreens\u00e3o das altera\u00e7\u00f5es \n\nrelacionadas ao proteoma tumoral (Sidhu and Koide, 2007).  \n\nA tecnologia de apresenta\u00e7\u00e3o por fagos (Phage Display) consiste na fus\u00e3o g\u00eanica \n\nde sequ\u00eancias nucleot\u00eddicas que codificam prote\u00ednas ou pept\u00eddeos ao DNA de um v\u00edrus \n\nbacteri\u00f3fago e resultam na express\u00e3o heter\u00f3loga dessas sequ\u00eancias na superf\u00edcie do \n\ncaps\u00eddeo viral (Smith, 1985). A constru\u00e7\u00e3o de uma biblioteca pept\u00eddica com sequ\u00eancias \n\naleat\u00f3rias (geralmente com mais de 1011 sequ\u00eancias) constitui uma popula\u00e7\u00e3o de ligantes \n\ncom diferentes capacidades de intera\u00e7\u00e3o com mol\u00e9culas alvo provenientes de tecidos ou \n\nc\u00e9lulas (Scott and Smith,1990; Sidhu et al., 2000).  \n\nT\u00e9cnicas combinatoriais permitem a sele\u00e7\u00e3o imparcial de ligantes em um ensaio \n\nfuncional sem conhecimento sobre a natureza do alvo na doen\u00e7a. Entretanto, \u00e9 dif\u00edcil \n\nisolar ligantes espec\u00edficos devido \u00e0 complexidade de alvos expressos simultaneamente \n\nem um tecido ou popula\u00e7\u00e3o celular. Estudos recentes detectaram um grande n\u00famero de \n\nalvos moleculares super regulados em c\u00e9lulas tumorais ou associadas a tumores (St Croix \n\net al., 2000; Ruoslahti, 2001; Vogelstein and Kinzler, 2004). \n\nA identifica\u00e7\u00e3o de receptores e seus ligantes correspondentes seletivamente \n\nexpressos em patologias espec\u00edficas podem ser \u00fateis no desenvolvimento de sistemas de \n\nentrega de drogas, realiza\u00e7\u00e3o de terapia com o uso de vetores e drogas citot\u00f3xicas, o que \n\naumentaria a janela terap\u00eautica at\u00e9 mesmo para os tratamentos j\u00e1 utilizados (Sergeeva et \n\nal., 2006).  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n \n\n \n\n \n\n\n\n \n\n  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                                          Justificativa\n\n\n\nSilva, K.T.S.                                                                                                                  Justificativa \n\n25 \n\n2- JUSTIFICATIVA \n\n \n\nA import\u00e2ncia dos hidrocarbonetos polic\u00edclicos arom\u00e1ticos e a escassez de estudos \n\ntoxicol\u00f3gicos relacionados \u00e0s consequ\u00eancias da contamina\u00e7\u00e3o ambiental pelos agentes \n\nDibenzotiofeno e Dibenzotiofeno Sulfona, colocam essas subst\u00e2ncias como importantes \n\nobjetos de investiga\u00e7\u00e3o cient\u00edfica. Poucos trabalhos demonstram a caracteriza\u00e7\u00e3o \n\ntoxicol\u00f3gica desses compostos em modelos animais, especialmente em mam\u00edferos, \n\nressaltando a relev\u00e2ncia do presente estudo. No que se refere \u00e0 exposi\u00e7\u00e3o a subst\u00e2ncias \n\nqu\u00edmicas com baixa solubilidade em \u00e1gua, e presentes em pequenas propor\u00e7\u00f5es no \n\nambiente, a avalia\u00e7\u00e3o de tratamentos cr\u00f4nicos utilizando baixas doses \u00e9 de extrema \n\nimport\u00e2ncia para uma real avalia\u00e7\u00e3o toxicol\u00f3gica. Nesse sentido, esse trabalho tem como \n\npreocupa\u00e7\u00e3o iniciar uma investiga\u00e7\u00e3o voltada para a busca de biomarcadores proteicos \n\nassociados ao processo de indu\u00e7\u00e3o cr\u00f4nica de c\u00e2ncer promovida por Dibenzotiofeno e \n\nDibenzotiofeno Sulfona. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                                              Objetivos\n\n\n\nSilva, K.T.S.                                                                                                                        Objetivos \n\n27 \n\n3- OBJETIVOS \n\n \n\n3.1- Objetivo Geral \n\nAvaliar as altera\u00e7\u00f5es moleculares desenvolvidas ap\u00f3s a administra\u00e7\u00e3o cr\u00f4nica dos \n\nhidrocarbonetos polic\u00edclicos arom\u00e1ticos sulfurados Dibenzotiofeno e Dibenzotiofeno \n\nSulfona em ratos Wistar. \n\n \n\n3.1.1- Objetivos espec\u00edficos \n\n \n\nA) Avaliar poss\u00edveis altera\u00e7\u00f5es na estrutura tecidual de \u00f3rg\u00e3os relacionados ao \n\nmetabolismo de xenobi\u00f3ticos ap\u00f3s tratamento com Dibenzotiofeno e \n\nDibenzotiofeno Sulfona; \n\n \n\nB) Avaliar altera\u00e7\u00f5es na express\u00e3o proteica de tecidos intestinais dos animais \n\ntratados com Dibenzotiofeno e Dibenzotiofeno Sulfona visando a \n\nidentifica\u00e7\u00e3o de marcadores tumorais; \n\n \n\nC) Selecionar pept\u00eddeos com capacidade de liga\u00e7\u00e3o a prote\u00ednas com express\u00e3o \n\nalterada presentes nos p\u00f3lipos intestinais resultantes dos tratamentos \n\nempregados; \n\n \n\nD) Identificar os alvos de liga\u00e7\u00e3o dos pept\u00eddeos isolados visando um melhor \n\nentendimento do mecanismo de indu\u00e7\u00e3o promovido; \n\n \n\nE) Realizar estudos histoqu\u00edmicos utilizando pept\u00eddeos sint\u00e9ticos que \n\npossibilitem a marca\u00e7\u00e3o e identifica\u00e7\u00e3o espec\u00edfica de altera\u00e7\u00f5es neopl\u00e1sicas \n\nintestinais. \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                               Material e M\u00e9todos\n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n29 \n\n4- MATERIAL E M\u00c9TODOS \n\n \n\nEste trabalho foi aprovado pela Comiss\u00e3o de \u00c9tica no Uso de Animais (CEUA) \n\nda Universidade Federal de Ouro Preto e catalogado sob o protocolo n\u00ba: 2010/14. Para a \n\nrealiza\u00e7\u00e3o do mesmo, o n\u00famero de animais utilizados assim como o tratamento aplicado \n\nrestringiu-se ao estabelecido pelos objetivos delineados. \n\n \n\n4.1. Material Biol\u00f3gico \n\n  \n\n 4.1.1. Indu\u00e7\u00e3o de C\u00e2ncer em Ratos Wistar Tratados com DMH, DBT e \n\nDBTO2 \n\n \n\nRatos da linhagem Wistar, machos, com aproximadamente 60 dias de idade, \n\npesando 200-250 g, foram obtidos no Centro de Ci\u00eancia Animal (CCA) da Universidade \n\nFederal de Ouro Preto, sendo mantidos \u00e0 temperatura ambiente com ra\u00e7\u00e3o e \u00e1gua ad \n\nlibitum e ciclo claro/escuro de 12 horas.  \n\nOs animais foram divididos em cinco grupos, a saber: \n\n \n\nGrupo I: Controle salina (n=5); \n\nGrupo II: Teste DMH 30 mg/kg (n=15); \n\nGrupo III: Controle \u00f3leo (n=5);  \n\nGrupo IV: Teste DBT 30 mg/kg (n=15); \n\nGrupo V: Teste DBTO2 30 mg/kg (n=10). \n\n \n\nNos animais pertencentes aos grupos I e III administraram-se, respectivamente, \n\ninje\u00e7\u00f5es intraperitoneais semanais de salina e \u00f3leo vegetal durante 10 semanas. Os \n\nanimais dos grupos II, IV e V receberam inje\u00e7\u00f5es de solu\u00e7\u00f5es de DMH (Sigma-Aldrich) \n\nem salina, DBT e DBTO2 (Sigma-Aldrich) em \u00f3leo vegetal na dose de 30 mg/kg no \n\nmesmo regime de tempo dos grupos anteriores. Todos os grupos passaram por um per\u00edodo \n\nde lat\u00eancia de 98 dias (14 semanas) ap\u00f3s a \u00faltima inje\u00e7\u00e3o (Fig. 13) para o \n\ndesenvolvimento das altera\u00e7\u00f5es patol\u00f3gicas, como esperado para a subst\u00e2ncia de \n\nrefer\u00eancia DMH (Newell and Heddle, 2004). Semanalmente, durante os seis meses de \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n30 \n\nexecu\u00e7\u00e3o do experimento, os animais foram pesados e avaliados quanto a apar\u00eancia \n\ncorporal externa. \n\n \n\n \n\nFigura 13: Esquema representativo do tempo de tratamento e espera para o desenvolvimento de altera\u00e7\u00f5es \n\npatol\u00f3gicas nos animais tratados com DMH, DBT e DBTO2. \n\n \n\n4.1.2. Necropsia \n\n \n\nDecorridos os tempos de inje\u00e7\u00e3o e espera, os animais receberam dose letal de \n\nassocia\u00e7\u00e3o quetamina 10% e xilazina 2% atrav\u00e9s de inje\u00e7\u00e3o intraperitoneal. \n\nPosteriormente, realizou-se a coleta do ba\u00e7o, pulm\u00e3o, f\u00edgado, est\u00f4mago e intestinos para \n\na realiza\u00e7\u00e3o das an\u00e1lises histol\u00f3gicas, imunohistoqu\u00edmicas e prote\u00f4micas, e do sangue \n\npara an\u00e1lise do hemograma, e dosagens de enzimas hep\u00e1ticas e pancre\u00e1ticas. \n\n \n\n4.2. An\u00e1lise Histol\u00f3gica  \n\n \n\nOs segmentos de tecidos biopsiados foram fixados em formol tamponado e \n\nposteriormente processados e inclu\u00eddos em parafina. Para a an\u00e1lise histol\u00f3gica, sec\u00e7\u00f5es \n\nde 4 ?m foram coradas com hematoxilina-eosina (HE) e examinadas ao microsc\u00f3pio. \n\nAvaliaram-se qualitativamente os seguintes par\u00e2metros para os intestinos: \n\npresen\u00e7a/aus\u00eancia de atipias celulares nas camadas mucosa e m\u00e9dia, inflama\u00e7\u00e3o na \n\nmucosa, presen\u00e7a de necrose, atipias estruturais e hiperplasia de n\u00f3dulos linf\u00f3ides. Para \n\ndigitaliza\u00e7\u00e3o das imagens utilizou-se o microsc\u00f3pio Leica DM5000B com c\u00e2mera \n\nacoplada, por meio do programa Leica Application Suite (vers\u00e3o 2.4.0 R1, Leica \n\nMicrosystems).  \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n31 \n\n4.2.1. Imunohistoqu\u00edmica: CEA e CD44  \n\n \n\nA imunohistoqu\u00edmica foi realizada utilizando-se anticorpos secund\u00e1rios \n\ncomplexados com biotina seguida de estreptavidina ligada \u00e0 peroxidase para permitir a \n\nrevela\u00e7\u00e3o. Para tal, sec\u00e7\u00f5es histol\u00f3gicas de 4 ?m fixadas em formol-parafina foram \n\ndesparafinizadas (lavagens sequenciais em xilol, etanol absoluto, etanol 90%, etanol 80%, \n\netanol 70% e \u00e1gua) e reativadas antigenicamente atrav\u00e9s do aquecimento das mesmas em \n\nmicro-ondas (5 ciclos de 3 minutos cada) em tamp\u00e3o citrato de s\u00f3dio 0,1 M pH 6,0. \n\nLavaram-se as l\u00e2minas por 3 vezes de 5 min. cada com tamp\u00e3o fosfato de s\u00f3dio 0,01 M \n\npH 7,4, NaCl 0,15 M (PBSS). A atividade da peroxidase end\u00f3gena foi inibida por \n\nincuba\u00e7\u00e3o com H2O2 3,5% em PBSS por 30 minutos \u00e0 temperatura ambiente e as l\u00e2minas \n\nforam novamente lavadas com PBSS. Bloquearam-se as intera\u00e7\u00f5es n\u00e3o espec\u00edficas \n\nutilizando leite em p\u00f3 14% em PBSS por 30 minutos em c\u00e2mara \u00famida.  Os anticorpos \n\nprim\u00e1rios anti-CEA e anti-CD44 foram dilu\u00eddos separadamente na propor\u00e7\u00e3o de 1:1.000 \n\nsendo utilizados 100 ?L por l\u00e2mina incubados a 4\u00ba C, overnight em c\u00e2mara \u00famida. \n\nAp\u00f3s nova lavagem com PBSS os cortes foram cobertos com quantidade \n\nsuficiente da solu\u00e7\u00e3o link (anticorpo secund\u00e1rio-biotina) do kit para imunohistoqu\u00edmica \n\nLSAB Universal (Dako), e mantidos por 30 minutos \u00e0 temperatura ambiente em c\u00e2mara \n\n\u00famida. Realizou-se a lavagem com PBSS como descrito anteriormente sendo os cortes \n\ncobertos com a solu\u00e7\u00e3o estreptavidina-peroxidase do kit LSAB, mantidos por mais 30 \n\nminutos \u00e0 temperatura ambiente em c\u00e2mara \u00famida. \n\nA forma\u00e7\u00e3o do precipitado marrom que indica a positividade da rea\u00e7\u00e3o ocorre \n\nap\u00f3s a adi\u00e7\u00e3o de solu\u00e7\u00e3o de cromog\u00eaneo DAB 0,05% (3-3\u2019-Diaminobenzidine \n\nTetrahidrochloride Hidrate \u2013 Ambresco) em PBSS acrescido de 0,02% de per\u00f3xido de \n\nhidrog\u00eanio. As l\u00e2minas foram contra coradas por imers\u00e3o em hematoxilina e montadas \n\npara avalia\u00e7\u00e3o. \n\n \n\n4.3. Extra\u00e7\u00e3o de Prote\u00ednas e An\u00e1lise Prote\u00f4mica \n\n \n\nPara extra\u00e7\u00e3o de prote\u00ednas dos tecidos obtidos ap\u00f3s a necropsia dos animais foram \n\nutilizados 100 mg de tecido (tr\u00eas amostras de diferentes animais por grupo) em 500 ?L \n\nde tamp\u00e3o de rehidrata\u00e7\u00e3o (ur\u00e9ia 7 M, thio-ur\u00e9ia 2 M, CHAPS 2%, azul de bromofenol \n\n0,002%) adicionados de 10 ?L de tamp\u00e3o PIC (Coquetel de Inibidores de Proteases, \n\nSigma-Aldrich). Homogeneizou-se cada mistura em tubo de vidro com aux\u00edlio de motor \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n32 \n\nPotter S (B. Braun Biotech International) por 15 minutos a 1.000 x rpm em banho de gelo, \n\nseguido por tr\u00eas ciclos de sonica\u00e7\u00e3o de 20 segundos a 25 W, com intervalos de 45 \n\nsegundos entre cada ciclo (Sonifier 250, Branson). As suspens\u00f5es resultantes foram \n\ncentrifugadas a 4\u00baC e 20.000 x g por 1 hora em centr\u00edfuga Mikro 200R (Hettich).  \n\nAp\u00f3s a centrifuga\u00e7\u00e3o, separou-se o sobrenadante contendo a fra\u00e7\u00e3o sol\u00favel para a \n\nrealiza\u00e7\u00e3o de eletroforeses uni e bidimensionais e descartou-se os precipitados contendo \n\no debrit celular. \n\n \n\n4.3.1. Eletroforese Uni e Bidimensional (1D/2D SDS-PAGE) \n\n \n\nAnteriormente \u00e0 confec\u00e7\u00e3o dos g\u00e9is uni e bidimensionais, fez-se a dosagem de \n\nprote\u00ednas sol\u00faveis obtidas conforme o item 4.3 atrav\u00e9s de densitometria comparativa de \n\ncanaletas (30 ?g de Prote\u00ednas Sol\u00faveis) por meio do software Quantity One vers\u00e3o 4.6.9 \n\n(Bio-Rad).  \n\nOs extratos proteicos foram analisados por meio de eletroforese em gel de \n\npoliacrilamida em condi\u00e7\u00f5es desnaturantes (10%, 1D SDS-PAGE) como descrito por \n\nLaemmli em 1970. Para o preparo das amostras, cerca de 30 ?g de prote\u00edna foram \n\nsolubilizadas em 10 ?L de tamp\u00e3o de amostra (tris-HCl 0,125 M pH 6,8, SDS 4%, glicerol \n\n20%, azul de bromofenol 0,002%) e posteriormente fervidas em banho-maria por 5 \n\nminutos. Aplicou-se 20 mA de corrente por gel durante aproximadamente 1,5 horas. Para \n\ncolora\u00e7\u00e3o, utilizou-se solu\u00e7\u00e3o de Coomassie Brilhant Blue G250 (Coomassie Brilhant \n\nBlue G 250 0,2%, Etanol 40%, \u00c1cido Ac\u00e9tico 7%) por 2 horas e descolora\u00e7\u00e3o do \n\nbackground com solu\u00e7\u00e3o de \u00c1cido Ac\u00e9tico 7% e Etanol 10% overnight. As imagens dos \n\ng\u00e9is foram capturadas utilizando-se o scanner ImageScanner III (GE Healthcare).  \n\nPara a confec\u00e7\u00e3o de g\u00e9is bidimensionais, solubilizaram-se 250 ?g de prote\u00edna em \n\ntamp\u00e3o de rehidrata\u00e7\u00e3o contendo dithiotreitol (DTT) 1% e anf\u00f3litos pH 3-10 0,8%. \n\nAcondicionou-se as amostras em sarc\u00f3fagos de porcelana (Strip Holder 13 cm, GE \n\nHealthcare) para incorpora\u00e7\u00e3o e isoeletrofocaliza\u00e7\u00e3o das prote\u00ednas no gel de primeira \n\ndimens\u00e3o (Immobiline DryStrip Gels 13 cm pH 3-10 NL, GE Healthcare). Ap\u00f3s a \n\nfocaliza\u00e7\u00e3o isoel\u00e9trica, as prote\u00ednas presentes nos g\u00e9is de primeira dimens\u00e3o foram \n\nsubmetidas \u00e0 redu\u00e7\u00e3o com DTT 1% em solu\u00e7\u00e3o de equil\u00edbrio (ur\u00e9ia 6 M, tris-HCl 1,5 M \n\npH 8,8, glicerol 30%, SDS 2%, azul de bromofenol 1%) e, em seguida, alquiladas com \n\niodoacetamida 4% em solu\u00e7\u00e3o de equil\u00edbrio. \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n33 \n\nA separa\u00e7\u00e3o de prote\u00ednas por massa molecular (segunda dimens\u00e3o - 2D SDS-\n\nPAGE) foi realizada em gel de poliacrilamida 10%. A eletroforese foi conduzida a 50 \n\nV/gel nos primeiros 10 minutos e, posteriormente a 100 V/gel por aproximadamente 2 \n\nhoras. Para a colora\u00e7\u00e3o, utilizou-se Coomassie Brilhant Blue G 250 Coloidal (Sigma-\n\nAldrich) (tr\u00eas lavagens de 20 minutos cada com solu\u00e7\u00e3o de \u00e1cido fosf\u00f3rico 2% e etanol \n\n30%; seguidas de adicionais tr\u00eas lavagens de 10 minutos com solu\u00e7\u00e3o de \u00e1cido fosf\u00f3rico \n\n2%; e colora\u00e7\u00e3o em solu\u00e7\u00e3o de \u00e1cido fosf\u00f3rico 2%, etanol 18% e sulfato de am\u00f4nio 15% \n\ncontendo Coomassie 0,02%). As imagens foram capturadas com o scanner ImageScanner \n\nIII (GE Healthcare) e analisadas atrav\u00e9s de sobreposi\u00e7\u00e3o realizada pelo software \n\nSameSpots (TotalLab Ltd. v. 20, UK). \n\n \n\n4.3.2. Digest\u00e3o in gel  \n\n \n\nAp\u00f3s a obten\u00e7\u00e3o dos g\u00e9is bidimensionais, os spots de interesse (prote\u00ednas \n\ndiferencialmente expressas entre os respectivos grupos Controles e Testes) foram \n\nexcisados e transferidos para tubos pl\u00e1sticos de 1,5 mL contendo 300 ?L de solu\u00e7\u00e3o \n\ndescorante (etanol 20%, \u00e1cido ac\u00e9tico 7%) e mantidos a 37\u00ba C at\u00e9 a completa \n\ndescolora\u00e7\u00e3o. Retirou-se a solu\u00e7\u00e3o descorante e lavou-se cada spot com 500 ?L de \u00e1gua \n\nmili-Q para remover o excesso da mesma. Em seguida, lavou-se cada spot por 3 vezes de \n\n5 minutos cada com 300 ?L de solu\u00e7\u00e3o NH4HCO3 20 mM em acetonitrila (ACN) 50%.  \n\nOs spots foram desidratados em concentrador a v\u00e1cuo (Speed Vac System \u2013 \n\nIss110, Thermo) durante 30 minutos e rehidratados com 15 ?L de solu\u00e7\u00e3o de tripsina 0,1 \n\n?g/?L (Promega) em NH4HCO3 20 mM. Ap\u00f3s 20 minutos retirou-se o excesso de solu\u00e7\u00e3o \n\nde tripsina e recobriu-se os spots com 40 ?L de NH4HCO3 20 mM. Os tubos foram \n\nmantidos a 37\u00baC por 18 horas para digest\u00e3o das prote\u00ednas. Recuperou-se o sobrenadante \n\nda rea\u00e7\u00e3o contendo pept\u00eddeos tr\u00edpticos e adicionou-se 30 ?L de solu\u00e7\u00e3o de \u00e1cido \n\ntrifluoroac\u00e9tico (TFA) 2% e ACN 50% aos spots que permaneceram nos tubos para \n\nextrair os fragmentos tr\u00edpticos que ainda se encontravam no interior dos mesmos. \n\nDecorridos 30 minutos da adi\u00e7\u00e3o TFA/ACN retirou-se o sobrenadante e combinou-se \n\ncom o primeiro sobrenadante obtido para secagem em concentrador a v\u00e1cuo. \n\nMantiveram-se as amostras secas a 4\u00baC para posterior an\u00e1lise por espectrometria de \n\nmassas. \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n34 \n\n4.3.3. An\u00e1lise de Prote\u00ednas por Espectrometria de Massas \n\n \n\nAs amostras obtidas conforme a descri\u00e7\u00e3o do item anterior foram ressuspendidas \n\nem 10 ?L de \u00e1cido f\u00f3rmico 0,1% para an\u00e1lise por espectrometria de massas. 4,5 ?L de \n\ncada prepara\u00e7\u00e3o de pept\u00eddeos foram injetados em cromat\u00f3grafo nanoAcquity UPLC \n\n(Waters) sendo direcionado primeiramente \u00e0 pr\u00e9-coluna de C18 Trap Symetry (5 ?m, \n\n180?m x 20 mm \u2013 Waters) e logo ap\u00f3s, para a coluna anal\u00edtica de C18 BEH130 (1,7 ?m, \n\n100?m x 100 mm \u2013 Waters) condicionada a 35\u00baC.  A cromatografia ocorreu com fluxo \n\nde 0,6 ?L/min acoplada com espectr\u00f4metro de massas Q-Tof Premier (Waters) com fonte \n\nnanoeletrospray. Foi aplicado um gradiente de 10 minutos com 10-90% de ACN em 0,1% \n\nde \u00e1cido f\u00f3rmico por spot. Os espectros MS e MS/MS foram adquiridos por meio do \n\nsoftware MassLynx v. 4.1.  \n\nOs experimentos foram executados utilizando tempo de escaneamento de 1 \n\nsegundo e raz\u00e3o massa/carga de 100 a 2000 durante o processo cromatogr\u00e1fico. As \n\naquisi\u00e7\u00f5es de dados MS/MS foram realizadas utilizando os primeiros cinco \u00edons \n\nprecursores com carga +2, +3 ou +4. As buscas foram realizadas por meio do software \n\nMascot engine v.2.3.02 (Matrix Science Ltd.) utilizando o banco de dados n\u00e3o redundante \n\npara Rattus sp. (NCBInr_012014 - com 61.059 sequ\u00eancias de prote\u00ednas).  \n\nOs par\u00e2metros de busca utilizados inclu\u00edram carbamidometila\u00e7\u00e3o de ciste\u00ednas \n\ncomo modifica\u00e7\u00e3o fixa, oxida\u00e7\u00e3o de metionina como modifica\u00e7\u00e3o vari\u00e1vel, permiss\u00e3o \n\npara ocorr\u00eancia de perda de um s\u00edtio de clivagem e toler\u00e2ncia de 0,1 Da para os \u00edons \n\nprecursores e fragmentados. A identifica\u00e7\u00e3o de prote\u00ednas foi considerada v\u00e1lida caso a \n\ntaxa de falsos positivos fosse ? 3% e a porcentagem de cobertura fosse ? 8%. \n\nForam considerados significativos os pept\u00eddeos com valor de threshold p ? 0,05 \n\nsendo identificadas as prote\u00ednas cujas entradas mostraram uma porcentagem de cobertura \n\nde sequ\u00eancia ? 15%, FDR ? 3% e ao menos um pept\u00eddeo \u00fanico identificado. \n\n \n\n4.3.4. Categoriza\u00e7\u00e3o Funcional e Mapa de Intera\u00e7\u00e3o Proteica \n\n \n\nCom o objetivo de se obter uma vis\u00e3o integrada das altera\u00e7\u00f5es observadas, as \n\nprote\u00ednas identificadas por espectrometria de massas foram categorizadas em classes \n\ndistintas de acordo com sua fun\u00e7\u00e3o biol\u00f3gica, e submetidas a uma an\u00e1lise de intera\u00e7\u00e3o \n\ncom outras prote\u00ednas e mol\u00e9culas por meio do software STITCH v.4.0 (dispon\u00edvel em \n\nhttp://stitch.embl.de/).  \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n35 \n\n4.4. Western blotting \n\n \n\nRealizou-se a t\u00e9cnica de Western blotting para a detec\u00e7\u00e3o da express\u00e3o das \n\nprote\u00ednas ACTB, CANX, e CEA. Foi preparado um extrato total de prote\u00ednas sol\u00faveis \n\npara os animais pertencentes a todos os grupos conforme descrito no item 4.3.1. \n\nSubmeteu-se as amostras de prote\u00ednas obtidas a eletroforeses em gel de poliacrilamida \n\n10% e realizou-se a transfer\u00eancia para membranas de PVDF (Invitrogen) a 200 mA em \n\ntamp\u00e3o tris-HCl  25 mM, glicina 192 mM, etanol 20% e SDS  10% sob refrigera\u00e7\u00e3o por \n\nduas horas. Em seguida, as membranas foram bloqueadas overnight com tamp\u00e3o tris-HCl \n\n50 mM pH 7,5, Tween-20 0,3% e leite em p\u00f3 desnatado 5%, sendo posteriormente \n\nlavadas por tr\u00eas vezes com tris-HCl 10 mM pH 7,5. Os anticorpos monoclonais anti-CEA \n\n(1:1000); anti-?-actina (1:2000) e anti-calnexina (1:1000), todos Sigma Aldrich, foram \n\nincubados no tamp\u00e3o de immunoblotting (tris-HCl 50 mM pH 7,5, Tween-20 0,013%, \n\nleite em p\u00f3 desnatado 5%) \u00e0 temperatura ambiente por 3 horas e posteriormente \n\nsubmetidos a detec\u00e7\u00e3o com o anticorpo secund\u00e1rio IgG anti-mouse conjugado com \n\nfosfatase alcalina (1:2000) \u00e0 temperatura ambiente por 2 horas. Ap\u00f3s as lavagens com \n\ntamp\u00e3o tris-HCl 10 mM pH 7,5, detectaram-se os sinais com os substratos enzim\u00e1ticos \n\nnitro-blue tetrazoluim chloride e 5-bromo-4-chloro-31-indolyphosphate p-toluidine salt \n\n(Sigma Aldrich). \n\n \n\n4.5. Biopanning (Phage Display) \n\n \n\n 4.5.1. Extra\u00e7\u00e3o de Prote\u00ednas para Phage Display \n\n \n\nA extra\u00e7\u00e3o de prote\u00ednas para a execu\u00e7\u00e3o da t\u00e9cnica de Phage Display foi realizada \n\natrav\u00e9s da macera\u00e7\u00e3o de 50 mg de tecido com nitrog\u00eanio l\u00edquido e suspens\u00e3o do mesmo \n\nem 1 mL de tamp\u00e3o tris-HCl 20 mM pH 7, sacarose 250 mM e PIC. As amostras foram \n\nsonicadas como descrito no item 4.3, e centrifugadas a 20.000 x g, 4\u00ba C por 30 minutos. \n\nA qualidade da extra\u00e7\u00e3o foi verificada atrav\u00e9s da visualiza\u00e7\u00e3o das prote\u00ednas em 1D SDS-\n\nPAGE corado com solu\u00e7\u00e3o de Coomassie Brilhant Blue G250 como descrito no item \n\n4.3.1. \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n36 \n\n4.5.2. Ciclos de Sele\u00e7\u00e3o de Phage Display \n\n \n\nA sele\u00e7\u00e3o dos ep\u00edtopos (expressos nas 5 c\u00f3pias da prote\u00edna III - pIII - do caps\u00eddeo \n\nde fagos filamentosos) foi realizada utilizando-se uma biblioteca de pept\u00eddeos de 12 \n\namino\u00e1cidos (Ph.D.\u2122-12 mer - New England Biolabs). As bibliotecas expressas em \n\nfagos M13 s\u00e3o compostas por pept\u00eddeos rand\u00f4micos seguidos por uma curta sequ\u00eancia \n\nespa\u00e7adora Gly-Gly-Gly-Ser fusionada \u00e0 regi\u00e3o N - terminal da prote\u00edna caps\u00eddica pIII. \n\nEsta biblioteca consiste de aproximadamente 2,0 x 1014 clones com redund\u00e2ncia \n\nde 105 clones, os quais representam 2,7 x 109 poss\u00edveis combina\u00e7\u00f5es entre os res\u00edduos de \n\namino\u00e1cidos. Realizou-se o procedimento de sele\u00e7\u00e3o atrav\u00e9s de tr\u00eas ciclos sequenciais. \n\nPrimeiramente sensibilizou-se uma placa de microtitula\u00e7\u00e3o (Costar 3590, Corning \n\nIncorporated) com 160 ?L de extrato proteico de intestinos provenientes dos Grupos \n\nTeste (1 po\u00e7o/grupo) na concentra\u00e7\u00e3o de 100 ?g/mL em tamp\u00e3o bicarbonato de s\u00f3dio 0,1 \n\nM pH 8,6 a 4\u00baC, overnight sob agita\u00e7\u00e3o lenta em c\u00e2mara \u00famida. \n\nA seguir, secou-se a placa batendo-a contra papel toalha autoclavado. Bloqueou-\n\nse os s\u00edtios livres de intera\u00e7\u00e3o por meio da adi\u00e7\u00e3o de 250 ?L/po\u00e7o de tamp\u00e3o de bloqueio \n\n(NaHCO3 0,1 M, BSA 5 mg/mL) mantido por 1 hora a 4\u00baC sob agita\u00e7\u00e3o lenta. Ap\u00f3s a \n\nincuba\u00e7\u00e3o, o excesso de tamp\u00e3o de bloqueio foi descartado e a placa foi lavada por 6 \n\nvezes com 200 ?L/po\u00e7o de TBS-T (tris-HCl 50 mM pH 7,5, NaCl 150 mM, Tween 20 \n\n0,1%) por 1 minuto, sendo seca em seguida com papel toalha.  \n\nRealizou-se a dilui\u00e7\u00e3o de 10 ?L (aproximadamente 4 x 1010 fagos) da biblioteca \n\nde fagos em 100 ?L de TBS-T e adicionou-se aos po\u00e7os contendo extrato proteico dos \n\nGrupos Teste (100 ?L/po\u00e7o). Incubou-se a placa por 1 hora sob agita\u00e7\u00e3o lenta \u00e0 \n\ntemperatura ambiente. Os fagos n\u00e3o ligantes (F1) foram recolhidos do sobrenadante com \n\no aux\u00edlio de pipeta e descartados. Realizou-se a lavagem com TBS-T 0,1% por 10 vezes \n\nde 1 minuto cada.  \n\nA elui\u00e7\u00e3o dos fagos ligantes foi realizada com 100 ?L de tamp\u00e3o glicina 200 mM \n\npH 2,2 por 10 minutos sendo os fagos (F2) recolhidos e armazenados em tubo pl\u00e1stico de \n\n0,5 mL. A seguir, adicionou-se 15 ?L de tris-HCl 1 M pH 9,1 nos tubos para neutralizar \n\no pH. Os fagos recuperados (F2) foram amplificados em E. coli ER2738 (OD600nm ? 0,3) \n\nem meio Luria-Bertani (LB, triptona 10 g/L, extrato de levedura 5 g/L, NaCl 5 g/L) a \n\n37\u00baC por 4,5 horas finalizando o primeiro ciclo de sele\u00e7\u00e3o (Fig. 14). \n\nPara o segundo e terceiro ciclos de sele\u00e7\u00e3o, realizou-se uma pr\u00e9-sele\u00e7\u00e3o \n\nprimeiramente utilizando po\u00e7os contendo prote\u00ednas imobilizadas referentes aos grupos \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n37 \n\nControle. Desta vez, os pept\u00eddeos n\u00e3o ligantes (F1) foram recolhidos, amplificados como \n\ndescrito anteriormente e ent\u00e3o utilizados para a sele\u00e7\u00e3o frente aos extratos dos grupos \n\nTestes.  \n\n \n\n \n\nFigura 14: Biopanning com a biblioteca de pept\u00eddeos Ph.D. Sele\u00e7\u00e3o de ligantes espec\u00edficos. \n\n \n\n4.5.3. Titula\u00e7\u00e3o dos Clones Obtidos no Phage Display \n\n  \n\nA titula\u00e7\u00e3o \u00e9 um procedimento que permite o isolamento dos fagos para posterior \n\nsequenciamento dos mesmos. Para a realiza\u00e7\u00e3o da titula\u00e7\u00e3o, 1 ?L de solu\u00e7\u00e3o de fagos foi \n\ndilu\u00eddo em 9 ?L de meio LB obtido ao fim do 3\u00ba ciclo de sele\u00e7\u00e3o e submetido a dilui\u00e7\u00f5es \n\nseriadas crescentes exponenciais sob log10 em meio LB. Para cada dilui\u00e7\u00e3o \n\nacrescentaram-se 200 ?L de cultura de ER2738 em fase exponencial (OD600nm ? 0,5), \n\nagitou-se a solu\u00e7\u00e3o rapidamente e incubou-se por 5 minutos a temperatura ambiente. As \n\nc\u00e9lulas bacterianas, agora infectadas, foram transferidas para tubos de cultura contendo 3 \n\nmL de \u00c1gar-TOP (LB, MgCl2.6H2O 1 g/L) a 45\u00baC e espalhadas sobre placas de Petri \n\ncontendo meio LB s\u00f3lido, com IPTG 0,5 mM, Xgal 40 ?g/mL e tetraciclina 20 mg/mL. \n\nPara cada dilui\u00e7\u00e3o foi preparada uma placa. Incubaram-se as placas \u00e0 37\u00baC por 12 horas \n\npara obten\u00e7\u00e3o das col\u00f4nias isoladas utilizadas no sequenciamento de DNA dos fagos. \n\n \n\n4.5.4. Extra\u00e7\u00e3o de DNA de Fagos e Sequenciamento \n\n  \n\nAleatoriamente, 32 col\u00f4nias referentes a cada grupo foram retiradas das placas de \n\nPetri e transferidas individualmente para po\u00e7os de placa deepwell contendo 1 mL de meio \n\nLB autoclavado com tetraciclina 100 ?L/mL. A placa foi vedada e incubada por 5 horas \n\na 37\u00baC sob forte agita\u00e7\u00e3o. Ap\u00f3s a incuba\u00e7\u00e3o, centrifugou-se a placa por 40 minutos a \n\n2.500 x g e 800 ?L do sobrenadante foram transferidos para outra placa Deepwell est\u00e9ril. \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n38 \n\nAdicionou-se 200 ?L de polietilenoglicol 8000 (PEG)/NaCl (20% PEG, NaCl 2,5 M) \n\nest\u00e9ril para precipita\u00e7\u00e3o dos fagos presentes na solu\u00e7\u00e3o e incubou-se a temperatura \n\nambiente por 15 minutos. A placa foi novamente submetida \u00e0 centrifuga\u00e7\u00e3o a 2.500 x g \n\npor 40 minutos, sendo o sobrenadante descartado por invers\u00e3o. \n\nAdicionou-se 100 ?l de tamp\u00e3o iodeto (Tris-HCl 10mM pH 8,0, EDTA 1 mM, \n\nNaI 4 M) a cada po\u00e7o da placa deepwell para se romper as c\u00e1psulas dos fagos e precipitar \n\no DNA. A placa foi vortexada fortemente por 5 minutos. Ap\u00f3s a agita\u00e7\u00e3o, adicionou-se \n\n250 ?L de etanol e manteve-se a placa em repouso absoluto por 10 minutos \u00e0 temperatura \n\nambiente. Novamente realizou-se a centrifuga\u00e7\u00e3o da placa a 2.500 x g por 40 minutos e \n\ndescartou-se o sobrenadante por invers\u00e3o da placa com secagem em papel absorvente. \n\nLavou-se cada po\u00e7o com 500 ?L de etanol 70% e procedeu-se nova centrifuga\u00e7\u00e3o com \n\ndescarte do sobrenadante por invers\u00e3o. O DNA purificado foi obtido ap\u00f3s a adi\u00e7\u00e3o de 20 \n\n?L de \u00e1gua mili-Q a cada po\u00e7o. A qualidade do DNA extra\u00eddo foi avaliada por meio de \n\neletroforese em gel de agarose 0,8% corado com solu\u00e7\u00e3o de brometo de et\u00eddeo. \n\nAp\u00f3s a observa\u00e7\u00e3o das bandas eletrofor\u00e9ticas obtidas no gel de agarose, pode-se \n\nconcluir que em m\u00e9dia, extraiu-se 200-300 ng de DNA/3 ?L de solu\u00e7\u00e3o. Utilizaram-se \n\naproximadamente 400 ng de DNA molde por rea\u00e7\u00e3o de sequenciamento acrescidos de 5 \n\npmol de Primer -96 gIII (5\u2019-OHCCC TCA TAG TTA GCG TAA CG-3\u2019 Biolabs), Premix \n\n4 ?L (DYEnamic ET Dye Terminator Cycle kit \u2013 Amersham Biosciences). \n\nRealizou-se uma rea\u00e7\u00e3o de 35 ciclos em termociclador de placas (MasterCycler \n\nEppendorf) nas seguintes condi\u00e7\u00f5es: (1) Desnatura\u00e7\u00e3o \u2013 95\u00baC por 20 segundos, (2) \n\nAnelamento \u2013 50\u00baC por 15 segundos, (3) Extens\u00e3o \u2013 60\u00baC por 1 minuto. O DNA \n\namplificado foi precipitado com 1 ?L de Acetato de Am\u00f4nio 7,5 M e 27,5 ?L de etanol \n\nabsoluto por po\u00e7o homogeneizando-se a placa com leves batidas sobre a bancada. A placa \n\nfoi centrifugada a 2.500 x g por 45 minutos a 4\u00baC e o sobrenadante foi descartado por \n\ninvers\u00e3o. \n\nAdicionou-se 150 ?L de etanol 70% ao precipitado e centrifugou-se a placa a \n\n2.500 x g por 10 minutos. O sobrenadante foi descartado e o etanol remanescente foi \n\nevaporado \u00e0 temperatura ambiente no escuro. O precipitado resultante foi ressuspendido \n\nem 10 ?L de tamp\u00e3o de dilui\u00e7\u00e3o (DYEnamic ET Dye Terminator Cycle kit \u2013 Amersham \n\nBiosciences). Realizou-se o sequenciamento em um sequenciador autom\u00e1tico \n\nMegaBACE 1000 (Amersham Biosciences) nas seguintes condi\u00e7\u00f5es: (1) Voltagem de \n\nInje\u00e7\u00e3o \u2013 2kV, (2) Voltagem de Corrida \u2013 7kV, (3) Tempo de Inje\u00e7\u00e3o \u2013 120 segundos, \n\n(4) Tempo de corrida \u2013 200 minutos. \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n39 \n\nA identifica\u00e7\u00e3o das sequ\u00eancias correspondentes aos pept\u00eddeos selecionados foi \n\nrealizada manualmente observando-se as sequ\u00eancias Start (ACCTCCACC) e End \n\n(AGAGTGAGA) que indicam respectivamente o in\u00edcio e fim das sequ\u00eancias de \n\npept\u00eddeos de interesse. Selecionou-se as sequ\u00eancias de nucleot\u00eddeos obtidas (36 \n\nnucleot\u00eddeos) e converteu-se as mesmas em sequ\u00eancias de amino\u00e1cidos por meio do \n\nsoftware Expasy dispon\u00edvel em http://web.expasy.org/translate/ com frame de leitura 1 \n\n3\u2019-5\u2019. \n\n   \n\n4.5.5. An\u00e1lise in silico dos Pept\u00eddeos Obtidos \n\n \n\nOs pept\u00eddeos selecionados por Phage Display podem corresponder a um pequeno \n\nfragmento de uma prote\u00edna maior que desempenha papel espec\u00edfico em processos \n\nbiol\u00f3gicos complexos. A simples sele\u00e7\u00e3o de pept\u00eddeos marcadores para uma determinada \n\npatologia n\u00e3o fornece informa\u00e7\u00f5es a respeito desse processo biol\u00f3gico. Sendo assim, \n\nestrat\u00e9gias que utilizam bioinform\u00e1tica podem fornecer informa\u00e7\u00f5es complementares, \n\nauxiliar na compreens\u00e3o da doen\u00e7a estudada e relacionar poss\u00edveis prote\u00ednas envolvidas \n\naos pept\u00eddeos selecionados.  \n\nOs m\u00e9todos aplicados para a obten\u00e7\u00e3o dessas informa\u00e7\u00f5es foram baseados no \n\nalinhamento das sequ\u00eancias por meio do software ClustalW \n\n(http://www.ebi.ac.uk/tools/msa/clustalw2/), sele\u00e7\u00e3o de prote\u00ednas alvo por meio do \n\nBlastP do NCBI (http://blast.ncbi.nlm.nih.gov), an\u00e1lise das vias funcionais onde est\u00e3o \n\ninseridas as prote\u00ednas alvo atrav\u00e9s do software STITCH 4.0 (http://stitch.embl.de).  \n\nO BlastP foi selecionado por permitir alinhamento entre prote\u00ednas. A base de \n\ndados utilizada foi a RefSeq por apresentar resultados com boa especificidade e \n\nsensibilidade. O organismo selecionado foi Rattus norvegicus devido \u00e0 esp\u00e9cie utilizada \n\nnesse estudo, sendo os demais par\u00e2metros, ajustados automaticamente pelo aplicativo. As \n\nanota\u00e7\u00f5es dos primeiros 40 alvos com melhor score foram analisadas, sendo avaliadas \n\nquais demonstram alguma rela\u00e7\u00e3o com c\u00e2ncer. Esse n\u00famero de alvos foi escolhido de \n\nmaneira arbitr\u00e1ria at\u00e9 que se obtivesse informa\u00e7\u00e3o qualitativa significativa. \n\nDevido ao grande n\u00famero de pept\u00eddeos identificados e ao custo e tempo \n\nnecess\u00e1rios para que se realizasse a valida\u00e7\u00e3o da sele\u00e7\u00e3o com todos eles, esta estrat\u00e9gia \n\npermitiria selecionar, inicialmente, os pept\u00eddeos a serem sintetizados para a realiza\u00e7\u00e3o \n\ndos experimentos subsequentes. \n\n \n\nhttp://web.expasy.org/translate/\nhttp://blast.ncbi.nlm.nih.gov/\nhttp://stitch.embl.de/\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n40 \n\n4.6. S\u00edntese de Pept\u00eddeos  \n\n \n\nA s\u00edntese dos pept\u00eddeos propostos (Tab. 01) foi realizada sob a forma sol\u00favel, \n\nutilizando-se um protocolo de s\u00edntese em fase s\u00f3lida estabelecido por Merrifield (1965), \n\ncom algumas modifica\u00e7\u00f5es. Utilizou-se a resina Rink Amide Resin HL (Merck), obtendo-\n\nse um rendimento de aproximadamente 40 \u00b5moles de pept\u00eddeo por lote de s\u00edntese. \n\n \n\nTabela 01: Pept\u00eddeos selecionados por Phage display para s\u00edntese em fase s\u00f3lida. \n\nGrupo Tratamento Pept\u00eddeo Selecionado \n\nDMH (Intestino Grosso) QPHKVFFPNLPR \n\nDBT (Intestino Grosso) \n\nEYQLPSRTVPRD \n\nKDPTQFKPMSLW \n\nFDTKAGLTSLVA \n\nDBT (Intestino Delgado) \nTNTPPSQRVHLS \n\nLAAQQYTSALKS \n\n \n\nPara a ativa\u00e7\u00e3o da resina adotou-se o seguinte procedimento: 40 \u00b5moles de resina \n\n(52 mg) foram adicionados em um tubo de s\u00edntese contendo dimetilformamida (DMF) \n\nsuficiente para cobrir toda a resina, permanecendo sob agita\u00e7\u00e3o constante por tr\u00eas horas \n\na 37\u00ba C. Para a libera\u00e7\u00e3o do grupamento Fmoc de prote\u00e7\u00e3o, cobriu-se a resina com 3 mL \n\nde 4-metilpiperidina 20% em DMF e lavou-se por 3 vezes de 20 minutos cada, sob \n\nagita\u00e7\u00e3o cont\u00ednua a temperatura de 37\u00ba C. Em seguida, a resina foi lavada 3 vezes \n\nalternadamente com metanol e DMF utilizando-se 2 mL de solvente por etapa. Todas as \n\nlavagens foram realizadas com aux\u00edlio de uma bomba de v\u00e1cuo. \n\nOs amino\u00e1cidos e demais reagentes auxiliares foram adicionados em \n\nconcentra\u00e7\u00f5es quatro vezes superiores (160 \u00b5moles) \u00e0 quantidade de resina para favorecer \n\no acoplamento. Esses s\u00e3o ligados pelo seu grupamento carboxila ao grupamento amino \n\nda resina, formando uma liga\u00e7\u00e3o pept\u00eddica. Adicionou-se o primeiro amino\u00e1cido ao tubo \n\nde s\u00edntese em um volume de 2 mL de DMF, acrescido de 25 \u00b5L de di-isopropil \n\ncarbodiimida (DIPC) e 23 mg de oxima [ethyl 2-cyano-2-(hydroxyimino)acetate]. Ap\u00f3s \n\n2 horas de agita\u00e7\u00e3o a 37\u00baC, retirou-se todo o l\u00edquido do tubo de s\u00edntese, sendo o pept\u00eddeo \n\ncrescente submetido \u00e0 acetila\u00e7\u00e3o para preven\u00e7\u00e3o do crescimento de cadeias que n\u00e3o \n\nreagiram com o amino\u00e1cido a ser incorporado. Dessa forma, 50 \u00b5L de uma solu\u00e7\u00e3o 1:1 \n\nde DIPC e anidrido ac\u00e9tico foram adicionados a 1 mL de DMF no tubo de s\u00edntese, \n\npermanecendo sob agita\u00e7\u00e3o a 37\u00baC por 30 minutos. Ao fim desta etapa, lavou-se a resina \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n41 \n\n3 vezes alternadamente com metanol e DMF. O grupamento amino desse primeiro \n\namino\u00e1cido acoplado foi ent\u00e3o desprotegido, lavando-se a resina com 3 mL de uma \n\nsolu\u00e7\u00e3o de 4-metilpiperidina 20% em DMF, por tr\u00eas vezes de 10 minutos cada, com \n\nagita\u00e7\u00e3o cont\u00ednua a 37\u00b0C. Os demais amino\u00e1cidos foram processados conforme descrito \n\nanteriormente para o acoplamento do primeiro amino\u00e1cido.    \n\nTerminados os 12 ciclos de acoplamento, eliminou-se o \u00faltimo grupamento Fmoc \n\ncom 4-metilpiperidina 20% em DMF, como descrito previamente, e lavou-se a resina por \n\n4 vezes, durante 5 minutos, com 3 mL de diclorometano (DCM). As cadeias laterais foram \n\ndesprotegidas e o pept\u00eddeo dissociado da resina pelo uso de 5 mL de uma solu\u00e7\u00e3o de \n\nclivagem contendo 95% de TFA. O tubo de rea\u00e7\u00e3o permaneceu sob agita\u00e7\u00e3o por quatro \n\nhoras. Coletou-se a solu\u00e7\u00e3o contendo os pept\u00eddeos, transferiu-se para tubos de ensaio e \n\nos produtos de s\u00edntese foram precipitados com 50 mL de \u00e9ter et\u00edlico, permanecendo em \n\nrepouso durante a noite \u00e0 4\u00ba C. Posteriormente, lavou-se os precipitados com \u00e9ter et\u00edlico \n\ne centrifugou-se por 3 vezes a 1.500 x g por 5 minutos. Na \u00faltima etapa, desprezou-se o \n\nsobrenadante e ressuspendeu-se o pept\u00eddeo em 3 mL de \u00e1gua milli-Q.  \n\nPara a obten\u00e7\u00e3o de pept\u00eddeos fluorescentes foi utilizado o mesmo protocolo \n\ndescrito anteriormente com a adi\u00e7\u00e3o do fluor\u00f3foro 5,6-carboxifluoresce\u00edna (Sigma-\n\nAldrich) na regi\u00e3o N-terminal do \u00faltimo amino\u00e1cido adicionado. A adi\u00e7\u00e3o do fluor\u00f3foro \n\nfoi realizada da mesma maneira que a adi\u00e7\u00e3o dos amino\u00e1cidos constituintes de cada \n\nsequ\u00eancia. Os pept\u00eddeos obtidos foram liofilizados, analisados em sistema HPLC (High \n\nPerformance Liquid Chromatography) e caracterizados em espectr\u00f4metro de massas ESI \n\nLCMS-IT-TOF e atrav\u00e9s do software BCEPRED (http://www.imtech.res.in). \n\n  \n\n4.6.1. An\u00e1lise de Pureza e Confirma\u00e7\u00e3o de Identidade \n\n \n\nOs pept\u00eddeos sintetizados em fase s\u00f3lida foram submetidos \u00e0 cromatografia em \n\nfase reversa para a an\u00e1lise de sua pureza. As cromatografias foram realizadas em coluna \n\nC18 (250 mm x 10 mm) (LiChroCART\u00ae 250-10 Purospher, Merk), em sistema HPLC \n\nShimadzu. A coluna foi previamente equilibrada com uma solu\u00e7\u00e3o de \u00e1gua mili-Q e TFA \n\n0,1%. Inicialmente, eluiram-se al\u00edquotas de todos os pept\u00eddeos (20 ?L) em um gradiente \n\nde ACN de 20 a 60% e TFA 0,1% durante 80 minutos com um fluxo de 1 mL/minuto. \n\nMonitorou-se a elui\u00e7\u00e3o a 280 nm, 260 nm ou 230 nm de maneira dependente da sequ\u00eancia \n\nsintetizada.  \n\nhttp://www.imtech.res.in/\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n42 \n\nAp\u00f3s a purifica\u00e7\u00e3o, os pept\u00eddeos foram caracterizados por espectrometria de \n\nmassas para confirma\u00e7\u00e3o de sua identidade.  Para tal, utilizou-se o espectr\u00f4metro de \n\nmassas LCMS-IT-TOF (Liquid Chromatography Ion Trap Time Of Flight), que opera \n\npor ioniza\u00e7\u00e3o do tipo electrospray (Shimadzu\u00ae). O equipamento foi calibrado utilizando \n\ntrifluoroacetato de s\u00f3dio. A voltagem capilar foi de 4500 V no modo positivo de \n\nioniza\u00e7\u00e3o, com tempo de acumula\u00e7\u00e3o de 10 ms. Aplicaram-se as amostras atrav\u00e9s de \n\ninje\u00e7\u00f5es diretas (al\u00edquotas de 5 ?L). Utilizou-se a ferramenta ExPASy \u2013 Compute PI/Mw \n\ntool (dispon\u00edvel em http://web.expasy.org/compute_pi/) para a predi\u00e7\u00e3o das massas \n\nmoleculares dos pept\u00eddeos sintetizados. \n\n \n\n4.7. S\u00edntese de Colunas de Afinidade \n\n \n\nPara a obten\u00e7\u00e3o de colunas de afinidade com os pept\u00eddeos de interesse \n\nimobilizados, realizaram-se as seguintes etapas de ativa\u00e7\u00e3o/imobiliza\u00e7\u00e3o do suporte \n\ncromatogr\u00e1fico Sepharose 4B (Sigma-Aldrich): ativa\u00e7\u00e3o com epicloridrina, amina\u00e7\u00e3o, \n\nsuccinila\u00e7\u00e3o, ativa\u00e7\u00e3o com N-hidroxisuccinimida (NHS) e diciclohexilcarbodiimida \n\n(DCC), imobiliza\u00e7\u00e3o dos pept\u00eddeos e bloqueio dos grupos carbox\u00edlicos livres. As rea\u00e7\u00f5es \n\nenvolvidas nas etapas citadas encontram-se descritas a seguir.  \n\nPara a etapa de ativa\u00e7\u00e3o, lavou-se a resina (Sepharose 4B) em funil de vidro \n\nsinterizado com \u00e1gua destilada e suspendeu-se a mesma em 4 volumes de NaOH 0,4 M \n\ncontendo  5%  de  epicloridrina (Matsumoto, Mizuno et al. 1979). Manteve-se a suspens\u00e3o \n\nem banho-maria a 40\u00ba C por 2 horas sob agita\u00e7\u00e3o leve e novamente procedeu-se lavagem \n\ncom excesso de \u00e1gua destilada.  \n\nA sepharose ep\u00f3xi-ativada foi aminada utilizando-se 1,5 volumes de solu\u00e7\u00e3o de \n\nhidr\u00f3xido de am\u00f4nio P.A., onde foi suspendida a resina lavada. Manteve-se a suspens\u00e3o \n\npor 1,5 horas em banho-maria a 40\u00ba C sob agita\u00e7\u00e3o. Decorrido o per\u00edodo de espera, lavou-\n\nse novamente a resina aminada com \u00e1gua destilada em excesso e NaCl 0,1 M.  \n\nSuspendeu-se a resina aminada em 1,5 volumes de NaCl 0,1 M sendo \n\nposteriormente adicionados 0,08 g de anidrido succ\u00ednico por g de resina para que \n\nocorresse a succinila\u00e7\u00e3o da mesma. Manteve-se o pH da suspens\u00e3o em 6 atrav\u00e9s da adi\u00e7\u00e3o \n\ngradual de NaOH 20%, e, ap\u00f3s a estabiliza\u00e7\u00e3o do pH respeitou-se um tempo de espera de \n\ncinco horas \u00e0 temperatura ambiente. Realizou-se uma nova lavagem com NaOH 0,1 M e \n\na resina foi novamente suspendida nesta mesma solu\u00e7\u00e3o por 30 minutos.  \n\nhttp://web.expasy.org/compute_pi/\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n43 \n\nA sepharose succinilada foi ent\u00e3o lavada com 3 volumes de dioxano para tornar a \n\nresina anidra e suspensa em dioxano onde adicionou-se NHS e DCC na concentra\u00e7\u00e3o de \n\n0,1 M cada para ativa\u00e7\u00e3o. Esta suspens\u00e3o foi mantida por 70 minutos sob agita\u00e7\u00e3o leve \u00e0 \n\ntemperatura ambiente, sendo ent\u00e3o lavada com 8 volumes de dioxano seguidos de 4 \n\nvolumes de metanol e 3 volumes de dioxano.  \n\nAp\u00f3s a ativa\u00e7\u00e3o, realizou-se uma lavagem r\u00e1pida com 1 volume de \u00e1gua destilada \n\nsendo a resina rapidamente transferida para um b\u00e9quer com 3 volumes de solu\u00e7\u00e3o \n\nNaHCO3 0,01 M, NaCl 0,9% pH 7,5 contendo o pept\u00eddeo de interesse na concetra\u00e7\u00e3o de \n\n1 mg/mL. Ap\u00f3s 1 hora \u00e0 temperatura ambiente seguida de 12 horas sob refrigera\u00e7\u00e3o, \n\nocorreu a imobiliza\u00e7\u00e3o do mesmo.  \n\nA etapa final consistiu no bloqueio dos grupos carbox\u00edlicos livres com solu\u00e7\u00e3o de \n\netanolamina 0,1 M pH 9,0 por 1 hora a temperatura ambiente. Ap\u00f3s este procedimento, \n\nprocedeu-se nova lavagem com \u00e1gua destilada. Manteve-se o produto a 4\u00ba C at\u00e9 o \n\nmomento do uso. \n\n \n\n4.7.1. Identifica\u00e7\u00e3o de Prote\u00ednas Ligantes  \n\n \n\nExtratos proteicos de 100 mg de intestino foram preparados em 500 \u00b5L de tris-\n\nHCl 50 mM, NaCl 150 mM pH 7,5 e PIC como descrito no item 4.5.1 e submetidos a \n\ncromatografia de afinidade utilizando-se as resinas com pept\u00eddeos imobilizados conforme \n\no item 4.7.  \n\nDuas colunas de afinidade por pept\u00eddeo, contendo 3 mL de suporte, foram \n\nmontadas em seringas pl\u00e1sticas e equilibradas com 30 mL de tamp\u00e3o de equil\u00edbrio tris-\n\nHCl 50 mM, NaCl 150 mM pH 7,5. Amostras relativas aos grupos I e III foram \n\nsubmetidas \u00e0 sele\u00e7\u00e3o pelo pept\u00eddeo QPHKVFFPNLPR e amostras pertencentes aos \n\ngrupos II, IV e V foram submetidas \u00e0 cromatografia com os demais pept\u00eddeos \n\n(EYQLPSRTVPRD; KDPTQFKPMSLW; FDTKAGLTSLVA; TNTPPSQRVHLS e \n\nLAAQQYTSALKS).  \n\nOs extratos foram expostos por 10 passagens cada um em suas respectivas colunas \n\nde afinidade para assegurar a liga\u00e7\u00e3o com os pept\u00eddeos imobilizados. As colunas foram \n\nent\u00e3o lavadas com 40 mL de tamp\u00e3o de equil\u00edbrio para remo\u00e7\u00e3o das prote\u00ednas n\u00e3o ligadas. \n\nA elui\u00e7\u00e3o das prote\u00ednas especificamente ligadas foi realizada com solu\u00e7\u00e3o de 2,5 mL de \n\nsolu\u00e7\u00e3o de NaCl 1 M tamb\u00e9m recromatografada por 10 vezes. As amostras elu\u00eddas foram \n\nent\u00e3o dialisadas para remo\u00e7\u00e3o do excesso de sal (solu\u00e7\u00e3o de acetato de am\u00f4nio 0,01 M \n\n\n\nSilva, K.T.S.                                                                               Material e M\u00e9todos \n\n44 \n\npH 7,4 por 24 horas) e concentradas em liofilizador (Benchtop K -  Virtis). O precipitado \n\nobtido foi ressuspendido em tamp\u00e3o de amostra e submetido \u00e0 eletroforese \n\nunidimensional conforme descrito em 4.3.1.  \n\nAs bandas eletrofor\u00e9ticas observadas para os grupos controle e teste elu\u00eddas para \n\ncada pept\u00eddeo e coradas com Coomassie G250 foram excisadas para digest\u00e3o in gel e \n\nposterior identifica\u00e7\u00e3o por espectrometria de massas como descrito nos itens 4.3.2 e 4.3.3. \n\n \n\n4.7.2. An\u00e1lise in silico da Intera\u00e7\u00e3o Prote\u00edna/Pept\u00eddeo \n\n \n\nAp\u00f3s a identifica\u00e7\u00e3o das prote\u00ednas alvo ligadas por afinidade aos pept\u00eddeos \n\nselecionados por Phage Display, foi realizada uma an\u00e1lise in silico para avalia\u00e7\u00e3o da \n\nintera\u00e7\u00e3o prote\u00edna/pept\u00eddeo. Para tal, as estruturas tridimensionais referentes \u00e0s prote\u00ednas \n\ndispon\u00edveis em RSCB PDB (http://www.rscb.org/pdb) foram utilizadas juntamente com \n\nas estruturas tridimensionais dos pept\u00eddeos geradas por meio do software Mobyle@RPBS \n\n(dispon\u00edvel em http://mobyle.rpbs.univ-paris-diderot.fr/cgi-bin/portal.py). A predi\u00e7\u00e3o de \n\nintera\u00e7\u00e3o foi realizada por meio do software PatchDock (dispon\u00edvel em \n\nhttp://bioinfo3d.cs.tau.ac.il/PatchDock/) sem altera\u00e7\u00e3o dos par\u00e2metros previamente \n\nsetados pelo servidor. As 5 primeiras solu\u00e7\u00f5es com melhores scores geom\u00e9tricos, energia \n\nde dessolvata\u00e7\u00e3o e \u00e1rea de interface foram avaliadas para observa\u00e7\u00e3o da regi\u00e3o de \n\nintera\u00e7\u00e3o do pept\u00eddeo com a prote\u00edna. Tal avalia\u00e7\u00e3o poderia fornecer dados sobre o local \n\nde intera\u00e7\u00e3o dos pept\u00eddeos com a estrutura nativa das prote\u00ednas ligantes auxiliando no \n\ndelineamento de experimentos que utilizassem tais mol\u00e9culas para a identifica\u00e7\u00e3o de \n\naltera\u00e7\u00f5es relacionadas ao processo carcinog\u00eanico. \n\n \n\n4.8. An\u00e1lise Estat\u00edstica \n\n \n\nA an\u00e1lise estat\u00edstica dos resultados foi realizada por meio do software Graph Pad \n\nPrism (vers\u00e3o 5.0). Utilizou-se ANOVA para testar as diferen\u00e7as entre os tratamentos, \n\nseguido de p\u00f3s-teste de Tukey para determina\u00e7\u00e3o das diferen\u00e7as significativas entre os \n\ngrupos expostos e os grupos controle no que diz respeito \u00e0s medi\u00e7\u00f5es enzim\u00e1ticas, \n\nhemograma, rela\u00e7\u00f5es entre os pesos dos animais e diferen\u00e7as de intensidade entre spots \n\neletrofor\u00e9ticos. Para an\u00e1lise das diferen\u00e7as entre os par\u00e2metros histol\u00f3gicos observados \n\nutilizaram-se os testes exato de Fisher e Qui-quadrado. Adotou-se o n\u00edvel de signific\u00e2ncia \n\np &lt;0,05 para todas as an\u00e1lises.\n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                        Resultados e Discuss\u00e3o\n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n46 \n\n5- RESULTADOS E DISCUSS\u00c3O \n\n \n\nConsiderando a import\u00e2ncia toxicol\u00f3gica do DBT e DBTO2, e devido \u00e0 escassez \n\nde estudos que empreguem estas mol\u00e9culas nesse sentido, foram realizados experimentos \n\nempregando-se doses sub letais destas subst\u00e2ncias, administradas de forma cr\u00f4nica pela \n\nvia intraperitoneal, com o intuito de observar efeitos tardios decorrentes da exposi\u00e7\u00e3o \n\nprolongada a esses compostos.  \n\n \n\n5.1- Efeitos Biol\u00f3gicos do Tratamento com DMH, DBT e DBTO2  \n\n \n\nAo longo do tratamento, os animais foram observados quanto \u00e0 apar\u00eancia f\u00edsica e \n\nmedida do peso corporal. A Figura 15 apresenta o acompanhamento do peso de todos os \n\ngrupos ao longo de 24 semanas (tratamento/lat\u00eancia). Como pode ser observado, n\u00e3o \n\nhouve varia\u00e7\u00e3o estat\u00edstica significativa de peso entre os diversos grupos, indicando que a \n\ninocula\u00e7\u00e3o dessas subst\u00e2ncias, no regime proposto, n\u00e3o interferiu no crescimento normal \n\ndos animais. Al\u00e9m disso, n\u00e3o foi observada a presen\u00e7a de altera\u00e7\u00f5es macrosc\u00f3picas \n\npercept\u00edveis na superf\u00edcie corporal externa. \n\n \n\n \n\nFigura 15: Gr\u00e1fico de acompanhamento de peso dos animais pertencentes aos grupos controles e testes ao \n\nlongo de 24 semanas de tratamento/lat\u00eancia. \n\n  \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n47 \n\n5.1.1- Hemograma e Dosagens S\u00e9ricas de ALT, AST e Amilase  \n\n \n\nOs par\u00e2metros hematol\u00f3gicos, dosagens s\u00e9ricas de enzimas pancre\u00e1ticas e \n\nhep\u00e1ticas foram avaliadas durante a execu\u00e7\u00e3o de meu trabalho de mestrado. Os gr\u00e1ficos \n\nrelacionados aos resultados obtidos nestes experimentos encontram-se nos Ap\u00eandices A \n\ne B respectivamente (Ap\u00eandice A \u2013 Fig. 01.A e Ap\u00eandice B \u2013 Fig. 01.B).  \n\nAp\u00f3s a necropsia e coleta do sangue realizou-se o hemograma para avalia\u00e7\u00e3o de \n\nposs\u00edveis altera\u00e7\u00f5es das c\u00e9lulas sangu\u00edneas. O hemat\u00f3crito foi o primeiro par\u00e2metro \n\navaliado, n\u00e3o sendo observadas varia\u00e7\u00f5es estat\u00edsticas significativas entre os grupos \n\ncontroles e testes indicando que o volume globular n\u00e3o \u00e9 afetado pelos tratamentos \n\nrealizados mesmo em doses mais elevadas. \n\nAl\u00e9m do volume globular normal verificado, a observa\u00e7\u00e3o dos esfrega\u00e7os de \n\nsangue total n\u00e3o evidenciou altera\u00e7\u00f5es morfol\u00f3gicas, presen\u00e7a de inclus\u00f5es, presen\u00e7a de \n\nhem\u00e1cias nucleadas ou empilhamento dos gl\u00f3bulos vermelhos indicando eritropoese \n\nnormal e aus\u00eancia de processos inflamat\u00f3rios. Tais achados demonstraram que os \n\ntratamentos n\u00e3o interferiram na produ\u00e7\u00e3o ou sobrevida na circula\u00e7\u00e3o das hem\u00e1cias no \n\nsangue perif\u00e9rico. As contagens globais e diferenciais de leuc\u00f3citos do sangue perif\u00e9rico \n\ntamb\u00e9m n\u00e3o demonstraram varia\u00e7\u00f5es diante da an\u00e1lise estat\u00edstica aplicada. Al\u00e9m disso, \n\nquando avaliados os resultados individuais das contagens diferenciais de leuc\u00f3citos n\u00e3o \n\nfoi poss\u00edvel detectar diferen\u00e7as que possam indicar import\u00e2ncia diagn\u00f3stica. \n\nDeterminaram-se tamb\u00e9m as atividades s\u00e9ricas das enzimas amilase, AST e ALT. \n\nAs atividades s\u00e9ricas das enzimas AST e ALT s\u00e3o comumente utilizadas como \n\nmarcadores de les\u00f5es hep\u00e1ticas. Em conjunto, as duas enzimas (AST e ALT) s\u00e3o \n\nconsideradas os mais importantes par\u00e2metros para detec\u00e7\u00e3o de les\u00f5es ao f\u00edgado \n\n(Anderson et al., 2000).  \n\nEscolheu-se medir a atividade  das enzimas AST, ALT e amilase por \n\nrepresentarem os principais meios de detec\u00e7\u00e3o s\u00e9rica de altera\u00e7\u00f5es das fun\u00e7\u00f5es hep\u00e1tica \n\ne pancre\u00e1tica respectivamente. Como esses \u00f3rg\u00e3os est\u00e3o diretamente relacionados ao \n\nmetabolismo, as altera\u00e7\u00f5es nas fun\u00e7\u00f5es normais dos mesmos representam informa\u00e7\u00f5es \n\nimportantes a respeito da atividade toxicol\u00f3gica dessas subst\u00e2ncias. \n\nOs resultados encontrados demonstraram que as atividades s\u00e9ricas individuais das \n\nenzimas ALT e AST dos grupos controle salina e controle \u00f3leo n\u00e3o apresentaram \n\ndiferen\u00e7as estat\u00edsticas significativas. Com rela\u00e7\u00e3o aos testes DBT e DBTO2, os n\u00edveis de \n\nALT e AST encontraram-se diminu\u00eddas estatisticamente em aproximadamente 30%, \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n48 \n\nquando comparadas com o grupo controle \u00f3leo. Embora a rela\u00e7\u00e3o AST/ALT tenha se \n\napresentado ligeiramente maior que 1 para todos os grupos avaliados de forma \n\nindiscriminada entre os grupos controles e testes, n\u00e3o foram observadas les\u00f5es hep\u00e1ticas \n\nno exame histopatol\u00f3gico do f\u00edgado. \n\nA atividade s\u00e9rica de amilase foi avaliada com o objetivo de investigar a \n\nintegridade tecidual pancre\u00e1tica. N\u00edveis alterados desta enzima tamb\u00e9m est\u00e3o \n\nrelacionados \u00e0 doen\u00e7a da ves\u00edcula biliar e alguns dist\u00farbios gastrointestinais. A amilase \u00e9 \n\nproduzida principalmente nas gl\u00e2ndulas salivares e no p\u00e2ncreas. Na pancreatite aguda, os \n\nn\u00edveis de amilase podem alcan\u00e7ar valores de quatro a seis vezes o limite superior de \n\nrefer\u00eancia, elevando-se de 2 a 12 horas e retornando aos n\u00edveis normais ap\u00f3s 3 a 4 dias. \n\nA magnitude da eleva\u00e7\u00e3o da atividade amil\u00e1sica n\u00e3o se correlaciona com a gravidade da \n\nles\u00e3o pancre\u00e1tica. As pancreatites cr\u00f4nicas, assim como o carcinoma pancre\u00e1tico, cursam \n\ncom n\u00edveis normais ou pouco elevados de amilase (Burtis and Ashwood, 1996). \n\nEntre os grupos estudados n\u00e3o foram detectadas altera\u00e7\u00f5es nos n\u00edveis s\u00e9ricos de \n\namilase indicando que n\u00e3o houve a ocorr\u00eancia de pancreatite aguda. Entretanto, n\u00e3o se \n\npode concluir que n\u00e3o houve altera\u00e7\u00e3o da fun\u00e7\u00e3o pancre\u00e1tica, sendo necess\u00e1rio que esses \n\ndados sejam complementados com outros estudos cl\u00ednicos para os animais em quest\u00e3o. \n\n \n\n5.1.2- Avalia\u00e7\u00f5es Morfol\u00f3gicas Macro e Microsc\u00f3picas de Tecidos Extra\u00eddos \n\nDurante a Necropsia \n\n \n\nAp\u00f3s avalia\u00e7\u00f5es macro e microsc\u00f3picas do pulm\u00e3o, f\u00edgado, ba\u00e7o e est\u00f4mago, \n\nobservou-se que esses \u00f3rg\u00e3os de todos os grupos estudados apresentaram aspecto e \n\ncolora\u00e7\u00e3o compat\u00edveis com a normalidade (dados n\u00e3o mostrados). Nos intestinos, o \n\nquadro de aparente normalidade foi observado nos animais dos grupos Controle I e III. \n\nNo grupo Teste DMH observou-se a presen\u00e7a de proje\u00e7\u00f5es papiliformes na mucosa para \n\na luz do intestino grosso, de aspecto avermelhado e consist\u00eancia r\u00edgida, sugerindo a \n\nforma\u00e7\u00e3o de p\u00f3lipos. Este aspecto n\u00e3o foi observado no intestino delgado desses animais \n\n(Fig. 16 \u2013 A). Em contraste, nos animais pertencentes aos grupos Teste DBT e DBTO2 \n\nforam visualizadas proje\u00e7\u00f5es similares apenas no intestino delgado e em menor \n\nintensidade quando comparadas \u00e0quelas visualizadas no intestino grosso dos animais \n\ntratados com DMH (Fig. 16 \u2013 B). \n\nO epit\u00e9lio intestinal cont\u00e9m todas as enzimas envolvidas na ativa\u00e7\u00e3o e \n\ndetoxifica\u00e7\u00e3o dos HPA, embora essas atividades sejam geralmente menores que no \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n49 \n\nf\u00edgado. Tais n\u00edveis enzim\u00e1ticos no trato gastrointestinal podem influenciar o \n\ndesenvolvimento ocasional de tumores nos intestinos delgado e grosso como \n\nconsequ\u00eancia do contato com agentes carcin\u00f3genos. Estudos realizados por Uno e col. e \n\nShi e col. demonstraram ainda que as isoenzimas CYP1A1 e CYP1B1 relacionadas \u00e0 \n\nmetaboliza\u00e7\u00e3o de HPA apresentam maior express\u00e3o no intestino delgado de \n\ncamundongos quando comparadas aos n\u00edveis encontrados no intestino grosso (Uno et al., \n\n2004; Uno et al., 2008; Shi et al., 2010; Diggs et al., 2011). Tais fatos poderiam explicar \n\na maior frequ\u00eancia de desenvolvimento de p\u00f3lipos no intestino delgado dos animais \n\ntratados com DBT e DBTO2. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 16: A) Fotografia de parte do intestino grosso de animal pertencente ao Grupo III (Teste DMH 30 \n\nmg/kg) onde podem ser observadas as forma\u00e7\u00f5es de p\u00f3lipos. B) Fotografia de parte do intestino delgado \n\nde animais pertencentes aos Grupos IV (acima) e V (abaixo) (Testes DBT 30 mg/kg e DBTO2 30 mg/kg \n\nrespectivamente) onde podem ser observados p\u00f3lipos. As setas em vermelho indicam a localiza\u00e7\u00e3o dos \n\np\u00f3lipos. As barras em preto representam 1 cm. \n \n\nPara a avalia\u00e7\u00e3o microsc\u00f3pica das les\u00f5es realizou-se a an\u00e1lise histol\u00f3gica dos \n\nintestinos, observando a ocorr\u00eancia de altera\u00e7\u00f5es celulares, estruturais e inflamat\u00f3rias \n\noriundas dos grupos Controles e Testes avaliados.  \n\nCom o objetivo de eliminar qualquer possibilidade de os efeitos observados nos \n\ngrupos tratados com DBT e DBTO2 serem decorrentes da administra\u00e7\u00e3o cr\u00f4nica de \u00f3leo \n\nvegetal pela via intraperitoneal, introduziu-se um grupo experimental controle de animais \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n50 \n\ntratados com salina para efeito de compara\u00e7\u00e3o com animais tratados com \u00f3leo. Nestes \n\ngrupos, o quadro geral foi compat\u00edvel com a normalidade histol\u00f3gica onde foi poss\u00edvel a \n\nplena observa\u00e7\u00e3o das t\u00fanicas intestinais bem como de todas as estruturas histol\u00f3gicas do \n\n\u00f3rg\u00e3o. No intestino delgado de poucos animais de ambos os grupos Controle observou-\n\nse aumento de c\u00e9lulas inflamat\u00f3rias que, quando presentes, se apresentavam de maneira \n\ndifusa e de intensidade leve. Al\u00e9m disso, no grupo Controle \u00d3leo foram observadas \n\nrea\u00e7\u00f5es hiperpl\u00e1sicas dos n\u00f3dulos linfoides do intestino delgado em apenas 25% dos \n\nanimais (Ap\u00eandice C \u2013 Tab. 01.C). Ao contr\u00e1rio, no intestino grosso de animais \n\npertencentes ao grupo controle salina foi observado certo grau de inflama\u00e7\u00e3o (40%) \n\n(Ap\u00eandice C \u2013 Tab. 02.C). Por\u00e9m, considerando o tratamento invasivo ao qual esses \n\nanimais foram submetidos, e a diferen\u00e7a estat\u00edstica encontrada quando analisados esses \n\ndados contra os dados de animais tratados com DMH, DBT e DBTO2, pode-se dizer que \n\npara os animais dos grupos controle o quadro geral observado representa a refer\u00eancia \n\nhistol\u00f3gica. \n\nA compara\u00e7\u00e3o entre os grupos Controle Salina e Teste DMH nos intestinos grosso \n\ne delgado (Tab. 02 e 03) revelou aumento estatisticamente significativo para todas os \n\npar\u00e2metros avaliadas. As atipias observadas foram principalmente altera\u00e7\u00f5es na \n\nmorfologia das mucosas, presen\u00e7a de gl\u00e2ndulas irregulares e de c\u00e9lulas com morfologia \n\nirregular de dif\u00edcil identifica\u00e7\u00e3o. As \u00e1reas de necrose observadas apresentaram-se de \n\nmaneira geral focais atingindo principalmente as t\u00fanicas mucosas e m\u00e9dias. As \n\nhiperplasias das regi\u00f5es nodulares eram caracterizadas pelo aumento conc\u00eantrico de \n\nlinf\u00f3citos e macr\u00f3fagos e apresentavam correla\u00e7\u00e3o com as proje\u00e7\u00f5es papiliformes \n\nobservadas macroscopicamente no intestino grosso (Fig.17).  \n\nUma avalia\u00e7\u00e3o semelhante foi realizada com os grupos Controle \u00d3leo, Teste DBT \n\ne DBTO2 (Tab. 02 e 03) revelando tamb\u00e9m, aumento significativo para todas as altera\u00e7\u00f5es \n\nobservadas. Apesar de a avalia\u00e7\u00e3o macrosc\u00f3pica ter revelado somente a presen\u00e7a de \n\nproje\u00e7\u00f5es no intestino grosso para o Grupo Teste DMH, e no intestino delgado para os \n\nGrupos Teste DBT e DBTO2, pode-se observar que quando avaliados \n\nmicroscopicamente, foram encontradas les\u00f5es com caracter\u00edsticas similares em ambos os \n\nintestinos dos 3 grupos de tratamento. \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n51 \n\nTabela 02: Frequ\u00eancia de les\u00f5es observadas no intest. grosso dos animais pertencentes aos Grupos I-V.  \n\nLes\u00f5es Observadas \nControle Salina (I)  \n\n% (n) \n\nDMH (II)  \n\n% (n) \n\nControle \u00d3leo (III) \n\n% (n) \n\nDBT (IV) \n\n % (n) \n\nDBTO2 (V) \n\n% (n) \n\nAtipia celular na mucosa 0 (0/5)a 64 (9/14)b 0 (0/4)a 29 (4/14)c 55 (5/9)b \n\nAtipia celular na submucosa  0 (0/5)a 14 (2/14)b 0 (0/4)a 7 (1/14)c 33 (3/9)d \n\nInflama\u00e7\u00e3o na mucosa 40 (2/5)a 100 (14/14)b 0 (0/4)c 43 (6/14)a 55 (5/9)a \n\nNecrose 20 (1/5)a 79 (11/14)b 0 (0/4)c 36 (5/14)d 55 (5/9)e \n\nAtipia estrutural 0 (0/5)a 71 (10/14)b 25 (1/4)c 36 (5/14)c 55 (5/9)d \n\nHiperplasia de n\u00f3dulos linf\u00f3ides  20 (1/5)a 43 (6/14)b 25 (1/4)a 50 (7/14)b,c 55 (5/9)c \n\na,b,c,d,eLetras diferentes sinalizam diferen\u00e7as estat\u00edticas significativas (p ? 0.05) entre grupos para um dado \n\npar\u00e2metro. \n\nL\u00e2minas pertencentes a todos os animais controle e teste foram avaliadas. \n\n \n\nTabela 03: Frequ\u00eancia de les\u00f5es observadas no intest. delgado dos animais pertencentes aos Grupos I-V. \n\nLes\u00f5es Observadas \nControle Salina (I) \n\n% (n) \n\nDMH (II)  \n\n% (n) \n\nControle \u00d3leo (III)  \n\n% (n) \n\nDBT (IV) \n\n % (n) \n\nDBTO2 (V) \n\n% (n) \n\nAtipia celular na mucosa 20 (1/5)a 71 (10/14)b 25 (1/4)a 50 (7/14)c 55 (5/9)c \n\nAtipia celular na submucosa  0 (0/5)a 43 (6/14)b 0 (0/4)a 36 (5/14)b 44 (4/9)b \n\nInflama\u00e7\u00e3o na mucosa 20 (1/5)a 71 (10/14)b 0 (0/4)c 79 (11/14)b 67 (6/9)b \n\nNecrose 0 (0/5)a 64 (9/14)b 0 (0/4)a 64 (9/14)b 67 (6/9)b \n\nAtipia estrutural 20 (1/5)a 57 (8/14)b 25 (1/4)a 29 (4/14)a 67 (6/9)b \n\nHiperplasia de n\u00f3dulos linf\u00f3ides  0 (0/5)a 43 (6/14)b 25 (1/4)c 79 (11/14)d 55 (5/9)b \n\na,b,c,d,eLetras diferentes sinalizam diferen\u00e7as estat\u00edticas significativas (p ? 0.05) entre grupos para um dado \n\npar\u00e2metro. \n\nL\u00e2minas pertencentes a todos os animais controle e teste foram avaliadas. \n\n \n\nEm geral, o metabolismo de HPAs ocorre atrav\u00e9s da ativa\u00e7\u00e3o do receptor aril-\n\nhidrocarboneto (AHR). A liga\u00e7\u00e3o do hidrocarboneto ao receptor promove a forma\u00e7\u00e3o de \n\num complexo que migra para o n\u00facleo celular. O complexo ativa  a express\u00e3o de diversos \n\ngenes alvo relacionados ao metabolismo de xenobi\u00f3ticos como as enzimas do citocromo \n\nP450, alde\u00eddo desidrogenase e glutationa transferase (Shimada, 2006; Zhang and Walker, \n\n2006). Tais enzimas podem converter os HPAs em diversos produtos hidrof\u00edlicos com o \n\nobjetivo de elimin\u00e1-los do organismo. Alguns dos metab\u00f3litos formados possuem a \n\ncapacidade de se ligar ao DNA e formar adutos com esta mol\u00e9cula podendo levar \u00e0 \n\naltera\u00e7\u00f5es na estrutura do pr\u00f3prio DNA e na express\u00e3o de prote\u00ednas codificadas por ele \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n52 \n\n(Marinkovic et al., 2013). Em particular,  foi demonstrada a citotoxicidade dose \n\ndependente promovida pelo DBT em cultura de c\u00e9lulas HepG2 e a forma\u00e7\u00e3o de adutos \n\nde DNA ap\u00f3s 24 horas de exposi\u00e7\u00e3o ao HPAS (Amat et al., 2004). \n\n Diversos trabalhos constataram a presen\u00e7a do metab\u00f3lito do DBT, o DBTO2, em \n\nmodelos animais. Apesar disso, o DBT, assim como outros HPAs de 2-3 an\u00e9is, \u00e9 \n\nconsiderado um ativador fraco do receptor AHR, consequentemente levando a uma baixa \n\nexpress\u00e3o de enzimas CYP450 (Ciganek et al., 2004; Hecht et al., 2010). Devido a este \n\nfato, tem sido especulado que a toxicidade do DBT ocorre atrav\u00e9s de outros mecanismos \n\ndiferentes da ativa\u00e7\u00e3o de AHR, mas tais vias ainda permanecem desconhecidas \n\n(Incardona et al., 2004).  \n\nA presen\u00e7a de inflama\u00e7\u00e3o e necrose aumentadas nos grupos Testes indica o \n\npotencial irritativo e lesivo das drogas utilizadas. Tal observa\u00e7\u00e3o corrobora com estudos \n\nque demonstraram atrav\u00e9s da an\u00e1lise de transcritos de zebra fish tratados com DBT, um \n\naumento de quatro vezes nos n\u00edveis da enzima colesterol 25-hidroxilase. Esta mol\u00e9cula \n\ndesempenha um conhecido papel no desenvolvimento da resposta inflamat\u00f3ria (Goodale \n\net al., 2013). Diversos HPAs s\u00e3o conhecidamente capazes de induzir o estresse oxidativo \n\nem culturas de c\u00e9lulas levando ao aumento da express\u00e3o de citocinas inflamat\u00f3rias \n\n(Suresh et al., 2009; Ovrevik et al., 2010). Al\u00e9m disso, as observa\u00e7\u00f5es de crescimento \n\ncelular aumentado e altera\u00e7\u00f5es nas estruturas teciduais demonstram um est\u00e1gio inicial de \n\ndisplasia caracter\u00edstico de les\u00f5es pr\u00e9-neopl\u00e1sicas (Fig. 17).  \n\nDiante da constata\u00e7\u00e3o de indu\u00e7\u00e3o de les\u00f5es de natureza neopl\u00e1sica nos animais \n\ntratados com DBT e DBTO2 com caracter\u00edsticas semelhantes \u00e0quelas provocadas pela \n\nadministra\u00e7\u00e3o cr\u00f4nica de mesma dose de DMH, fica clara a import\u00e2ncia desses resultados \n\ncomo contribui\u00e7\u00e3o para a avalia\u00e7\u00e3o toxicol\u00f3gica dessas subst\u00e2ncias de irrefut\u00e1vel \n\nrelev\u00e2ncia ambiental. \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n53 \n\n \n\nFigura 17: Fotomicrografias de cortes histol\u00f3gicos de intestino delgado e grosso corados pela t\u00e9cnica de \n\nHE. A, C, E, G, I 110x. B, D, F 220x. H, J 440x. A, B, E) Detalhes da t\u00fanica mucosa apresentando aspecto \n\nhistol\u00f3gico normal. F) Notar aumento de c\u00e9lulas inflamat\u00f3rias na regi\u00e3o glandular (setas). C) Observar \n\nhiperplasia linfoide na regi\u00e3o mucosa (estrela). D) Observar c\u00e9lulas displ\u00e1sicas (seta) determinando a \n\nforma\u00e7\u00e3o de estruturas irregulares e de dif\u00edcil identifica\u00e7\u00e3o e processo inflamat\u00f3rio associado (estrela). G) \n\nObservar \u00e1rea de necrose (estrela) associada \u00e0 atrofia mucosa. H, J) Observar gl\u00e2ndulas com c\u00e9lulas at\u00edpicas \n\ne grande polimorfismo nuclear e celular (seta).  I) Aumento irregular da camada mucosa.  \n\nL\u00e2minas pertencentes a todos os animais controle e teste foram avaliadas. \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n54 \n\n5.1.3- Marca\u00e7\u00e3o Imunohistoqu\u00edmica: CEA e CD44 \n\n \n\nCom o objetivo de confirmar o diagn\u00f3stico obtido atrav\u00e9s da an\u00e1lise histol\u00f3gica \n\ndos intestinos grosso e delgado dos animais pertencentes aos grupos Controles e Testes, \n\nrealizou-se a marca\u00e7\u00e3o imunohistoqu\u00edmica com os antincorpos anti-CEA e anti-CD44. \n\nTais prote\u00ednas s\u00e3o conhecidos marcadores tumorais para CCR e outros tipos de c\u00e2ncer \n\nencontrados em diferentes est\u00e1gios do desenvolvimento tumoral (McLeod and Murray, \n\n1999; Duffy et al., 2003; Wang et al., 2009b).  \n\nO Ant\u00edgeno Carcinoembrion\u00e1rio (CEA) \u00e9 o marcador proteico mais utilizado na \n\ncl\u00ednica para avalia\u00e7\u00e3o do c\u00e2ncer colorretal.  A detec\u00e7\u00e3o de altos n\u00edveis de express\u00e3o desta \n\nprote\u00edna no soro ou tecidos est\u00e1 relacionada a um progn\u00f3stico ruim da doen\u00e7a (Duffy et \n\nal., 2003). O CEA \u00e9 um membro da fam\u00edlia de imunoglobulinas que atua na ades\u00e3o \n\nintercelular, fun\u00e7\u00e3o esta, que est\u00e1 intimamente ligada \u00e0 ocorr\u00eancia de met\u00e1stases (Kitadai \n\net al., 1996).  \n\nA avalia\u00e7\u00e3o da capacidade celular de polariza\u00e7\u00e3o do CEA tamb\u00e9m vem sendo \n\nproposta como m\u00e9todo auxiliar no estadiamento do CCR atualmente realizado pela \n\navalia\u00e7\u00e3o das caracter\u00edsticas morfol\u00f3gicas do tumor (TNM). Tal proposta considera as \n\ncaracter\u00edsticas morfol\u00f3gicas e funcionais e melhora o entendimento do comportamento \n\ntumoral. Nos tecidos normais ocorre uma polariza\u00e7\u00e3o da prote\u00edna CEA que geralmente \n\natinge a regi\u00e3o apical da c\u00e9lula. Nos tecidos neopl\u00e1sicos bem polarizados (est\u00e1gio inicial) \n\nocorre manuten\u00e7\u00e3o parcial da capacidade de polariza\u00e7\u00e3o, enquanto em est\u00e1gios mais \n\navan\u00e7ados ocorre uma distribui\u00e7\u00e3o difusa desse ant\u00edgeno (Priolli et al., 2007).  \n\nA prote\u00edna CD44 (Cluster of differentiation 44) \u00e9 um receptor de membrana que \n\npossui uma regi\u00e3o ligante para o \u00e1cido hialur\u00f4nico da matriz extracelular atrav\u00e9s da qual \n\nparticipa de diversas vias de sinaliza\u00e7\u00e3o celular ligadas \u00e0 progress\u00e3o tumoral incluindo \n\ninvas\u00e3o e met\u00e1stase (Wang et al., 2009a). Essas mol\u00e9culas de ades\u00e3o controlam o \n\ncomportamento celular atrav\u00e9s da media\u00e7\u00e3o de contato entre as c\u00e9lulas ou entre as c\u00e9lulas \n\ne a matriz extracelular, sendo essenciais para a manuten\u00e7\u00e3o da integridade tecidual \n\n(Orian-Rosseau, 2010).  \n\nOs membros da fam\u00edlia CD44 podem ser encontrados na forma padr\u00e3o (CD44s), \n\nusualmente associada ao tecido linf\u00f3ide, ou como isoformas (CD44v) em c\u00e9lulas \n\nepiteliais embrion\u00e1rias e em diversos carcinomas humanos (Coppola et al., 1998; de Paula \n\nCarli et al., 2012). No CCR, a isoforma CD44v3 parece estar associada \u00e0 promo\u00e7\u00e3o de \n\ninvas\u00e3o e resist\u00eancia a apoptose, enquanto a isoforma CD44v6 associa-se com a \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n55 \n\nocorr\u00eancia de met\u00e1stase e diminui\u00e7\u00e3o na sobrevida do paciente (Kuniyasu et al., 2001; \n\nKuhn et al., 2007).  \n\nA express\u00e3o epitelial de CD44 em tecidos intestinais normais tamb\u00e9m ocorre de \n\nmaneira localizada. Rudzki e colaboradores demonstraram por imunohistoqu\u00edmica que \n\nessa prote\u00edna encontra-se limitada \u00e0 por\u00e7\u00e3o interna do epit\u00e9lio, n\u00e3o sendo observada na \n\nsuperf\u00edcie do mesmo. Em tecidos neopl\u00e1sicos ocorre aumento de express\u00e3o das isoformas \n\nCD44v, e esse padr\u00e3o de distribui\u00e7\u00e3o torna-se alterado (Rudzki and Jothy, 1997). \n\nComo pode ser observado na Figura 18, os gr\u00e1ficos 1 e 2 demonstram a contagem \n\nde c\u00e9lulas intestinais marcadas com os anticorpos anti-CEA e anti-CD44. Em ambos os \n\ngr\u00e1ficos foram encontradas diferen\u00e7as estatisticamente significativas entre os grupos \n\nControles e seus respectivos grupos Testes. Al\u00e9m disso, os grupos Controle apresentaram \n\ncontagens semelhantes entre si para cada anticorpo utilizado, assim como os grupos \n\nTestes demonstrando similaridade entre os efeitos promovidos pelo DBT, DMH e DBTO2 \n\nna altera\u00e7\u00e3o dos n\u00edveis de express\u00e3o desses ant\u00edgenos. Em ambos os gr\u00e1ficos o aumento \n\nencontrado entre os grupos Controle e Testes foi de aproximadamente 3 vezes, \n\nconfirmando o car\u00e1ter neopl\u00e1sico das les\u00f5es avaliadas histologicamente. \n\nA distribui\u00e7\u00e3o celular das prote\u00ednas CEA e CD44 tamb\u00e9m foi avaliada de maneira \n\nqualitativa para auxiliar na caracteriza\u00e7\u00e3o das altera\u00e7\u00f5es morfofuncionais observadas nos \n\nanimais dos grupos Testes. Pode-se observar que para os animais pertencentes aos grupos \n\nTestes DMH, DBT e DBTO2 a marca\u00e7\u00e3o imunohistoqu\u00edmica com anti-CEA apresentou-\n\nse de maneira relativamente difusa no citoplasma celular quando comparada com a \n\nmarca\u00e7\u00e3o encontrada nos animais pertencentes aos grupos Controle. Quanto \u00e0 marca\u00e7\u00e3o \n\nobtida com o anticorpo anti-CD44 para os grupos Controle pode-se observar a localiza\u00e7\u00e3o \n\nda express\u00e3o proteica no interior da camada submucosa, enquanto para os animais dos \n\ngrupos Testes tal marca\u00e7\u00e3o foi encontrada por toda a extens\u00e3o tecidual. Em conjunto, as \n\nduas observa\u00e7\u00f5es parecem indicar um est\u00e1gio leve a moderado de progress\u00e3o tumoral \n\ncomo descrito anteriormente. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n56 \n\n \n\nFigura 18: Fotomicrografias de cortes histol\u00f3gicos de intestino delgado e grosso corados pela t\u00e9cnica de \n\nimunohistoqu\u00edmica e contra corados com hematoxilina. Aumentos de 440x. A, C, E, G, I) Detalhes das \n\nt\u00fanicas mucosa e sub mucosa reveladas com anticorpo anti-CEA (C, G, I animais dos grupos Testes DMH, \n\nDBT e DBTO2 \u2013 notar marca\u00e7\u00e3o mais acentuada quando comparado com A, e E que s\u00e3o animais dos grupos \n\nControle Salina e \u00d3leo). B, D, F, H, J) Detalhes das t\u00fanicas mucosa e sub mucosa reveladas com anticorpo \n\nanti-CD44 (D, H, J animais dos Grupos Testes DMH, DBT e DBTO2 \u2013 notar marca\u00e7\u00e3o mais acentuada \n\nquando comparado com B, F que s\u00e3o animais dos grupos Controle Salina e \u00d3leo). 1 e 2) An\u00e1lise estat\u00edstica \n\nmostrando as diferen\u00e7as entre grupos Controles e Testes para o n\u00ba de c\u00e9lulas marcadas com anti-CEA e \n\nanti-CD44. Contagem realizada por meio do software Image J. \n\nL\u00e2minas pertencentes a quatro animais de cada grupo controle e teste foram avaliadas. \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n57 \n\n5.2- An\u00e1lise Prote\u00f4mica  \n\n \n\nA rela\u00e7\u00e3o entre biomarcadores tumorais e o CCR tem sido extensivamente \n\ninvestigada. Prote\u00ednas envolvidas em diversos aspectos da progress\u00e3o da doen\u00e7a \n\nincluindo invas\u00e3o, met\u00e1stase, regula\u00e7\u00e3o do ciclo celular, fatores de crescimento e \n\napoptose t\u00eam sido descritas como potenciais marcadores (O\u2019Dwyer et al., 2011). As vias \n\nbiol\u00f3gicas que podem formar a base para novos agentes terap\u00eauticos t\u00eam sido \n\nidentificadas para diversos tipos de c\u00e2ncer. Embora algumas muta\u00e7\u00f5es de alta frequ\u00eancia \n\nsejam alvos atrativos para o desenvolvimento de drogas, vias de sinaliza\u00e7\u00e3o comuns, \n\nrelacionadas a essas muta\u00e7\u00f5es, tamb\u00e9m podem ser alvos para terapia (Markowitz and \n\nBertagnolli, 2009).  \n\nSendo assim, torna-se interessante um estudo molecular das les\u00f5es desenvolvidas \n\npelos animais tratados com os agentes carcinog\u00eanicos, considerando a similaridade entre \n\nas altera\u00e7\u00f5es macro e microsc\u00f3picas dos tecidos intestinais dos ratos tratados com DBT \n\ne DBTO2, e aquelas encontradas nos animais tratados com DMH. Tal abordagem, poderia \n\nauxiliar na verifica\u00e7\u00e3o das poss\u00edveis rela\u00e7\u00f5es entre as vias biol\u00f3gicas envolvidas no \n\nestabelecimento do processo carcinog\u00eanico promovido por ambos os tratamentos. Sendo \n\nassim, inicialmente foram extra\u00eddas prote\u00ednas sol\u00faveis de tecidos intestinais provenientes \n\nde todos os grupos citados para identifica\u00e7\u00e3o e an\u00e1lise da express\u00e3o diferencial das \n\nmesmas. \n\nAs figuras 19, 20 e 21 apresentam os perfis eletrofor\u00e9ticos representativos de \n\ntriplicatas referentes aos extratos proteicos de fra\u00e7\u00e3o sol\u00favel obtidos por 2D SDS-PAGE \n\n10% para os grupos III/IV, III/V e I/II, respectivamente. Mediante a an\u00e1lise da \n\nsobreposi\u00e7\u00e3o e densitometria das imagens realizada atrav\u00e9s do software SameSpots \n\n(TotalLab), foi poss\u00edvel observar a express\u00e3o diferenciada de diversas prote\u00ednas entre os \n\ngrupos Controle e seus respectivos grupos Testes (indicada pelas setas numeradas). \n\nForam consideradas quantitativamente significativas, as diferen\u00e7as de express\u00e3o para \n\ncima ou para baixo, com valores de pelo menos 1,5 vez na triplicata biol\u00f3gica realizada, \n\ncom um desvio padr\u00e3o m\u00e1ximo aceit\u00e1vel de 10%. \n\nA qualidade das prepara\u00e7\u00f5es pode ser atestada pela observa\u00e7\u00e3o da cobertura de \n\ntoda a extens\u00e3o da faixa de pH provida pela strip durante a isoeletrofocaliza\u00e7\u00e3o (pH3-\n\n10), e tamb\u00e9m pela presen\u00e7a de spots representando diversas massas moleculares \n\nindicando a manuten\u00e7\u00e3o da integridade proteica. \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n58 \n\n \n\nFigura 19: G\u00e9is 2D SDS-PAGE 10% representativos da extra\u00e7\u00e3o de prote\u00ednas sol\u00faveis de intestinos delgados dos \n\nA) Grupo Controle \u00d3leo (III) e B) Teste DBT (IV). Nas setas numeradas est\u00e3o marcados os spots identificados por \n\nespectrometria de massas que apresentaram diferen\u00e7a de 1,5 vez na express\u00e3o. Colora\u00e7\u00e3o realizada com solu\u00e7\u00e3o de \n\nCoomassie Coloidal. Para cada experimento foi realizada uma triplicata biol\u00f3gica independente.  \n\n \n\n \n\nFigura 20: G\u00e9is 2D SDS-PAGE 10% representativos da extra\u00e7\u00e3o de prote\u00ednas sol\u00faveis de intestinos delgados dos \n\nA) Grupo Controle \u00d3leo (III) e B) Teste DBTO2 (V). Nas setas numeradas est\u00e3o marcados os spots identificados \n\npor espectrometria de massas que apresentaram diferen\u00e7a de 1,5 vez na express\u00e3o. Colora\u00e7\u00e3o realizada com solu\u00e7\u00e3o \n\nde Coomassie Coloidal. Para cada experimento foi realizada uma triplicata biol\u00f3gica independente.  \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n59 \n\n \nFigura 21: G\u00e9is 2D SDS-PAGE 10% representativos da extra\u00e7\u00e3o de prote\u00ednas sol\u00faveis de intestinos delgados dos \n\nA) Grupo Controle Salina (I) e B) Teste DMH (II). Nas setas numeradas est\u00e3o marcados os spots identificados por \n\nespectrometria de massas que apresentaram diferen\u00e7a de 1,5 vez na express\u00e3o. Colora\u00e7\u00e3o realizada com solu\u00e7\u00e3o de \n\nCoomassie Coloidal. Para cada experimento foi realizada uma triplicata biol\u00f3gica independente.  \n\n \n\nEm m\u00e9dia, 1700 spots foram detectados por par de gel controle/teste analisado. A \n\ngrande maioria destas prote\u00ednas mostrou n\u00edveis equivalentes de express\u00e3o entre os grupos \n\navaliados. Entretanto, foi poss\u00edvel detectar altera\u00e7\u00f5es em 84 spots pertencentes aos grupos \n\nControle e Teste DBT e DBTO2. Destes, 16 spots relativos ao grupo IV e 20 relativos ao \n\ngrupo V demonstraram diminui\u00e7\u00e3o na express\u00e3o dos testes em rela\u00e7\u00e3o ao controle e 68 e \n\n64 spots revelaram aumento na express\u00e3o de prote\u00ednas relativas aos mesmos grupos (n\u00e3o \n\nmostrado nas figuras), respectivamente. Quanto \u00e0 avalia\u00e7\u00e3o dos g\u00e9is preparados para os \n\ngrupos Controle Salina e Teste DMH foram detectados 88 spots com altera\u00e7\u00e3o na \n\nexpress\u00e3o proteica. Destes, 19 mostraram diminui\u00e7\u00e3o e 69, aumento na densidade dos \n\nspots avaliados. \n\nTodos os spots que demonstraram algum tipo de altera\u00e7\u00e3o de express\u00e3o foram \n\nexcisados e digeridos com tripsina para identifica\u00e7\u00e3o por espectrometria de massas. Ap\u00f3s \n\no sequenciamento e aplica\u00e7\u00e3o dos crit\u00e9rios de sele\u00e7\u00e3o descritos no item 4.3.3, 22 prote\u00ednas \n\nisoladas nos g\u00e9is relativos aos grupos III, IV e V e 38 prote\u00ednas isoladas nos g\u00e9is relativos \n\naos grupos I e II foram identificadas e agrupadas de acordo com as fun\u00e7\u00f5es moleculares \n\npor elas desempenhadas nas c\u00e9lulas (Tab. 04 e 05). Dados referentes \u00e0 identifica\u00e7\u00e3o dos \n\npept\u00eddeos tr\u00edpticos encontram-se no Ap\u00eandice D ao fim deste trabalho (Ap\u00eandice D \u2013 Tab. \n\n01.D e Tab. 02.D). \n\n\n\nSilva, K.T.S.                                                                                                                                                         Resultados e Discuss\u00e3o \n\n60 \n\nTabela 04: Prote\u00ednas identificadas por spot nos g\u00e9is referentes aos grupos Teste IV e V que apresentaram altera\u00e7\u00e3o na express\u00e3o ? 1,5 vezes em rela\u00e7\u00e3o ao grupo Controle III. \n\nSpot Gene Prote\u00edna Identificada N\u00ba de acesso \nPept\u00eddeos \n\n\u00danicos \n\n% \n\nCobertura \npI \n\nMassa Molecular \n\nEsperada (kDa) \n\nMassa Molecular \n\nObservada (kDa) \n\nResposta a estresse       \n\n1 \n\n2 \n\n19 \n\nHSPA5 \n\nHSPA2 \n\nHSP70 \n\nGRP78 \n\nChaperona hsp72-ps1 \n\nProte\u00edna Heat shock 70 \n\ngi|25742763 \n\ngi|347019 \n\ngi|149038951 \n\n15 \n\n12 \n\n4 \n\n42 \n\n46 \n\n23 \n\n5.07 \n\n5.43 \n\n5.03 \n\n72.4 \n\n71.1 \n\n56.3 \n\n66 \n\n61.8 \n\n27.7 \n\nCitoesqueleto        \n\n20 \n\n26 \n\n44 \n\n82 \n\nTPM5 \n\nACTB \n\nCFL1 \n\nCORO1A \n\nTropomiosina 5 \n\nActina subunidade beta \n\nCofilina 1 \n\nCoronina 1A \n\ngi|9653293 \n\ngi|4501885 \n\ngi|8393101 \n\ngi|18426834 \n\n1 \n\n6 \n\n5 \n\n7 \n\n37 \n\n48 \n\n62 \n\n37 \n\n4.72 \n\n5.29 \n\n8.22 \n\n6.05 \n\n29.2 \n\n42.1 \n\n18.7 \n\n51.7 \n\n27.3 \n\n34.8 \n\n15.5 \n\n50.5 \n\nAtividade Antioxidante       \n\n43 PRDX1 Peroxiredoxina 1 gi|16923958 6 72 8.27 22.3 19.7 \n\nSinaliza\u00e7\u00e3o Celular       \n\n22 \n\n57 \n\nARHGDIA \n\nGNB2L1 \n\nInibidor de Dissocia\u00e7\u00e3o-Rho GDP 1 \n\nProte\u00edna ligante-nucleot\u00eddeo Guanina \n\ngi|31982030 \n\ngi|5174447 \n\n6 \n\n15 \n\n49 \n\n77 \n\n5.12 \n\n7.6 \n\n23.5 \n\n35.5 \n\n23 \n\n28.4 \n\nMetabolismo de Carboidratos       \n\n32 \n\n37 \n\n54 \n\n59 \n\n64 \n\nPGK1 \n\nLDHA \n\nAKR1B1 \n\nPGAM1 \n\nTKT \n\nFosfoglicerato quinase 1 \n\nL-lactato dehidrogenase A  \n\nAldose redutase \n\nFosfoglicerato mutase 1 \n\nTranscetolase, isoforma CRA_a \n\ngi|40254752 \n\ngi|8393706 \n\ngi|6978491 \n\ngi|114326546 \n\ngi|149034221 \n\n13 \n\n9 \n\n5 \n\n9 \n\n1 \n\n62 \n\n61 \n\n26 \n\n72 \n\n39 \n\n8.02 \n\n8.45 \n\n6.26 \n\n6.67 \n\n7.54 \n\n44.9 \n\n36.7 \n\n36.2 \n\n29.8 \n\n71.9 \n\n42.1 \n\n31.4 \n\n31.8 \n\n24.2 \n\n45.3 \n\nMetabolismo de Lip\u00eddeos       \n\n17 \n\n31 \n\nANXA5 \n\nPNLIP \n\nAnexina 5 \n\nTriacilglicerol lipase  \n\ngi|2981437 \n\ngi|6981376 \n\n1 \n\n15 \n\n8 \n\n53 \n\n4.99 \n\n6.31 \n\n33.9 \n\n52.1 \n\n29.5 \n\n44 \n\nMetabolismo de Nucleot\u00eddeos/Fosfato       \n\n48 CKB Creatina quinase B gi|401461784 15 66 5.39 42.9 40.3 \n\nModelamento de Prote\u00ednas       \n\n41 \n\n79 \n\nRFESD \n\nCANX \n\nProte\u00edna Rieske Fe-S   \n\nCalnexina \n\ngi|149043682 \n\ngi|25282419 \n\n1 \n\n6 \n\n26 \n\n20 \n\n8.9 \n\n4.49 \n\n27.9 \n\n67.6 \n\n22.7 \n\n56.2 \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MKFTVVAAALLLLCAVRAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFFEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSPEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSGGPPPTGEEDTSEKDEL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQAAKDAGTIAGLNVLRIINEPTAAAIAYGLDKKVRAERNVLIFDLGGGTFDVSILTTEDGIFEVKSTAGDTHLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIISWLDKNQTAEKEEFEHQQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFFEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSPEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSGGPPPTGEEDTSEKDEL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAGSTTIEAVKRKIQVLQQQADDAEERAERLQREVEGERRAREQAEAEVASLNRRIQLVEEELDRAQEPLATALQKLEEAEKAADESERGMKVIENRALKDEEKMELQEIQLKEAKHIAEEADRKYEEVARKLVIIEGDLERTEERAELAESRCREMDEQIRLMDQNLKCLSAAEEKYSQKEDKYEEEIKILTDKLKEAETRAEFAERSVAKLEKTIDDLEDKLKCTKEEHLCTQRMLDQTLLDLNEM&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDDDIAALVVDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREKMTQIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRLDLAGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEKSYELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTVLSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKQEYDESGPSIVHRKCF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MASGVAVSDGVIKVFNDMKVRKSSTPEEVKKRKKAVLFCLSEDKKNIILEEGKEILVGDVGQTVDDPYTTFVKMLPDKDCRYALYDATYETKESKKEDLVFIFWAPESAPLKSKMIYASSKDAIKKKLTGIKHELQANCYEEVKDRCTLAEKLGGSAVISLEGKPL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSRQVVRSSKFRHVFGQPAKADQCYEDVRVSQTTWDSGFCAVNPKFMALICEASGGGAFLVLPLGKTGRVDKNVPLVCGHTAPVLDIAWCPHNDNVIASGSEDCTVMVWEIPDGGLVLPLREPVVTLEGHTKRVGIVAWHPTAQNVLLSAGCDNVILVWDVGTGAAVLTLGPDVHPDTIYSVDWSRDGALICTSCRDKRVRVIEPRKGTVVAEKERPHEGTRPVHAVFVSEGKILTTGFSRMSERQVALWDTKHLEEPLSLQELDTSSGVLLPFFDPDTNIVYLCGKGDSSIRYFEITSEAPFLHYLSMFSSKESQRGMGYMPKRGLEVNKCEIARFYKLHERKCEPIAMTVPRKSDLFQEDLYPPTAGPDPALTAEEWLSGRDAGPLLISLKDGYVPPKSRELRVNRGLDSARRRATPEPSSTLSSDTVSRLEEDVRNLNAIVQKLQERLDRLEETVQAK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSSGNAKIGHPAPSFKATAVMPDGQFKDISLSDYKGKYVVFFFYPLDFTFVCPTEIIAFSDRAEEFKKLNCQVIGASVDSHFCHLAWINTPKKQGGLGPMNIPLVSDPKRTIAQDYGVLKADEGISFRGLFIIDDKGILRQITINDLPVGRSVDEILRLVQAFQFTDKHGEVCPAGWKPGSDTIKPDVNKSKEYFSKQK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRKYKEALLGRVAVSADPNVPNVIVTRLTLVCSTAPGPLELDLTGDLESFKKQSFVLKEGVEYRIKISFRVNREIVSGMKYIQHTYRKGVKIDKTDYMVGSYGPRAEEYEFLTPMEEAPKGMLARGSYNIKSRFTDDDKTDHLSWEWNLTIKKEWKD&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MTEQMTLRGTLKGHNGWVTQIATTPQFPDMILSASRDKTIIMWKLTRDETNYGIPQRALRGHSHFVSDVVISSDGQFALSGSWDGTLRLWDLTTGTTTRRFVGHTKDVLSVAFSSDNRQIVSGSRDKTIKLWNTLGVCKYTVQDESHSEWVSCVRFSPNSSNPIIVSCGWDKLVKVWNLANCKLKTNHIGHTGYLNTVTVSPDGSLCASGGKDGQAMLWDLNEGKHLYTLDGGDIINALCFSPNRYWLCAATGPSIKIWDLEGKIIVDELKQEVISTSSKAEPPQCTSLAWSADGQTLFAGYTDNLVRVWQVTIGTR&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQRIKAAVPSIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAAELKSLLGKDVLFLKDCVGSEVENACANPAAGTVILLENLRFHVEEEGKGKDASGNKVKAEPAKIDAFRASLSKLGDVYVNDAFGTAHRAHSSMVGVNLPQKAGGFLMKKELNYFAKALESPERPFLAILGGAKVADKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLYDEEGAKIVKDLMAKAEKNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGTESSKKYAEAVARAKQIVWNGPVGVFEWEAFARGTKSLMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGKVLPGVDALSNV&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAALKDQLIVNLLKEEQVPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLKTPKIVSSKDYSVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPQCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGVNVAGVSLKSLNPQLGTDADKEQWKDVHKQVVDSAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPISTMIKGLYGIKEDVFLSVPCILGQNGISDVVKVTLTPDEEARLKKSADTLWGIQKELQF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MASHLELNNGTKMPTLGLGTWKSPPGQVTEAVKVAIDMGYRHIDCAQVYQNEKEVGVALQEKLKEQVVKRQDLFIVSKLWCTFHDQSMVKGACQKTLSDLQLDYLDLYLIHWPTGFKPGPDYFPLDASGNVIPSDTDFVDTWTAMEQLVDEGLVKAIGVSNFNPLQIERILNKPGLKYKPAVNQIECHPYLTQEKLIEYCHCKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKEIAAKYNKTTAQVLIRFPIQRNLVVIPKSVTPARIAENFKVFDFELSNEDMATLLSYNRNWRVCALMSCAKHKDYPFHAEV&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAAYKLVLIRHGESAWNLENRFSGWYDADLSPAGHEEAKRGGQALRDAGYEFDICFTSVQKRAIRTLWTVLDAIDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEAQVKIWRRSYDVPPPPMEPDHPFYSNISKDRRYADLTEDQLPSCESLKDTIARALPFWNEEIVPQIKEGKRVLIAAHGNSLRGIVKHLEGLSEEAIMELNLPTGIPIVYELDKNLKPIKPMQFLGDEETVRKAMEAVAAQGKVKK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDPVRQIQCDREGKRFPFLSAPPASTSSPDRAMEGYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKALDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLPEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCMLGDGEVSEGSVWEAMAFAGIYKLDNLVAIFDINRLGQSDPAPLQHQVDVYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIAKTFKGRGITGIEDKEAWHGKPLPKNMAEQIIQEIYSQVQSKKKILATPPQEDAPSVDIANIRMPTPPNYKVGDKIATRKAYGLALAKLGHASDRIIALDGDTKNSTFSELFKKEHPDRFIECYIAEQNMVSIAVGCATRDRTVPFCSTFAAFFTRAFDQIRMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPMSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAIIYSNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAEMLKKEKIGVRVLDPFTIKPLDKKLILDCARATKGRILTVEDHYYEGGIGEAVSAAVVGEPGVTVTRLAVSQVPRSGKPAELLKMFGIDKDAIVQAVKGLVTKG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MALRGTVTDFSGFDGRADAEVLRKAMKGLGTDEDSILNLLTARSNAQRQQIAEEFKTLFGRDLVNDMKSELTGKFEKLIVALMKPSRLYDAYELKHALKGAGTDEKVLTEIIASRTPEELRAIKQAYEEEYGSNLEDDVVGDTSGYYQRMLVVLLQANRDPDTAIDDAQVELDAQALFQAGELKWGTDEEKFITILGTRSVSHLRRVFDKYMTISGFQIEETIDRETSGNLENLLLAVVKSIRSIPAYLAETLYYAMKGAGTDDHTLIRVIVSRSEIDLFNIRKEFRKNFATSLYSMIKGDT&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MLMLWTFAVLLGAVAGKEVCFDKLGCFSDDAPWSGTIDRPLKALPWSPAQINTRFLLYTNENQDNYQKITSDASSIRNSNFKTNRKTRIIIHGFIDKGEENWLSDMCKNMFKVESVNCICVDWKGGSRATYTQATQNVRVVGAEVALLVNVLKSDLGHPPDNVHLIGHSLGSHVAGEAGKRTFGAIGRITGLDAAEPYFQGTPEEVRLDPTDAQFVDAIHTDAAPIIPNLGFGMSQTVGHLDFFPNGGMEMPGCQKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPTGFSGFSCSSYNVFSANKCFPCGSEGCPQMGHYADKYPGKTKELYQKFYLNTGDKSNFARWRYQVTVTLSGQKVTGHILVSLFGNGGNSKQYEVFKGSLHPGDTHVKEFDSDMDVGDLQKVKFIWYNNVINPTLPKVGASRISVERNDGRVFNFCSQDTVREDVLLTLSAC&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MPFSNSHNTQKLRFPAEDEFPDLSSHNNHMAKVLTPELYAELRAKCTPSGFTLDDAIQTGVDNPGHPYIMTVGAVAGDEESYDVFKDLFDPIIEDRHGGYQPSDEHKTDLNPDNLQGGDDLDPNYVLSSRVRTGRSIRGFCLPPHCSRGERRAIEKLAVEALSSLDGDLSGRYYALKSMTEAEQQQLIDDHFLFDKPVSPLLLASGMARDWPDARGIWHNDNKTFLVWINEEDHLRVISMQKGGNMKEVFTRFCTGLTQIETLFKSKNYEFMWNPHLGYILTCPSNLGTGLRAGVHIKLPHLGKHEKFSEVLKRLRLQKRGTGGVDTAAVGGVFDVSNADRLGFSEVELVQMVVDGVKLLIEMEQRLEQGQPIDDLMPAQK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MKGEKGSRGEKGSRGPKGYKGEKGKRGIDGVDGMKGETGYPGLPGCKGSPGFDGIQGPPGPKGDAGAFGLKGEKGEAGAEGEAGRPGNSGPPGDEGEPGEPGPPGEKGEAGDEGNAGPDGAPGERGGPGERGPRGTPGVRGPRGDPGEAGPQGDQGREGPVGIPGDPGESGPIGPKGYRGDEGPPGPEGLRGAPGPVGPPGDPGLMGERGEDGPPGNGTEGFPGFPGYPGNRGPPGINGTKGYPGLKGDEGEAGDPGEDNNDVSPRGVKGAKGYRGPEGPQGPPGHVGPPGPDECEILDIIMKMCSCCECTCGPIDILFVLDSSESIGLQNFEIAKDFIIKVIDRLSKDELVKFEPGQSHAGVVQYSHNQMQEHVDMRSPNVRNAQDFKEAVKKLQWMAGGTFTGEALQYTRDRLLPPTQNNRIALVITDGRSDTQRDTTPLSVLCGSDIQVVSVGIKDVFGFVAGSDQLNVISCQGLSQSRPGISLVKENYAELLDDGFLKNITAQICIDKKCPDYTCPITFSSPTDITILLDSSASVGSHNFETTKVFAKRLAERFLSAGREDPTQVVRVAVVQYSGQGQQQPGRASLQFQQNYTVLASSVDSMDFINDATDVNDALSYVTRFYRENSSGATKKRVLLFSDGNSQGATAEAIEKAVQEAQRGGIEIFVMVVGPQVNEPHIRVLVTGKTAEYDVAFGERHLFRVPNYQALLRGVLYQTVSRKVALG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MEGKWLLCLLLVLGTAAIQAHDGHDDDMIDIEDDLDDVIEEVEDSKSKSDTSTPPSPKVTYKAPVPTGEVYFADSFDRGSLSGWILSKAKKDDTDDEIAKYDGKWEVDEMKETKLPGDKGLVLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTSELNLDQFHDKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGVYEEKHAKRPDADLKTYFTDKKTHLYTLILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIADPDAVKPDDWDEDAPSKIPDEEATKPEGWLDDEPEYIPDPDAEKPEDWDEDMDGEWEAPQIANPKCESAPGCGVWQRPMIDNPNYKGKWKPPMIDNPNYQGIWKPRKIPNPDFFEDLEPFRMTPFSAIGLELWSMTSDIFFDNFIISGDRRVVDDWANDGWGLKKAADGAAEPGVVGQMLEAAEERPWLWVVYILTVALPVFLVILFCCSGKKQSNAMEYKKTDAPQPDVKDEEGKEEEKNKGDEEEEEEKLEEKQKSDAEEDGGTGSQDEEDSKPKAEEDEILNRSPRNRKPRRE&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                         Resultados e Discuss\u00e3o \n\n61 \n\nOutros Processos       \n\n23 \n\n62 \n\n63 \n\nFCGBP \n\nTF \n\nTF \n\nFragmento Fc de IgG  \n\nTransferrina \n\nTransferrina \n\ngi|257467629 \n\ngi|1854476 \n\ngi|1854476 \n\n10 \n\n16 \n\n7 \n\n9 \n\n33 \n\n24 \n\n4.92 \n\n6.94 \n\n6.94 \n\n28.7 \n\n78.5 \n\n78.5 \n\n93 \n\n69.3 \n\n63.2 \n\n \n\n \n\nTabela 05: Prote\u00ednas identificadas por spot nos g\u00e9is referentes ao grupo Teste II que apresentaram altera\u00e7\u00e3o na express\u00e3o ? 1,5 vezes em rela\u00e7\u00e3o ao grupo Controle I. \n\nSpot Gene Prote\u00edna Identificada N\u00ba de acesso \nPept\u00eddeos \n\n\u00danicos \n% Cobertura pI \n\nMassa Molecular \n\nEsperada (kDa) \n\nMassa Molecular \n\nObservada (kDa) \n\nS\u00edntese/Degrada\u00e7\u00e3o de Prote\u00ednas       \n\n25 \n\n57 \n\nEEF2 \n\nMCPT1 \n\nFator de elonga\u00e7\u00e3o 2 \n\nProtease de mast\u00f3citos 1 \n\ngi|8393296 \n\ngi|8393764 \n\n19 \n\n11 \n\n38 \n\n68 \n\n6,41 \n\n6,55 \n\n96,2 \n\n27,6 \n\n86,1 \n\n20,5 \n\nCitoesqueleto        \n\n1 \n\n5/6 \n\n12 \n\n45 \n\n70 \n\n75 \n\n76 \n\nTPM1 \n\nACTB \n\nTAGLN \n\nTPM5 \n\nMYL \n\nKRT8 \n\nEZR \n\nTropomiosina 1, alfa  \n\nActina subunidade beta \n\nTransgelina \n\nTropomyosina 5 \n\nMiosina, cadeia leve \n\nCitoqueratina 8  \n\nEzrina \n\n gi|149028892 \n\n gi|4501883 \n\n  gi|13928744 \n\ngi|9653293 \n\ngi|71037403 \n\ngi|203734 \n\ngi|40804381 \n\n13 \n\n13 \n\n11 \n\n4 \n\n9 \n\n24 \n\n9 \n\n58 \n\n56 \n\n53 \n\n51 \n\n66 \n\n63 \n\n29 \n\n4.69 \n\n5,23 \n\n8,87 \n\n4,72 \n\n4,67 \n\n5,49 \n\n5,83 \n\n32,7 \n\n42,4 \n\n22,6 \n\n29,1 \n\n19,9 \n\n52,7 \n\n69,4 \n\n32,9 \n\n36,7 \n\n15,1 \n\n24,9 \n\n15,9 \n\n46,7 \n\n70,5 \n\nAtividade Antioxidante       \n\n36 \n\n38 \n\n44 \n\nPRDX1 \n\nADH \n\nSOD \n\nPeroxiredoxina 1 \n\n\u00c1lcool Dehidrogenase \n\nSuper\u00f3xido Dismutase [Mn] \n\ngi|16923958 \n\ngi|202727 \n\n gi|8394331  \n\n8 \n\n1 \n\n9 \n\n77 \n\n69 \n\n42 \n\n8,27 \n\n8,52 \n\n8,96 \n\n22.3 \n\n40,5 \n\n24,9 \n\n40,3 \n\n35,9 \n\n17,9 \n\nSinaliza\u00e7\u00e3o Celular       \n\n60\u00aa \n\n60b \n\n61a \n\n61b \n\n63 \n\n72 \n\n88 \n\nDPP7 \n\nTRA1 \n\nLUM \n\nRBBP4 \n\nYWHAE \n\nARHGDIA \n\nLGALS3 \n\nDipeptidil peptidase 2 \n\nProte\u00edna associada a transcri\u00e7\u00e3o 1 \n\nLumican \n\nProte\u00edna ligante de histona RBBP4 \n\n14-3-3 prote\u00edna epsilon \n\nInibidor de Dissocia\u00e7\u00e3o-Rho GDP 1 \n\nGalectina 3 \n\n gi|14010871 \n\ngi|51858886 \n\ngi|13591983 \n\ngi|5032027 \n\n gi|5803225 \n\ngi|31982030 \n\ngi|13929190 \n\n5 \n\n10 \n\n5 \n\n9 \n\n14 \n\n8 \n\n8 \n\n22 \n\n23 \n\n21 \n\n30 \n\n58 \n\n57 \n\n37 \n\n4,87 \n\n5,02 \n\n6 \n\n4,74 \n\n4,63 \n\n5.12 \n\n8,93 \n\n55,6 \n\n74,3 \n\n38,6 \n\n47,9 \n\n29,3 \n\n23,4 \n\n27,3 \n\n46,7 \n\n46,7 \n\n44,4 \n\n44,4 \n\n24,3 \n\n21,8 \n\n22,3 \n\nMetabolismo de Lip\u00eddeos       \n\n42 ANXA2 Anexina 2 gi|9845234 24 75 7,55 38,9 32,1 \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=257467629&amp;SERVICE=plain&amp;SET_DEFAULTS.x=21&amp;SET_DEFAULTS.y=7&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRFAVGALLACAALGLCLAVPDKTVKWCAVSEHENTKCISFRDHMKTVLPADGPRLACVKKTSYQDCIKAISGGEADAITLDGGWVYDAGLTPNNLKPVAAEFYGSLEHPQTHYLAVAVVKKGTDFQLNQLQGKKSCHTGLGRSAGWIIPIGLLFCNLPEPRKPLEKAVASFFSGSCVPCADPVAFPQLCQLCPGCGCSPTQPFFGYVGAFKCLRDGGGDVAFVKHTTIFEVLPQKADRDQYELLCLDNTRKPVDQYEDCYLARIPSHAVVARNGDGKEDLIWEILKVAQEHFGKGKSKDFQLFGSPLGKDLLFKDSAFGCYGVPPRMDYRLYLGHSYVTAIRNQREGVCPEASIDSAPVKWCALSHQERAKCDEWSVTSNGQIECESAESTEDCIDKIVNGEADAMSLDGGHAYIAGQCGLVPVMAENYDISSCTNPQSDVFPKGYYAVAVVKASDSSINWNNLKGKKSCHTGVDRTAGWNIPMGLLFSRINHCKFDEFFSQGCAPGYKKNSTLCDLCIGPAKCAPNNREGYNGYTGAFQCLVEKGDVAFVKHQTVLENTNGKNTAAWAKDLKQEDFQLLCPDGTKKPVTEFATCHLAQAPNHVVVSRKEKAARVSTVLTAQKDLFWKGDKDCTGNFCLFRSSTKDLLFRDDTKCLTKLPEGTTYEEYLGAEYLQAVGNIRKCSTSRLLEACTFHKS&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRFAVGALLACAALGLCLAVPDKTVKWCAVSEHENTKCISFRDHMKTVLPADGPRLACVKKTSYQDCIKAISGGEADAITLDGGWVYDAGLTPNNLKPVAAEFYGSLEHPQTHYLAVAVVKKGTDFQLNQLQGKKSCHTGLGRSAGWIIPIGLLFCNLPEPRKPLEKAVASFFSGSCVPCADPVAFPQLCQLCPGCGCSPTQPFFGYVGAFKCLRDGGGDVAFVKHTTIFEVLPQKADRDQYELLCLDNTRKPVDQYEDCYLARIPSHAVVARNGDGKEDLIWEILKVAQEHFGKGKSKDFQLFGSPLGKDLLFKDSAFGCYGVPPRMDYRLYLGHSYVTAIRNQREGVCPEASIDSAPVKWCALSHQERAKCDEWSVTSNGQIECESAESTEDCIDKIVNGEADAMSLDGGHAYIAGQCGLVPVMAENYDISSCTNPQSDVFPKGYYAVAVVKASDSSINWNNLKGKKSCHTGVDRTAGWNIPMGLLFSRINHCKFDEFFSQGCAPGYKKNSTLCDLCIGPAKCAPNNREGYNGYTGAFQCLVEKGDVAFVKHQTVLENTNGKNTAAWAKDLKQEDFQLLCPDGTKKPVTEFATCHLAQAPNHVVVSRKEKAARVSTVLTAQKDLFWKGDKDCTGNFCLFRSSTKDLLFRDDTKCLTKLPEGTTYEEYLGAEYLQAVGNIRKCSTSRLLEACTFHKS&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MVNFTVDQIRAIMDKKANIRNMSVIAHVDHGKSTLTDSLVCKAGIIASARAGETRFTDTRKDEQERCITIKSTAISLFYELSENDLNFIKQSKDGSGFLINLIDSPGHVDFSSEVTAALRVTDGALVVVDCVSGVCVQTETVLRQAIAERIKPVLMMNKMDRALLELQLEPEELYQTFQRIVENVNVIISTYGEGESGPMGNIMIDPVLGTVGFGSGLHGWAFTLKQFAEMYVAKFAAKGEGQLGAAERAKKVEDMMKKLWGDRYFDPANGKFSKSANSPDGKKLPRTFCQLILDPIFKVFDAIMNFRKEETAKLIEKLDIKLDSEDKDKEGKPLLKAVMRRWLPAGDALLQMITIHLPSPVTAQKYRCELLYEGPPDDEAAMGIKSCDPKGPLMMYISKMVPTSDKGRFYAFGRVFSGVVSTGLKVRIMGPNYTPGKKEDLYLKPIQRTILMMGRYVEPIEDVPCGNIVGLVGVDQFLVKTGTITTFEHAHNMRVMKFSVSPVVRVAVEAKNPADLPKLVEGLKRLAKSDPMVQCIIEESGEHIIAGAGELHLEICLKDLEEDHACIPIKKSDPVVSYRETVSEESNVLCLSKSPNKHNRLYMKARPFPDGLAEDIDKGEVSARQELKARARYLAEKYEWDVAEARKIWCFGPDGTGPNILTDITKGVQYLNEIKDSVVAGFQWATKEGALCEENMRGVRFDVHDVTLHADAIHRGGGQIIPTARRCLYASVLTAQPRLMEPIYLVEIQCPEQVVGGIYGVLNRKRGHVFEESQVAGTPMFVVKAYLPVNESFGFTADLRSNTGGQAFPQCVFDHWQILPGDPFDNSSRPSQVVAETRKRKGLKEGIPALDNFLDKL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MQALLFLMALLLPSGAGAEEIIGGVESIPHSRPYMAHLDIITERGLKDSCGGFLITRQFVLTAAHCRGREITVTLGAHDVSKREYTQQKIKVEKQFIHKNYNFLPNLHDIMLLKLEKQVELTPAVDVVPLPSPSDFIHPGTLCWTAGWGRTGVKDPTSDTLREVALRIMDEEACKIYRHYDNNFQVCVGLSTRLQTAYTGDSGGPLLCAGVVHGIVSYGHPDATPPAVFTRIAPYVPWINTVLRESS&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDAIKKKMQMLKLDKENALDRAEQAEADKKAAEDRSKQLEEDISAKEKLLRASEDERDRVLEELHKAEDSLLAADETAAKAEADVASLNRRIQLVEEELDRAQERLATALQKLEEAEKAADESERGMKVIESRAQKDEEKMEIQEIQLKEAKHIAEDADRKYEEVARKLVIIESDLERAEERAELSEGKCAELEEELKTVTNNLKSLEAQAEKYSQKEDKYEEEIKVLSDKLKEAETRAEFAERSVTKLEKSIDDLEEKVAHAKEENLSMHQMLDQTLLELNNM&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MCEEEDSTALVCDNGSGLCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIITNWDDMEKIWHHSFYNELRVAPEEHPTLLTEAPLNPKANREKMTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRLDLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEKSYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNVLSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKQEYDEAGPSIVHRKCF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MCEEETTALVCDNGSGLCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIITNWDDMEKIWHHSFYNELRVAPEEHPTLLTEAPLNPKANREKMTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRLDLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEKSYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNVLSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKPEYDEAGPSIVHRKCF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MCEEETTALVCDNGSGLCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIITNWDDMEKIWHHSFYNELRVAPEEHPTLLTEAPLNPKANREKMTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRLDLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEKSYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNVLSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKPEYDEAGPSIVHRKCF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAGSTTIEAVKRKIQVLQQQADDAEERAERLQREVEGERRAREQAEAEVASLNRRIQLVEEELDRAQEPLATALQKLEEAEKAADESERGMKVIENRALKDEEKMELQEIQLKEAKHIAEEADRKYEEVARKLVIIEGDLERTEERAELAESRCREMDEQIRLMDQNLKCLSAAEEKYSQKEDKYEEEIKILTDKLKEAETRAEFAERSVAKLEKTIDDLEDKLKCTKEEHLCTQRMLDQTLLDLNEM&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSSKRAKTKTTKKRPQRATSNVFAMFDQSQIQEFKEAFNMIDQNRDGFIDKEDLHDMLASMGKNPTDEYLDAMMNEAPGPINFTMFLTMFGEKLNGTDPEDVIRNAFACFDEEAIGTIQEDYLRELLTTMGDRFTDEEVDELYREAPIDKKGNFNYIEFTRILKHGAKDKDD&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSTSGPRAFSSRSFTSGPGARISSSSFSRVGSSSSSFRGSLGGFGGAGVGGITAVTVNQSLLNPLKLEVDPNIQAVRTQEKEQIKTLNNKFASFIDKVRFLEQQNKMLETKWSLLQQQKTSRSNMDNMFESYINNLRRQLEALGQEKLKLEVELGNMQGLVEDFKNKYEDEINKRTEMENEFVLIKKDVDEAYMNKVELESRLEGLTDEINFLRQIHEEEIRELQSQISDTSVVLSMDNSRSLDMDSIIAEVRAQYEEIANRSRAEAETMYQIKYEELQTLAGKHGDDLRRSKTEISEMNRNISRLQAEIDALKGQRATLEAAIADAEQRGELAVKDANAKLEDLKNALQKAKQDMARQLREYQELMNVKLALDIEIATYRKLLEGEESRLESGMQNMSIHTKTTSGYAGGLSSSYGGLTSPGFSYGMSSFQPGFGSVGGSSTYSRTKAVVVKKIETRDGKLVSESSDIMSK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MPKPINVRVTTMDAELEFAIQPNTTGKQLFDQVVKTIGLREVWYFGLQYVDNKGFPTWLKLDKKVSAQEVRKENPVQFKFRAKFYPEDVADELIQDITQKLFFLQVKEGILSDEIYCPPETAVLLGSYAVQAKFGDYNKEMHKSGYLSSERLIPQRVMDQHKLSRDQWEDRIQVWHAEHRGMLKDSAMLEYLKIAQDLEMYGINYFEIKNKKGTDLWLGVDALGLNIYEKDDKLTPKIGFPWSEIRNISFNDKKFVIKPIDKKAPDFVFYAPRLRINKRILQLCMGNHELYMRRRKPDTIEVQQMKAQAREEKHQKQLERQQLETEKKRRETVEREKEQMLREKEELMLRLQDFEQKTKRAEKELSEQIEKALQLEEERRRAQEEAERLEADRMAALRAKEELERQAQDQIKSQEQLAAELAEYTAKIALLEEARRRKEDEVEEWQHRAKEAQDDLVKTKEELHLVMTAPPPPPPPVYEPVNYHVQEGLQDEGAEPMGYSAELSSEGILDDRNEEKRITEAEKNERVQRQLQTLSNELSQARDENKRTHNDIIHNENMRQGRDKYKTLRQIRQGNTKQRIDEFEAM&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSSGNAKIGHPAPSFKATAVMPDGQFKDISLSDYKGKYVVFFFYPLDFTFVCPTEIIAFSDRAEEFKKLNCQVIGASVDSHFCHLAWINTPKKQGGLGPMNIPLVSDPKRTIAQDYGVLKADEGISFRGLFIIDDKGILRQITINDLPVGRSVDEILRLVQAFQFTDKHGEVCPAGWKPGSDTIKPDVNKSKEYFSKQK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSTAGKVIKCKAAVLWEPHKPFTIEDIEVAPPKAHEVRIKMVATGVCRSDDHAVSGSLFTPLPAVLGHEGAGIVESIGEGVTCVKPGDKVIPLFSPQCGKCRICKHPESNLCCQTKNLTQPKGALLDGTSRFSCRGKPIHHFLSTSTFSQYTVVDDIAVAKIDAAAPLDKVCLIGCGFSTGYGSAVQVAKVTPGSTCAVFGLGGVGLSVVIGCKTAGAAKIIAVDINKDKFAKAKELGATDCINPQDYTKPIQEVLQEMTDGGVDFSFEVIGRLDTMTSALLSCHSACGVSVIVGVPPSAQSLSVNPMSLLLGRTWKGAIFGGFKSKDAVPKLVADFMAKKFPLEPLITHVLPFEKINEAFDLLRAGKSIRTVLTF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MLCRAACSAGRRLGPAASTAGSRHKHSLPDLPYDYGALEPHINAQIMQLHHSKHHATYVNNLNVTEEKYHEALAKGDVTTQVALQPALKFNGGGHINHSIFWTNLSPKGGGEPKGELLEAIKRDFGSFEKFKEKLTAVSVGVQGSGWGWLGFNKEQGRLQIAACSNQDPLQGTTGLIPLLGIDVWEHAYYLQYKNVRPDYLKAIWNVINWENVSQRYIVCKK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MGLHPCSPVDHGVPSWVLVLLLTLGLCSLQATADSVLDPDFRENYFEQYMDHFNFESFSNKTFGQRFLVSDKFWKMGEGPIFFYTGNEGDIWSLANNSGFIVELAAQQEALLVFAEHRYYGKSLPFGVQSTQRGYTQLLTVEQALADFAVLLQALRHNLGVQDAPTIAFGGSYGGMLSAYMRMKYPHLVAGALAASAPVIAVAGLGNPDQFFRDVTADFYGQSPKCAQAVRDAFQQIKDLFLQGAYDTISQNFGTCQSLSSPKDLTQLFGFARNAFTVLAMMDYPYPTNFLGPLPANPVKVGCERLLSEGQRIMGLRALAGLVYNSSGMEPCFDIYQMYQSCADPTGCGTGSNARAWDYQACTEINLTFDSNNVTDMFPEIPFSDELRQQYCLDTWGVWPRPDWLQTSFWGGDLKAASNIIFSNGDLDPWAGGGIQRNLSTSIIAVTIQGGAHHLDLRASNSEDPPSVVEVRKLEATLIREWVAAARLKQPAEAQWPGPK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRVLWVLGLCCVLLTFGFVRADDEVDVDGTVEEDLGKSREGSRTDDEVVQREEEAIQLDGLNASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFLRELISNASDALDKIRLISLTDENALAGNEELTVKIKCDREKNLLHVTDTGVGMTREELVKNLGTIAKSGTSEFLNKMTEAQEDGQSTSELIGQFGVGFYSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLGRGTTITLVLKEEASDYLELDTIKNLVRKYSQFINFPIYVWSSKTETVEEPLEEDETAQEEKEEADDEAAVEEEEEEKKPKTKKVEKTVWDWELMNDIKPIWQRPSKEVEEDEYKAFYKSFSKESDDPMAYIHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVRRVFITDDFHDMMPKYLNFVKGVVDSDDLPLNVSRETLQQHKLLKVIRKKLVRKTLDMIKKIADEKYNDTFWKEFGTNIKLGVIEDHSNRTRLAKLLRFQSSHHSTDITSLDQYVERMKEKQDKIYFMAGSSRKEAESSPFVERLLKKGYEVIYLTEPVDEYCIQALPEFDGKRFQNVAKEGVKFDESEKSKESREATEKEFEPLLNWMKDKALKDKVFGPQTVVSPHRN&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MNVCTFTLVLALVGSVSGQYYDYDAPLFMYGELSPNCAPECNCPHSYPTAMYCDDLKLKSVPMVPPGIKYLYLRNNQIDHIDEKAFENVTDLQWLILDHNLLENSKIKGKVFSKLKQLKKLHINYNNLTESVGPLPKSLQDLQLANNKISKLGSFDGLVNLTFIYLQHNQLKEEAVSASLKGLKSLEYLDLSFNQMSKLPAGLPTSLLTLYLDNNKITNIPDEYFNRFTGLQYLRLSHNELADSGVPGNSFNISSLLELDLSYNKLKSIPTVNENLENYYLEVNKLEKFDVKSFCKILGPLSYSKIKHLRLDGNPLTQSSLPPDMYECLRVANEITVN&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MADKEAAFDDAVEERVINEEYKIWKKNTPFLYDLVMTHALEWPSLTAQWLPDVTRPEGKDFSIHRLVLGTHTSDEQNHLVIASVQLPNDDAQFDASHYDSEKGEFGGFGSVSGKIEIEIKINHEGEVNRARYMPQNPCIIATKTPSSDVLVFDYTKHPSKPDPSGECNPDLRLRGHQKEGYGLSWNPNLSGHLLSASDDHTICLWDISAVPKEGKVVDAKTIFTGHTAVVEDVSWHLLHESLFGSVADDQKLMIWDTRSNNTSKPSHSVDAHTAEVNCLSFNPYSEFILATGSADKTVALWDLRNLKLKLHSFESHKDEIFQVQWSPHNETILASSGTDRRLNVWDLSKIGEEQSPEDAEDGPPELLFIHGGHTAKISDFSWNPNEPWVICSVSEDNIMQVWQMAENIYNDEDPEGSVDPEGQGS&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDDREDLVYQAKLAEQAERYDEMVESMKKVAGMDVELTVEERNLLSVAYKNVIGARRASWRIISSIEQKEENKGGEDKLKMIREYRQMVETELKLICCDILDVLDKHLIPAANTGESKVFYYKMKGDYHRYLAEFATGNDRKEAAENSLVAYKAASDIAMTELPPTHPIRLGLALNFSVFYYEILNSPDRACRLAKAAFDDAIAELDTLSEESYKDSTLIMQLLRDNLTLWTSDMQGDGEEQNKEALQDVEDENQ&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRKYKEALLGRVAVSADPNVPNVIVTRLTLVCSTAPGPLELDLTGDLESFKKQSFVLKEGVEYRIKISFRVNREIVSGMKYIQHTYRKGVKIDKTDYMVGSYGPRAEEYEFLTPMEEAPKGMLARGSYNIKSRFTDDDKTDHLSWEWNLTIKKEWKD&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MADGFSLNDALAGSGNPNPRGWPGAWGNQPGAGGYPGASYPGAYPGQAPPGGYPGQAPPSAYPGPTGPSAYPGPTAPGAYPGPTAPGAFPGQPGGPGAYPSAPGAYPSAPGAYPATGPFGAPTGPLTVPYDMPLPGGVMPRMLITIIGTVKPNANSITLNFKKGNDIAFHFNPRFNENNRRVIVCNTKQDNNWGREERQSAFPFESGKPFKIQVLVEADHFKVAVNDVHLLQYNHRMKNLREISQLGIIGDITLTSASHAMI&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                         Resultados e Discuss\u00e3o \n\n62 \n\nMetabolismo de Carboidratos       \n\n30 \n\n31 \n\n33 \n\n39 \n\n41 \n\n54 \n\n55 \n\n83 \n\nTKT \n\nPKM2 \n\nDLD \n\nALDOA \n\nGAPDH \n\nGAPDH \n\nENO1 \n\nPGK1 \n\nTranscetolase \n\nPiruvato quinase M2 \n\nDihidrolipoil dehidrogenase \n\nAldolase A \n\nGlicerald.-3-fosf. Dehidrogenase \n\nGlicerald.-3-fosf. Dehidrogenase \n\nEnolase alfa \n\nFosfoglicerato quinase 1 \n\ngi|12018252 \ngi|206205  \n\ngi|40786469 \n\ngi|202837 \n\n gi|8393418 \n\ngi|56188 \n\ngi|38649320 \n\ngi|40254752 \n\n1 \n\n25 \n\n10 \n\n1 \n\n1 \n\n6 \n\n5 \n\n15 \n\n39 \n\n61 \n\n28 \n\n60 \n\n62 \n\n21 \n\n23 \n\n64 \n\n7,54 \n\n7,15 \n\n7,96 \n\n8,31 \n\n8,14 \n\n8,43 \n\n6,7 \n\n8 \n\n71,9 \n\n58,3 \n\n54,6 \n\n39,7 \n\n36,1 \n\n36,1 \n\n51,7 \n\n44,9 \n\n60,7 \n\n52 \n\n50,6 \n\n34,3 \n\n31,5 \n\n30,1 \n\n43,3 \n\n38,4 \n\nMetabolismo de Nucleot\u00eddeos/Fosfato       \n\n29 \n\n80 \n\nATIC \n\nCMPK \n\nBioss\u00edntese de purina bifunc. PURH \n\nCitidina monofosfato quinase \n\ngi|48675845 \n\n gi|150383503 \n\n16 \n\n10 \n\n41 \n\n62 \n\n6,69 \n\n5,66 \n\n64,6 \n\n22,4 \n\n53,5 \n\n17,5 \n\nModelamento de Prote\u00ednas       \n\n18 \n\n20 \n\n29 \n\nCALR \n\nHSP90B1 \n\nCCT6 \n\nCalreticulina \n\nEndoplasmina \n\nProte\u00edna Complexo-T 1 sub. zeta \n\n gi|11693172 \n\n gi|210032365  \n\n gi|76253725 \n\n15 \n\n19 \n\n14 \n\n52 \n\n30 \n\n48 \n\n4,33 \n\n4,72 \n\n6,63 \n\n48,2 \n\n92,9 \n\n58,4 \n\n50,6 \n\n88,9 \n\n53,5 \n\nOutros Processos       \n\n7 \n\n27 \n\n43 \n\n50 \n\nSELENBP \n\nWDR1 \n\nVDAC2 \n\nIGG2A \n\nProte\u00edna ligante de sel\u00eanio 1 \n\nRepeti\u00e7\u00e3o WD contendo prote\u00edna 1 \n\nCanal sele\u00e7\u00e3o \u00e2nion voltagem dep.2 \n\nImunogl. Gama-2a cadeia pesada \n\ngi|18266692 \n\ngi|62078997 \n\ngi|13786202 \n\ngi|1220486 \n\n25 \n\n17 \n\n11 \n\n10 \n\n58 \n\n32 \n\n51 \n\n30 \n\n6,1 \n\n6,15 \n\n7,44 \n\n8,15 \n\n53,1 \n\n66,8 \n\n32,4 \n\n52,2 \n\n47,9 \n\n58,7 \n\n25,4 \n\n43,3 \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDPVRQIQCDREGKRFPFLSAPPASTSSPDRAMEGYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKALDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLPEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCMLGDGEVSEGSVWEAMAFAGIYKLDNLVAIFDINRLGQSDPAPLQHQVDVYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIAKTFKGRGITGIEDKEAWHGKPLPKNMAEQIIQEIYSQVQSKKKILATPPQEDAPSVDIANIRMPTPPNYKVGDKIATRKAYGLALAKLGHASDRIIALDGDTKNSTFSELFKKEHPDRFIECYIAEQNMVSIAVGCATRDRTVPFCSTFAAFFTRAFDQIRMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPMSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAIIYSNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAEMLKKEKIGVRVLDPFTIKPLDKKLILDCARATKGRILTVEDHYYEGGIGEAVSAVVVGEPGVTVTRLAVSQVPRSGKPAELLKMFGIDKDAIVQAVKGLVTKG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MPKPDSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSAPITARNTGIICTIGPASRSVEMLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRAATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKEKGADYLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKAADVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEAAAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDAVLDAWAEDVDLRVNLAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPVP&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MQSWSRVYCSLAKKGHFNRLSHGLQGASSVPLRTYSDQPIDADVTVIGSGPGGYVAAIKAAQLGFKTVCIEKNETLGGTCLNVGCIPSKALLNNSHYYHLAHGKDFASRGIEIPEVRLNLEKMMEQKRSAVKALTGGIAHLFKQNKVVHVNGFGKITGKNQVTATTADGSTQVIGTKNILIATGSEVTPFPGITIDEDTIVSSTGALSLKKVPEKLVVIGAGVIGVELGSVWQRLGADVTAVEFLGHVGGIGIDMEISKNFQRILQKQGFKFKLNTKVTGATKKSDGKIDVSVEAASGGKAEVITCDVLLVCIGRRPFTQNLGLEELGIELDPKGRIPVNTRFQTKIPNIFAIGDVVAGPMLAHKAEDEGIICVEGMAGGAVHIDYNCVPSVIYTHPEVAWVGKSEEQLKEEGVEFKVGKFPFAANSRAKTNADTDGMVKILGHKSTDRILGAHILGPGAGEMVNEAALALEYGASCEDVARVCHAHPTLSEAFREANLAASFGKPINF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MPHPYPALTPEQKKELADIAHRIVAPGKGILAADESTGSIAKRLQSIGTENTEENRRFYRQLLLTADDRVNPCIGGVILFHETLYQKADDGRPFPQVIKSKGGVVGIKVDKGVVPLAGTNGETTTQGLDGLSERCAQYKKDGADSAKWRCVLKIGEHTPSSLAIVENANVLARYASICQQNGIVPIVEPEILPDGDHDLKRCQYVTEKVLAAVYKALSDHHVYLEGTLLKPNMVTPGHACTQKFSNEEIAMATVTALRRTVPPAVPGVTFLSGGQSEEEASINLNAINKCPLLKPWALTFSYGRALQASALKAWGGKKENLKAAQEEYIKRALANSLACQGKYTPSGQSGAAASESLFISNHAY&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MVKVGVNGFGRIGRLVTRAAFSCDKVDIVAINDPFIDLNYMVYMFQYDSTHGKFNGTVKAENGKLVINGKPITIFQERDPANIKWGDAGAEYVVESTGVFTTMEKAGAHLKGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIVSNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGAAQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTPNVSVVDLTCRLEKPAKYDDIKKVVKQAAEGPLKGILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNFVKLISWYDNEYGYSNRVVDLMAYMASKE&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MVKVGVNGFGRIGRLVTRAAFSCDKVDIVAINDPFIDLNYMVYMFQYDSTHGKFNGTVKAENGKLVINGKPITIFQERDPVKIKWGDAGAEYVVESTGVFTTMEKAGAHLKGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIVSNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGAAQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTPNVSVVDLTCRLEKPAKYDDIKKVVKQAAEGPLKGILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNIVKLISWYDNEYGYSNRVVDLMAYMASKE&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=GECCSGTESRSRLSLRLPSVSPGPSFLPPQRSYCQNFTMSILKIHAREIFDSRGNPTVEVDLYTAKGLFRAAVPSGASTGIYEALELRDNDKTRFMGKGVSKAVEHINKTIAPALVSKKLNVVEQEKIDQLMIEMDGTENKSKFGANAILGVSLAVCKAGAVEKGVPLYRHIADLAGNPEVILPVPAFNVINGGSHAGNKLAMQEFMILPVGASSFREAMRIGAEVYHNLKNVIKEKYGKDATNVGDEGGFAPNILENKEALELLKSAIAKAGYTDQVVIGMDVAASEFYRAGKYDLDFKSPDDASRYITPDQLADLYKSFIKDYPVVSIEDPFDQDDWDAWQKFTATAGIQVVGDDLTVTNPKRIAKAAGEKSCNCLLLKVNQIGSVTESLQACKLAQSNGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQILRIEEELGSKAKFAGRSFRNPLAK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQRIKAAVPSIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAAELKSLLGKDVLFLKDCVGSEVENACANPAAGTVILLENLRFHVEEEGKGKDASGNKVKAEPAKIDAFRASLSKLGDVYVNDAFGTAHRAHSSMVGVNLPQKAGGFLMKKELNYFAKALESPERPFLAILGGAKVADKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLYDEEGAKIVKDLMAKAEKNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGTESSKKYAEAVARAKQIVWNGPVGVFEWEAFARGTKSLMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGKVLPGVDALSNV&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MASSQLALFSVSDKTGLVEFARNLASLGLSLVASGGTAKAIRDAGLAVRDVSELTGFPEMLGGRVKTLHPAVHAGILARNIPEDAADMARLDFNLIRVVVCNLYPFVKTVASPDVTVEAAVEQIDIGGVTLLRAAAKNHARVTVVCEPEDYGAVAAEMQGSGNKDTSLETRRHLALKAFTHTAQYDEAISDYFRRQYSKGISQMPLRYGMNPHQTPAQLYTLKPKLPITVLNGAPGFINLCDALNAWQLVTELRGAVDIPAAASFKHVSPAGAAVGVPLSEDEARVCMVYDLYPTLTPLAIAYARARGADRMSSFGDFVALSDVCDVPTAKIISREVSDGIVAPGYEEEALKILSKKKNGSYCVLQMDQSYKPDENEVRTLFGLRLSQKRNNGVVDKSLFSNIVTKNKDLPESALRDLIVATIAVKYTQSNSVCYAKDGQVIGIGAGQQSRIHCTRLAGDKANSWWLRHHPRVLSMKFKAGVKRAEVSNAIDQYVTGTIGEGEDLVKWKALFEEVPELLTEAEKKEWVDKLSGVSVSSDAFFPFRDNVDRAKRSGVAYIVAPSGSTADKVVIEACDELGIVLAHTDLRLFHH&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MKPLVVFVLGGPGAGKGTQCARIVEKYGYTHLSAGELLRDERKNPDSQYGELIEKYIKEGKIVPVEITISLLKREMDQTMAANAQKNKFLIDGFPRNQDNLQGWNKTMDGKADVSFVLFFDCNNEICIDRCLERGKSSGRSDDNRESLEKRIQTYLESTKPIIDLYEEMGKVKKIDASKSVDEVFGDVMKIFDKEG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MLLSVPLLLGLLGLAAADPAIYFKEQFLDGDAWTNRWVESKHKSDFGKFVLSSGKFYGDQEKDKGLQTSQDARFYALSARFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPGGLDQKDMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDNTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDAAKPEDWDERAKIDDPTDSKPEDWDKPEHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYSPDANIYAYDSFAVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDKQDEEQRLKEEEEDKKRKEEEEAEDKEDEDDRDEDEDEEDEKEEDEEDATGQAKDEL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRVLWVLGLCCVLLTFGFVRADDEVDVDGTVEEDLGKSREGSRTDDEVVQREEEAIQLDGLNASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFLRELISNASDALDKIRLISLTDENALAGNEELTVKIKCDREKNLLHVTDTGVGMTREELVKNLGTIAKSGTSEFLNKMTEAQEDGQSTSELIGQFGVGFYSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLGRGTTITLVLKEEASDYLELDTIKNLVRKYSQFINFPIYVWSSKTETVEEPLEEDETAQEEKEEADDEAAVEEEEEEKKPKTKKVEKTVWDWELMNDIKPIWQRPSKEVEEDEYKAFYKSFSKESDDPMAYIHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVRRVFITDDFHDMMPKYLNFVKGVVDSDDLPLNVSRETLQQHKLLKVIRKKLVRKTLDMIKKIADEKYNDTFWKEFGTNIKLGVIEDHSNRTRLAKLLRFQSSHHSTDITSLDQYVERMKEKQDKIYFMAGSSRKEAESSPFVERLLKKGYEVIYLTEPVDEYCIQALPEFDGKRFQNVAKEGVKFDESEKSKESREATEKEFEPLLNWMKDKALKDKIEKAVVSQRLTESPCALVASQYGWSGNMERIMKAQAYQTGKDISTNYYASQKKTFEINPRHPLIRDMLRRVKEDEDDKTVMDLAVVLFETATLRSGYLLPDTKAYGDRIERMLRLSLNIDPEAQVEEEPEEEPEDTTEDTTDDSEQDEEETDAGAEEEEEEQETEKEPTEKDEL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAAVKTLNPKAEVARAQAALAVNISAARGLQDVLRTNLGPKGTMKMLVSGAGDIKLTKDGNVLLHEMQIQHPTASLIAKVATAQDDITGDGTTSNVLIIGELLKQADLYISEGLHPRIITEGFEAAKEKALQFLEQVKVSKEMDRETLIDVARTSLRTKVHAELADVLTEAVVDSILAIRKKDEPIDLFMVEIMEMKHKSETDTSLIRGLVLDHGARHPDMKKRVENAYILTCNVSLEYEKTEVNSGFFYKSAEEREKLVKAERKFIEDRVKKIVELKKKVCGDSDKGFVVINQKGIDPFSLDALAKEGIVALRRAKRRNMERLTLACGGIALNSFDDLNPDCLGHAGLVYEYTLGEEKFTFIEKCNNPRSVTLLVKGPNKHTLTQIKDAIRDGLRAVKNAIDDGCVVPGAGAVEVALAEALIKYKPSVKGRAQLGVQAFADALLIIPKVLAQNSGFDLQETLVKVQAEHSESGQLVGVDLNTGEPMVAAEMGVWDNYCVKKQLLHSCTVIATNILLVDEIMRAGMSSLKG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MATKCTKCGPGYATPLEAMKGPREEIVYLPCIYRNTGIEAPDYLATVDVDPKSPHYSQVIHRLPMPHLKDELHHSGWNTCSSCFGDSTKSRDKLILPSIISSRIYVVDVGSEPRAPKLHKVIEPNEIHAKCNLGNLHTSHCLASGEVMISSLGDPQGNGKGGFVLLDGETFEVKGTWEKPGGEAPMGYDFWYQPRHNIMVSTEWAAPNVFKDGFNPAHVEAGLYGSHIHVWDWQRHEIIQTLQMKDGLIPLEIRFLHDPDATQGFVGCALSSNIQRFYKNEGGTWSVEKVIQVPSKKVKGWMLPEMPGLITDILLSLDDRFLYFSNWLHGDIRQYDISNPKKPRLTGQIFLGGSIVKGGSVQVLEDQELTCQPEPLVVKGKRVPGGPQMIQLSLDGKRLYVTTSLYSAWDKQFYPNLIREGSVMLQIDVDTANGGLKLNPNFLVDFGKEPLGPALAHELRYPGGDCSSDIWI&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MPYEIKKVFASLPQVERGVSKILGGDPKGDNFLYTNGKCVILRNIDNPAVADIYTEHAHQVVVAKYAPSGFYIASGDISGKLRIWDTTQKEHILKYEYQPFAGKIKDIAWTEDSKRIAVVGEGREKFGAVFLWDTGSSVGEITGHNKVINSVDIKQNRPYRLATGSDDNCAAFFEGPPFKFKFTIGDHSRFVNCVRFSPDGNRFATASADGQIFIYDGKTGEKVCALGGSKAHDGGIYAISWSPDSTHLLSASGDKTSKIWDVNVNSVVSTFPMGSNVLDQQLGCLWQKDHLLSISLSGYINYLDKNNPSKPLRVIKGHSKSIQCLTVHKNGGKSYIYSGSHDGHINYWDSETGENDSFSGKGHTNQVSRMTVDESGQLVSCSMDDTVRYTNLTLRDYSGQGVVKLDVQPKCVAVGPGGYTVVVCIGQIVLLKDQKKCFSIDNPGYEPEVVAVHPGGDTVAVGGSDGNVRVYSILGATLKDEGKLLEAKGPVTDLAYSHDGAFLAVCDASKVVTVFSVADGYSENNVFYGHHAKIVCLAWSPDNEHFASGGMDMMVYVWTLSDPETKVKIQDAHRLHHVSSLAWLDEHTLVTTSHDASVKEWTITY&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAECCVPVCQRPICIPPPYADLGKAARDIFNKGFGFGLVKLDVKTKSCSGVEFSTSGSSNTDTGKVSGTLETKYKWCEYGLTFTEKWNTDNTLGTEIAIEDQICQGLKLTFDTTFSPNTGKKSGKIKSAYKRECINLGCDVDFDFAGPAIHGSAVFGYEGWLAGYQMTFDSAKSKLTRSNFAVGYRTGDFQLHTNVNNGTEFGGSIYQKVCEDFDTSVNLAWTSGTNCTRFGIAAKYQLDPTASISAKVNNSSLIGVGYTQTLRPGVKLTLSALVDGKSFNAGGHKLGLALELEA&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MKLWLNWIFLLTLLNGIQCEVKLLESGGGLVQPGGSMRLSCAASGFTFTDFYMNWIRQPAGKAPEWLGFIRNKANGYTTEYNPSVKGRFTISRDNTQNMLYLQMNTLRAEDTATYYCARGDYFNNYMFPYVMDAWGQGGSVTVSSAETTAPSVYPLAPGTALKSNSMVTLGCLVKGYFPEPVTVTWNSGALSSGVHTFPAVLQSGLYTLTSSVTVPSSTWSSQAVTCNVAHPASSTKVDKKIVPRECNPCGCTGSEVSSVFIFPPKTKDVLTITLTPKVTCVVVDISQNDPEVRFSWFIDDVEVHTAQTHAPEKQSNSTLRSVSELPIVHRDWLNGKTFKCKVNSGAFPAPIEKSISKPEGTPRGPQVYTMAPPKEEMTQSQVSITCMVKGFYPPDIYTEWKMNGQPQENYKNTPPTMDTDGSYFLYSKLNVKKETWQQGNTFTCSVLHEGLHNHHTEKSLSHSPGK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n63 \n\n Os n\u00edveis de altera\u00e7\u00e3o na express\u00e3o para cada prote\u00edna descrita nas tabelas \n\nanteriores podem ser observados nas Figuras 22 e 24. As mol\u00e9culas identificadas foram \n\ncategorizadas de acordo com sua fun\u00e7\u00e3o biol\u00f3gica em prote\u00ednas envolvidas na resposta \n\nao estresse, organiza\u00e7\u00e3o de citoesqueleto, atividade antioxidante, sinaliza\u00e7\u00e3o celular, \n\nmetabolismo de carboidratos, lip\u00eddeos e nucleot\u00eddeos, modelamento, s\u00edntese e degrada\u00e7\u00e3o \n\nde prote\u00ednas. \n\n \n\n  \n\nFigura 22:  Diferen\u00e7a nos n\u00edveis de express\u00e3o proteica dos grupos Teste DBT IV (barras brancas) e Teste \n\nDBTO2 V (barras pretas) em rela\u00e7\u00e3o ao grupo Controle \u00d3leo III. Os resultados representam a m\u00e9dia \u00b1 SEM \n\nde triplicatas biol\u00f3gicas independentes. Asteriscos indicam diferen\u00e7as estatisticamente significativas entre \n\nos grupos IV e V para uma dada prote\u00edna.  \n\n \n\n \n\nNa Figura 22 que compara as altera\u00e7\u00f5es encontradas nos grupos Teste IV e V em \n\nrela\u00e7\u00e3o ao grupo Controle III, podemos observar que apenas as prote\u00ednas HSPA2 e \n\nHSPA5 tiveram seus n\u00edveis diminu\u00eddos para ambos os grupos. Interessantemente, os spots \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n64 \n\nidentificados como ARHGDIA, PGK1 e CKB demonstraram n\u00edveis de express\u00e3o opostos \n\nentre os dois grupos Testes em quest\u00e3o. As prote\u00ednas ACTB e CANX tiveram n\u00edveis \n\naumentados de express\u00e3o e foram utilizadas na valida\u00e7\u00e3o dos resultados obtidos por \n\nan\u00e1lise prote\u00f4mica via 2D SDS-PAGE atrav\u00e9s de Western blotting (Ap\u00eandice E \u2013 Fig. \n\n01.E). \n\nMol\u00e9culas envolvidas na organiza\u00e7\u00e3o do citoesqueleto como cofilina 1, coronina \n\n1, actina e tropomiosina 5, merecem aten\u00e7\u00e3o por estarem super expressas. Nesse contexto, \n\ndiversos trabalhos j\u00e1 demonstraram aumento nos n\u00edveis de express\u00e3o da prote\u00edna coronina \n\n1 em tecidos tumorais de mama onde ela parece contribuir para invas\u00e3o e migra\u00e7\u00e3o das \n\nc\u00e9lulas tumorais. A super express\u00e3o de CORO1A parece estar relacionada \u00e0 transloca\u00e7\u00e3o \n\nde Rac1 para a membrana plasm\u00e1tica. Rac1 GTPase, por sua vez, controla diversos \n\nprocesso gerais como a din\u00e2mica do citoesqueleto, regula\u00e7\u00e3o de tamanho celular e entrada \n\nno ciclo celular al\u00e9m da transcri\u00e7\u00e3o g\u00eanica. Para tal, Rac1 interage com efetores como \n\nprote\u00ednas quinases, enzimas, prote\u00ednas de modelamento e reguladores diretos do \n\ncrescimento, estabiliza\u00e7\u00e3o e ramifica\u00e7\u00e3o do filamento de actina. A atividade de Rac1 \u00e9 \n\ncontrolada atrav\u00e9s da transi\u00e7\u00e3o do estado inativo, ligado a GDP, ao estado ativo, ligado a \n\nGTP. Fatores de troca GDP/GTP, prote\u00ednas ativadoras de GTPases e inibidores de \n\ndissocia\u00e7\u00e3o de Rho GDP (RhoGDI) realizam esse controle. CORO1A parece estar \n\nenvolvida tamb\u00e9m na modula\u00e7\u00e3o da resposta imune desempenhando papel na \n\nsobreviv\u00eancia, migra\u00e7\u00e3o, ativa\u00e7\u00e3o e regula\u00e7\u00e3o de Ca2+ em c\u00e9lulas T al\u00e9m de suprimir a \n\nativa\u00e7\u00e3o de NF-?B inibindo a degrada\u00e7\u00e3o de I?B? e a transloca\u00e7\u00e3o nuclear de p65 (Kim \n\net al., 2009; Castro-Castro et al., 2011; Kaminski et al., 2011; Liu et al., 2014). \n\nN\u00edveis aumentados de cofilina 1 parecem estar associados com um progn\u00f3stico \n\nruim em pacientes com c\u00e2ncer de pulm\u00e3o. Esta prote\u00edna desempenha um papel central no \n\ncontrole da polimeriza\u00e7\u00e3o de filamentos de actina. Sua atividade pode ser regulada por \n\nfosforila\u00e7\u00e3o/defosforila\u00e7\u00e3o em res\u00edduos de serina ap\u00f3s a estimula\u00e7\u00e3o de receptores \n\nligados \u00e0 prote\u00edna G regulados predominantemente por via dependente de Rac2 e GSK3. \n\nPI3K pode promover ativa\u00e7\u00e3o da fosfatase SSH1 induzida por insulina e defosforila\u00e7\u00e3o \n\nde CFL1 em c\u00e9lulas de c\u00e2ncer de mama (Peng et al., 2011; Bravo-Cordero et al.,2013).  \n\nA diminui\u00e7\u00e3o da express\u00e3o da tropomiosina 5 em c\u00e9lulas de melanoma de \n\ncamundongos levou ao comprometimento e diminui\u00e7\u00e3o da motilidade, contribuindo para \n\na redu\u00e7\u00e3o do potencial metast\u00e1tico dessas c\u00e9lulas, demonstrando o papel desempenhado \n\npor essa prote\u00edna no estabelecimento e migra\u00e7\u00e3o tumoral (Miyado et al., 1996). A \n\nexpress\u00e3o alterada de isoformas celulares e nucleares de actina tem sido demonstrada \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n65 \n\ndurante a tumorog\u00eanese como resultado de sinaliza\u00e7\u00e3o epigen\u00e9tica e perfil gen\u00e9tico \n\nalterado para as sequ\u00eancias espec\u00edficas relacionadas com tais genes (Rao et al., 1997).  \n\nInteressantemente, a prote\u00edna ARHGDIA (Rho-GDI), que tamb\u00e9m apresentou \n\nn\u00edveis aumentados de express\u00e3o celular, encontra-se relacionada \u00e0 YWHAE atuando em \n\nvias de sinaliza\u00e7\u00e3o relacionadas. ARHGDIA regula a troca GDP/GTP em prote\u00ednas \n\nGTPases relacionadas a Ras (subfam\u00edlia de prote\u00ednas Rho - CDC42, RAC1 e RHOA) \n\nimpedindo a dissocia\u00e7\u00e3o de GDP e mantendo-as em estado inativado, protegendo-as de \n\ndegrada\u00e7\u00e3o. N\u00edveis elevados de Rho-GDI podem resultar em migra\u00e7\u00e3o celular aumentada \n\ne preven\u00e7\u00e3o de apoptose contribuindo para a sobreviv\u00eancia e migra\u00e7\u00e3o tumoral como \n\ndescrito para c\u00e2ncer de pulm\u00e3o e c\u00f3lon, al\u00e9m de serem associados com quimioresist\u00eancia \n\nem diversas linhagens celulares. A for\u00e7a da intera\u00e7\u00e3o Rac1/RhoGDI \u00e9 modulada \n\nnegativamente por diversos sinais incluindo prote\u00edna quinase C (Adra et al., 1997; Faure \n\nand Dagher, 2001; Wei et al., 2002; Dovas and Couchman, 2005; Zhao et al., 2008). \n\nEnzimas envolvidas no metabolismo de lip\u00eddeos e carboidratos tamb\u00e9m \n\napresentaram aumento significativo nos tecidos displ\u00e1sicos avaliados. Um aumento \n\nsignificativo na express\u00e3o da enzima triacilglicerol lipase aponta para um papel chave \n\ndesempenhado por essa prote\u00edna para sustentar a alta demanda energ\u00e9tica requerida pelas \n\nc\u00e9lulas proliferativas. Em paralelo, a super express\u00e3o de enzimas envolvidas no \n\nmetabolismo de carboidratos, particularmente aquelas relacionadas \u00e0 via glicol\u00edtica, \n\npodem permitir a utiliza\u00e7\u00e3o do glicerol proveniente do metabolismo lip\u00eddico aumentado. \n\nO mapa de intera\u00e7\u00e3o proteica observado na Figura 23, ilustra estas rela\u00e7\u00f5es. Mais \n\nde 50% das prote\u00ednas identificadas demonstram algum grau de intera\u00e7\u00e3o intracelular. De \n\nrelev\u00e2ncia particular, os altos n\u00edveis de triacilglicerol lipase e de enzimas envolvidas no \n\nprocessamento de glicerol/carboidrato, fornecem um ind\u00edcio prim\u00e1rio sobre o \n\nmetabolismo dos tecidos displ\u00e1sicos induzidos pela exposi\u00e7\u00e3o ao DBT e DBTO2. \n\nAinda em concord\u00e2ncia com o exposto anteriormente, os n\u00edveis aumentados \n\nobservados para peroxiredoxina 1 podem explicar seu papel no metabolismo de radicais \n\nlivres, particularmente per\u00f3xidos, gerados por ?-oxida\u00e7\u00e3o de \u00e1cidos graxos. Um papel \n\nadicional para o aumento de express\u00e3o para prote\u00ednas relacionadas ao estresse oxidativo, \n\nincluindo HSP70, seria controlar o efeito t\u00f3xico promovido pelo intenso infiltrado \n\ninflamat\u00f3rio observado. Membros da fam\u00edlia da HSP70 relacionam-se com o \n\nmodelamento de prote\u00ednas contribuindo significativamente para a homeostase proteica. \n\nA isoforma HSP70-1 \u00e9 expressa em altos n\u00edveis em tecidos normais e tumorais \n\nsendo simplesmente referida como HSP70 (Murphy, 2013). Em contraste, a express\u00e3o de \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n66 \n\nHSP70-2, conhecida como HSPA2, mostra n\u00edveis diminu\u00eddos em diversos tecidos, com \n\nexce\u00e7\u00e3o descrita em literatura para test\u00edculos de ratos (Scieglinska et al., 2011). \n\nConcordando com os resultados obtidos neste trabalho, Scieglinska e colaboradores \n\nreportaram n\u00edveis indetect\u00e1veis de HSPA2 em tr\u00eas diferentes linhagens de c\u00e9lulas \n\ntumorais incluindo HCT116 de CCR (Scienglinska et al., 2008). A prote\u00edna HSPA5 \n\ntamb\u00e9m demonstrou baixos n\u00edveis de express\u00e3o nos grupos Teste IV e V, mas seu papel \n\nna progress\u00e3o de neoplasias em intestino delgado continua obscuro.    \n\n \n\n \n\nFigura 23: Mapa de intera\u00e7\u00e3o proteica para prote\u00ednas diferencialmente expressas entre grupos Teste IV e \n\nV e Controle III. Linhas azuis indicam intera\u00e7\u00f5es prote\u00edna-prote\u00edna. A espessura das linhas indica a for\u00e7a \n\ndas associa\u00e7\u00f5es. Mapa montado utilizando o software STITCH v. 4.0. \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n67 \n\nA Figura 24 apresenta os resultados obtidos com a an\u00e1lise prote\u00f4mica para o grupo \n\nTeste II em rela\u00e7\u00e3o ao grupo Controle I. Quando avaliadas as prote\u00ednas relacionadas \u00e0 \n\norganiza\u00e7\u00e3o do citoesqueleto, os spots identificados indicaram diferentes tipos de \n\nregula\u00e7\u00e3o sendo sub expressas as prote\u00ednas ACTB, TPM1 e TAGLN e super expressas as \n\nprote\u00ednas TPM5, MYL, KRT8 e EZR. TPM5 tamb\u00e9m apresentou n\u00edveis aumentados \n\nquando avaliados os grupos Teste IV e V. \n\n \n\n \nFigura 24:  Diferen\u00e7a nos n\u00edveis de express\u00e3o proteica entre o grupo Teste DMH (II) e o grupo Controle \n\nSalina (I). Os resultados representam a m\u00e9dia \u00b1 SEM de triplicatas biol\u00f3gicas independentes. \n\n \n\n \n\n Os spots identificados como PGK1 e ARHGDIA apresentaram resultados opostos \n\n\u00e0queles encontrados para as mesmas prote\u00ednas no grupo Teste V mas n\u00e3o no grupo IV. J\u00e1 \n\nas prote\u00ednas TKT, PRDX1 e ANXA apresentaram resultados semelhantes em rela\u00e7\u00e3o ao \n\naumento de express\u00e3o observado para todos os tratamentos. As demais prote\u00ednas \n\nidentificadas relacionadas \u00e0 atividade antioxidante, sinaliza\u00e7\u00e3o celular, metabolismo de \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n68 \n\ncarboidrato, lip\u00eddeos, de nucleot\u00eddeo/fosfato e modelamento de prote\u00ednas apresentaram \n\nn\u00edveis aumentados de express\u00e3o celular. \n\nAssim como encontrado para os grupos Teste IV e V, diversas prote\u00ednas \n\nrelacionadas ao metabolismo de carboidratos (TKT, PKM2, ALDOA, GAPDH, ENO1, \n\nPGK1, DLD) e a atividade antioxidante (PRDX1, ADH e SOD) mostraram aumento nos \n\nn\u00edveis de express\u00e3o. \n\nA prote\u00edna TAGLN est\u00e1 relacionada \u00e0 manuten\u00e7\u00e3o da organiza\u00e7\u00e3o dos filamentos \n\nde actina in vivo e a diminui\u00e7\u00e3o de sua express\u00e3o por inativa\u00e7\u00e3o via Ras pode ser \n\nobservada em linhagens celulares tumorais como mama e c\u00f3lon, sendo considerada um \n\nmarcador no in\u00edcio da transforma\u00e7\u00e3o tumoral (Zhang et al., 2010; Thompson et al., 2012). \n\nEm concord\u00e2ncia com o achado de Mlakar e colaboradores observamos a sub express\u00e3o \n\nda isoforma TPM1 em nossas amostras de CCR (Mlakar et al., 2009). Altera\u00e7\u00f5es no n\u00edvel \n\nde express\u00e3o da prote\u00edna EZR est\u00e3o relacionados com a ocorr\u00eancia de met\u00e1stase e \n\nprogn\u00f3stico ruim em diversos tipos de c\u00e2ncer. Tal prote\u00edna interage com diversas \n\nmol\u00e9culas de sinaliza\u00e7\u00e3o intracelular envolvidas na progress\u00e3o tumoral como receptor \n\nMet de fator de crescimento de hepat\u00f3cito (HGF), integrina ?4 e membros da fam\u00edlia de \n\nquinases Src (Ghaffari et al., 2014). \n\nEm rela\u00e7\u00e3o \u00e0 s\u00edntese e degrada\u00e7\u00e3o de prote\u00ednas observou-se um aumento nos \n\nn\u00edveis de EEF2 que realiza a transloca\u00e7\u00e3o da cadeia polipept\u00eddica crescente do s\u00edtio A ao \n\ns\u00edtio P do ribossomo. A super express\u00e3o dessa prote\u00edna foi relatada em tumores g\u00e1stricos, \n\nintestinais, entre outros e parece desempenhar tamb\u00e9m um papel regulat\u00f3rio na \n\nprogress\u00e3o do ciclo celular nas fases G2/M (Oji et al., 2014). MCPT1 \u00e9 uma protease \n\nenvolvida na degrada\u00e7\u00e3o de matriz extracelular e favorecimento da angiog\u00eanese. Alguns \n\ntrabalhos v\u00eam relacionando os n\u00edveis de express\u00e3o desta e de outras proteases secretadas \n\ncom o comportamento tumoral. Foi observado que a presen\u00e7a de mast\u00f3citos MCPT1 \n\nnegativos atuam inibindo o crescimento tumoral e a angiog\u00eanese por meio da libera\u00e7\u00e3o \n\nde diferentes est\u00edmulos (Dyduch et al., 2012). \n\n\u00c9 importante ressaltar o aumento observado na express\u00e3o de diversas prote\u00ednas de \n\nsinaliza\u00e7\u00e3o celular. Entre elas, TRA1 se destaca por ser um componente integral dos \n\ncomplexos histona acetiltransferase STAGA, TFTC e PCAF, equivalentes encontrados \n\nem mam\u00edferos para SAGA, e TIP60, o equivalente para NuA4 de leveduras. TRA1 \u00e9 um \n\nmembro da fam\u00edlia de prote\u00ednas quinase fosfatidilinositol 3-quinase (PI3K), respons\u00e1veis \n\npor regular diversas vias de sinaliza\u00e7\u00e3o por fosforila\u00e7\u00e3o de serina/treoninas al\u00e9m de ser \n\nalvo de fatores de transcri\u00e7\u00e3o oncog\u00eanicos que incluem c-myc, E2F e E1a (Esseghir et \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n69 \n\nal., 2007; Helmlinger et al., 2011; Knutson and Hahn, 2011). A prote\u00edna de matriz \n\nextracelular LUM est\u00e1 relacionada com a modula\u00e7\u00e3o do comportamento celular incluindo \n\nmigra\u00e7\u00e3o e prolifera\u00e7\u00e3o atrav\u00e9s da reorganiza\u00e7\u00e3o do citoesqueleto de actina e \n\ndesestabiliza\u00e7\u00e3o de complexos de ades\u00e3o celular. Diversos estudos relatam a super \n\nexpress\u00e3o desta prote\u00edna em tumores no \u00fatero, p\u00e2ncreas e c\u00f3lon intestinal, aparentemente \n\nrelacionada a est\u00e1gios iniciais do desenvolvimento (Lu et al., 2012; Seya et al., 2006; \n\nPietraszek et al., 2013; Nikitovic et al., 2014). \n\nA fam\u00edlia de prote\u00ednas regulat\u00f3rias 14-3-3 (YWHAE) possui mais de 100 ligantes \n\ndescritos incluindo mol\u00e9culas de sinaliza\u00e7\u00e3o celular como a prote\u00edna quinase C (PKC), \n\nPI3K e fosfatase cdc25 de maneira dependente de fosforila\u00e7\u00e3o. Sua liga\u00e7\u00e3o \u00e0 Raf \u00e9 \n\nindispens\u00e1vel para a via de sinaliza\u00e7\u00e3o Ras/MAPK, enquanto a liga\u00e7\u00e3o \u00e0 Bcl-2 est\u00e1 \n\nrelacionada \u00e0 inibi\u00e7\u00e3o de apoptose. A isoforma ? liga-se a p190RhoGEF atrav\u00e9s de \n\nintera\u00e7\u00e3o independente de fosforila\u00e7\u00e3o e modula a forma\u00e7\u00e3o do citoesqueleto via FAK. \n\nYWHAE demonstra super express\u00e3o nos c\u00e2nceres de mama, pulm\u00e3o, tire\u00f3ide e c\u00f3lon \n\nsendo que a presen\u00e7a da isoforma ? parece proteger as c\u00e9lulas tumorais e endoteliais de \n\nc\u00f3lon de apoptose induzida por estresse oxidativo (Zhai et al., 2003; Satoh et al., 2004; \n\nLiu et al., 2013).  \n\nA prote\u00edna Galectina-3 (LGALS3) atua como fator de splicing de pr\u00e9-mRNAs no \n\nn\u00facleo al\u00e9m de estar envolvida na resposta inflamat\u00f3ria aguda incluindo ativa\u00e7\u00e3o e ades\u00e3o \n\nde neutr\u00f3filos, quimioatra\u00e7\u00e3o de mon\u00f3citos e ativa\u00e7\u00e3o de mast\u00f3citos. Parece participar da \n\nregula\u00e7\u00e3o de diversas vias de sinaliza\u00e7\u00e3o celular: (1) envolvimento na transloca\u00e7\u00e3o \n\nnuclear de ?-catenina juntamente com as prote\u00ednas importina-?/?, nucleoporinas e \n\nFoxM1, na fosforila\u00e7\u00e3o de GSK3 e ativa\u00e7\u00e3o de TCF na via Wnt/?-catenina; (2) \n\nenvolvimento na via de sinaliza\u00e7\u00e3o Notch atrav\u00e9s da intera\u00e7\u00e3o com a prote\u00edna de \n\nmembrana Tumor-derived jagged-1 (Laubli et al, 2014; Nakajima et al., 2014; Shim et \n\nal., 2015). \n\nComo pode ser observado na Figura 25, mais de 85% das prote\u00ednas que \n\napresentaram algum grau de altera\u00e7\u00e3o na express\u00e3o encontram-se relacionadas \n\nintracelularmente, refor\u00e7ando a ideia de que elas participam de vias de sinaliza\u00e7\u00e3o ligadas \n\nao desenvolvimento tumoral nos animais estudados. \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n70 \n\n \n\nFigura 25: Mapa de intera\u00e7\u00e3o prote\u00edna-metab\u00f3lito para prote\u00ednas diferencialmente expressas entre grupos \n\nTeste II e Controle I. Linhas azuis indicam intera\u00e7\u00f5es prote\u00edna-prote\u00edna. A espessura das linhas indica a \n\nfor\u00e7a das associa\u00e7\u00f5es. Mapa montado utilizando o software STITCH v. 4.0. \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n71 \n\n5.3- Identifica\u00e7\u00e3o de Pept\u00eddeos Ligantes \u00e0 Tecidos Neopl\u00e1sicos Intestinais de \n\nAnimais Tratados com DMH, DBT e DBTO2 \n\n \n\nAl\u00e9m da abordagem prote\u00f4mica que avaliou os extratos celulares das fra\u00e7\u00f5es \n\nsol\u00faveis atrav\u00e9s da digest\u00e3o tr\u00edptica, buscamos marcadores moleculares utilizando a \n\nt\u00e9cnica de Phage Display, que seleciona pept\u00eddeos ligantes \u00e0s prote\u00ednas diferencialmente \n\nexpressas entre os Grupos Controles e Testes atrav\u00e9s da afinidade de liga\u00e7\u00e3o aos mesmos.  \n\nSendo assim, realizou-se uma extra\u00e7\u00e3o de prote\u00ednas sol\u00faveis com posterior \n\nquantifica\u00e7\u00e3o por densitometria e submeteu-se essas amostras \u00e0 eletroforese \n\nunidimensional para verifica\u00e7\u00e3o da qualidade de extra\u00e7\u00e3o. Como pode ser observado na \n\nFigura 26, obteve-se uma ampla variedade de prote\u00ednas com perfis eletrofor\u00e9ticos bem \n\ndefinidos demonstrando que a amostra encontrava-se adequada para a utiliza\u00e7\u00e3o no \n\nexperimento de Phage Display. \n\n \n\n \n\nFigura 26: Perfis eletrofor\u00e9ticos representativos em 1D SDS-PAGE 12% de prote\u00ednas de Intestino Delgado \n\n(Controle DBT; Teste DBT (D)) e de Intestino Grosso (Teste DBT (G); Controle DMH; Teste DMH) para \n\na verifica\u00e7\u00e3o da qualidade da extra\u00e7\u00e3o proteica. Colora\u00e7\u00e3o realizada com Coomassie. \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n72 \n\n5.3.1- Biopanning de Tecido Intestinal \n\n \n\nA sele\u00e7\u00e3o de pept\u00eddeos foi realizada utilizando-se uma biblioteca expressa na \n\nsuperf\u00edcie de fagos filamentosos M13. Para tal, utilizaram-se 3 etapas de subtra\u00e7\u00e3o \n\nempregando amostras proteicas de tecidos intestinais de grupos Controle e Testes para \n\nDMH e DBT. Como as altera\u00e7\u00f5es apresentadas pelo grupo Teste DBTO2 n\u00e3o \n\napresentaram diferen\u00e7as substanciais do grupo Teste DBT diante da abordagem \n\nprote\u00f4mica, e, presumivelmente este tratamento promove altera\u00e7\u00f5es moleculares atrav\u00e9s \n\nde vias semelhantes, o primeiro n\u00e3o foi utilizado para sele\u00e7\u00e3o de pept\u00eddeos por essa \n\nt\u00e9cnica a fim de se simplificar o processo. \n\nFinalizados os 3 ciclos de sele\u00e7\u00e3o para extratos provenientes do intestino grosso \n\ndos grupos Controle/Teste DMH, intestino grosso Controle/Teste DBT e intestino \n\ndelgado Controle/Teste DBT, as col\u00f4nias de ER2738 contendo os fagos relativos ao \n\n\u00faltimo ciclo de sele\u00e7\u00e3o foram plaqueadas e tituladas para que se pudesse obter fagos \n\nisolados para extra\u00e7\u00e3o e sequenciamento do DNA. Como pode ser observado na Figura \n\n27, n\u00e3o houve aparecimento de col\u00f4nias brancas indicando aus\u00eancia de contamina\u00e7\u00e3o das \n\nbact\u00e9rias por fagos do tipo selvagem, demonstrando que a infec\u00e7\u00e3o das bact\u00e9rias ER2738 \n\nfoi adequada (col\u00f4nias azuis indicando a presen\u00e7a de fagos M13 que carregam o gene da \n\n?-galactosidase).  \n\nSelecionaram-se de maneira rand\u00f4mica 32 col\u00f4nias isoladas pertencentes a cada \n\ngrupo avaliado para nova amplifica\u00e7\u00e3o e extra\u00e7\u00e3o e sequenciamento do DNA a fim de se \n\nobter as sequ\u00eancias de pept\u00eddeos espec\u00edficas ligantes para os grupos testes. O DNA \n\nextra\u00eddo foi submetido \u00e0 eletroforese em gel de agarose 0,8% para verificar sua qualidade \n\ne estimar sua concentra\u00e7\u00e3o. Realizou-se ent\u00e3o a rea\u00e7\u00e3o de PCR para amplifica\u00e7\u00e3o do \n\nDNA e sequenciamento utilizando-se o sequenciador autom\u00e1tico MegaBACE 1000. \n\nForam obtidas ao todo 27 sequ\u00eancias para o grupo DMH sendo 16 delas sequ\u00eancias \u00fanicas \n\n(n\u00e3o repetidas), 25 sequ\u00eancias para o grupo DBT intestino grosso, sendo 10 delas \u00fanicas \n\ne 29 sequ\u00eancias para o grupo DBT intestino delgado sendo 11 \u00fanicas. \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n73 \n\n \n\nFigura 27: Fotografias representativas da titula\u00e7\u00e3o dos fagos obtidos no \u00faltimo ciclo de sele\u00e7\u00e3o de cada \n\ngrupo para isolamento das col\u00f4nias de ER2738 e consequente amplifica\u00e7\u00e3o e sequenciamento do DNA. A) \n\nTitula\u00e7\u00f5es de 10-1 a 10-3 para o grupo DMH intestino grosso; B) Titula\u00e7\u00f5es de 10-1 a 10-3 para o grupo DBT \n\nintestino delgado; C) Titula\u00e7\u00f5es de 10-1 a 10-3 para o grupo DBT intestino grosso. \n\n \n\n5.3.2- An\u00e1lise in silico de Pept\u00eddeos Selecionados \n\n \n\nOs pept\u00eddeos obtidos a partir do sequenciamento de DNA de fagos foram \n\navaliados primeiramente quanto \u00e0 similaridade da sequ\u00eancia de amino\u00e1cidos por meio do \n\nsoftware ClustalW. Ap\u00f3s a realiza\u00e7\u00e3o do alinhamento foi observado que nenhuma das \n\nsequ\u00eancias apresentou repeti\u00e7\u00f5es de amino\u00e1cidos em posi\u00e7\u00f5es semelhantes intra ou \n\nintergrupos (Figura 28). O alinhamento das sequ\u00eancias poderia revelar a ocorr\u00eancia de \n\nep\u00edtopos e direcionar a sele\u00e7\u00e3o daqueles que seriam primariamente utilizados nos \n\nexperimentos subsequentes.  \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n74 \n\n \n\nFigura 28: Alinhamento das sequ\u00eancias pept\u00eddicas obtidas ap\u00f3s sequenciamento do DNA dos fagos \n\nselecionados randomicamente ao fim do terceiro ciclo de biopanning para os tr\u00eas grupos avaliados. \n\nUtilizado o software ClustalW. As cores iguais indicam a similaridade entre os res\u00edduos alinhados.  \n\n \n\nEscolheram-se as sequ\u00eancias para a realiza\u00e7\u00e3o dos testes posteriores com base na \n\nfrequ\u00eancia de repeti\u00e7\u00e3o das mesmas dentro de cada grupo e tamb\u00e9m na rela\u00e7\u00e3o que cada \n\npept\u00eddeo apresentou com prote\u00ednas relacionadas ao c\u00e2ncer quando sua sequ\u00eancia foi \n\nalinhada com sequ\u00eancias de prote\u00ednas atrav\u00e9s do software BLASTp e base de dados \n\nRefSeq. Atrav\u00e9s de busca na literatura utilizando o banco de dados NCBI pode-se avaliar \n\na rela\u00e7\u00e3o entre as prote\u00ednas que apresentaram regi\u00f5es de similaridade com as sequ\u00eancias \n\npept\u00eddicas e diversos tipos de c\u00e2ncer. Considerando que os pept\u00eddeos selecionados com \n\nbase na frequ\u00eancia de repeti\u00e7\u00e3o apresentaram de maneira geral, alinhamento com \n\nprote\u00ednas que desempenham importantes pap\u00e9is no desenvolvimento tumoral j\u00e1 relatado \n\npor diversos pesquisadores (Ap\u00eandice F \u2013 Tab. 03.F), julgamos que a escolha de tais \n\npept\u00eddeos para a s\u00edntese e realiza\u00e7\u00e3o de testes posteriores, ainda que primariamente, \u00e9 \n\nadequada \u00e0 realiza\u00e7\u00e3o dos objetivos propostos neste trabalho. \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n75 \n\nSendo assim, as sequ\u00eancias escolhidas com base na frequ\u00eancia de repeti\u00e7\u00e3o, como \n\nmencionado anteriormente, foram: Grupo DMH (G) \u2013 QPHKVFFPNLPR (10x); Grupo \n\nDBT (D) \u2013 TNTPPSQRVHLS (9x) e LAAQQYTSALKS (10x); Grupo DBT (G) \u2013 \n\nEYQLPSRTVPRD (4x), KDPTQFKPMSLW (5x) e FDTKAGLTSLVA (5x). \n\n   \n\n5.3.3- S\u00edntese de Pept\u00eddeos \n\n \n\nSintetizaram-se os seis pept\u00eddeos mencionados no item anterior considerando as \n\nrela\u00e7\u00f5es encontradas entre os mesmos e prote\u00ednas diretamente relacionadas ao c\u00e2ncer, \n\nal\u00e9m da maior frequ\u00eancia de repeti\u00e7\u00e3o quando comparados aos demais pept\u00eddeos \n\nselecionados em cada grupo de tratamento. \n\nA qualidade da s\u00edntese foi verificada ap\u00f3s a observa\u00e7\u00e3o do cromatograma obtido \n\nem HPLC e todos os pept\u00eddeos apresentaram grau de pureza satisfat\u00f3rio para utiliza\u00e7\u00e3o \n\nnos testes subsequentes. A massa molecular correspondente aos picos encontrados em \n\nHPLC foi verificada por espectrometria de massas para confirma\u00e7\u00e3o da identidade do \n\npept\u00eddeo em quest\u00e3o. Como pode ser observado ao somarem-se as \u00e1reas dos picos \n\nidentificados como possuidores de massa igual \u00e0quela prevista pelo programa ExPASy \u2013 \n\nCompute PI/Mw tool, obtivemos aproximadamente de 90% de pureza para cada pept\u00eddeo \n\n(Fig. 29 e Tab. 06). \n\n \n\nTabela 06: Massas moleculares preditas e observadas para cada pept\u00eddeo sintetizado. \n\nPept\u00eddeo pI \nMassa \n\nPredita \n\nMassa observada \n\nP1 \n\nMassa observada \n\nP2 \n\nQPHKVFFPNLPR 11,0 1477,81 1477,83 1477,83 \n\nEYQLPRRTVPRD 6,17 1458,74 1458,76 - \n\nKDPTQFKPMSLW 8,59 1475,74 1475,76 1475,76 \n\nFDTKAGLTSLVA 5,84 1220,66 1220,68 1220,68 \n\nTNTPPSQRVHLS 9,44 1334,69 1334,71 1334,70 \n\nLAAQQYTSALKS 8,59 1278,68 1278,70 - \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n76 \n\n \n\nFigura 29: Perfis cromatogr\u00e1ficos em sistema HPLC dos pept\u00eddeos obtidos em fase reversa. Gradiente de \n\nACN de 20 a 60% e TFA 0,1% durante 80 minutos com um fluxo de 1 mL/minuto (coluna C18 250 mm x \n\n10 mm (LiChroCART\u00ae 250-10 Purospher, Merk)). Os pept\u00eddeos representados por picos indicados por P1 \n\ne P2 nas figuras de A a F correspondem \u00e0s massas preditas para cada pept\u00eddeo pelo software ExPASy \u2013 \n\nCompute PI/Mw tool. \n\n \n\nTais pept\u00eddeos foram utilizados primeiramente na tentativa de isolamento de \n\nprote\u00ednas alvo com as quais eles interagem atrav\u00e9s de sua imobiliza\u00e7\u00e3o em matriz \n\nSepharose 4B. Ap\u00f3s a imobiliza\u00e7\u00e3o, foram constru\u00eddas colunas cromatogr\u00e1ficas para \n\nsele\u00e7\u00e3o de prote\u00ednas que demonstrassem afinidade por cada pept\u00eddeo. Para tal, os extratos \n\nproteicos de intestinos grosso e delgado dos animais tratados com DMH, DBT e DBTO2 \n\nforam submetidos \u00e0 cromatografia de afinidade. As prote\u00ednas isoladas foram \n\nposteriormente submetidas a eletroforese unidimensional sendo posteriormente digeridas \n\ncom tripsina e identificadas por espectrometria de massas. \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n77 \n\n Al\u00e9m disso, realizou-se tamb\u00e9m o acoplamento do fluor\u00f3foro 5,6-\n\ncarboxifluoresce\u00edna a esses pept\u00eddeos para realizar uma histoqu\u00edmica com fluoresc\u00eancia \n\nque permitir\u00e1 a avalia\u00e7\u00e3o da especificidade da liga\u00e7\u00e3o com tecidos neopl\u00e1sicos intestinais.  \n\n \n\n5.3.4- Isolamento de Prote\u00ednas por Afinidade aos Pept\u00eddeos Selecionados por \n\nPhage Display \n\n \n\nAp\u00f3s realizar a s\u00edntese de colunas de afinidade e submeter amostras de extratos \n\nproteicos \u00e0 cromatografia de afinidade, foi poss\u00edvel identificar a liga\u00e7\u00e3o diferencial de \n\nprote\u00ednas a quatro dos seis pept\u00eddeos imobilizados. A Figura 30 mostra os g\u00e9is \n\nunidimensionais com os perfis proteicos obtidos ap\u00f3s a sele\u00e7\u00e3o pelos seis pept\u00eddeos \n\ntestados. \n\n \n\n \n\nFigura 30: Perfis eletrofor\u00e9ticos de 1D SDS-PAGE de extratos proteicos referentes a grupos Controle e \n\nTestes ap\u00f3s cromatografia de afinidade. A) Bandas 1 a 5 selecionadas pelo pept\u00eddeo QPHKVFFPNLPR a \n\npartir de extrato proteico de Intestino Grosso de animais pertencentes aos grupos Controle I (canaleta 1) e \n\nTeste II (canaleta 2); B) Bandas 1 a 3 selecionadas pelo pept\u00eddeo KDPTQFKPMSLW a partir de extrato \n\nproteico de Intestino Delgado de animais pertencentes aos grupos Controle III (canaleta 1) e Teste IV \n\n(canaleta 2); C) Bandas 1 e 2 selecionadas pelo pept\u00eddeo FDTKAGLTSLVA a partir de extrato proteico de \n\nIntestino Delgado de animais pertencentes aos grupos Controle III (canaleta 1) e Teste IV (canaleta 2); D) \n\nBandas 1 a 4 selecionadas pelo pept\u00eddeo TNTPPSQRVHLS a partir de extrato proteico de Intestino Delgado \n\nde animais pertencentes aos grupos Controle III (canaleta 1) e Teste IV (canaleta 2); As bandas indicadas \n\npela numera\u00e7\u00e3o em vermelho foram excisadas digeridas e identificadas por espectrometria de massas como \n\ndescrito nos itens 4.3.2 e 4.3.3. \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n78 \n\nNa Figura 30 \u2013 A podemos observar cinco bandas de prote\u00ednas isoladas a partir de \n\ncromatografia de afinidade utilizando o pept\u00eddeo QPHKVFFPNLPR e extratos proteicos \n\nprovenientes de intestino grosso dos animais Controle I e Teste II. A identifica\u00e7\u00e3o das \n\nprote\u00ednas por espectrometria de massas, revelou que as bandas 1 e 4 s\u00e3o compostas \n\nprincipalmente por tropomiosina e as bandas 2 e 6 pela prote\u00edna ribossomal L10A. A \n\nbanda 3 vis\u00edvel somente na canaleta 2 e referente ao grupo Teste II \u00e9 composta pela \n\nprote\u00edna SET. Esta prote\u00edna pertence \u00e0 classe das metiltransferases que est\u00e3o envolvidas \n\nna bioss\u00edntese de lip\u00eddeos, inativa\u00e7\u00e3o hormonal, diferencia\u00e7\u00e3o tecidual e no controle \n\nepigen\u00e9tico (Lehman et al., 2008; Albert and Helin, 2010; Eom et al., 2011). Uma parcela \n\nsignificante de nossas prote\u00ednas (208 prote\u00ednas humanas) compreende as enzimas que \n\ncatalisam a transfer\u00eancia do grupo metil do cofator S-adenosil-L-metionina para um \n\nsubstrato. Destas, aproximadamente 30% est\u00e3o associadas a doen\u00e7as sendo mais \n\nfrequentemente ligadas a desordens do sistema nervoso central e c\u00e2ncer (Martin and \n\nMcMillan, 2002; Schubert et al., 2003; Petrossian and Clarke, 2011). \n\nCom base em seus arranjos estruturais, as metiltransferases podem ser agrupadas \n\nem duas classes: membros que possuem o dom\u00ednio SET e membros que possuem o \n\ndom\u00ednio DOT1 (Jones and Gelbart, 1993; Tschiersch et al., 1994; Stassen et al., 1995). \n\nA fun\u00e7\u00e3o regulat\u00f3ria da metila\u00e7\u00e3o de prote\u00ednas n\u00e3o \u00e9 restrita ao c\u00f3digo de histonas, sendo \n\nvinculada a diversos processos celulares. Esta modifica\u00e7\u00e3o pode ocorrer tamb\u00e9m em \n\nprote\u00ednas citos\u00f3licas e nucleares, sendo que os efeitos destas metila\u00e7\u00f5es ainda pouco \n\ncaracterizados (Egorova et al., 2010; Zhang et al., 2012). \n\nUma das modifica\u00e7\u00f5es mais estudadas \u00e9 a metila\u00e7\u00e3o do fator supressor de tumor \n\np53. Esta prote\u00edna possui papel central no controle do ciclo celular apoptose e reparo de \n\nDNA em resposta a v\u00e1rios tipos de estresse (Brooks and Gu, 2010). A metila\u00e7\u00e3o dos \n\nres\u00edduos de lisina presentes no dom\u00ednio regulat\u00f3rio C-terminal regula positiva e \n\nnegativamente sua fun\u00e7\u00e3o. A metila\u00e7\u00e3o realizada por SET7/9 em Lys372 promove \n\naumento de express\u00e3o dos genes alvo de p53. Em contraste, a metila\u00e7\u00e3o de Lys382 por \n\nSET8 e Lys370 por SYMD2 suprime a atividade transcricional (Chuikov et al., 2004; \n\nHuang et al., 2006; Shi et al., 2007).   \n\nA banda 3, referente \u00e0 Figura 30 \u2013 B, apresentou liga\u00e7\u00e3o diferencial entre controle \n\ne teste sendo identificada como histona H4 e H2. A unidade b\u00e1sica da cromatina \n\neucari\u00f3tica, o nucleossomo, consiste em uma volta de DNA sobre um oct\u00e2mero de \n\nhistonas (d\u00edmeros H2A/H2B e tetr\u00e2mero H3/H4). Modifica\u00e7\u00f5es covalentes nestas \n\nprote\u00ednas podem alterar o grau de compacta\u00e7\u00e3o do DNA, inativar a eucromatina ou ativar \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n79 \n\na heterocromatina. Essas modifica\u00e7\u00f5es ocorrem na regi\u00e3o N-terminal das histonas, s\u00e3o \n\nrevers\u00edveis e incluem acetila\u00e7\u00e3o, metila\u00e7\u00e3o, fosforila\u00e7\u00e3o e ubiquitina\u00e7\u00e3o. Diversas \n\nfam\u00edlias de prote\u00ednas podem realizar tais modifica\u00e7\u00f5es (acetiltransferases, deacetilases, \n\nmetiltransferases, entre outras) (Wong et al., 2007). \n\nGeralmente a estrutura ativa da cromatina que corresponde a atividade \n\ntranscricional aumentada est\u00e1 associada a aumento na acetila\u00e7\u00e3o de histonas. Um padr\u00e3o \n\nde altera\u00e7\u00f5es nas histonas H4 caracterizado pela perda de monoacetila\u00e7\u00e3o em Lys16 e de \n\ntrimetila\u00e7\u00e3o em Lys20 tem sido proposto como marcador universal de transforma\u00e7\u00e3o \n\nmaligna. Al\u00e9m disso, as histonas podem ser substitu\u00eddas por variantes com pequenas \n\nvaria\u00e7\u00f5es de sequ\u00eancia que levam a altera\u00e7\u00f5es no padr\u00e3o de express\u00e3o como por exemplo \n\na substitui\u00e7\u00e3o de H2A por H2A.Z (Goel and Boland, 2012; Jia and Guo, 2013). \n\nAmbos os extratos utilizados para cromatografia com o pept\u00eddeo \n\nKDPTQFKPMSLW mostraram intera\u00e7\u00e3o entre o pept\u00eddeo e a prote\u00edna dermicidina \n\n(canaleta 1 e 2 \u2013 B). Tal prote\u00edna possui propriedades antimicrobianas e \u00e9 \n\nconstitutivamente expressa em humanos pelas gl\u00e2ndulas sudor\u00edparas, leuc\u00f3citos \n\nperif\u00e9ricos, c\u00e9lulas neuronais e placenta. Ela pode estar tamb\u00e9m relacionada a outras \n\ndoen\u00e7as humanas como c\u00e2ncer e aterosclerose (Schittek, 2012; Wang, 2014). \n\nA cromatografia de afinidade com o pept\u00eddeo FDTKAGLTSLVA isolou as \n\nprote\u00ednas ribossomais 60S P0 e L10A (Fig. 30 \u2013 C, 1 e 2). P0 \u00e9 uma fosfoprote\u00edna \n\nribossomal que forma heterod\u00edmeros com as fosfoprote\u00ednas ac\u00eddicas P1 e P2 localizadas \n\nna parte ativa do ribossomo. O complexo formado atua interagindo com mRNAs, tRNAs \n\ne fatores de tradu\u00e7\u00e3o (EF2) sendo, a presen\u00e7a de P0, mas n\u00e3o de P1 e P2, essencial para \n\nesta fun\u00e7\u00e3o. O aumento na express\u00e3o de P0 foi relatado em c\u00e9lulas tumorais de c\u00f3lon e \n\nf\u00edgado sugerindo que esta prote\u00edna exer\u00e7a outras fun\u00e7\u00f5es celulares al\u00e9m da tradu\u00e7\u00e3o de \n\nprote\u00ednas (Barnard et al., 1992; Kondoh et al., 1999). Chang e colaboradores \n\ndemonstraram que P0 pode interagir com a prote\u00edna GCIP (Grap2 and Cyclin D \n\nInteracting Protein) levando ao aumento de prolifera\u00e7\u00e3o celular por inibi\u00e7\u00e3o da redu\u00e7\u00e3o \n\nde fosforila\u00e7\u00e3o de pRb (Retinoblastome protein) e aumentando a express\u00e3o de ciclina D1 \n\n(Chang et al., 2008). \n\nPor \u00faltimo, ap\u00f3s espectrometria de massas, foi poss\u00edvel identificar as prote\u00ednas \n\nasporina e case\u00edna quinase II (Fig. 30 \u2013 D, 1 e 2) isoladas por cromatografia utilizando o \n\npept\u00eddeo TNTPPSQRVHLS como ligante. A asporina \u00e9 um proteoglicano de matriz \n\nextracelular rica em leucinas. O aumento de express\u00e3o dessa prote\u00edna e de outros \n\nproteoglicanos como decorina e biglicano foi encontrado em diversos pacientes com \n\n\n\nSilva, K.T.S.                                                                         Resultados e Discuss\u00e3o \n\n80 \n\nc\u00e2ncer g\u00e1strico, pancre\u00e1tico, de mama e pr\u00f3stata. Quadros de inflama\u00e7\u00e3o tamb\u00e9m \n\ndemonstram eleva\u00e7\u00e3o na express\u00e3o dessa mol\u00e9cula. A asporina parece coordenar invas\u00e3o \n\nde c\u00e9lulas cancerosas no tecido normal adjacente por meio da ativa\u00e7\u00e3o de Rac1 via \n\nintera\u00e7\u00e3o com CD44 (Nakajima et al., 2007; Turtoi et al., 2011; Ding et al., 2015; \n\nSatoyoshi et al., 2015).  \n\nN\u00edveis elevados da prote\u00edna case\u00edna quinase 2 (CK2) foram encontrados em \n\ntumores de mama, pr\u00f3stata, rins, coloretal, cabe\u00e7a e pesco\u00e7o e pulm\u00e3o. Sabe-se que essa \n\nprote\u00edna est\u00e1 envolvida em diversas vias de sinaliza\u00e7\u00e3o que regulam a prolifera\u00e7\u00e3o \n\ncelular, diferencia\u00e7\u00e3o e apoptose. A CK2 parece regular a via Wnt em m\u00faltiplos n\u00edveis \n\nsendo capaz de fosforilar o co-fator ?-catenina, Dvl, APC e tamb\u00e9m o fator de transcri\u00e7\u00e3o \n\nTCF/LEF. Al\u00e9m disso, associa\u00e7\u00f5es funcionais sugerem que CK2, NF-?B e a via Wnt \n\npodem atuar em conjunto na promo\u00e7\u00e3o da tumorog\u00eanese na gl\u00e2ndula mam\u00e1ria. CK2 \n\npromove degrada\u00e7\u00e3o constitutiva de I?B e ativa\u00e7\u00e3o de NF-?B, atuando tamb\u00e9m em \n\npontos posteriores da via (Dominguez et al., 2009; Montenarh, 2014). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                                           Conclus\u00f5es\n\n\n\nSilva, K.T.S.                                                                                                                    Conclus\u00f5es \n\n  82  \n\n6- CONCLUS\u00d5ES \n\n \n\n O tratamento cr\u00f4nico a que os animais foram submetidos permitiu as seguintes \n\nconclus\u00f5es: \n\n-  Os perfis de c\u00e9lulas sangu\u00edneas e de enzimas utilizadas na avalia\u00e7\u00e3o da fun\u00e7\u00e3o \n\nhep\u00e1tica e pancre\u00e1tica n\u00e3o foram alterados, corroborando com a an\u00e1lise histol\u00f3gica e \n\nobserva\u00e7\u00e3o de esfrega\u00e7os sangu\u00edneos;  \n\n- A dose de 30 mg/Kg utilizada para as subst\u00e2ncias DMH, DBT e DBTO2 foi \n\nsuficiente para induzir altera\u00e7\u00f5es de car\u00e1ter neopl\u00e1sico nos intestinos dos animais \n\ntratados, por\u00e9m, n\u00e3o provocou altera\u00e7\u00f5es hep\u00e1ticas ou nos demais tecidos avaliados \n\nhistologicamente (est\u00f4mago, pulm\u00e3o e p\u00e2ncreas); \n\n-  As les\u00f5es identificadas pelas an\u00e1lises histopatol\u00f3gicas dos intestinos grosso e \n\ndelgado indicaram a ocorr\u00eancia de processo neopl\u00e1sico em fase inicial de \n\ndesenvolvimento tanto para os animais tratados com DBT e DBTO2 quanto para os \n\nanimais tratados com DMH com caracter\u00edsticas e intensidade similares. Tal fato situa os \n\nagentes DBT e DBTO2 como indutores de c\u00e2ncer de express\u00e3o toxicol\u00f3gica; \n\n-  A an\u00e1lise comparativa dos perfis eletrofor\u00e9ticos dos extratos proteicos totais dos \n\ngrupos Controles e Testes revelou diferen\u00e7as na express\u00e3o de algumas prote\u00ednas, levando \n\na identifica\u00e7\u00e3o de marcadores proteicos para as altera\u00e7\u00f5es celulares consistentes com \n\naltera\u00e7\u00f5es neopl\u00e1sicas, decorrentes da exposi\u00e7\u00e3o a esses agentes; \n\n- A identifica\u00e7\u00e3o de prote\u00ednas ligantes a pept\u00eddeos selecionados por Phage Display \n\npor cromatografia de afinidade, juntamente com a identifica\u00e7\u00e3o de prote\u00ednas \n\ndiferencialmente expressas selecionadas por 2D SDS-PAGE, proporcionou um avan\u00e7o \n\nno entendimento acerca das altera\u00e7\u00f5es bioqu\u00edmicas e poss\u00edveis mecanismos envolvidos \n\nno estabelecimento do processo neopl\u00e1sico promovido pelo DBT e DBTO2. Foi poss\u00edvel \n\nobservar altera\u00e7\u00f5es em vias de sinaliza\u00e7\u00e3o gerais de maneira comum aos 3 grupos Teste \n\navaliados. \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                                         Perspectivas\n\n\n\nSilva, K.T.S.                                                                                                                 Perspectivas \n\n  84  \n\n7- PERSPECTIVAS \n\n \n\nConsiderando a limita\u00e7\u00e3o no diagn\u00f3stico de les\u00f5es tumorais decorrentes de \n\nindu\u00e7\u00e3o qu\u00edmica com os agentes estudados, e a import\u00e2ncia ambiental dos mesmos, torna-\n\nse atraente a busca por novos marcadores proteicos e o desenvolvimento de m\u00e9todos \n\ndiagn\u00f3sticos para a detec\u00e7\u00e3o dos mesmos.  Sendo assim, pretende-se avan\u00e7ar com os \n\nexperimentos utilizando os pept\u00eddeos selecionados por Phage Display atrav\u00e9s da \n\nrealiza\u00e7\u00e3o de histoqu\u00edmica com pept\u00eddeos fluorescentes. Pretende-se tamb\u00e9m empregar \n\ntais pept\u00eddeos na avalia\u00e7\u00e3o de uma poss\u00edvel atividade antitumoral utilizando cultura de \n\nc\u00e9lulas tumorais. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                    Refer\u00eancias Bibliogr\u00e1ficas\n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n86 \n\n8- REFER\u00caNCIAS BIBLIOGR\u00c1FICAS \n\n \n \n\nAas, E., Baussant, T., Balk, L., Liewenborg, B. and Andersen, O.K., 2000. PAH \n\nmetabolites in bile, cytochrome P4501A and DNA adducts as environmental risk \n\nparameters for chronic oil exposure: a laboratory experiment with Atlantic cod. \n\nAquatic toxicology, 51(2): 241-58. \n\nAdra, C.N. et al., 1997. RhoGDIgamma: a GDP-dissociation inhibitor for Rho proteins \n\nwith preferential expression in brain and pancreas. Proceedings of the National \n\nAcademy of Sciences of the United States of America, 94(9): 4279-84. \n\nAhlquist, D.A., 2010. Molecular detection of colorectal neoplasia. Gastroenterology, \n\n138(6): 2127-39. \n\nAlbert, M. and Helin, K., 2010. Histone methyltransferases in cancer. Seminars in cell &amp; \n\ndevelopmental biology, 21(2): 209-20. \n\nAnderson, F.H., Zeng, L., Rock, N.R. and Yoshida, E.M., 2000. An assessment of the \n\nclinical utility of serum ALT and AST in chronic hepatitis C. Hepatology research \n\n: the official journal of the Japan Society of Hepatology, 18(1): 63-71. \n\nAmat, A., Pfohl-Leszkowicz, A., Castegnaro, M., 2004. Genotoxic activity of thiophenes \n\non liver human cell line (HepG2). Polycyclic Aromatic Compounds, 24: 733?742. \n\nAngerer, J., Mannschreck, C. and Gundel, J., 1997. Biological monitoring and \n\nbiochemical effect monitoring of exposure to polycyclic aromatic hydrocarbons. \n\nInternational archives of occupational and environmental health, 70(6): 365-77. \n\nArimura, S. et al., 2009. Reduced level of smoothened suppresses intestinal tumorigenesis \n\nby down-regulation of Wnt signaling. Gastroenterology, 137(2): 629-38. \n\nBabich, I.V. and Moulijn, J.A., 2003. Science and technology of novel processes for deep \n\ndesulfurization of oil refinery streams: a review. Fuel, 82(6): 607-631. \n\nBale, A.E. and Yu, K.P., 2001. The hedgehog pathway and basal cell carcinomas. Human \n\nmolecular genetics, 10(7): 757-62. \n\nBarnard, G.F. et al., 1992. Increased expression of human ribosomal phosphoprotein P0 \n\nmessenger RNA in hepatocellular carcinoma and colon carcinoma. Cancer \n\nresearch, 52(11): 3067-72. \n\nBellati, F. et al., 2009. Immunology of gynecologic neoplasms: analysis of the prognostic \n\nsignificance of the immune status. Current cancer drug targets, 9(4): 541-65. \n\nBrabletz, T. et al., 1998. Nuclear overexpression of the oncoprotein beta-catenin in \n\ncolorectal cancer is localized predominantly at the invasion front. Pathology, \n\nresearch and practice, 194(10): 701-4. \n\nBravo-Cordero, J.J., Magalhaes, M.A., Eddy, R.J., Hodgson, L. and Condeelis, J., 2013. \n\nFunctions of cofilin in cell locomotion and invasion. Nature reviews. Molecular \n\ncell biology, 14(7): 405-15. \n\nBrooks, C.L. and Gu, W., 2010. New insights into p53 activation. Cell research, 20(6): \n\n614-21. \n\nBrosens, L.A. et al., 2007. Gastrointestinal polyposis syndromes. Current molecular \n\nmedicine, 7(1): 29-46. \n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n87 \n\nBrown, K.K. and Toker, A., 2015. The phosphoinositide 3-kinase pathway and therapy \n\nresistance in cancer. F1000prime reports, 7: 13. \n\nBurtis, C.A. and Ashwood, E.R., 1996.  Tietz fundamentals of clinical chemistry. \n\nPhiladelphia [etc.], W. B. Saunders Company. \n\nCardoso, J., Boer, J., Morreau, H. and Fodde, R., 2007. Expression and genomic profiling \n\nof colorectal cancer. Biochimica et biophysica acta, 1775(1): 103-37. \n\nCastro-Castro, A. et al., 2011. Coronin 1A promotes a cytoskeletal-based feedback loop \n\nthat facilitates Rac1 translocation and activation. The EMBO journal, 30(19): \n\n3913-27. \n\nCavret, S. and Feidt, C., 2005. Intestinal metabolism of PAH: in vitro demonstration and \n\nstudy of its impact on PAH transfer through the intestinal epithelium. \n\nEnvironmental research, 98(1): 22-32. \n\nCecconello, I., 2008. Atualiza\u00e7\u00e3o em cirurgia do aparelho digestivo e em coloproctologia. \n\nS\u00e3o Paulo, Departamento de gastroenterologia da Faculdade de Medicina da \n\nUniversidade de S\u00e3o Paulo. \n\nCecconi, D. and Zam\u00f2, A., 2011. Proteomics of human cancer tissues and cells. TrAC \n\nTrends in Analytical Chemistry, 30(2): 346-359. \n\nChang, H. et al., 2005. Using a combination of cytochrome P450 1B1 and beta-catenin \n\nfor early diagnosis and prevention of colorectal cancer. Cancer detection and \n\nprevention, 29(6): 562-9. \n\nChang, T.W. et al., 2008. Ribosomal phosphoprotein P0 interacts with GCIP and \n\noverexpression of P0 is associated with cellular proliferation in breast and liver \n\ncarcinoma cells. Oncogene, 27(3): 332-8. \n\nChang, W.W., 1984. Histogenesis of colon cancer in experimental animals. Scandinavian \n\njournal of gastroenterology. Supplement, 104: 27-43. \n\nChen, J. and Huang, X.F., 2009. The signal pathways in azoxymethane-induced colon \n\ncancer and preventive implications. Cancer biology &amp; therapy, 8(14): 1313-7. \n\nCho, M. et al., 1997. Mucins secreted by cell lines derived from colorectal mucinous \n\ncarcinoma and adenocarcinoma. European journal of cancer, 33(6): 931-41. \n\nCho, W.C., 2007. Contribution of oncoproteomics to cancer biomarker discovery. \n\nMolecular cancer, 6: 25. \n\nChuikov, S. et al., 2004. Regulation of p53 activity through lysine methylation. Nature, \n\n432(7015): 353-60. \n\nChuthapisith, S., Layfield, R., Kerr, I.D. and Eremin, O., 2007. Principles of proteomics \n\nand its applications in cancer. The surgeon : journal of the Royal Colleges of \n\nSurgeons of Edinburgh and Ireland, 5(1): 14-22. \n\nCiganek, M., Neca, J, Adamec, V., Janosek, J., Machala, M., 2004. A combined chemical \n\nand bioassay analysis of traffic-emitted polycyclic aromatic hydrocarbons. Sci. \n\nTotal Environ., 334?335, 141?148. \n\nCoppola, D. et al., 1998. CD44V6 expression in human colorectal carcinoma. Human \n\npathology, 29(6): 627-35. \n\nCroce, C.M., 2008. Oncogenes and cancer. The New England journal of medicine, \n\n358(5): 502-11. \n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n88 \n\nda Silva Madeira, L., Ferreira-Leit\u00e3o, V.S., et al., 2008. Dibenzothiophene oxidation by \n\nhorseradish peroxidase in organic media: Effect of the DBT:H2O2 molar ratio and \n\nH2O2 addition mode. Chemosphere, 71(1): 189-194. \n\nde Paula Carli, A. et al., 2012. Bowman-Birk inhibitors, proteasome peptidase activities \n\nand colorectal pre neoplasias induced by 1,2-dimethylhydrazine in Swiss mice. \n\nFood and chemical toxicology : an international journal published for the British \n\nIndustrial Biological Research Association, 50(5): 1405-12. \n\nDiggs, D.L. et al., 2011. Polycyclic aromatic hydrocarbons and digestive tract cancers: a \n\nperspective. Journal of environmental science and health. Part C, Environmental \n\ncarcinogenesis &amp; ecotoxicology reviews, 29(4): 324-57. \n\nDing, Q., Zhang, M. and Liu, C., 2015. Asporin participates in gastric cancer cell growth \n\nand migration by influencing EGF receptor signaling. Oncology reports, 33(4): \n\n1783-90. \n\nDominguez, I., Sonenshein, G.E. and Seldin, D.C., 2009. Protein kinase CK2 in health \n\nand disease: CK2 and its role in Wnt and NF-kappaB signaling: linking \n\ndevelopment and cancer. Cellular and molecular life sciences : CMLS, 66(11-12): \n\n1850-7. \n\nDovas, A. and Couchman, J.R., 2005. RhoGDI: multiple functions in the regulation of \n\nRho family GTPase activities. The Biochemical journal, 390(Pt 1): 1-9. \n\nDuffy, M.J. et al., 2003. Clinical utility of biochemical markers in colorectal cancer: \n\nEuropean Group on Tumour Markers (EGTM) guidelines. European journal of \n\ncancer, 39(6): 718-27. \n\nDunn, G.P., Old, L.J. and Schreiber, R.D., 2004. The immunobiology of cancer \n\nimmunosurveillance and immunoediting. Immunity, 21(2): 137-48. \n\nDyduch, G., Kaczmarczyk, K. and Okon, K., 2012. Mast cells and cancer: enemies or \n\nallies? Polish journal of pathology : official journal of the Polish Society of \n\nPathologists, 63(1): 1-7. \n\nEgorova, K.S., Olenkina, O.M. and Olenina, L.V., 2010. Lysine methylation of \n\nnonhistone proteins is a way to regulate their stability and function. Biochemistry. \n\nBiokhimiia, 75(5): 535-48. \n\nEom, G.H. et al., 2011. Histone methyltransferase SETD3 regulates muscle \n\ndifferentiation. The Journal of biological chemistry, 286(40): 34733-42. \n\nEsseghir, S. et al., 2007. Identification of NTN4, TRA1, and STC2 as prognostic markers \n\nin breast cancer in a screen for signal sequence encoding proteins. Clinical cancer \n\nresearch : an official journal of the American Association for Cancer Research, \n\n13(11): 3164-73. \n\nFaure, J. and Dagher, M.C., 2001. Interactions between Rho GTPases and Rho GDP \n\ndissociation inhibitor (Rho-GDI). Biochimie, 83(5): 409-14. \n\nFearon, E.R. and Vogelstein, B., 1990. A genetic model for colorectal tumorigenesis. \n\nCell, 61(5): 759-67. \n\nFre, S. et al., 2005. Notch signals control the fate of immature progenitor cells in the \n\nintestine. Nature, 435(7044): 964-8. \n\nGhaffari, A. et al., 2014. A novel role for ezrin in breast cancer angio/lymphangiogenesis. \n\nBreast cancer research : BCR, 16(5): 438. \n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n89 \n\nGoel, A. and Boland, C.R., 2012. Epigenetics of colorectal cancer. Gastroenterology, \n\n143(6): 1442-1460 e1. \n\nGoodale, B.C. et al., 2013. Structurally distinct polycyclic aromatic hydrocarbons induce \n\ndifferential transcriptional responses in developing zebrafish. Toxicology and \n\napplied pharmacology, 272(3): 656-70. \n\nGray, K.A. et al., 1996. Molecular mechanisms of biocatalytic desulfurization of fossil \n\nfuels. Nature biotechnology, 14(13): 1705-9. \n\nGuengerich, F.P., 2001. Forging the links between metabolism and carcinogenesis. \n\nMutation research, 488(3): 195-209. \n\nGupta, S., Takebe, N. and Lorusso, P., 2010. Targeting the Hedgehog pathway in cancer. \n\nTherapeutic advances in medical oncology, 2(4): 237-50. \n\nHassanein, M., Rahman, J.S., Chaurand, P. and Massion, P.P., 2011. Advances in \n\nproteomic strategies toward the early detection of lung cancer. Proceedings of the \n\nAmerican Thoracic Society, 8(2): 183-8. \n\nHecht, S.S., Carmella, S.G., Villalta, P.W. and Hochalter, J.B., 2010. Analysis of \n\nphenanthrene and benzo[a]pyrene tetraol enantiomers in human urine: relevance \n\nto the bay region diol epoxide hypothesis of benzo[a]pyrene carcinogenesis and \n\nto biomarker studies. Chemical research in toxicology, 23(5): 900-8. \n\nHeilmann, J., Boulyga, S.F. and Heumann, K.G., 2004. Accurate determination of sulfur \n\nin gasoline and related fuel samples using isotope dilution ICP-MS with direct \n\nsample injection and microwave-assisted digestion. Analytical and bioanalytical \n\nchemistry, 380(2): 190-7. \n\nHelmlinger, D. et al., 2011. Tra1 has specific regulatory roles, rather than global \n\nfunctions, within the SAGA co-activator complex. The EMBO journal, 30(14): \n\n2843-52. \n\nH\u00f6ner, A. 2001. Chapter 4 Polycyclic aromatic hydrocarbon (PAH) metabolites. \n\nHandbook of Analytical Separations. K. Wolfgang, Elsevier Science B.V, 3: 99-\n\n121. \n\nHoops, T.C. and Traber, P.G., 1997. Molecular pathogenesis of colorectal cancer. \n\nHematology/oncology clinics of North America, 11(4): 609-33. \n\nHuang, J. et al., 2006. Repression of p53 activity by Smyd2-mediated methylation. \n\nNature, 444(7119): 629-32. \n\nIARC Publications, 2007. The World Health Organization\u2019s Fight Against Cancer: \n\nStrategies That Prevent, Cure and Care. WHO Library. Geneva, Switzerland.  \n\nIARC Publications, 2008. World Cancer Report 2008. Boyle, P.; Levin, B. WHO Library. \n\nWHO Library. Geneva, Switzerland. \n\nIncardona, J.P., Collier, T.K. and Scholz, N.L., 2004. Defects in cardiac function precede \n\nmorphological abnormalities in fish embryos exposed to polycyclic aromatic \n\nhydrocarbons. Toxicology and applied pharmacology, 196(2): 191-205. \n\nIngham, P.W. and McMahon, A.P., 2001. Hedgehog signaling in animal development: \n\nparadigms and principles. Genes &amp; development, 15(23): 3059-87. \n\nInternational Union Against Cancer, 2005.  Introduction UICC Global Cancer Control. \n\nGeneve, Switzerland, UICC. \n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n90 \n\nIrigaray, P. and Belpomme, D., 2010. Basic properties and molecular mechanisms of \n\nexogenous chemical carcinogens. Carcinogenesis, 31(2): 135-48. \n\nJacob, J. and Grimmer, G., 1996. Metabolism and excretion of polycyclic aromatic \n\nhydrocarbons in rat and in human. Central European journal of public health, 4 \n\nSuppl: 33-9. \n\nJemal, A. et al., 2005. Cancer statistics, 2005. CA: a cancer journal for clinicians, 55(1): \n\n10-30. \n\nJia, Y. and Guo, M., 2013. Epigenetic changes in colorectal cancer. Chinese journal of \n\ncancer, 32(1): 21-30. \n\nJones, J.M., Anderson, J.W. and Tukey, R.H., 2000. Using the metabolism of PAHs in a \n\nhuman cell line to characterize environmental samples. Environmental toxicology \n\nand pharmacology, 8(2): 119-126. \n\nJones, R.S. and Gelbart, W.M., 1993. The Drosophila Polycomb-group gene Enhancer of \n\nzeste contains a region with sequence similarity to trithorax. Molecular and \n\ncellular biology, 13(10): 6357-66. \n\nKahlenberg, M.S., Sullivan, J.M., Witmer, D.D. and Petrelli, N.J., 2003. Molecular \n\nprognostics in colorectal cancer. Surgical oncology, 12(3): 173-86. \n\nKaminski, S. et al., 2011. Coronin 1A is an essential regulator of the TGFbeta \n\nreceptor/SMAD3 signaling pathway in Th17 CD4(+) T cells. Journal of \n\nautoimmunity, 37(3): 198-208. \n\nKim, D.H. et al., 2009. Proteomic analysis of breast cancer tissue reveals upregulation of \n\nactin-remodeling proteins and its relevance to cancer invasiveness. Proteomics. \n\nClinical applications, 3(1): 30-40. \n\nKitadai, Y. et al., 1996. Regulation of carcinoembryonic antigen expression in human \n\ncolon carcinoma cells by the organ microenvironment. The American journal of \n\npathology, 149(4): 1157-66. \n\nKlimczak, M., 2015. Oncogenesis and induced pluripotency - commonalities of signalling \n\npathways. Contemporary oncology, 19(1A): A16-21. \n\nKnutson, B.A. and Hahn, S., 2011. Domains of Tra1 important for activator recruitment \n\nand transcription coactivator functions of SAGA and NuA4 complexes. Molecular \n\nand cellular biology, 31(4): 818-31. \n\nKobayashi, M. et al., 2000. Desulfurization of alkylated forms of both dibenzothiophene \n\nand benzothiophene by a single bacterial strain. FEMS microbiology letters, \n\n187(2): 123-6. \n\nKondoh, N. et al., 1999. Identification and characterization of genes associated with \n\nhuman hepatocellular carcinogenesis. Cancer research, 59(19): 4990-6. \n\nKrausova, M. and Korinek, V., 2014. Wnt signaling in adult intestinal stem cells and \n\ncancer. Cellular signalling, 26(3): 570-9. \n\nKropp, K.G., Andersson, J.T. and Fedorak, P.M., 1997. Bacterial transformations of \n\n1,2,3,4-tetrahydrodibenzothiophene and dibenzothiophene. Applied and \n\nenvironmental microbiology, 63(8): 3032-42. \n\nKuhn, S. et al., 2007. A complex of EpCAM, claudin-7, CD44 variant isoforms, and \n\ntetraspanins promotes colorectal cancer progression. Molecular cancer research : \n\nMCR, 5(6): 553-67. \n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n91 \n\nKulasingam, V. and Diamandis, E.P., 2008. Strategies for discovering novel cancer \n\nbiomarkers through utilization of emerging technologies. Nature clinical practice. \n\nOncology, 5(10): 588-99. \n\nKuniyasu, H., Oue, N., Tsutsumi, M., Tahara, E. and Yasui, W., 2001. Heparan sulfate \n\nenhances invasion by human colon carcinoma cell lines through expression of \n\nCD44 variant exon 3. Clinical cancer research : an official journal of the American \n\nAssociation for Cancer Research, 7(12): 4067-72. \n\nLaubli, H. et al., 2014. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) \n\nis a tumor-associated immunomodulatory ligand for CD33-related Siglecs. The \n\nJournal of biological chemistry, 289(48): 33481-91. \n\nLea, I.A. et al., 2007. Genetic pathways and mutation profiles of human cancers: site- and \n\nexposure-specific patterns. Carcinogenesis, 28(9): 1851-8. \n\nLehmann, L., Jiang, L. and Wagner, J., 2008. Soy isoflavones decrease the catechol-O-\n\nmethyltransferase-mediated inactivation of 4-hydroxyestradiol in cultured MCF-\n\n7 cells. Carcinogenesis, 29(2): 363-70. \n\nLeighton, F.A., 1989. Acute oral toxicity of dibenzothiophene for male CD-1 mice: \n\nLD50, lesions, and the effect of preinduction of mixed-function oxidases. \n\nFundamental and applied toxicology : official journal of the Society of \n\nToxicology, 12(4): 787-92. \n\nLi, A. et al., 2001. Comparative study for histology, proliferative activity, glycoproteins, \n\nand p53 protein between old and recent colorectal adenomas in Japan. Cancer \n\nletters, 170(1): 45-52. \n\nLipniak, M., Brandys, J. and Stepniewska, B., 1993. [Determination of polycyclic \n\naromatic hydrocarbons in grass]. Roczniki Panstwowego Zakladu Higieny, 44(2-\n\n3): 205-12. \n\nLiu, C. et al., 2014. Porcine coronin 1A contributes to nuclear factor-kappa B (NF-\n\nkappaB) inactivation during Haemophilus parasuis infection. PloS one, 9(8): \n\ne103904. \n\nLiu, T.A. et al., 2013. 14-3-3epsilon overexpression contributes to epithelial-\n\nmesenchymal transition of hepatocellular carcinoma. PloS one, 8(3): e57968. \n\nLoeb, L.A. and Harris, C.C., 2008. Advances in chemical carcinogenesis: a historical \n\nreview and prospective. Cancer research, 68(17): 6863-72. \n\nLopez, M.J. and Monafo, W.W., 1993. Role of extended resection in the initial treatment \n\nof locally advanced colorectal carcinoma. Surgery, 113(4): 365-72. \n\nLu, Y.P. et al., 2002. Expression of lumican in human colorectal cancer cells. Pathology \n\ninternational, 52(8): 519-26. \n\nMacDonald, B.T., Tamai, K. and He, X., 2009. Wnt/beta-catenin signaling: components, \n\nmechanisms, and diseases. Developmental cell, 17(1): 9-26. \n\nMalhotra, G.K., Zhao, X., Band, H. and Band, V., 2011. Shared signaling pathways in \n\nnormal and breast cancer stem cells. Journal of carcinogenesis, 10: 38. \n\nMarinkovic, N., Pasalic, D. and Potocki, S., 2013. Polymorphisms of genes involved in \n\npolycyclic aromatic hydrocarbons' biotransformation and atherosclerosis. \n\nBiochemia medica, 23(3): 255-65. \n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n92 \n\nMarkowitz, S.D. and Bertagnolli, M.M., 2009. Molecular origins of cancer: Molecular \n\nbasis of colorectal cancer. The New England journal of medicine, 361(25): 2449-\n\n60. \n\nMarkowska, A., Pawalowska, M., Lubin, J. and Markowska, J., 2014. Signalling \n\npathways in endometrial cancer. Contemporary oncology, 18(3): 143-8. \n\nMarques-Vidal, P., Ravasco, P. and Ermelinda Camilo, M., 2006. Foodstuffs and \n\ncolorectal cancer risk: a review. Clinical nutrition, 25(1): 14-36. \n\nMartin, J.L. and McMillan, F.M., 2002. SAM (dependent) I AM: the S-\n\nadenosylmethionine-dependent methyltransferase fold. Current opinion in \n\nstructural biology, 12(6): 783-93. \n\nMazumdar, T. et al., 2011. Hedgehog signaling drives cellular survival in human colon \n\ncarcinoma cells. Cancer research, 71(3): 1092-102. \n\nMcLeod, H.L. and Murray, G.I., 1999. Tumour markers of prognosis in colorectal cancer. \n\nBritish journal of cancer, 79(2): 191-203. \n\nMerrifield, R.B., 1965. Solid-Phase Peptide Syntheses. Endeavour, 24: 3-7. \n\nMiyado, K., Kimura, M. and Taniguchi, S., 1996. Decreased expression of a single \n\ntropomyosin isoform, TM5/TM30nm, results in reduction in motility of highly \n\nmetastatic B16-F10 mouse melanoma cells. Biochemical and biophysical research \n\ncommunications, 225(2): 427-35. \n\nMiyamoto, S. and Rosenberg, D.W., 2011. Role of Notch signaling in colon homeostasis \n\nand carcinogenesis. Cancer science, 102(11): 1938-42. \n\nMlakar, V. et al., 2009. Presence of activating KRAS mutations correlates significantly \n\nwith expression of tumour suppressor genes DCN and TPM1 in colorectal cancer. \n\nBMC cancer, 9: 282. \n\nMontenarh, M., 2014. Protein kinase CK2 and angiogenesis. Advances in clinical and \n\nexperimental medicine : official organ Wroclaw Medical University, 23(2): 153-\n\n8. \n\nMontesano, R. and Hall, J., 2001. Environmental causes of human cancers. European \n\njournal of cancer, 37 Suppl 8: S67-87. \n\nMurphy, M.E., 2013. The HSP70 family and cancer. Carcinogenesis, 34(6): 1181-8. \n\nNakajima, K. et al., 2014. Galectin-3 inhibits osteoblast differentiation through notch \n\nsignaling. Neoplasia, 16(11): 939-49. \n\nNakajima, M. et al., 2007. Mechanisms for asporin function and regulation in articular \n\ncartilage. The Journal of biological chemistry, 282(44): 32185-92. \n\nNambiar, P.R., Gupta, R.R. and Misra, V., 2010. An \"Omics\" based survey of human \n\ncolon cancer. Mutation research, 693(1-2): 3-18. \n\nNewell, L.E. and Heddle, J.A., 2004. The potent colon carcinogen, 1,2-dimethylhydrazine \n\ninduces mutations primarily in the colon. Mutation research, 564(1): 1-7. \n\nNikitovic, D., Papoutsidakis, A., Karamanos, N.K. and Tzanakakis, G.N., 2014. Lumican \n\naffects tumor cell functions, tumor-ECM interactions, angiogenesis and \n\ninflammatory response. Matrix biology : journal of the International Society for \n\nMatrix Biology, 35: 206-14. \n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n93 \n\nO'Dwyer, D., Ralton, L.D., O'Shea, A. and Murray, G.I., 2011. The proteomics of \n\ncolorectal cancer: identification of a protein signature associated with prognosis. \n\nPloS one, 6(11): e27718. \n\nOji, Y. et al., 2014. The translation elongation factor eEF2 is a novel tumorassociated \n\nantigen overexpressed in various types of cancers. International journal of \n\noncology, 44(5): 1461-9. \n\nOrian-Rousseau, V., 2010. CD44, a therapeutic target for metastasising tumours. \n\nEuropean journal of cancer, 46(7): 1271-7. \n\nOvrevik, J. et al., 2010. Differential effects of nitro-PAHs and amino-PAHs on cytokine \n\nand chemokine responses in human bronchial epithelial BEAS-2B cells. \n\nToxicology and applied pharmacology, 242(3): 270-80. \n\nPapanikolaou, A., Wang, Q.S., Delker, D.A. and Rosenberg, D.W., 1998. Azoxymethane-\n\ninduced colon tumors and aberrant crypt foci in mice of different genetic \n\nsusceptibility. Cancer letters, 130(1-2): 29-34. \n\nPapanikolaou, A., Wang, Q.S., Papanikolaou, D., Whiteley, H.E. and Rosenberg, D.W., \n\n2000. Sequential and morphological analyses of aberrant crypt foci formation in \n\nmice of differing susceptibility to azoxymethane-induced colon carcinogenesis. \n\nCarcinogenesis, 21(8): 1567-72. \n\nPeng, X.C. et al., 2011. Comparative proteomic approach identifies PKM2 and cofilin-1 \n\nas potential diagnostic, prognostic and therapeutic targets for pulmonary \n\nadenocarcinoma. PloS one, 6(11): e27309. \n\nPerse, M. and Cerar, A., 2011. Morphological and molecular alterations in 1,2 \n\ndimethylhydrazine and azoxymethane induced colon carcinogenesis in rats. \n\nJournal of biomedicine &amp; biotechnology, 2011: 473964. \n\nPetrossian, T.C. and Clarke, S.G., 2011. Uncovering the human methyltransferasome. \n\nMolecular &amp; cellular proteomics : MCP, 10(1): M110 000976. \n\nPietraszek, K. et al., 2013. Lumican - derived peptides inhibit melanoma cell growth and \n\nmigration. PloS one, 8(10): e76232. \n\nPriolli, D.G., Cardinalli, I.A., et al., 2007. Proposta para estadiamento do c\u00e2ncer colorretal \n\nbaseada em crit\u00e9rios morfofuncionais: correla\u00e7\u00e3o com n\u00edveis s\u00e9ricos do ant\u00edgeno \n\ncarcinoembrion\u00e1rio. Revista Brasileira de Coloproctologia, 27: 374-383. \n\nQiao, L. and Wong, B.C., 2009. Role of Notch signaling in colorectal cancer. \n\nCarcinogenesis, 30(12): 1979-86. \n\nQiu, Y. et al., 2008. Plasma glycoprotein profiling for colorectal cancer biomarker \n\nidentification by lectin glycoarray and lectin blot. Journal of proteome research, \n\n7(4): 1693-703. \n\nRangel, M.F., Silva, M.V.M., et al., 2000. Tumores malignos do intestino delgado. \n\nRevista do Col\u00e9gio Brasileiro de Cirurgi\u00f5es 27: 385-388. \n\nRao, J.Y. et al., 1997. Quantitative changes in cytoskeletal and nuclear actins during \n\ncellular transformation. International journal of cancer. Journal international du \n\ncancer, 70(4): 423-9. \n\nRobbins, S.L., V. Kumar, et al., 2010. Robbins and Cotran pathologic basis of disease. \n\nPhiladelphia, PA, Saunders/Elsevier. \n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n94 \n\nRosenberg, D.W., Giardina, C. and Tanaka, T., 2009. Mouse models for the study of \n\ncolon carcinogenesis. Carcinogenesis, 30(2): 183-96. \n\nRosenberg, D.W. and Liu, Y., 1995. Induction of aberrant crypts in murine colon with \n\nvarying sensitivity to colon carcinogenesis. Cancer letters, 92(2): 209-14. \n\nRosenberg, S.A., Yang, J.C. and Restifo, N.P., 2004. Cancer immunotherapy: moving \n\nbeyond current vaccines. Nature medicine, 10(9): 909-15. \n\nRudzki, Z. and Jothy, S., 1997. CD44 and the adhesion of neoplastic cells. Molecular \n\npathology : MP, 50(2): 57-71. \n\nRuoslahti, E., 2002. Specialization of tumour vasculature. Nature reviews. Cancer, 2(2): \n\n83-90. \n\nSatoh, J., Yamamura, T. and Arima, K., 2004. The 14-3-3 protein epsilon isoform \n\nexpressed in reactive astrocytes in demyelinating lesions of multiple sclerosis \n\nbinds to vimentin and glial fibrillary acidic protein in cultured human astrocytes. \n\nThe American journal of pathology, 165(2): 577-92. \n\nSatoyoshi, R., Kuriyama, S., Aiba, N., Yashiro, M. and Tanaka, M., 2015. Asporin \n\nactivates coordinated invasion of scirrhous gastric cancer and cancer-associated \n\nfibroblasts. Oncogene, 34(5): 650-60. \n\nScherer, R.P., Malvesti, \u00c1.L. et al., 2009. Estudo de adsor\u00e7\u00e3o de compostos sulfurados \n\nutilizando um diesel comercial dopado com benzotiofeno e dibenzotiofeno. \n\nQu\u00edmica Nova, 32: 34-37. \n\nSchittek, B., 2012. The multiple facets of dermcidin in cell survival and host defense. \n\nJournal of innate immunity, 4(4): 349-60. \n\nSchoket, B., 1999. DNA damage in humans exposed to environmental and dietary \n\npolycyclic aromatic hydrocarbons. Mutation research, 424(1-2): 143-53. \n\nSchubert, H.L., Blumenthal, R.M. and Cheng, X., 2003. Many paths to methyltransfer: a \n\nchronicle of convergence. Trends in biochemical sciences, 28(6): 329-35. \n\nScieglinska, D., Piglowski, W., Chekan, M., Mazurek, A. and Krawczyk, Z., 2011. \n\nDifferential expression of HSPA1 and HSPA2 proteins in human tissues; tissue \n\nmicroarray-based immunohistochemical study. Histochemistry and cell biology, \n\n135(4): 337-50. \n\nScieglinska, D. et al., 2008. The HspA2 protein localizes in nucleoli and centrosomes of \n\nheat shocked cancer cells. Journal of cellular biochemistry, 104(6): 2193-206. \n\nScott, J.K. and Smith, G.P., 1990. Searching for peptide ligands with an epitope library. \n\nScience, 249(4967): 386-90. \n\nSergeeva, A., Kolonin, M.G., Molldrem, J.J., Pasqualini, R. and Arap, W., 2006. Display \n\ntechnologies: application for the discovery of drug and gene delivery agents. \n\nAdvanced drug delivery reviews, 58(15): 1622-54. \n\nSeya, T. et al., 2006. Lumican expression in advanced colorectal cancer with nodal \n\nmetastasis correlates with poor prognosis. Oncology reports, 16(6): 1225-30. \n\nShi, X. et al., 2007. Modulation of p53 function by SET8-mediated methylation at lysine \n\n382. Molecular cell, 27(4): 636-46. \n\nShi, Z. et al., 2010. Organ-specific roles of CYP1A1 during detoxication of dietary \n\nbenzo[a]pyrene. Molecular pharmacology, 78(1): 46-57. \n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n95 \n\nShim, A.R., Dong, G.Z., Lee, H.J. and Ryu, J.H., 2015. Atractylochromene Is a Repressor \n\nof Wnt/beta-Catenin Signaling in Colon Cancer Cells. Biomolecules &amp; \n\ntherapeutics, 23(1): 26-30. \n\nShimada, T., 2006. Xenobiotic-metabolizing enzymes involved in activation and \n\ndetoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug \n\nmetabolism and pharmacokinetics, 21(4): 257-76. \n\nShubik, P. and Sice, J., 1956. Chemical carcinogenesis as a chronic toxicity test; a review. \n\nCancer research, 16(8): 728-42. \n\nSidhu, S.S. and Koide, S., 2007. Phage display for engineering and analyzing protein \n\ninteraction interfaces. Current opinion in structural biology, 17(4): 481-7. \n\nSidhu, S.S., Lowman, H.B., Cunningham, B.C. and Wells, J.A., 2000. Phage display for \n\nselection of novel binding peptides. Methods in enzymology, 328: 333-63. \n\nSimpson, D.R., Mell, L.K. and Cohen, E.E., 2015. Targeting the PI3K/AKT/mTOR \n\npathway in squamous cell carcinoma of the head and neck. Oral oncology, 51(4): \n\n291-298. \n\nSimpson, R.J. and Dorow, D.S., 2001. Cancer proteomics: from signaling networks to \n\ntumor markers. Trends in biotechnology, 19(10 Suppl): S40-8. \n\nSmith, G.P., 1985. Filamentous fusion phage: novel expression vectors that display \n\ncloned antigens on the virion surface. Science, 228(4705): 1315-7. \n\nSoontjens, C.D., Holmberg, K., et al., 1997. Characterization of polycyclic aromatic \n\ncompounds in diesel exhaust particulate extract responsible for aryl hydrocarbon \n\nreceptor activity. Atmospheric Environment, 31(2): 219-225. \n\nSpeight, J.G., 2002. Handbook of petroleum product analysis. from \n\nhttp://www.knovel.com/knovel2/Toc.jsp?BookID=1108. \n\nSt Croix, B. et al., 2000. Genes expressed in human tumor endothelium. Science, \n\n289(5482): 1197-202. \n\nStassen, M.J., Bailey, D., Nelson, S., Chinwalla, V. and Harte, P.J., 1995. The Drosophila \n\ntrithorax proteins contain a novel variant of the nuclear receptor type DNA \n\nbinding domain and an ancient conserved motif found in other chromosomal \n\nproteins. Mechanisms of development, 52(2-3): 209-23. \n\nStrickland, P. and Kang, D., 1999. Urinary 1-hydroxypyrene and other PAH metabolites \n\nas biomarkers of exposure to environmental PAH in air particulate matter. \n\nToxicology letters, 108(2-3): 191-9. \n\nSuresh, R. et al., 2009. Assessment of association of exposure to polycyclic aromatic \n\nhydrocarbons with bronchial asthma and oxidative stress in children: A case \n\ncontrol study. Indian journal of occupational and environmental medicine, 13(1): \n\n33-7. \n\nTabata, T. and Takei, Y., 2004. Morphogens, their identification and regulation. \n\nDevelopment, 131(4): 703-12. \n\nThompson, O., Moghraby, J.S., Ayscough, K.R. and Winder, S.J., 2012. Depletion of the \n\nactin bundling protein SM22/transgelin increases actin dynamics and enhances \n\nthe tumourigenic phenotypes of cells. BMC cell biology, 13: 1. \n\nhttp://www.knovel.com/knovel2/Toc.jsp?BookID=1108\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n96 \n\nTschiersch, B. et al., 1994. The protein encoded by the Drosophila position-effect \n\nvariegation suppressor gene Su(var)3-9 combines domains of antagonistic \n\nregulators of homeotic gene complexes. The EMBO journal, 13(16): 3822-31. \n\nTurtoi, A. et al., 2011. Identification of novel accessible proteins bearing diagnostic and \n\ntherapeutic potential in human pancreatic ductal adenocarcinoma. Journal of \n\nproteome research, 10(9): 4302-13. \n\nUno, S. et al., 2004. Oral exposure to benzo[a]pyrene in the mouse: detoxication by \n\ninducible cytochrome P450 is more important than metabolic activation. \n\nMolecular pharmacology, 65(5): 1225-37. \n\nUno, S. et al., 2008. Basal and inducible CYP1 mRNA quantitation and protein \n\nlocalization throughout the mouse gastrointestinal tract. Free radical biology &amp; \n\nmedicine, 44(4): 570-83. \n\nvan den Brink, G.R. and Hardwick, J.C., 2006. Hedgehog Wnteraction in colorectal \n\ncancer. Gut, 55(7): 912-4. \n\nVermeulen, L. et al., 2010. Wnt activity defines colon cancer stem cells and is regulated \n\nby the microenvironment. Nature cell biology, 12(5): 468-76. \n\nVogelstein, B. and Kinzler, K.W., 2004. Cancer genes and the pathways they control. \n\nNature medicine, 10(8): 789-99. \n\nVries, R.G., Huch, M. and Clevers, H., 2010. Stem cells and cancer of the stomach and \n\nintestine. Molecular oncology, 4(5): 373-84. \n\nWang, G., 2014. Human antimicrobial peptides and proteins. Pharmaceuticals, 7(5): 545-\n\n94. \n\nWang, S.J., Wong, G., de Heer, A.M., Xia, W. and Bourguignon, L.Y., 2009a. CD44 \n\nvariant isoforms in head and neck squamous cell carcinoma progression. The \n\nLaryngoscope, 119(8): 1518-30. \n\nWang, Y., Qu, L. and Hao, Y., 2009b. [The pitfall of transbronchial lung biopsy in the \n\nsmall cell carcinoma--attach 64 cases immunohistochemistry research.]. \n\nZhongguo fei ai za zhi = Chinese journal of lung cancer, 12(8): 901-4. \n\nWei, L. et al., 2002. Inhibition of Rho family GTPases by Rho GDP dissociation inhibitor \n\ndisrupts cardiac morphogenesis and inhibits cardiomyocyte proliferation. \n\nDevelopment, 129(7): 1705-14. \n\nWhite, B.D., Chien, A.J. and Dawson, D.W., 2012. Dysregulation of Wnt/beta-catenin \n\nsignaling in gastrointestinal cancers. Gastroenterology, 142(2): 219-32. \n\nWilkins, M.R. et al., 1996. Progress with proteome projects: why all proteins expressed \n\nby a genome should be identified and how to do it. Biotechnology &amp; genetic \n\nengineering reviews, 13: 19-50. \n\nWong, J.J., Hawkins, N.J. and Ward, R.L., 2007. Colorectal cancer: a model for \n\nepigenetic tumorigenesis. Gut, 56(1): 140-8. \n\nWozny, M. et al., 2010. CYP1A expression in liver and gills of rainbow trout \n\n(Oncorhynchus mykiss) after short-term exposure to dibenzothiophene (DBT). \n\nChemosphere, 79(1): 110-2. \n\nWulfkuhle, J.D., Liotta, L.A. and Petricoin, E.F., 2003. Proteomic applications for the \n\nearly detection of cancer. Nature reviews. Cancer, 3(4): 267-75. \n\n\n\nSilva, K.T.S.                                                                       Refer\u00eancias Bibliogr\u00e1ficas \n\n97 \n\nXie, Z.Y., Gong, L.B., Zhang, W.T. and Lv, X.P., 2014. Expression of Notch-signaling \n\npathway in familial adenomatous polyposis and its clinical significance. European \n\nreview for medical and pharmacological sciences, 18(21): 3183-8. \n\nZbar, A.P., 2004. The immunology of colorectal cancer. Surgical oncology, 13(2-3): 45-\n\n53. \n\nZhai, J. et al., 2003. Direct interaction of focal adhesion kinase with p190RhoGEF. The \n\nJournal of biological chemistry, 278(27): 24865-73. \n\nZhang, N. and Walker, M.K., 2007. Crosstalk between the aryl hydrocarbon receptor and \n\nhypoxia on the constitutive expression of cytochrome P4501A1 mRNA. \n\nCardiovascular toxicology, 7(4): 282-90. \n\nZhang, X., Wen, H. and Shi, X., 2012. Lysine methylation: beyond histones. Acta \n\nbiochimica et biophysica Sinica, 44(1): 14-27. \n\nZhang, Z.W., Yang, Z.M., Zheng, Y.C. and Chen, Z.D., 2010. Transgelin induces \n\napoptosis of human prostate LNCaP cells through its interaction with p53. Asian \n\njournal of andrology, 12(2): 186-95. \n\nZhang, Z.Z. et al., 2005. [Comparative study on the genotoxicity of gasoline-fueled \n\nvehicle exhaust and methanol-fueled vehicle exhaust]. Sichuan da xue xue bao. \n\nYi xue ban = Journal of Sichuan University. Medical science edition, 36(2): 249-\n\n52. \n\nZhao, L., Wang, H., Li, J., Liu, Y. and Ding, Y., 2008. Overexpression of Rho GDP-\n\ndissociation inhibitor alpha is associated with tumor progression and poor \n\nprognosis of colorectal cancer. Journal of proteome research, 7(9): 3994-4003. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n                                                              Ap\u00eandice\n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n99 \n\n \n\nAp\u00eandice A \n\n \n\n \n\nFigura 01.A: Contagens global e diferencial de leuc\u00f3citos provenientes dos grupos Controles (I e III) e \n\nTestes (II, IV e V) ao final do per\u00edodo de tratamento/lat\u00eancia. Os resultados representam m\u00e9dia \u00b1 SD de \n\ntriplicatas biol\u00f3gicas independentes. \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n100 \n\n \n\n \n\nAp\u00eandice B \n\n \n\n \n\nFigura 01.B: Dosagens enzim\u00e1ticas s\u00e9ricas: A) Raz\u00e3o AST/ALT; B) Amilase provenientes dos grupos \n\nControles (I e III) e Testes (II, IV e V) ao final do per\u00edodo de tratamento/lat\u00eancia. Os resultados representam \n\nm\u00e9dia \u00b1 SD de triplicatas biol\u00f3gicas independentes. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n101 \n\n \n\n \n\n \n\nAp\u00eandice C \n\n \n\nTabela 01.C: Compara\u00e7\u00e3o de frequ\u00eancia das les\u00f5es observadas no intestino delgado para os grupos \n\nControle \u00d3leo e Controle Salina. \n\nLes\u00f5es Observadas \nControle \u00d3leo \n\n% (n) \n\nControle Salina \n\n% (n) \np \n\nAtipias Celulares na Mucosa 25 (1/4) 20 (1/5) 0,4985 \n\nAtipias Celulares na Submucosa 0 (0/4) 0 (0/5) - \n\nInflama\u00e7\u00e3o na Mucosa 0 (0/4) 20 (1/5) &lt;0,0001 \n\nNecrose 0 (0/4) 0 (0/5) - \n\nAtipias Estruturais 25 (1/4) 20 (1/5) 0,4985 \n\nHiperplasia de N\u00f3dulos Linf\u00f3ides 25 (1/4) 0 (0/5) &lt;0,0001 \n\n \n\n \n\nTabela 02.C: Compara\u00e7\u00e3o de frequ\u00eancia das les\u00f5es observadas no intestino grosso para os grupos Controle \n\n\u00d3leo e Controle Salina. \n\nLes\u00f5es Observadas \nControle \u00d3leo \n\n% (n) \n\nControle Salina \n\n% (n) \np \n\nAtipias Celulares na Mucosa 0 (0/4) 0 (0/5) - \n\nAtipias Celulares na Submucosa 0 (0/4) 0 (0/5) - \n\nInflama\u00e7\u00e3o na Mucosa 0 (0/4) 40 (2/5) &lt;0,0001 \n\nNecrose 0 (0/4) 20 (1/5) &lt;0,0001 \n\nAtipias Estruturais 25 (1/4) 0 (0/5) &lt;0,0001 \n\nHiperplasia de N\u00f3dulos Linf\u00f3ides 25 (1/4) 20 (1/5) 0,4985 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n102 \n\n \n\nAp\u00eandice D \n\nTabela 01.D: Pept\u00eddeos sequenciados por prote\u00edna identificada atrav\u00e9s de espectrometria de massas para os grupos Teste IV e V em rela\u00e7\u00e3o ao grupo Controle III no experimento \n\nempregando 2D SDS-PAGE. \n\nSPOT Identidade pI kDa Cobertura Acesso emPAI (M+H) obs (M+H) exp (M+H) calc delta (ppm) miss score expect \nPept\u00eddeos \n\n\u00fanicos Sequ\u00eancia de Pept\u00eddeo \n\n1 HSPA5 5,07 \n \n72473 42 \n\n \ngi|25742763 1,32 467.7540   933.4934   933.4953   -0.0019  0   34   0.048  U     R.STMKPVQK.V + Oxidation (M) \n\n       523.7904   1045.5662   1045.5655   0.0007  1   38   0.02  U     K.VLEDSDLKK.S \n\n       537.7794   1073.5443   1073.5465   -0.0022  0   55   0.00035  U     K.ITITNDQNR.L \n\n       596.3201   1190.6257   1190.6295   -0.0038  0   63   4.8e-005  U     K.VYEGERPLTK.D \n\n       657.3116   1312.6086   1312.6122   -0.0035  0   68   1.1e-005  U     K.FEELNMDLFR.S \n\n       658.8198   1315.6250   1315.6295   -0.0046  0   45   0.0028  U     R.NELESYAYSLK.N \n\n       715.8490   1429.6834   1429.6838   -0.0003  0   63   4.1e-005  U     R.TWNDPSVQQDIK.F \n\n       768.8981   1535.7816   1535.7905   -0.0089  0   90   8.1e-008  U     K.TFAPEEISAMVLTK.M \n\n       776.8968   1551.7789   1551.7854   -0.0065  0   (85)  2.5e-007  U     K.TFAPEEISAMVLTK.M + Oxidation (M) \n\n       783.8888   1565.7631   1565.7726   -0.0094  0   61   5.4e-005  U     R.ITPSYVAFTPEGER.L \n\n       794.9267   1587.8389   1587.8468   -0.0079  1   52   0.00043  U     K.KSDIDEIVLVGGSTR.I \n\n       830.4483   1658.8820   1658.8879   -0.0058  0   51   0.00049  U     R.IINEPTAAAIAYGLDK.R \n\n       839.4007   1676.7867   1676.8006   -0.0138  0   68   8.9e-006  U     K.NQLTSNPENTVFDAK.R \n\n       908.4982   1814.9819   1814.9890   -0.0070  1   (67)  9.7e-006  U     R.IINEPTAAAIAYGLDKR.E \n\n       908.4982   1814.9819   1814.9890   -0.0070  1   79   6.3e-007  U     R.IINEPTAAAIAYGLDKR.E \n\n       967.5069   1932.9993   1933.0058   -0.0065  0   (92)  3.1e-008  U     K.DNHLLGTFDLTGIPPAPR.G \n\n       967.5069   1932.9993   1933.0058   -0.0065  0   (104)  2.4e-009  U     K.DNHLLGTFDLTGIPPAPR.G \n\n       967.5076   1933.0006   1933.0058   -0.0052  0   138   9.5e-013  U     K.DNHLLGTFDLTGIPPAPR.G \n\n       967.5089   1933.0032   1933.0058   -0.0025  0   (95)  1.9e-008  U     K.DNHLLGTFDLTGIPPAPR.G \n\n       967.5093   1933.0040   1933.0058   -0.0018  0   (49)  0.00075  U     K.DNHLLGTFDLTGIPPAPR.G \n\n       1074.9993   2147.9840   2147.9899   -0.0058  0   77   6.3e-007  U     R.IEIESFFEGEDFSETLTR.A \n\n2 HSPA2 5,43 \n \n71112 46 \n\n \ngi|347019 1,76 402.7255   803.4365   803.4389   -0.0023  0   43   0.0077        K.ITITNDK.G \n\n       600.3397   1198.6648   1198.6670   -0.0021  0   57   0.00016  U     K.DAGTIAGLNVLR.I \n\n       600.3412   1198.6679   1198.6670   0.0010  0   (47)  0.0018  U     K.DAGTIAGLNVLR.I \n\n       614.8143   1227.6140   1227.6207   -0.0067  0   36   0.022        K.VEIIANDQGNR.T \n\n       618.3137   1234.6128   1234.6169   -0.0040  0   42   0.0056  U     R.MVNHFIAEFK.R \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MKFTVVAAALLLLCAVRAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFFEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSPEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSGGPPPTGEEDTSEKDEL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQAAKDAGTIAGLNVLRIINEPTAAAIAYGLDKKVRAERNVLIFDLGGGTFDVSILTTEDGIFEVKSTAGDTHLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIISWLDKNQTAEKEEFEHQQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n103 \n\n \n\n       627.3104   1252.6062   1252.6088   -0.0026  0   66   2.2e-005  U     R.FEELNADLFR.G \n\n       627.3104   1252.6062   1252.6088   -0.0026  0   (61)  6.5e-005  U     R.FEELNADLFR.G \n\n       639.3117   1276.6089   1276.6122   -0.0032  0   63   3.8e-005  U     K.CNEIISWLDK.N \n\n       744.3528   1486.6910   1486.6940   -0.0030  0   67   1.4e-005        R.TTPSYVAFTDTER.L \n\n       808.8928   1615.7711   1615.7804   -0.0092  0   62   4e-005  U     K.SFYPEEVSSMVLTK.M \n\n       816.8927   1631.7708   1631.7753   -0.0045  0   (50)  0.00059  U     K.SFYPEEVSSMVLTK.M + Oxidation (M) \n\n       825.3951   1648.7757   1648.7879   -0.0122  0   (90)  6e-008  U     K.NQVAMNPTNTVFDAK.R \n\n       833.3949   1664.7752   1664.7828   -0.0076  0   95   1.7e-008  U     K.NQVAMNPTNTVFDAK.R + Oxidation (M) \n\n       846.3639   1690.7133   1690.7183   -0.0050  0   107   5.4e-010  U     K.STAGDTHLGGEDFDNR.M \n\n       582.6064   1744.7973   1744.8016   -0.0043  1   35   0.018  U     K.NQTAEKEEFEHQQK.E \n\n       596.6657   1786.9752   1786.9828   -0.0077  1   61   3.1e-005  U     R.IINEPTAAAIAYGLDKK.V \n\n       991.4881   1980.9615   1980.9905   -0.0290  0   77   9.1e-007  U     K.TVTNAVVTVPAYFNDSQR.Q \n\n       1130.5768   2259.1390   2259.1383   0.0008  0   159   6.4e-015  U     K.SINPDEAVAYGAAVQAAILSGDK.S \n\n       755.0398   2262.0975   2262.1104   -0.0128  0   98   6.1e-009  U     K.GPAVGIDLGTTYSCVGVFQHGK.V \n\n       925.4430   2773.3071   2773.3195   -0.0125  0   65   9e-006        K.QTQTFTTYSDNQPGVLIQVYEGER.A \n\n       1387.6656   2773.3166   2773.3195   -0.0029  0   (60)  3.1e-005        K.QTQTFTTYSDNQPGVLIQVYEGER.A \n\n17 ANXA5 4,99 \n \n33944 8 \n\n \ngi|2981437 0,1 844.4426   1686.8707   1686.8788   -0.0081  0   147   1.2e-013  U     R.EPGEGAITYLVTSVLR.V \n\n                K.GLGTDEDSILNLLTAR.S \n\n19 HSP70 5,03 \n \n56324 23 \n\n \ngi|149038951 0,3 699.3947   1396.7749   1396.7813   -0.0064  0   42   0.0039  U     K.ELEEIVQPIISK.L \n\n       918.9622   1835.9098   1835.9265   -0.0167  0   59   6.9e-005  U     K.SQIFSTASDNQPTVTIK.V \n\n       967.5077   1933.0008   1933.0058   -0.0049  0   51   0.0004  U     K.DNHLLGTFDLTGIPPAPR.G \n\n       967.5095   1933.0044   1933.0058   -0.0013  0   (32)  0.035  U     K.DNHLLGTFDLTGIPPAPR.G \n\n       645.3436   1933.0091   1933.0058   0.0033  0   (47)  0.0011  U     K.DNHLLGTFDLTGIPPAPR.G \n\n       645.3436   1933.0091   1933.0058   0.0033  0   (36)  0.012  U     K.DNHLLGTFDLTGIPPAPR.G \n\n       658.9720   1973.8941   1973.9007   -0.0065  0   30   0.035  U     K.IEWLESHQDADIEDFK.A \n\n20 TPM5 4,72 \n \n29158 37 \n\n \ngi|9653293 1,13 416.7258   831.4371   831.4338   0.0034  1   43   0.0071        R.ALKDEEK.M \n\n       447.7323   893.4501   893.4606   -0.0106  1   36   0.026        R.KYEEVAR.K \n\n       454.2117   906.4088   906.4117   -0.0028  0   35   0.031        K.CLSAAEEK.Y \n\n       578.8309   1155.6472   1155.6499   -0.0027  0   55   0.00029        K.LVIIEGDLER.T \n\n       578.8309   1155.6472   1155.6499   -0.0027  0   (35)  0.028        K.LVIIEGDLER.T \n\n       595.3195   1188.6245   1188.6238   0.0007  1   42   0.0064        K.TIDDLEDKLK.C \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MALRGTVTDFSGFDGRADAEVLRKAMKGLGTDEDSILNLLTARSNAQRQQIAEEFKTLFGRDLVNDMKSELTGKFEKLIVALMKPSRLYDAYELKHALKGAGTDEKVLTEIIASRTPEELRAIKQAYEEEYGSNLEDDVVGDTSGYYQRMLVVLLQANRDPDTAIDDAQVELDAQALFQAGELKWGTDEEKFITILGTRSVSHLRRVFDKYMTISGFQIEETIDRETSGNLENLLLAVVKSIRSIPAYLAETLYYAMKGAGTDDHTLIRVIVSRSEIDLFNIRKEFRKNFATSLYSMIKGDT&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFFEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSPEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSGGPPPTGEEDTSEKDEL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAGSTTIEAVKRKIQVLQQQADDAEERAERLQREVEGERRAREQAEAEVASLNRRIQLVEEELDRAQEPLATALQKLEEAEKAADESERGMKVIENRALKDEEKMELQEIQLKEAKHIAEEADRKYEEVARKLVIIEGDLERTEERAELAESRCREMDEQIRLMDQNLKCLSAAEEKYSQKEDKYEEEIKILTDKLKEAETRAEFAERSVAKLEKTIDDLEDKLKCTKEEHLCTQRMLDQTLLDLNEM&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n104 \n\n \n\n       642.8779   1283.7413   1283.7449   -0.0036  1   (48)  0.00091        R.KLVIIEGDLER.T \n\n       642.8785   1283.7425   1283.7449   -0.0024  1   84   2.2e-007        R.KLVIIEGDLER.T \n\n       658.8225   1315.6304   1315.6368   -0.0063  0   46   0.0021  U     R.EQAEAEVASLNR.R \n\n22 ARHGDIA  5,12 \n \n23450 49 \n\n \ngi|31982030 2,8 475.2759   948.5372   948.5392   -0.0020  1   38   0.018  U     K.YKEALLGR.V \n\n       490.7470   979.4794   979.4875   -0.0081  0   47   0.0017  U     K.YIQHTYR.K \n\n       825.9464   1649.8782   1649.9101   -0.0318  0   103   2.7e-009  U     R.VAVSADPNVPNVIVTR.L \n\n       825.9578   1649.9010   1649.9101   -0.0090  0   (48)  0.00081  U     R.VAVSADPNVPNVIVTR.L \n\n       892.4037   1782.7928   1782.8022   -0.0094  0   33   0.019  U     R.AEEYEFLTPMEEAPK.G \n\n       788.7039   2363.0898   2363.1070   -0.0172  1   67   5.2e-006  U     R.FTDDDKTDHLSWEWNLTIK.K \n\n       859.4381   2575.2924   2575.3091   -0.0167  0   (52)  0.00018  U     R.LTLVCSTAPGPLELDLTGDLESFK.K \n\n       1288.6577   2575.3008   2575.3091   -0.0083  0   120   3.2e-011  U     R.LTLVCSTAPGPLELDLTGDLESFK.K \n\n       902.1300   2703.3681   2703.4041   -0.0360  1   (93)  1.4e-008  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n       902.1366   2703.3879   2703.4041   -0.0162  1   (54)  9.7e-005  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n       902.1367   2703.3882   2703.4041   -0.0159  1   108   4.4e-010  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n       902.1367   2703.3882   2703.4041   -0.0159  1   (107)  5.5e-010  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n23 FCGBP  4,92 \n \n287312 9 \n\n \ngi|257467629 0,24 458.2647   914.5148   914.5185   -0.0037  0   40   0.013  U     R.NVVLQTNK.G \n\n       562.3104   1122.6062   1122.6073   -0.0011  0   54   0.00035  U     K.VLSPLEYFR.Q \n\n       734.4457   1466.8769   1466.8821   -0.0052  0   100   2.4e-009  U     R.VVVTVADQVVVLAR.G \n\n       734.4466   1466.8786   1466.8821   -0.0034  0   (70)  2.5e-006  U     R.VVVTVADQVVVLAR.G \n\n       734.4484   1466.8823   1466.8821   0.0003  0   (36)  0.0053  U     R.VVVTVADQVVVLAR.G \n\n       880.4096   1758.8046   1758.8141   -0.0096  0   61   3.9e-005  U     R.AAGCPSGQVCEIQAGVR.Q \n\n       917.4774   1832.9403   1832.9495   -0.0092  0   36   0.014  U     K.VHIFFQDGMVTVIPSK.G + Oxidation (M) \n\n       961.4407   1920.8668   1920.8716   -0.0049  0   99   5.3e-009  U     R.YYVLGATFYPGPECER.L \n\n       669.0089   2004.0048   2004.0139   -0.0091  0   (65)  2e-005  U     K.VLFDGDAHILMSIPSSFR.G \n\n       1003.0123   2004.0100   2004.0139   -0.0038  0   100   5.2e-009  U     K.VLFDGDAHILMSIPSSFR.G \n\n       695.0338   2082.0796   2082.0898   -0.0102  0   46   0.00091  U     R.QLQVNGEFVALPFHLDQK.L \n\n       885.7755   2654.3046   2654.3197   -0.0150  0   30   0.031  U     R.GPDACGIITAPEGPLAPCHSLVPPTK.Y \n\n       1075.1135   3222.3187   3222.3298   -0.0111  0   22   0.011  U     R.EGCVCDSGFVLSGDTCVPVGQCGCLYNGR.Y \n\n26 ACTB 5,29 \n \n42052 48 \n\n \ngi|4501885 1,93 499.7437   997.4729   997.4790   -0.0061  0   43   0.0038        R.DLTDYLMK.I \n\n       499.7437   997.4729   997.4790   -0.0061  0   (34)  0.029        R.DLTDYLMK.I \n\n       566.7599   1131.5052   1131.5197   -0.0144  0   37   0.014  U     R.GYSFTTTAER.E \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRKYKEALLGRVAVSADPNVPNVIVTRLTLVCSTAPGPLELDLTGDLESFKKQSFVLKEGVEYRIKISFRVNREIVSGMKYIQHTYRKGVKIDKTDYMVGSYGPRAEEYEFLTPMEEAPKGMLARGSYNIKSRFTDDDKTDHLSWEWNLTIKKEWKD&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=257467629&amp;SERVICE=plain&amp;SET_DEFAULTS.x=21&amp;SET_DEFAULTS.y=7&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDDDIAALVVDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREKMTQIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRLDLAGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEKSYELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTVLSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKQEYDESGPSIVHRKCF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n105 \n\n \n\n       581.3012   1160.5878   1160.6111   -0.0233  0   42   0.0063        K.EITALAPSTMK.I \n\n       599.7554   1197.4961   1197.5150   -0.0188  0   58   6e-005        K.DSYVGDEAQSK.R \n\n       677.8100   1353.6054   1353.6161   -0.0107  1   84   2.3e-007        K.DSYVGDEAQSKR.G \n\n       977.5199   1953.0253   1953.0571   -0.0318  0   (48)  0.00065  U     R.VAPEEHPVLLTEAPLNPK.A \n\n       652.0158   1953.0255   1953.0571   -0.0316  0   56   0.00011  U     R.VAPEEHPVLLTEAPLNPK.A \n\n       1108.0183   2214.0220   2214.0627   -0.0406  0   (135)  1.2e-012  U     K.DLYANTVLSGGTTMYPGIADR.M \n\n       1108.0183   2214.0220   2214.0627   -0.0406  0   173   1.7e-016  U     K.DLYANTVLSGGTTMYPGIADR.M \n\n       1116.0242   2230.0338   2230.0576   -0.0238  0   (82)  2.6e-007  U     K.DLYANTVLSGGTTMYPGIADR.M + Oxidation (M) \n\n       1116.0242   2230.0338   2230.0576   -0.0238  0   (122)  2.6e-011  U     K.DLYANTVLSGGTTMYPGIADR.M + Oxidation (M) \n\n       1275.5795   2549.1444   2549.1665   -0.0221  0   (87)  4.1e-008  U     K.LCYVALDFEQEMATAASSSSLEK.S \n\n       1275.5795   2549.1444   2549.1665   -0.0221  0   (108)  3.1e-010  U     K.LCYVALDFEQEMATAASSSSLEK.S \n\n       1275.5795   2549.1444   2549.1665   -0.0221  0   131   1.6e-012  U     K.LCYVALDFEQEMATAASSSSLEK.S \n\n       850.7232   2549.1477   2549.1665   -0.0188  0   (77)  4.1e-007  U     K.LCYVALDFEQEMATAASSSSLEK.S \n\n       1061.8711   3182.5915   3182.6071   -0.0156  0   (52)  0.00012  U     R.TTGIVMDSGDGVTHTVPIYEGYALPHAILR.L \n\n       1061.8711   3182.5915   3182.6071   -0.0156  0   81   1.5e-007  U     R.TTGIVMDSGDGVTHTVPIYEGYALPHAILR.L \n\n       1077.8177   3230.4313   3230.4545   -0.0232  0   91   9.1e-009  U     R.CPEALFQPSFLGMESCGIHETTFNSIMK.C \n\n       1083.1521   3246.4345   3246.4494   -0.0149  0   (67)  2e-006  U     R.CPEALFQPSFLGMESCGIHETTFNSIMK.C + Oxidation (M) \n\n31 PNLIP 6,31 \n \n52149 53 \n\n \ngi|6981376 2,2 475.2485   948.4824   948.4876   -0.0052  0   57   0.00025        K.ITSDASSIR.N \n\n       479.2348   956.4551   956.4603   -0.0053  0   34   0.035  U     K.FYLNTGDK.S \n\n       528.3134   1054.6123   1054.6175   -0.0052  0   33   0.036  U     R.IIIHGFIDK.G \n\n       552.2552   1102.4959   1102.4978   -0.0019  0   47   0.0019  U     R.DFAACNHLR.S \n\n       574.2940   1146.5735   1146.5782   -0.0047  0   48   0.0017  U     K.GSLHPGDTHVK.E \n\n       612.3329   1222.6513   1222.6558   -0.0045  0   72   5.1e-006  U     R.YQVTVTLSGQK.V \n\n       626.8112   1251.6078   1251.6208   -0.0130  0   58   0.00013  U     R.ATYTQATQNVR.V \n\n       677.3606   1352.7066   1352.7201   -0.0135  0   67   1.7e-005        K.ALPWSPAQINTR.F \n\n       686.8125   1371.6105   1371.6242   -0.0136  0   68   9.2e-006  U     R.VFNFCSQDTVR.E \n\n       686.8167   1371.6189   1371.6242   -0.0053  0   (63)  3.3e-005  U     R.VFNFCSQDTVR.E \n\n       712.4380   1422.8613   1422.8810   -0.0196  0   101   1.4e-009  U     R.VVGAEVALLVNVLK.S \n\n       712.4473   1422.8801   1422.8810   -0.0009  0   (66)  3.3e-006  U     R.VVGAEVALLVNVLK.S \n\n       712.4486   1422.8826   1422.8810   0.0016  0   (24)  0.049  U     R.VVGAEVALLVNVLK.S \n\n       712.4486   1422.8826   1422.8810   0.0016  0   (38)  0.002  U     R.VVGAEVALLVNVLK.S \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MLMLWTFAVLLGAVAGKEVCFDKLGCFSDDAPWSGTIDRPLKALPWSPAQINTRFLLYTNENQDNYQKITSDASSIRNSNFKTNRKTRIIIHGFIDKGEENWLSDMCKNMFKVESVNCICVDWKGGSRATYTQATQNVRVVGAEVALLVNVLKSDLGHPPDNVHLIGHSLGSHVAGEAGKRTFGAIGRITGLDAAEPYFQGTPEEVRLDPTDAQFVDAIHTDAAPIIPNLGFGMSQTVGHLDFFPNGGMEMPGCQKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPTGFSGFSCSSYNVFSANKCFPCGSEGCPQMGHYADKYPGKTKELYQKFYLNTGDKSNFARWRYQVTVTLSGQKVTGHILVSLFGNGGNSKQYEVFKGSLHPGDTHVKEFDSDMDVGDLQKVKFIWYNNVINPTLPKVGASRISVERNDGRVFNFCSQDTVREDVLLTLSAC&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n106 \n\n \n\n       749.8188   1497.6231   1497.6293   -0.0062  0   (55)  8.8e-005  U     K.EFDSDMDVGDLQK.V \n\n       754.8357   1507.6568   1507.6799   -0.0232  0   101   3.5e-009  U     K.VESVNCICVDWK.G \n\n       757.8127   1513.6109   1513.6243   -0.0133  0   64   8.8e-006  U     K.EFDSDMDVGDLQK.V + Oxidation (M) \n\n       859.9476   1717.8806   1717.9192   -0.0386  0   78   1.1e-006  U     K.FIWYNNVINPTLPK.V \n\n       859.9632   1717.9118   1717.9192   -0.0073  0   (36)  0.014  U     K.FIWYNNVINPTLPK.V \n\n       895.4075   1788.8005   1788.8318   -0.0313  0   47   0.00089        R.FLLYTNENQDNYQK.I \n\n       964.9988   1927.9830   1928.0003   -0.0173  0   147   1e-013  U     K.NILSQIVDIDGIWEGTR.D \n\n       965.0037   1927.9929   1928.0003   -0.0074  0   (129)  7.2e-012  U     K.NILSQIVDIDGIWEGTR.D \n\n       1047.0117   2092.0088   2092.0113   -0.0024  0   (97)  9.4e-009  U     R.ITGLDAAEPYFQGTPEEVR.L \n\n       1047.0117   2092.0088   2092.0113   -0.0024  0   127   9.8e-012  U     R.ITGLDAAEPYFQGTPEEVR.L \n\n       712.3407   2134.0002   2134.0154   -0.0152  0   51   0.00032        K.LGCFSDDAPWSGTIDRPLK.A \n\n       1004.7790   3011.3152   3011.3284   -0.0132  0   30   0.0093  U     K.YYTDSIVNPTGFSGFSCSSYNVFSANK.C \n\n32 PGK1 8,02 \n \n44909 62 \n\n \ngi|40254752 2,84 610.3305   1218.6464   1218.6496   -0.0031  0   (40)  0.0098  U     K.YSLEPVAAELK.S \n\n       610.3305   1218.6464   1218.6496   -0.0031  0   47   0.002  U     K.YSLEPVAAELK.S \n\n       659.8656   1317.7167   1317.7180   -0.0013  0   (40)  0.0092  U     K.ITLPVDFVTADK.F \n\n       659.8656   1317.7167   1317.7180   -0.0013  0   73   4.2e-006  U     K.ITLPVDFVTADK.F \n\n       864.4448   1726.8750   1726.8786   -0.0036  0   81   4.9e-007  U     K.VNEMIIGGGMAFTFLK.V \n\n       870.9500   1739.8854   1739.9054   -0.0200  0   (40)  0.0057  U     K.VSHVSTGGGASLELLEGK.V \n\n       580.9736   1739.8989   1739.9054   -0.0065  0   56   0.00016  U     K.VSHVSTGGGASLELLEGK.V \n\n       872.4447   1742.8748   1742.8736   0.0013  0   (68)  1.1e-005  U     K.VNEMIIGGGMAFTFLK.V + Oxidation (M) \n\n       877.8921   1753.7696   1753.7798   -0.0101  0   122   3.2e-011  U     R.GCITIIGGGDTATCCAK.W \n\n       880.4396   1758.8646   1758.8685   -0.0039  0   (71)  4.6e-006  U     K.VNEMIIGGGMAFTFLK.V + 2 Oxidation (M) \n\n       590.3331   1767.9774   1767.9883   -0.0109  0   (65)  1.2e-005  U     K.ALESPERPFLAILGGAK.V \n\n       884.9961   1767.9777   1767.9883   -0.0106  0   91   3.2e-008  U     K.ALESPERPFLAILGGAK.V \n\n       991.9688   1981.9230   1981.9302   -0.0072  0   (51)  0.00034  U     K.VLNNMEIGTSLYDEEGAK.I \n\n       991.9688   1981.9230   1981.9302   -0.0072  0   (55)  0.00014  U     K.VLNNMEIGTSLYDEEGAK.I \n\n       999.9667   1997.9189   1997.9252   -0.0063  0   94   1.9e-008  U     K.VLNNMEIGTSLYDEEGAK.I + Oxidation (M) \n\n       675.0131   2022.0175   2022.0310   -0.0135  1   79   6.8e-007  U     K.ITLPVDFVTADKFDENAK.T \n\n       1053.0319   2104.0492   2104.0531   -0.0038  0   (93)  2.4e-008  U     K.QIVWNGPVGVFEWEAFAR.G \n\n       1053.0319   2104.0492   2104.0531   -0.0038  0   (92)  3.1e-008  U     K.QIVWNGPVGVFEWEAFAR.G \n\n       1053.0333   2104.0520   2104.0531   -0.0010  0   132   3.5e-012  U     K.QIVWNGPVGVFEWEAFAR.G \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQRIKAAVPSIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAAELKSLLGKDVLFLKDCVGSEVENACANPAAGTVILLENLRFHVEEEGKGKDASGNKVKAEPAKIDAFRASLSKLGDVYVNDAFGTAHRAHSSMVGVNLPQKAGGFLMKKELNYFAKALESPERPFLAILGGAKVADKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLYDEEGAKIVKDLMAKAEKNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGTESSKKYAEAVARAKQIVWNGPVGVFEWEAFARGTKSLMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGKVLPGVDALSNV&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n107 \n\n \n\n       1053.0333   2104.0520   2104.0531   -0.0010  0   (127)  9.5e-012  U     K.QIVWNGPVGVFEWEAFAR.G \n\n       870.4118   2608.2137   2608.2262   -0.0125  1   (31)  0.023  U     K.TGQATVASGIPAGWMGLDCGTESSKK.Y \n\n       870.4118   2608.2137   2608.2262   -0.0125  1   41   0.0021  U     K.TGQATVASGIPAGWMGLDCGTESSKK.Y \n\n       924.7741   2771.3004   2771.3218   -0.0214  0   (45)  0.00091  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n       924.7744   2771.3013   2771.3218   -0.0205  0   (58)  5e-005  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n       924.7744   2771.3013   2771.3218   -0.0205  0   (48)  0.00042  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n       924.7774   2771.3103   2771.3218   -0.0115  0   (88)  4.7e-008  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n       924.7774   2771.3103   2771.3218   -0.0115  0   (88)  4.6e-008  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n       924.7774   2771.3103   2771.3218   -0.0115  0   (108)  4.8e-010  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n       924.7777   2771.3112   2771.3218   -0.0106  0   143   1.4e-013  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n37 LDHA 8,45 \n \n36712 61 \n\n \ngi|8393706 1,37 392.6846   783.3546   783.3585   -0.0039  0   32   0.041  U     R.YLMGER.L + Oxidation (M) \n\n       528.3200   1054.6255   1054.6386   -0.0131  0   42   0.0048  U     K.DQLIVNLLK.E \n\n       528.3246   1054.6346   1054.6386   -0.0040  0   (37)  0.011  U     K.DQLIVNLLK.E \n\n       559.7924   1117.5703   1117.5768   -0.0064  0   47   0.0022  U     K.SADTLWGIQK.E \n\n       399.8953   1196.6642   1196.6700   -0.0058  1   39   0.0083  U     R.RVHPISTMIK.G + Oxidation (M) \n\n       624.7982   1247.5818   1247.5928   -0.0111  0   40   0.0086  U     R.VIGSGCNLDSAR.F \n\n       625.8283   1249.6421   1249.6554   -0.0133  0   73   4.9e-006  U     K.QVVDSAYEVIK.L \n\n       625.8283   1249.6421   1249.6554   -0.0133  0   (68)  1.5e-005  U     K.QVVDSAYEVIK.L \n\n       829.4225   1656.8304   1656.8458   -0.0154  0   119   8.6e-011  U     K.DLADELALVDVIEDK.L \n\n       829.4279   1656.8411   1656.8458   -0.0046  0   (113)  3.7e-010  U     K.DLADELALVDVIEDK.L \n\n       829.4279   1656.8411   1656.8458   -0.0046  0   (113)  3.1e-010  U     K.DLADELALVDVIEDK.L \n\n       829.4288   1656.8431   1656.8458   -0.0027  0   (75)  1.9e-006  U     K.DLADELALVDVIEDK.L \n\n       829.4290   1656.8435   1656.8458   -0.0023  0   (47)  0.0015  U     K.DLADELALVDVIEDK.L \n\n       972.5612   1943.1078   1943.1132   -0.0053  0   (48)  0.0003  U     K.LLIVSNPVDILTYVAWK.I \n\n       972.5636   1943.1126   1943.1132   -0.0006  0   126   4.6e-012  U     K.LLIVSNPVDILTYVAWK.I \n\n       1064.5335   2127.0524   2127.0558   -0.0033  0   114   1.7e-010  U     K.GYTSWAIGLSVADLAESIMK.N + Oxidation (M) \n\n       1064.5335   2127.0524   2127.0558   -0.0033  0   (107)  8.4e-010  U     K.GYTSWAIGLSVADLAESIMK.N + Oxidation (M) \n\n       1064.5351   2127.0556   2127.0558   -0.0001  0   (61)  3.6e-005  U     K.GYTSWAIGLSVADLAESIMK.N + Oxidation (M) \n\n41 RFESD 8,9 \n \n27956 26 \n\n \ngi|206681 0,4 1065.5102   2129.0058   2129.0133   -0.0074  0   115   1.3e-010  U     K.NAVSQFVSSMSASADVLAMSK.I \n\n       1065.5102   2129.0058   2129.0133   -0.0074  0   (89)  5.1e-008  U     K.NAVSQFVSSMSASADVLAMSK.I \n\n       1073.5094   2145.0042   2145.0082   -0.0039  0   (30)  0.047  U     K.NAVSQFVSSMSASADVLAMSK.I + Oxidation (M) \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAALKDQLIVNLLKEEQVPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLKTPKIVSSKDYSVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPQCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGVNVAGVSLKSLNPQLGTDADKEQWKDVHKQVVDSAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPISTMIKGLYGIKEDVFLSVPCILGQNGISDVVKVTLTPDEEARLKKSADTLWGIQKELQF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=SRGVAGALRPLLQSAVPATSEPPVLDVKRPFLCRESLSGQAATRPLVATVGLNVPASVRYSHTDIKVPDFSDYRRAEVLDSTKSSKESSEARKGFSYLVTATTTVGVAYAAKNAVSQFVSSMSASADVLAMSKIEIKLSDIPEGKNMAFKWRGKPLFVRHRTKKEIDQEAAVEVSQLRDPQHDLERVKKPEWVILIGVCTHLGCVPIANAGDFGGYYCPCHGSHYDASGRIRKGPAPLNLEVPTYEFTSGDVVVVG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n108 \n\n \n\n43 PRDX1 8,27 \n \n22323 72 \n\n \ngi|16923958 4,36 444.7227   887.4308   887.4389   -0.0081  1   48   0.0023        K.SKEYFSK.Q \n\n       447.7189   893.4233   893.4243   -0.0010  0   45   0.0036  U     K.ADEGISFR.G \n\n       447.7189   893.4233   893.4243   -0.0010  0   (44)  0.004  U     K.ADEGISFR.G \n\n       460.7579   919.5013   919.5015   -0.0002  0   41   0.0089        R.GLFIIDDK.G \n\n       477.2553   952.4961   952.5130   -0.0169  0   53   0.00047  U     K.IGHPAPSFK.A \n\n       554.2988   1106.5830   1106.5972   -0.0142  0   54   0.00041  U     R.TIAQDYGVLK.A \n\n       590.7868   1179.5591   1179.5594   -0.0003  0   61   6.4e-005  U     K.ATAVMPDGQFK.D + Oxidation (M) \n\n       598.8084   1195.6022   1195.6237   -0.0215  0   57   0.00016        R.LVQAFQFTDK.H \n\n       598.8151   1195.6156   1195.6237   -0.0081  0   (52)  0.00046        R.LVQAFQFTDK.H \n\n       613.3323   1224.6501   1224.6826   -0.0325  0   68   1.2e-005  U     R.QITINDLPVGR.S \n\n       613.3447   1224.6748   1224.6826   -0.0078  0   (41)  0.0057  U     R.QITINDLPVGR.S \n\n       613.3447   1224.6748   1224.6826   -0.0078  0   (43)  0.0041  U     R.QITINDLPVGR.S \n\n       811.9293   1621.8440   1621.8498   -0.0057  0   (68)  9.3e-006  U     K.QGGLGPMNIPLVSDPK.R \n\n       819.9220   1637.8295   1637.8447   -0.0152  0   97   1.2e-008  U     K.QGGLGPMNIPLVSDPK.R + Oxidation (M) \n\n       819.9220   1637.8295   1637.8447   -0.0152  0   (83)  3.1e-007  U     K.QGGLGPMNIPLVSDPK.R + Oxidation (M) \n\n       598.9879   1793.9420   1793.9458   -0.0038  1   38   0.0073  U     K.QGGLGPMNIPLVSDPKR.T + Oxidation (M) \n\n       798.0528   2391.1367   2391.1641   -0.0275  0   66   8.8e-006        K.HGEVCPAGWKPGSDTIKPDVNK.S \n\n44 CFL1 8,22 \n \n18749 62 \n\n \ngi|8393101 2,75 655.3428   1308.6711   1308.6748   -0.0037  1   67   1.5e-005  U     K.AVLFCLSEDKK.N \n\n       669.3140   1336.6134   1336.6187   -0.0053  0   60   6.6e-005        R.YALYDATYETK.E \n\n       670.8919   1339.7692   1339.7711   -0.0019  0   (37)  0.012  U     K.LGGSAVISLEGKPL.- \n\n       670.8923   1339.7701   1339.7711   -0.0010  0   107   9.6e-010  U     K.LGGSAVISLEGKPL.- \n\n       597.6070   1789.7992   1789.8053   -0.0061  1   92   2.3e-008  U     K.HELQANCYEEVKDR.C \n\n       597.6075   1789.8007   1789.8053   -0.0046  1   (41)  0.0032  U     K.HELQANCYEEVKDR.C \n\n       995.5358   1989.0571   1989.0611   -0.0040  1   67   8.9e-006        K.KEDLVFIFWAPESAPLK.S \n\n       1098.5519   2195.0892   2195.0998   -0.0106  0   94   1.7e-008  U     K.EILVGDVGQTVDDPYTTFVK.M \n\n       1031.5325   3091.5757   3091.5965   -0.0209  1   118   3.3e-011  U     K.NIILEEGKEILVGDVGQTVDDPYTTFVK.M \n\n48 CKB 5,39 \n \n42983 66 \n\n \ngi|401461784 3,4 439.7570   877.4994   877.5021   -0.0027  1   46   0.0027  U     K.FSEVLKR.L \n\n       516.2761   1030.5376   1030.5481   -0.0105  0   (57)  0.00026  U     K.LLIEMEQR.L \n\n       524.2771   1046.5396   1046.5430   -0.0034  0   64   4.3e-005  U     K.LLIEMEQR.L + Oxidation (M) \n\n       387.1840   1158.5303   1158.5418   -0.0115  0   (41)  0.0075  U     M.PFSNSHNTQK.L \n\n       580.2755   1158.5364   1158.5418   -0.0054  0   53   0.00047  U     M.PFSNSHNTQK.L \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSSGNAKIGHPAPSFKATAVMPDGQFKDISLSDYKGKYVVFFFYPLDFTFVCPTEIIAFSDRAEEFKKLNCQVIGASVDSHFCHLAWINTPKKQGGLGPMNIPLVSDPKRTIAQDYGVLKADEGISFRGLFIIDDKGILRQITINDLPVGRSVDEILRLVQAFQFTDKHGEVCPAGWKPGSDTIKPDVNKSKEYFSKQK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MASGVAVSDGVIKVFNDMKVRKSSTPEEVKKRKKAVLFCLSEDKKNIILEEGKEILVGDVGQTVDDPYTTFVKMLPDKDCRYALYDATYETKESKKEDLVFIFWAPESAPLKSKMIYASSKDAIKKKLTGIKHELQANCYEEVKDRCTLAEKLGGSAVISLEGKPL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MPFSNSHNTQKLRFPAEDEFPDLSSHNNHMAKVLTPELYAELRAKCTPSGFTLDDAIQTGVDNPGHPYIMTVGAVAGDEESYDVFKDLFDPIIEDRHGGYQPSDEHKTDLNPDNLQGGDDLDPNYVLSSRVRTGRSIRGFCLPPHCSRGERRAIEKLAVEALSSLDGDLSGRYYALKSMTEAEQQQLIDDHFLFDKPVSPLLLASGMARDWPDARGIWHNDNKTFLVWINEEDHLRVISMQKGGNMKEVFTRFCTGLTQIETLFKSKNYEFMWNPHLGYILTCPSNLGTGLRAGVHIKLPHLGKHEKFSEVLKRLRLQKRGTGGVDTAAVGGVFDVSNADRLGFSEVELVQMVVDGVKLLIEMEQRLEQGQPIDDLMPAQK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n109 \n\n \n\n       615.7762   1229.5378   1229.5434   -0.0056  0   35   0.019  U     R.GFCLPPHCSR.G \n\n       616.8066   1231.5986   1231.6085   -0.0099  0   65   3e-005  U     K.DLFDPIIEDR.H \n\n       652.3545   1302.6945   1302.7183   -0.0238  0   85   3.2e-007  U     K.VLTPELYAELR.A \n\n       652.3626   1302.7106   1302.7183   -0.0077  0   (70)  9.2e-006  U     K.VLTPELYAELR.A \n\n       779.3895   1556.7644   1556.7909   -0.0265  0   (85)  2.3e-007  U     R.FCTGLTQIETLFK.S \n\n       779.3946   1556.7747   1556.7909   -0.0161  0   118   1.1e-010  U     R.FCTGLTQIETLFK.S \n\n       801.9077   1601.8009   1601.8260   -0.0252  0   96   1.6e-008  U     K.LAVEALSSLDGDLSGR.Y \n\n       801.9137   1601.8128   1601.8260   -0.0132  0   (36)  0.019  U     K.LAVEALSSLDGDLSGR.Y \n\n       801.9170   1601.8194   1601.8260   -0.0066  0   (68)  1.3e-005  U     K.LAVEALSSLDGDLSGR.Y \n\n       801.9170   1601.8194   1601.8260   -0.0066  0   (59)  9.5e-005  U     K.LAVEALSSLDGDLSGR.Y \n\n       801.9170   1601.8194   1601.8260   -0.0066  0   (90)  8e-008  U     K.LAVEALSSLDGDLSGR.Y \n\n       801.9176   1601.8207   1601.8260   -0.0053  0   (46)  0.0018  U     K.LAVEALSSLDGDLSGR.Y \n\n       801.9176   1601.8207   1601.8260   -0.0053  0   (43)  0.0039  U     K.LAVEALSSLDGDLSGR.Y \n\n       836.4164   1670.8183   1670.8416   -0.0233  0   110   6.1e-010  U     K.TFLVWINEEDHLR.V \n\n       557.9489   1670.8249   1670.8416   -0.0167  0   (49)  0.00092  U     K.TFLVWINEEDHLR.V \n\n       557.9489   1670.8249   1670.8416   -0.0167  0   (50)  0.00063  U     K.TFLVWINEEDHLR.V \n\n       841.9173   1681.8201   1681.8345   -0.0144  0   (53)  0.00032  U     R.LEQGQPIDDLMPAQK.- \n\n       841.9214   1681.8282   1681.8345   -0.0063  0   (63)  2.8e-005  U     R.LEQGQPIDDLMPAQK.- \n\n       841.9214   1681.8282   1681.8345   -0.0063  0   (63)  2.8e-005  U     R.LEQGQPIDDLMPAQK.- \n\n       841.9214   1681.8282   1681.8345   -0.0063  0   67   1.1e-005  U     R.LEQGQPIDDLMPAQK.- \n\n       616.9929   1847.9570   1847.9703   -0.0133  0   (100)  5e-009  U     R.LGFSEVELVQMVVDGVK.L \n\n       924.9874   1847.9602   1847.9703   -0.0101  0   (44)  0.0018  U     R.LGFSEVELVQMVVDGVK.L \n\n       924.9874   1847.9602   1847.9703   -0.0101  0   (57)  9.9e-005  U     R.LGFSEVELVQMVVDGVK.L \n\n       924.9879   1847.9613   1847.9703   -0.0090  0   (89)  6.4e-008  U     R.LGFSEVELVQMVVDGVK.L \n\n       924.9887   1847.9628   1847.9703   -0.0075  0   (69)  5.7e-006  U     R.LGFSEVELVQMVVDGVK.L \n\n       932.9812   1863.9479   1863.9652   -0.0174  0   113   3.2e-010  U     R.LGFSEVELVQMVVDGVK.L + Oxidation (M) \n\n       982.9314   1963.8483   1963.9236   -0.0753  0   117   4.5e-011  U     R.GTGGVDTAAVGGVFDVSNADR.L \n\n       982.9648   1963.9151   1963.9236   -0.0085  0   (75)  1.3e-006  U     R.GTGGVDTAAVGGVFDVSNADR.L \n\n       729.3194   2184.9365   2184.9534   -0.0169  0   68   2.7e-006  U     R.FPAEDEFPDLSSHNNHMAK.V \n\n       1259.5820   2517.1494   2517.1619   -0.0125  0   150   2.6e-014  U     K.TDLNPDNLQGGDDLDPNYVLSSR.V \n\n       985.1302   2952.3687   2952.4051   -0.0363  0   118   3e-011  U     K.NYEFMWNPHLGYILTCPSNLGTGLR.A \n\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n110 \n\n \n\n54 AKR1B1 6,26 \n \n36230 26 \n\n \ngi|6978491 0,85 552.2965   1102.5784   1102.5845   -0.0061  0   63   5.9e-005  U     K.MPTLGLGTWK.S \n\n       553.3133   1104.6121   1104.6291   -0.0170  1   43   0.0052  U     K.RQDLFIVSK.L \n\n       752.8407   1503.6668   1503.6776   -0.0108  0   83   2.3e-007  U     R.HIDCAQVYQNEK.E \n\n       779.4057   1556.7968   1556.8311   -0.0342  0   106   1.7e-009  U     K.AIGVSNFNPLQIER.I \n\n       1132.5239   2263.0332   2263.0467   -0.0134  0   78   6.1e-007  U     K.VFDFELSNEDMATLLSYNR.N \n\n57 GNB2L1 7,6 \n \n35511 77 \n\n \ngi|5174447 3,98 430.7266   859.4386   859.4440   -0.0053  0   39   0.018  U     K.IWDLEGK.I \n\n       517.7879   1033.5612   1033.5630   -0.0019  1   50   0.0011  U     R.DKTIIMWK.L \n\n       530.2976   1058.5806   1058.5873   -0.0067  0   55   0.00039  U     R.VWQVTIGTR.- \n\n       596.7792   1191.5439   1191.5520   -0.0081  0   73   4.7e-006  U     R.DETNYGIPQR.A \n\n       632.8217   1263.6289   1263.6459   -0.0170  0   (61)  7.3e-005  U     R.LWDLTTGTTTR.R \n\n       632.8217   1263.6289   1263.6459   -0.0170  0   70   9.1e-006  U     R.LWDLTTGTTTR.R \n\n       655.3186   1308.6226   1308.6310   -0.0084  0   85   2.3e-007  U     K.DVLSVAFSSDNR.Q \n\n       655.3216   1308.6286   1308.6310   -0.0024  0   (41)  0.0057  U     K.DVLSVAFSSDNR.Q \n\n       655.3216   1308.6286   1308.6310   -0.0024  0   (38)  0.013  U     K.DVLSVAFSSDNR.Q \n\n       683.8439   1365.6732   1365.6751   -0.0018  0   (41)  0.0067  U     R.YWLCAATGPSIK.I \n\n       683.8452   1365.6758   1365.6751   0.0007  0   (60)  7.7e-005  U     R.YWLCAATGPSIK.I \n\n       683.8452   1365.6758   1365.6751   0.0007  0   60   7.3e-005  U     R.YWLCAATGPSIK.I \n\n       738.8386   1475.6626   1475.6715   -0.0089  0   (44)  0.0022  U     K.DGQAMLWDLNEGK.H \n\n       738.8406   1475.6666   1475.6715   -0.0048  0   (68)  1.1e-005  U     K.DGQAMLWDLNEGK.H \n\n       746.8386   1491.6626   1491.6664   -0.0038  0   74   2.2e-006  U     K.DGQAMLWDLNEGK.H + Oxidation (M) \n\n       894.9966   1787.9787   1787.9880   -0.0094  1   30   0.039  U     K.IIVDELKQEVISTSSK.A \n\n       954.4448   1906.8751   1906.8884   -0.0132  0   58   7.1e-005  U     R.FSPNSSNPIIVSCGWDK.L \n\n       661.2935   1980.8586   1980.8636   -0.0050  0   75   9.4e-007  U     K.YTVQDESHSEWVSCVR.F \n\n       759.3666   2275.0779   2275.1055   -0.0277  0   (100)  4e-009  U     K.HLYTLDGGDIINALCFSPNR.Y \n\n       759.3666   2275.0779   2275.1055   -0.0277  0   (120)  4.4e-011  U     K.HLYTLDGGDIINALCFSPNR.Y \n\n       759.3666   2275.0779   2275.1055   -0.0277  0   (121)  3.6e-011  U     K.HLYTLDGGDIINALCFSPNR.Y \n\n       759.3719   2275.0938   2275.1055   -0.0118  0   (64)  1.7e-005  U     K.HLYTLDGGDIINALCFSPNR.Y \n\n       1138.5560   2275.0974   2275.1055   -0.0081  0   145   1.5e-013  U     K.HLYTLDGGDIINALCFSPNR.Y \n\n       876.4348   2626.2825   2626.2962   -0.0137  0   75   1.1e-006  U     K.GHNGWVTQIATTPQFPDMILSASR.D \n\n       881.7681   2642.2824   2642.2911   -0.0087  0   (36)  0.0079  U     K.GHNGWVTQIATTPQFPDMILSASR.D + Oxidation (M) \n\n       1023.4743   3067.4011   3067.4346   -0.0335  0   (89)  2.1e-008  U     K.AEPPQCTSLAWSADGQTLFAGYTDNLVR.V \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MASHLELNNGTKMPTLGLGTWKSPPGQVTEAVKVAIDMGYRHIDCAQVYQNEKEVGVALQEKLKEQVVKRQDLFIVSKLWCTFHDQSMVKGACQKTLSDLQLDYLDLYLIHWPTGFKPGPDYFPLDASGNVIPSDTDFVDTWTAMEQLVDEGLVKAIGVSNFNPLQIERILNKPGLKYKPAVNQIECHPYLTQEKLIEYCHCKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKEIAAKYNKTTAQVLIRFPIQRNLVVIPKSVTPARIAENFKVFDFELSNEDMATLLSYNRNWRVCALMSCAKHKDYPFHAEV&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MTEQMTLRGTLKGHNGWVTQIATTPQFPDMILSASRDKTIIMWKLTRDETNYGIPQRALRGHSHFVSDVVISSDGQFALSGSWDGTLRLWDLTTGTTTRRFVGHTKDVLSVAFSSDNRQIVSGSRDKTIKLWNTLGVCKYTVQDESHSEWVSCVRFSPNSSNPIIVSCGWDKLVKVWNLANCKLKTNHIGHTGYLNTVTVSPDGSLCASGGKDGQAMLWDLNEGKHLYTLDGGDIINALCFSPNRYWLCAATGPSIKIWDLEGKIIVDELKQEVISTSSKAEPPQCTSLAWSADGQTLFAGYTDNLVRVWQVTIGTR&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n111 \n\n \n\n       1023.4743   3067.4011   3067.4346   -0.0335  0   112   1e-010  U     K.AEPPQCTSLAWSADGQTLFAGYTDNLVR.V \n\n       1023.4836   3067.4290   3067.4346   -0.0056  0   (83)  8.6e-008  U     K.AEPPQCTSLAWSADGQTLFAGYTDNLVR.V \n\n       1023.4838   3067.4296   3067.4346   -0.0050  0   (80)  1.6e-007  U     K.AEPPQCTSLAWSADGQTLFAGYTDNLVR.V \n\n59 PGAM1 6,67 \n \n28928 72 \n\n \ngi|114326546 1,97 384.7026   767.3907   767.3926   -0.0019  0   34   0.032  U     K.HGEAQVK.I \n\n       488.2505   974.4864   974.4855   0.0009  0   44   0.0054  U     K.AMEAVAAQGK.V \n\n       552.2957   1102.5769   1102.5804   -0.0035  1   58   0.00017  U     R.KAMEAVAAQGK.V \n\n       575.8363   1149.6581   1149.6618   -0.0037  0   71   6.2e-006  U     R.VLIAAHGNSLR.G \n\n       656.8041   1311.5937   1311.5956   -0.0019  0   49   0.00088  U     R.HGESAWNLENR.F \n\n       842.4474   1682.8802   1682.9032   -0.0230  0   (64)  2.6e-005  U     R.ALPFWNEEIVPQIK.E \n\n       842.4474   1682.8802   1682.9032   -0.0230  0   67   1.1e-005  U     R.ALPFWNEEIVPQIK.E \n\n       842.4510   1682.8875   1682.9032   -0.0157  0   (60)  6.1e-005  U     R.ALPFWNEEIVPQIK.E \n\n       890.3975   1778.7805   1778.7822   -0.0017  0   55   0.00012  U     R.DAGYEFDICFTSVQK.R \n\n       890.3975   1778.7805   1778.7822   -0.0017  0   (43)  0.0022  U     R.DAGYEFDICFTSVQK.R \n\n       660.6277   1978.8614   1978.8697   -0.0083  0   (64)  9.8e-006  U     R.FSGWYDADLSPAGHEEAK.R \n\n       660.6277   1978.8614   1978.8697   -0.0083  0   81   2.3e-007  U     R.FSGWYDADLSPAGHEEAK.R \n\n       705.7095   2114.1067   2114.1194   -0.0127  0   62   2.6e-005  U     K.NLKPIKPMQFLGDEETVR.K \n\n       809.0508   2424.1306   2424.1478   -0.0172  1   68   4.8e-006  U     R.YADLTEDQLPSCESLKDTIAR.A \n\n62 TF 6,94 \n \n78538 33 \n\n \ngi|1854476 1 458.2360   914.4574   914.4610   -0.0036  0   48   0.0018  U     K.VAQEHFGK.G \n\n       466.2049   930.3953   930.3978   -0.0025  0   43   0.0039  U     K.SCHTGVDR.T \n\n       475.2819   948.5492   948.5505   -0.0012  0   46   0.0026  U     R.IPSHAVVAR.N \n\n       507.7342   1013.4539   1013.4488   0.0051  0   35   0.024  U     K.TSYQDCIK.A \n\n       559.7844   1117.5542   1117.5590   -0.0048  0   56   0.0003  U     R.LLEACTFHK.S \n\n       604.8178   1207.6210   1207.6237   -0.0028  0   62   5.8e-005  U     K.DFQLFGSPLGK.D \n\n       645.2750   1288.5354   1288.5329   0.0025  0   59   4.3e-005  U     K.DCTGNFCLFR.S \n\n       674.8422   1347.6698   1347.6419   0.0279  0   75   2.7e-006  U     K.ASDSSINWNNLK.G \n\n       696.8813   1391.7479   1391.7561   -0.0082  0   53   0.00039  U     R.LYLGHSYVTAIR.N \n\n       712.3823   1422.7501   1422.7507   -0.0006  1   87   1.4e-007  U     K.SKDFQLFGSPLGK.D \n\n       781.9050   1561.7955   1561.8075   -0.0120  0   78   1.4e-006  U     R.TAGWNIPMGLLFSR.I \n\n       781.9077   1561.8008   1561.8075   -0.0067  0   (70)  8.1e-006  U     R.TAGWNIPMGLLFSR.I \n\n       781.9077   1561.8008   1561.8075   -0.0067  0   (42)  0.005  U     R.TAGWNIPMGLLFSR.I \n\n       789.9030   1577.7914   1577.8024   -0.0110  0   (60)  7.2e-005  U     R.TAGWNIPMGLLFSR.I + Oxidation (M) \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAAYKLVLIRHGESAWNLENRFSGWYDADLSPAGHEEAKRGGQALRDAGYEFDICFTSVQKRAIRTLWTVLDAIDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEAQVKIWRRSYDVPPPPMEPDHPFYSNISKDRRYADLTEDQLPSCESLKDTIARALPFWNEEIVPQIKEGKRVLIAAHGNSLRGIVKHLEGLSEEAIMELNLPTGIPIVYELDKNLKPIKPMQFLGDEETVRKAMEAVAAQGKVKK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRFAVGALLACAALGLCLAVPDKTVKWCAVSEHENTKCISFRDHMKTVLPADGPRLACVKKTSYQDCIKAISGGEADAITLDGGWVYDAGLTPNNLKPVAAEFYGSLEHPQTHYLAVAVVKKGTDFQLNQLQGKKSCHTGLGRSAGWIIPIGLLFCNLPEPRKPLEKAVASFFSGSCVPCADPVAFPQLCQLCPGCGCSPTQPFFGYVGAFKCLRDGGGDVAFVKHTTIFEVLPQKADRDQYELLCLDNTRKPVDQYEDCYLARIPSHAVVARNGDGKEDLIWEILKVAQEHFGKGKSKDFQLFGSPLGKDLLFKDSAFGCYGVPPRMDYRLYLGHSYVTAIRNQREGVCPEASIDSAPVKWCALSHQERAKCDEWSVTSNGQIECESAESTEDCIDKIVNGEADAMSLDGGHAYIAGQCGLVPVMAENYDISSCTNPQSDVFPKGYYAVAVVKASDSSINWNNLKGKKSCHTGVDRTAGWNIPMGLLFSRINHCKFDEFFSQGCAPGYKKNSTLCDLCIGPAKCAPNNREGYNGYTGAFQCLVEKGDVAFVKHQTVLENTNGKNTAAWAKDLKQEDFQLLCPDGTKKPVTEFATCHLAQAPNHVVVSRKEKAARVSTVLTAQKDLFWKGDKDCTGNFCLFRSSTKDLLFRDDTKCLTKLPEGTTYEEYLGAEYLQAVGNIRKCSTSRLLEACTFHKS&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n112 \n\n \n\n       795.3444   1588.6742   1588.6763   -0.0021  1   29   0.042  U     K.GDKDCTGNFCLFR.S \n\n       826.8530   1651.6915   1651.6977   -0.0062  0   35   0.0088  U     K.FDEFFSQGCAPGYK.K \n\n       918.4158   1834.8171   1834.8196   -0.0025  0   (81)  3.6e-007  U     R.EGYNGYTGAFQCLVEK.G \n\n       918.4158   1834.8171   1834.8196   -0.0025  0   85   1.2e-007  U     R.EGYNGYTGAFQCLVEK.G \n\n       862.7540   2585.2401   2585.2649   -0.0249  0   (69)  3.8e-006  U     K.LPEGTTYEEYLGAEYLQAVGNIR.K \n\n       1293.6300   2585.2454   2585.2649   -0.0195  0   131   2.6e-012  U     K.LPEGTTYEEYLGAEYLQAVGNIR.K \n\n       1649.4015   4945.1827   4945.1931   -0.0104  0   32   0.0018  U     K.AVASFFSGSCVPCADPVAFPQLCQLCPGCGCSPTQPFFGYVGAFK.C \n\n63 TF 6,94 \n \n78538 24 \n\n \ngi|1854476 0,57 656.8624   1311.7102   1311.7187   -0.0085  0   76   1.7e-006  U     K.HTTIFEVLPQK.A \n\n       674.8430   1347.6714   1347.6419   0.0296  0   101   7.8e-009  U     K.ASDSSINWNNLK.G \n\n       696.8804   1391.7463   1391.7561   -0.0098  0   37   0.016  U     R.LYLGHSYVTAIR.N \n\n       712.3783   1422.7420   1422.7507   -0.0087  1   50   0.00065  U     K.SKDFQLFGSPLGK.D \n\n       781.9057   1561.7967   1561.8075   -0.0108  0   91   6.4e-008  U     R.TAGWNIPMGLLFSR.I \n\n       789.9053   1577.7960   1577.8024   -0.0064  0   (78)  1.2e-006  U     R.TAGWNIPMGLLFSR.I + Oxidation (M) \n\n       826.8558   1651.6970   1651.6977   -0.0007  0   55   9.4e-005  U     K.FDEFFSQGCAPGYK.K \n\n       826.8558   1651.6970   1651.6977   -0.0007  0   (53)  0.00013  U     K.FDEFFSQGCAPGYK.K \n\n       918.4128   1834.8110   1834.8196   -0.0086  0   78   6.1e-007  U     R.EGYNGYTGAFQCLVEK.G \n\n64 TKT 7,54 \n \n71912 39 \n\n \ngi|149034221 1,04 378.1925   754.3705   754.3722   -0.0016  0   49   0.001        K.LGHASDR.I \n\n       489.7848   977.5550   977.5658   -0.0108  0   33   0.044        K.HQPTAIIAK.T \n\n       494.7818   987.5490   987.5535   -0.0045  1   44   0.0054        K.KLILDCAR.A \n\n       693.4014   1384.7882   1384.7966   -0.0084  0   59   7.1e-005        R.VLDPFTIKPLDK.K \n\n       701.8821   1401.7496   1401.7616   -0.0120  0   (44)  0.0028        K.LDNLVAIFDINR.L \n\n       701.8833   1401.7521   1401.7616   -0.0095  0   89   9.5e-008        K.LDNLVAIFDINR.L \n\n       701.8833   1401.7521   1401.7616   -0.0095  0   (86)  2e-007        K.LDNLVAIFDINR.L \n\n       775.9119   1549.8093   1549.8174   -0.0081  1   56   0.00018        K.MFGIDKDAIVQAVK.G + Oxidation (M) \n\n       826.3910   1650.7674   1650.7865   -0.0191  0   85   2e-007        R.TVPFCSTFAAFFTR.A \n\n       965.9537   1929.8928   1929.9030   -0.0102  0   80   4.3e-007        R.SVPMSTVFYPSDGVATEK.A + Oxidation (M) \n\n       1005.0006   2007.9866   2007.9935   -0.0069  0   (38)  0.0075        K.NMAEQIIQEIYSQVQSK.K \n\n       1010.5234   2019.0322   2019.0636   -0.0314  0   93   2.3e-008        K.ILATPPQEDAPSVDIANIR.M \n\n       1012.9932   2023.9718   2023.9884   -0.0166  0   61   3.9e-005        K.NMAEQIIQEIYSQVQSK.K + Oxidation (M) \n\n       675.6666   2023.9781   2023.9884   -0.0103  0   (45)  0.0016        K.NMAEQIIQEIYSQVQSK.K + Oxidation (M) \n\n       827.7318   2480.1736   2480.1931   -0.0196  0   35   0.01        R.TSRPENAIIYSNNEDFQVGQAK.V \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRFAVGALLACAALGLCLAVPDKTVKWCAVSEHENTKCISFRDHMKTVLPADGPRLACVKKTSYQDCIKAISGGEADAITLDGGWVYDAGLTPNNLKPVAAEFYGSLEHPQTHYLAVAVVKKGTDFQLNQLQGKKSCHTGLGRSAGWIIPIGLLFCNLPEPRKPLEKAVASFFSGSCVPCADPVAFPQLCQLCPGCGCSPTQPFFGYVGAFKCLRDGGGDVAFVKHTTIFEVLPQKADRDQYELLCLDNTRKPVDQYEDCYLARIPSHAVVARNGDGKEDLIWEILKVAQEHFGKGKSKDFQLFGSPLGKDLLFKDSAFGCYGVPPRMDYRLYLGHSYVTAIRNQREGVCPEASIDSAPVKWCALSHQERAKCDEWSVTSNGQIECESAESTEDCIDKIVNGEADAMSLDGGHAYIAGQCGLVPVMAENYDISSCTNPQSDVFPKGYYAVAVVKASDSSINWNNLKGKKSCHTGVDRTAGWNIPMGLLFSRINHCKFDEFFSQGCAPGYKKNSTLCDLCIGPAKCAPNNREGYNGYTGAFQCLVEKGDVAFVKHQTVLENTNGKNTAAWAKDLKQEDFQLLCPDGTKKPVTEFATCHLAQAPNHVVVSRKEKAARVSTVLTAQKDLFWKGDKDCTGNFCLFRSSTKDLLFRDDTKCLTKLPEGTTYEEYLGAEYLQAVGNIRKCSTSRLLEACTFHKS&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDPVRQIQCDREGKRFPFLSAPPASTSSPDRAMEGYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKALDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLPEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCMLGDGEVSEGSVWEAMAFAGIYKLDNLVAIFDINRLGQSDPAPLQHQVDVYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIAKTFKGRGITGIEDKEAWHGKPLPKNMAEQIIQEIYSQVQSKKKILATPPQEDAPSVDIANIRMPTPPNYKVGDKIATRKAYGLALAKLGHASDRIIALDGDTKNSTFSELFKKEHPDRFIECYIAEQNMVSIAVGCATRDRTVPFCSTFAAFFTRAFDQIRMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPMSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAIIYSNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAEMLKKEKIGVRVLDPFTIKPLDKKLILDCARATKGRILTVEDHYYEGGIGEAVSAAVVGEPGVTVTRLAVSQVPRSGKPAELLKMFGIDKDAIVQAVKGLVTKG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n113 \n\n \n\n       895.1294   2682.3664   2682.3898   -0.0234  1   38   0.0045        K.SKDDQVTVIGAGVTLHEALAAAEMLK.K + Oxidation (M) \n\n       1063.5333   3187.5781   3187.6037   -0.0257  0   63   1.1e-005  U     R.ILTVEDHYYEGGIGEAVSAAVVGEPGVTVTR.L \n\n79 CANX 4,49 \n \n67612 20 \n\n \ngi|25282419 0,77 616.3121   1230.6096   1230.6092   0.0004  1   80   9.5e-007  U     K.SKSDTSTPPSPK.V \n\n       635.3107   1268.6068   1268.6111   -0.0043  0   42   0.0045  U     K.TPYTIMFGPDK.C \n\n       723.8454   1445.6763   1445.6787   -0.0024  0   46   0.0019  U     K.TSELNLDQFHDK.T \n\n       868.4186   1734.8226   1734.8253   -0.0027  0   50   0.0007  U     K.IPNPDFFEDLEPFR.M \n\n       885.8948   1769.7750   1769.8261   -0.0511  0   103   2.1e-009  U     K.APVPTGEVYFADSFDR.G \n\n       885.9169   1769.8193   1769.8261   -0.0068  0   (100)  6.5e-009  U     K.APVPTGEVYFADSFDR.G \n\n       621.9790   1862.9152   1862.9203   -0.0051  1   (81)  5.1e-007  U     R.KIPNPDFFEDLEPFR.M \n\n       932.4651   1862.9157   1862.9203   -0.0046  1   (72)  3.6e-006  U     R.KIPNPDFFEDLEPFR.M \n\n       932.4656   1862.9167   1862.9203   -0.0036  1   83   2.7e-007  U     R.KIPNPDFFEDLEPFR.M \n\n       621.9795   1862.9167   1862.9203   -0.0036  1   (66)  1.6e-005  U     R.KIPNPDFFEDLEPFR.M \n\n       621.9795   1862.9167   1862.9203   -0.0036  1   (51)  0.00045  U     R.KIPNPDFFEDLEPFR.M \n\n82 CORO1A 6,05 \n \n51717 37 \n\n \ngi|18426834 \n\n \n1,15 513.8113   1025.6081   1025.6121   -0.0040  0   61   4.6e-005  U     R.DAGPLLISLK.D \n\n       605.3255   1208.6364   1208.6401   -0.0037  0   42   0.0055  U     R.EPVVTLEGHTK.R \n\n       817.8900   1633.7655   1633.7795   -0.0140  0   123   3.3e-011  U     R.ATPEPSSTLSSDTVSR.L \n\n       898.9005   1795.7864   1795.8200   -0.0336  0   74   1.4e-006  U     R.VSQTTWDSGFCAVNPK.F \n\n       1076.0667   2150.1188   2150.1268   -0.0080  0   (48)  0.00068  U     K.FMALICEASGGGAFLVLPLGK.T \n\n       1076.0691   2150.1236   2150.1268   -0.0032  0   (86)  1e-007  U     K.FMALICEASGGGAFLVLPLGK.T \n\n       1076.0691   2150.1236   2150.1268   -0.0032  0   134   1.6e-012  U     K.FMALICEASGGGAFLVLPLGK.T \n\n       1084.0675   2166.1204   2166.1217   -0.0013  0   (59)  5e-005  U     K.FMALICEASGGGAFLVLPLGK.T + Oxidation (M) \n\n       1084.0675   2166.1204   2166.1217   -0.0013  0   (37)  0.008  U     K.FMALICEASGGGAFLVLPLGK.T + Oxidation (M) \n\n       799.7164   2396.1274   2396.1398   -0.0124  0   75   1.1e-006  U     R.YFEITSEAPFLHYLSMFSSK.E \n\n       799.7164   2396.1274   2396.1398   -0.0124  0   (74)  1.4e-006  U     R.YFEITSEAPFLHYLSMFSSK.E \n\n       805.0477   2412.1214   2412.1348   -0.0133  0   (49)  0.00036  U     R.YFEITSEAPFLHYLSMFSSK.E + Oxidation (M) \n\n       1068.5213   3202.5421   3202.5459   -0.0038  1   (32)  0.011  U     R.KSDLFQEDLYPPTAGPDPALTAEEWLSGR.D \n\n       1068.5213   3202.5421   3202.5459   -0.0038  1   54   7.7e-005  U     R.KSDLFQEDLYPPTAGPDPALTAEEWLSGR.D \n\n \n\n \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MEGKWLLCLLLVLGTAAIQAHDGHDDDMIDIEDDLDDVIEEVEDSKSKSDTSTPPSPKVTYKAPVPTGEVYFADSFDRGSLSGWILSKAKKDDTDDEIAKYDGKWEVDEMKETKLPGDKGLVLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTSELNLDQFHDKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGVYEEKHAKRPDADLKTYFTDKKTHLYTLILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIADPDAVKPDDWDEDAPSKIPDEEATKPEGWLDDEPEYIPDPDAEKPEDWDEDMDGEWEAPQIANPKCESAPGCGVWQRPMIDNPNYKGKWKPPMIDNPNYQGIWKPRKIPNPDFFEDLEPFRMTPFSAIGLELWSMTSDIFFDNFIISGDRRVVDDWANDGWGLKKAADGAAEPGVVGQMLEAAEERPWLWVVYILTVALPVFLVILFCCSGKKQSNAMEYKKTDAPQPDVKDEEGKEEEKNKGDEEEEEEKLEEKQKSDAEEDGGTGSQDEEDSKPKAEEDEILNRSPRNRKPRRE&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSRQVVRSSKFRHVFGQPAKADQCYEDVRVSQTTWDSGFCAVNPKFMALICEASGGGAFLVLPLGKTGRVDKNVPLVCGHTAPVLDIAWCPHNDNVIASGSEDCTVMVWEIPDGGLVLPLREPVVTLEGHTKRVGIVAWHPTAQNVLLSAGCDNVILVWDVGTGAAVLTLGPDVHPDTIYSVDWSRDGALICTSCRDKRVRVIEPRKGTVVAEKERPHEGTRPVHAVFVSEGKILTTGFSRMSERQVALWDTKHLEEPLSLQELDTSSGVLLPFFDPDTNIVYLCGKGDSSIRYFEITSEAPFLHYLSMFSSKESQRGMGYMPKRGLEVNKCEIARFYKLHERKCEPIAMTVPRKSDLFQEDLYPPTAGPDPALTAEEWLSGRDAGPLLISLKDGYVPPKSRELRVNRGLDSARRRATPEPSSTLSSDTVSRLEEDVRNLNAIVQKLQERLDRLEETVQAK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n114 \n\n \n\n \n\nTabela 02.D: Pept\u00eddeos sequenciados por prote\u00edna identificada atrav\u00e9s de espectrometria de massas para o grupo Teste III em rela\u00e7\u00e3o ao grupo Controle I no experimento \n\nempregando 2D SDS-PAGE. \n\nSPOT Identidade pI kDa Cobertura Acesso emPAI (M+H) obs (M+H) exp (M+H) calc delta (ppm) miss score expect Unique Sequ\u00eancia de Pept\u00eddeo \n\n1 TPM1 4,69 32691 58 \n \n\ngi|149028892 5,27 423.7346   845.4547   845.4606   -0.0059  1   32   0.095        K.LKEAETR.A \n\n        423.7346   845.4547   845.4606   -0.0059  1   (31)  0.13        K.LKEAETR.A \n\n        424.2113   846.4081   846.4083   -0.0002  1   37   0.026  U     R.AQKDEEK.M \n\n        424.2113   846.4081   846.4083   -0.0002  1   (17)  2.7  U     R.AQKDEEK.M \n\n        434.2483   866.4821   866.4861   -0.0041  0   32   0.051  U     R.VLEELHK.A \n\n        447.7235   893.4324   893.4606   -0.0282  1   40   0.011        R.KYEEVAR.K \n\n        449.2177   896.4209   896.4239   -0.0031  1   4   34        K.YSQKEDK.Y \n\n        463.7184   925.4223   925.4253   -0.0031  0   54   0.00027  U     K.HIAEDADR.K \n\n        474.7263   947.4381   947.4447   -0.0067  0   43   0.0057  U     K.SIDDLEEK.V \n\n        489.2156   976.4166   976.4210   -0.0043  1   (26)  0.22  U     R.ASEDERDR.V \n\n        489.2163   976.4180   976.4210   -0.0030  1   (16)  2  U     R.ASEDERDR.V \n\n        489.2188   976.4230   976.4210   0.0021  1   30   0.1  U     R.ASEDERDR.V \n\n        489.2188   976.4230   976.4210   0.0021  1   (16)  2.3  U     R.ASEDERDR.V \n\n        495.2451   988.4756   988.4825   -0.0069  1   (55)  0.00036        R.AEQAEADKK.A \n\n        495.2455   988.4764   988.4825   -0.0060  1   (20)  1.3        R.AEQAEADKK.A \n\n        495.2466   988.4787   988.4825   -0.0038  1   (17)  2.4        R.AEQAEADKK.A \n\n        495.2466   988.4787   988.4825   -0.0038  1   (20)  1.2        R.AEQAEADKK.A \n\n        495.2475   988.4805   988.4825   -0.0020  1   (35)  0.038        R.AEQAEADKK.A \n\n        495.2479   988.4812   988.4825   -0.0013  1   (58)  0.0002        R.AEQAEADKK.A \n\n        495.2479   988.4812   988.4825   -0.0013  1   60   0.00012        R.AEQAEADKK.A \n\n        495.2484   988.4823   988.4825   -0.0001  1   (27)  0.26        R.AEQAEADKK.A \n\n        495.2484   988.4823   988.4825   -0.0001  1   (46)  0.0034        R.AEQAEADKK.A \n\n        523.2681   1044.5216   1044.5200   0.0016  0   53   0.0006  U     K.AEADVASLNR.R \n\n        523.2681   1044.5216   1044.5200   0.0016  0   (47)  0.0024  U     K.AEADVASLNR.R \n\n        537.2801   1072.5457   1072.5513   -0.0056  1   57   0.00024  U     K.LDKENALDR.A \n\n        560.7661   1119.5177   1119.5117   0.0060  0   46   0.0024  U     K.CAELEEELK.T \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDAIKKKMQMLKLDKENALDRAEQAEADKKAAEDRSKQLEEDISAKEKLLRASEDERDRVLEELHKAEDSLLAADETAAKAEADVASLNRRIQLVEEELDRAQERLATALQKLEEAEKAADESERGMKVIESRAQKDEEKMEIQEIQLKEAKHIAEDADRKYEEVARKLVIIESDLERAEERAELSEGKCAELEEELKTVTNNLKSLEAQAEKYSQKEDKYEEEIKVLSDKLKEAETRAEFAERSVTKLEKSIDDLEEKVAHAKEENLSMHQMLDQTLLELNNM&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDAIKKKMQMLKLDKENALDRAEQAEADKKAAEDRSKQLEEDISAKEKLLRASEDERDRVLEELHKAEDSLLAADETAAKAEADVASLNRRIQLVEEELDRAQERLATALQKLEEAEKAADESERGMKVIESRAQKDEEKMEIQEIQLKEAKHIAEDADRKYEEVARKLVIIESDLERAEERAELSEGKCAELEEELKTVTNNLKSLEAQAEKYSQKEDKYEEEIKVLSDKLKEAETRAEFAERSVTKLEKSIDDLEEKVAHAKEENLSMHQMLDQTLLELNNM&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n115 \n\n \n\n        566.3057   1130.5969   1130.6005   -0.0036  0   31   0.09  U     K.MEIQEIQLK.E \n\n        591.7657   1181.5168   1181.5452   -0.0283  1   50   0.00056        K.EDKYEEEIK.V \n\n        593.8350   1185.6555   1185.6605   -0.0050  0   72   5.5e-006  U     K.LVIIESDLER.A \n\n        622.3291   1242.6437   1242.6456   -0.0018  0   (58)  0.00016        R.IQLVEEELDR.A \n\n        622.3291   1242.6437   1242.6456   -0.0018  0   63   4.6e-005        R.IQLVEEELDR.A \n\n        657.8754   1313.7363   1313.7554   -0.0191  1   76   1.7e-006  U     R.KLVIIESDLER.A \n\n        700.3794   1398.7443   1398.7467   -0.0024  1   36   0.019        R.RIQLVEEELDR.A \n\n        700.3794   1398.7443   1398.7467   -0.0024  1   (24)  0.27        R.RIQLVEEELDR.A \n\n        702.8279   1403.6412   1403.6780   -0.0367  0   81   5.6e-007  U     K.AEDSLLAADETAAK.A \n\n        751.7212   2252.1419   2252.1535   -0.0117  1   27   0.085  U     R.VLEELHKAEDSLLAADETAAK.A \n\n        1202.0506   2402.0866   2402.0916   -0.0049  0   68   4.4e-006  U     K.EENLSMHQMLDQTLLELNNM.- \n\n        1210.0423   2418.0700   2418.0865   -0.0164  0   (68)  3.2e-006  U     K.EENLSMHQMLDQTLLELNNM.- + Oxidation (M) \n\n        1210.0440   2418.0734   2418.0865   -0.0130  0   (35)  0.0074  U     K.EENLSMHQMLDQTLLELNNM.- + Oxidation (M) \n\n        1210.0440   2418.0734   2418.0865   -0.0130  0   (41)  0.0016  U     K.EENLSMHQMLDQTLLELNNM.- + Oxidation (M) \n\n        1210.0442   2418.0738   2418.0865   -0.0126  0   (33)  0.012  U     K.EENLSMHQMLDQTLLELNNM.- + Oxidation (M) \n\n        1210.0442   2418.0738   2418.0865   -0.0126  0   (52)  0.00013  U     K.EENLSMHQMLDQTLLELNNM.- + Oxidation (M) \n\n        807.0330   2418.0770   2418.0865   -0.0095  0   (0)  21  U     K.EENLSMHQMLDQTLLELNNM.- + Oxidation (M) \n\n        1218.0421   2434.0696   2434.0814   -0.0118  0   (40)  0.0018  U     K.EENLSMHQMLDQTLLELNNM.- + 2 Oxidation (M) \n\n        812.3641   2434.0704   2434.0814   -0.0111  0   (19)  0.24  U     K.EENLSMHQMLDQTLLELNNM.- + 2 Oxidation (M) \n\n        812.3641   2434.0704   2434.0814   -0.0111  0   (13)  0.92  U     K.EENLSMHQMLDQTLLELNNM.- + 2 Oxidation (M) \n\n        1218.0444   2434.0742   2434.0814   -0.0072  0   (8)  3  U     K.EENLSMHQMLDQTLLELNNM.- + 2 Oxidation (M) \n\n        1226.0447   2450.0748   2450.0763   -0.0015  0   (1)  16  U     K.EENLSMHQMLDQTLLELNNM.- + 3 Oxidation (M) \n\n5 ACTB 5,23 42381 56  gi|4501883 3,49 488.7258   975.4370   975.4410   -0.0040  0   73   4.6e-006  U     K.AGFAGDDAPR.A \n\n        565.7766   1129.5386   1129.5404   -0.0018  0   40   0.01  U     R.GYSFVTTAER.E \n\n        581.3152   1160.6158   1160.6111   0.0047  0   (42)  0.0062  U     K.EITALAPSTMK.I \n\n        589.3092   1176.6038   1176.6060   -0.0022  0   44   0.0042  U     K.EITALAPSTMK.I + Oxidation (M) \n\n        594.2840   1186.5534   1186.5587   -0.0053  0   (4)  31  U     R.HQGVMVGMGQK.D + Oxidation (M) \n\n        594.2862   1186.5578   1186.5587   -0.0009  0   48   0.0012  U     R.HQGVMVGMGQK.D + Oxidation (M) \n\n        594.2862   1186.5578   1186.5587   -0.0009  0   (38)  0.012  U     R.HQGVMVGMGQK.D + Oxidation (M) \n\n        599.7632   1197.5118   1197.5150   -0.0031  0   52   0.00027  U     K.DSYVGDEAQSK.R \n\n        599.7677   1197.5208   1197.5150   0.0058  0   (10)  4.5  U     K.DSYVGDEAQSK.R \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MCEEEDSTALVCDNGSGLCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIITNWDDMEKIWHHSFYNELRVAPEEHPTLLTEAPLNPKANREKMTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRLDLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEKSYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNVLSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKQEYDEAGPSIVHRKCF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n116 \n\n \n\n        599.7677   1197.5208   1197.5150   0.0058  0   (10)  5.5  U     K.DSYVGDEAQSK.R \n\n        677.8144   1353.6143   1353.6161   -0.0018  1   51   0.00049  U     K.DSYVGDEAQSKR.G \n\n        750.8570   1499.6994   1499.7005   -0.0011  0   1   51  U     K.QEYDEAGPSIVHR.K \n\n        751.3669   1500.7192   1500.7262   -0.0070  0   (42)  0.0049  U     K.IWHHSFYNELR.V \n\n        501.2473   1500.7201   1500.7262   -0.0061  0   53   0.00034  U     K.IWHHSFYNELR.V \n\n        895.9433   1789.8720   1789.8846   -0.0126  0   (89)  7.4e-008  U     K.SYELPDGQVITIGNER.F \n\n        895.9471   1789.8797   1789.8846   -0.0050  0   101   5.2e-009  U     K.SYELPDGQVITIGNER.F \n\n        895.9471   1789.8797   1789.8846   -0.0050  0   (101)  5.3e-009  U     K.SYELPDGQVITIGNER.F \n\n        978.5157   1955.0167   1955.0364   -0.0196  0   84   2e-007  U     R.VAPEEHPTLLTEAPLNPK.A \n\n        652.6813   1955.0220   1955.0364   -0.0144  0   (63)  2.3e-005  U     R.VAPEEHPTLLTEAPLNPK.A \n\n        1114.5319   2227.0492   2227.0579   -0.0087  0   (118)  6e-011  U     K.DLYANNVLSGGTTMYPGIADR.M \n\n        1122.5256   2243.0366   2243.0528   -0.0162  0   126   8.7e-012  U     K.DLYANNVLSGGTTMYPGIADR.M + Oxidation (M) \n\n        846.0524   2535.1353   2535.1509   -0.0155  0   (79)  2.5e-007  U     K.LCYVALDFENEMATAASSSSLEK.S \n\n        1268.5772   2535.1398   2535.1509   -0.0110  0   137   3.6e-013  U     K.LCYVALDFENEMATAASSSSLEK.S \n\n        1268.5808   2535.1470   2535.1509   -0.0038  0   (33)  0.0096  U     K.LCYVALDFENEMATAASSSSLEK.S \n\n        1268.5808   2535.1470   2535.1509   -0.0038  0   (31)  0.015  U     K.LCYVALDFENEMATAASSSSLEK.S \n\n        1276.5815   2551.1484   2551.1458   0.0027  0   (14)  0.75  U     K.LCYVALDFENEMATAASSSSLEK.S + Oxidation (M) \n\n        1276.5815   2551.1484   2551.1458   0.0027  0   (25)  0.06  U     K.LCYVALDFENEMATAASSSSLEK.S + Oxidation (M) \n\n        1063.4917   3187.4533   3187.4664   -0.0132  0   87   2.9e-008  U     R.CPETLFQPSFIGMESAGIHETTYNSIMK.C \n\n        1066.2055   3195.5947   3195.6023   -0.0076  0   (64)  8.9e-006  U     R.TTGIVLDSGDGVTHNVPIYEGYALPHAIMR.L \n\n        1066.2055   3195.5947   3195.6023   -0.0076  0   84   9.2e-008  U     R.TTGIVLDSGDGVTHNVPIYEGYALPHAIMR.L \n\n        1066.2055   3195.5947   3195.6023   -0.0076  0   (59)  2.9e-005  U     R.TTGIVLDSGDGVTHNVPIYEGYALPHAIMR.L \n\n        1068.8230   3203.4472   3203.4613   -0.0142  0   (37)  0.0028  U     R.CPETLFQPSFIGMESAGIHETTYNSIMK.C + Oxidation (M) \n\n        1068.8230   3203.4472   3203.4613   -0.0142  0   (22)  0.09  U     R.CPETLFQPSFIGMESAGIHETTYNSIMK.C + Oxidation (M) \n\n        1068.8245   3203.4517   3203.4613   -0.0097  0   (46)  0.0003  U     R.CPETLFQPSFIGMESAGIHETTYNSIMK.C + Oxidation (M) \n\n6 ACTB 5,31 42249 58  gi|4501889  2,86 488.7269   975.4392   975.4410   -0.0018  0   70   1e-005  U     K.AGFAGDDAPR.A \n\n        581.3119   1160.6093   1160.6111   -0.0018  0   58   0.00018  U     K.EITALAPSTMK.I \n\n        589.3089   1176.6033   1176.6060   -0.0027  0   (18)  1.6  U     K.EITALAPSTMK.I + Oxidation (M) \n\n        594.2862   1186.5578   1186.5587   -0.0009  0   (3)  43  U     R.HQGVMVGMGQK.D + Oxidation (M) \n\n        594.2873   1186.5601   1186.5587   0.0014  0   62   6e-005  U     R.HQGVMVGMGQK.D + Oxidation (M) \n\n        599.7651   1197.5156   1197.5150   0.0006  0   51   0.00037  U     K.DSYVGDEAQSK.R \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MCEEETTALVCDNGSGLCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIITNWDDMEKIWHHSFYNELRVAPEEHPTLLTEAPLNPKANREKMTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRLDLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEKSYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNVLSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKPEYDEAGPSIVHRKCF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n117 \n\n \n\n        602.2796   1202.5446   1202.5536   -0.0090  0   (48)  0.0014  U     R.HQGVMVGMGQK.D + 2 Oxidation (M) \n\n        677.8150   1353.6155   1353.6161   -0.0006  1   18   1.2  U     K.DSYVGDEAQSKR.G \n\n        751.3618   1500.7091   1500.7262   -0.0171  0   42   0.0047  U     K.IWHHSFYNELR.V \n\n        501.2454   1500.7144   1500.7262   -0.0118  0   (26)  0.18  U     K.IWHHSFYNELR.V \n\n        501.2454   1500.7144   1500.7262   -0.0118  0   (23)  0.38  U     K.IWHHSFYNELR.V \n\n        501.2454   1500.7144   1500.7262   -0.0118  0   (37)  0.015  U     K.IWHHSFYNELR.V \n\n        895.9358   1789.8571   1789.8846   -0.0276  0   (48)  0.00094  U     K.SYELPDGQVITIGNER.F \n\n        895.9358   1789.8571   1789.8846   -0.0276  0   (40)  0.0054  U     K.SYELPDGQVITIGNER.F \n\n        895.9358   1789.8571   1789.8846   -0.0276  0   (86)  1.4e-007  U     K.SYELPDGQVITIGNER.F \n\n        895.9445   1789.8744   1789.8846   -0.0102  0   95   1.9e-008  U     K.SYELPDGQVITIGNER.F \n\n        978.5089   1955.0032   1955.0364   -0.0331  0   75   1.4e-006  U     R.VAPEEHPTLLTEAPLNPK.A \n\n        652.6826   1955.0260   1955.0364   -0.0104  0   (39)  0.0053  U     R.VAPEEHPTLLTEAPLNPK.A \n\n        1114.5309   2227.0472   2227.0579   -0.0107  0   (62)  2.7e-005  U     K.DLYANNVLSGGTTMYPGIADR.M \n\n        1122.5267   2243.0388   2243.0528   -0.0140  0   92   2.6e-008  U     K.DLYANNVLSGGTTMYPGIADR.M + Oxidation (M) \n\n        791.3881   2371.1426   2371.1478   -0.0052  1   91   3e-008  U     R.KDLYANNVLSGGTTMYPGIADR.M + Oxidation (M) \n\n        1186.5827   2371.1508   2371.1478   0.0031  1   (73)  1.9e-006  U     R.KDLYANNVLSGGTTMYPGIADR.M + Oxidation (M) \n\n        846.0519   2535.1338   2535.1509   -0.0171  0   (74)  7.8e-007  U     K.LCYVALDFENEMATAASSSSLEK.S \n\n        1268.5753   2535.1360   2535.1509   -0.0148  0   119   2.5e-011  U     K.LCYVALDFENEMATAASSSSLEK.S \n\n        1268.5753   2535.1360   2535.1509   -0.0148  0   (22)  0.12  U     K.LCYVALDFENEMATAASSSSLEK.S \n\n        1268.5753   2535.1360   2535.1509   -0.0148  0   (18)  0.29  U     K.LCYVALDFENEMATAASSSSLEK.S \n\n        1268.5811   2535.1476   2535.1509   -0.0032  0   (16)  0.57  U     K.LCYVALDFENEMATAASSSSLEK.S \n\n        1268.5811   2535.1476   2535.1509   -0.0032  0   (24)  0.077  U     K.LCYVALDFENEMATAASSSSLEK.S \n\n        1063.4914   3187.4524   3187.4664   -0.0141  0   97   2.9e-009  U     R.CPETLFQPSFIGMESAGIHETTYNSIMK.C \n\n        1066.2050   3195.5932   3195.6023   -0.0091  0   23   0.12  U     R.TTGIVLDSGDGVTHNVPIYEGYALPHAIMR.L \n\n        1068.8233   3203.4481   3203.4613   -0.0133  0   (2)  8.6  U     R.CPETLFQPSFIGMESAGIHETTYNSIMK.C + Oxidation (M) \n\n        1068.8245   3203.4517   3203.4613   -0.0097  0   (22)  0.074  U     R.CPETLFQPSFIGMESAGIHETTYNSIMK.C + Oxidation (M) \n\n        1074.1537   3219.4393   3219.4563   -0.0170  0   (27)  0.021  U     R.CPETLFQPSFIGMESAGIHETTYNSIMK.C + 2 Oxidation (M) \n\n        1074.1537   3219.4393   3219.4563   -0.0170  0   (0)  11  U     R.CPETLFQPSFIGMESAGIHETTYNSIMK.C + 2 Oxidation (M) \n\n        1100.5401   3298.5985   3298.6076   -0.0091  0   5   6.9  U     K.MTQIMFETFNVPAMYVAIQAVLSLYASGR.T + 3 Oxidation (M) \n\n7 SELEBP 6,1 53069 58 gi|18266692 3,24 513.3011   1024.5876   1024.5917   -0.0041  0   (24)  0.3  U     K.DGLIPLEIR.F \n\n        513.3011   1024.5876   1024.5917   -0.0041  0   28   0.099  U     K.DGLIPLEIR.F \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MATKCTKCGPGYATPLEAMKGPREEIVYLPCIYRNTGIEAPDYLATVDVDPKSPHYSQVIHRLPMPHLKDELHHSGWNTCSSCFGDSTKSRDKLILPSIISSRIYVVDVGSEPRAPKLHKVIEPNEIHAKCNLGNLHTSHCLASGEVMISSLGDPQGNGKGGFVLLDGETFEVKGTWEKPGGEAPMGYDFWYQPRHNIMVSTEWAAPNVFKDGFNPAHVEAGLYGSHIHVWDWQRHEIIQTLQMKDGLIPLEIRFLHDPDATQGFVGCALSSNIQRFYKNEGGTWSVEKVIQVPSKKVKGWMLPEMPGLITDILLSLDDRFLYFSNWLHGDIRQYDISNPKKPRLTGQIFLGGSIVKGGSVQVLEDQELTCQPEPLVVKGKRVPGGPQMIQLSLDGKRLYVTTSLYSAWDKQFYPNLIREGSVMLQIDVDTANGGLKLNPNFLVDFGKEPLGPALAHELRYPGGDCSSDIWI&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n118 \n\n \n\n        525.7880   1049.5615   1049.5658   -0.0043  0   44   0.0042  U     K.QFYPNLIR.E \n\n        549.8442   1097.6738   1097.6808   -0.0070  0   57   9.5e-005  U     K.LILPSIISSR.I \n\n        553.7579   1105.5013   1105.5040   -0.0027  0   55   0.00026  U     K.NEGGTWSVEK.V \n\n        575.3137   1148.6129   1148.6189   -0.0060  0   (43)  0.0051  U     K.VIEPNEIHAK.C \n\n        575.3137   1148.6129   1148.6189   -0.0060  0   51   0.00082  U     K.VIEPNEIHAK.C \n\n        612.3155   1222.6164   1222.6207   -0.0043  0   (15)  2.7  U     K.SPHYSQVIHR.L \n\n        612.3171   1222.6197   1222.6207   -0.0010  0   24   0.35  U     K.SPHYSQVIHR.L \n\n        612.3171   1222.6197   1222.6207   -0.0010  0   (22)  0.53  U     K.SPHYSQVIHR.L \n\n        617.3253   1232.6361   1232.6401   -0.0040  0   71   7.2e-006  U     R.IYVVDVGSEPR.A \n\n        632.3331   1262.6516   1262.6659   -0.0144  0   64   3.6e-005  U     K.LNPNFLVDFGK.E \n\n        632.3331   1262.6516   1262.6659   -0.0144  0   (18)  1.5  U     K.LNPNFLVDFGK.E \n\n        632.3331   1262.6516   1262.6659   -0.0144  0   (4)  34  U     K.LNPNFLVDFGK.E \n\n        651.8580   1301.7015   1301.7092   -0.0076  0   41   0.007  U     K.EPLGPALAHELR.Y \n\n        666.8904   1331.7662   1331.7813   -0.0151  0   84   2.1e-007  U     R.LTGQIFLGGSIVK.G \n\n        671.4050   1340.7954   1340.8027   -0.0073  1   31   0.036  U     R.DKLILPSIISSR.I \n\n        685.2892   1368.5639   1368.5656   -0.0017  0   18   0.5  U     R.YPGGDCSSDIWI.- \n\n        685.2892   1368.5639   1368.5656   -0.0017  0   (18)  0.55  U     R.YPGGDCSSDIWI.- \n\n        705.8200   1409.6254   1409.6319   -0.0065  0   24   0.2  U     K.CGPGYATPLEAMK.G + Oxidation (M) \n\n        727.8642   1453.7139   1453.7275   -0.0136  0   48   0.0011  U     R.EEIVYLPCIYR.N \n\n        755.8888   1509.7630   1509.7715   -0.0086  0   (33)  0.037  U     K.GGFVLLDGETFEVK.G \n\n        755.8904   1509.7662   1509.7715   -0.0053  0   69   9.3e-006  U     K.GGFVLLDGETFEVK.G \n\n        755.8918   1509.7691   1509.7715   -0.0024  0   (52)  0.00047  U     K.GGFVLLDGETFEVK.G \n\n        770.4101   1538.8056   1538.8127   -0.0070  0   (37)  0.014  U     R.VPGGPQMIQLSLDGK.R \n\n        773.8876   1545.7606   1545.7715   -0.0109  0   90   8.9e-008  U     R.LYVTTSLYSAWDK.Q \n\n        778.4055   1554.7965   1554.8076   -0.0111  0   70   7.5e-006  U     R.VPGGPQMIQLSLDGK.R + Oxidation (M) \n\n        834.4166   1666.8186   1666.8256   -0.0070  0   43   0.0034  U     R.FLYFSNWLHGDIR.Q \n\n        556.6146   1666.8221   1666.8256   -0.0035  0   (23)  0.3  U     R.FLYFSNWLHGDIR.Q \n\n        848.4609   1694.9072   1694.9138   -0.0065  1   57   0.00011  U     K.RVPGGPQMIQLSLDGK.R \n\n        571.3087   1710.9042   1710.9087   -0.0045  1   (46)  0.0012  U     K.RVPGGPQMIQLSLDGK.R + Oxidation (M) \n\n        930.4531   1858.8916   1858.9036   -0.0120  0   2   34  U     R.HNIMVSTEWAAPNVFK.D + Oxidation (M) \n\n        959.4615   1916.9083   1916.9367   -0.0284  0   90   4.6e-008  U     R.NTGIEAPDYLATVDVDPK.S \n\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n119 \n\n \n\n        959.4692   1916.9239   1916.9367   -0.0128  0   (2)  35  U     R.NTGIEAPDYLATVDVDPK.S \n\n        959.4692   1916.9239   1916.9367   -0.0128  0   (17)  1.1  U     R.NTGIEAPDYLATVDVDPK.S \n\n        809.0756   2424.2049   2424.2207   -0.0158  0   (19)  0.47  U     K.GGSVQVLEDQELTCQPEPLVVK.G \n\n        809.0756   2424.2049   2424.2207   -0.0158  0   (4)  18  U     K.GGSVQVLEDQELTCQPEPLVVK.G \n\n        1213.1123   2424.2100   2424.2207   -0.0106  0   53   0.0002  U     K.GGSVQVLEDQELTCQPEPLVVK.G \n\n        849.7897   2546.3471   2546.3645   -0.0174  1   125   7.2e-012  U     K.LNPNFLVDFGKEPLGPALAHELR.Y \n\n        931.1052   2790.2938   2790.3051   -0.0113  0   4   8.8  U     K.DGFNPAHVEAGLYGSHIHVWDWQR.H \n\n12 TAGLN 8,87 22645 53  gi|13928744 4,53 381.1715   760.3284   760.3252   0.0031  0   36   0.039  U     K.NDGHYR.G \n\n        381.1715   760.3284   760.3252   0.0031  0   (32)  0.078  U     K.NDGHYR.G \n\n        477.2313   952.4481   952.4502   -0.0021  0   35   0.026  U     K.AAEDYGVTK.T \n\n        495.7904   989.5663   989.5698   -0.0035  0   45   0.0037  U     R.LGFQVWLK.N \n\n        541.7359   1081.4571   1081.4563   0.0008  0   49   0.00062  U     K.YDEELEER.L \n\n        595.8433   1189.6721   1189.6740   -0.0019  0   61   7.7e-005  U     R.TVMALGSLAVTK.N \n\n        603.8420   1205.6695   1205.6690   0.0005  0   (12)  4.8  U     R.TVMALGSLAVTK.N + Oxidation (M) \n\n        605.7826   1209.5506   1209.5513   -0.0007  1   (46)  0.0017  U     K.KYDEELEER.L \n\n        605.7826   1209.5506   1209.5513   -0.0007  1   54   0.00031  U     K.KYDEELEER.L \n\n        611.3181   1220.6216   1220.6223   -0.0007  0   (10)  8.4  U     K.QMEQVAQFLK.A \n\n        611.3181   1220.6216   1220.6223   -0.0007  0   34   0.034  U     K.QMEQVAQFLK.A \n\n        619.3147   1236.6148   1236.6172   -0.0025  0   (33)  0.041  U     K.QMEQVAQFLK.A + Oxidation (M) \n\n        619.3147   1236.6148   1236.6172   -0.0025  0   (2)  47  U     K.QMEQVAQFLK.A + Oxidation (M) \n\n        630.8177   1259.6208   1259.6220   -0.0012  0   24   0.4  U     K.VPENPPSMVFK.Q + Oxidation (M) \n\n        641.3013   1280.5880   1280.5885   -0.0005  0   59   8.2e-005  U     R.EFTDSQLQEGK.H \n\n        765.8552   1529.6958   1529.7072   -0.0114  0   76   1.4e-006  U     K.TDMFQTVDLFEGK.D \n\n        765.8552   1529.6958   1529.7072   -0.0114  0   (26)  0.15  U     K.TDMFQTVDLFEGK.D \n\n        765.8607   1529.7068   1529.7072   -0.0004  0   (41)  0.0047  U     K.TDMFQTVDLFEGK.D \n\n        765.8607   1529.7068   1529.7072   -0.0004  0   (35)  0.021  U     K.TDMFQTVDLFEGK.D \n\n        765.8630   1529.7114   1529.7072   0.0042  0   (1)  47  U     K.TDMFQTVDLFEGK.D \n\n        765.8630   1529.7114   1529.7072   0.0042  0   (10)  7.5  U     K.TDMFQTVDLFEGK.D \n\n        773.8568   1545.6990   1545.7021   -0.0031  0   (50)  0.00068  U     K.TDMFQTVDLFEGK.D + Oxidation (M) \n\n        773.8568   1545.6990   1545.7021   -0.0031  0   (36)  0.015  U     K.TDMFQTVDLFEGK.D + Oxidation (M) \n\n        773.8578   1545.7010   1545.7021   -0.0011  0   (66)  1.8e-005  U     K.TDMFQTVDLFEGK.D + Oxidation (M) \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MANKGPSYGMSREVQSKIEKKYDEELEERLVEWIVMQCGPDVGRPDRGRLGFQVWLKNGVILSKLVNSLYPEGSKPVKVPENPPSMVFKQMEQVAQFLKAAEDYGVTKTDMFQTVDLFEGKDMAAVQRTVMALGSLAVTKNDGHYRGDPNWFMKKAQEHKREFTDSQLQEGKHVIGLQMGSNRGASQAGMTGYGRPRQIIS&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n120 \n\n \n\n        773.8578   1545.7010   1545.7021   -0.0011  0   (71)  4.9e-006  U     K.TDMFQTVDLFEGK.D + Oxidation (M) \n\n        709.6838   2126.0295   2126.0401   -0.0106  0   (33)  0.024  U     R.LVEWIVMQCGPDVGRPDR.G \n\n        1064.0252   2126.0358   2126.0401   -0.0043  0   (13)  2.5  U     R.LVEWIVMQCGPDVGRPDR.G \n\n        715.0156   2142.0251   2142.0350   -0.0100  0   34   0.018  U     R.LVEWIVMQCGPDVGRPDR.G + Oxidation (M) \n\n18 CALR 4,33 48137 52  gi|11693172 1,21 369.2126   736.4106   736.4119   -0.0013  0   (12)  7.2  U     K.FVLSSGK.F \n\n        369.2126   736.4106   736.4119   -0.0013  0   17   2.1  U     K.FVLSSGK.F \n\n        487.7690   973.5234   973.5233   0.0001  0   22   0.72  U     K.LFPGGLDQK.D \n\n        488.2467   974.4788   974.4781   0.0007  0   29   0.15  U     K.GLQTSQDAR.F \n\n        488.2467   974.4788   974.4781   0.0007  0   (15)  3.7  U     K.GLQTSQDAR.F \n\n        565.2631   1128.5116   1128.5087   0.0028  1   55   0.00022  U     K.FYGDQEKDK.G \n\n        609.8081   1217.6017   1217.6000   0.0017  1   51   0.0008  U     K.DKGLQTSQDAR.F \n\n        610.3520   1218.6895   1218.6972   -0.0078  0   60   8.4e-005  U     K.GQTLVVQFTVK.H \n\n        726.3301   1450.6457   1450.6477   -0.0020  0   77   1.1e-006  U     K.EQFLDGDAWTNR.W \n\n        738.8263   1475.6380   1475.6463   -0.0083  0   68   6.7e-006  U     K.HEQNIDCGGGYVK.L \n\n        595.6178   1783.8315   1783.8377   -0.0062  1   69   6.1e-006  U     K.IKDPDAAKPEDWDER.A \n\n        892.9239   1783.8333   1783.8377   -0.0044  1   (59)  6.5e-005  U     K.IKDPDAAKPEDWDER.A \n\n        1196.0507   2390.0868   2390.0914   -0.0046  0   121   2.7e-011  U     K.IDNSQVESGSLEDDWDFLPPK.K \n\n        1196.0520   2390.0894   2390.0914   -0.0020  0   (65)  1.1e-005  U     K.IDNSQVESGSLEDDWDFLPPK.K \n\n        1196.0520   2390.0894   2390.0914   -0.0020  0   (31)  0.026  U     K.IDNSQVESGSLEDDWDFLPPK.K \n\n        1196.0544   2390.0942   2390.0914   0.0028  0   (1)  27  U     K.IDNSQVESGSLEDDWDFLPPK.K \n\n        825.0055   2471.9947   2472.0032   -0.0085  0   38   0.00083  U     K.DMHGDSEYNIMFGPDICGPGTK.K + 2 Oxidation (M) \n\n        840.3968   2518.1685   2518.1864   -0.0178  1   76   8.5e-007  U     K.IDNSQVESGSLEDDWDFLPPKK.I \n\n        840.3978   2518.1716   2518.1864   -0.0148  1   (57)  7.3e-005  U     K.IDNSQVESGSLEDDWDFLPPKK.I \n\n        840.3978   2518.1716   2518.1864   -0.0148  1   (65)  1.2e-005  U     K.IDNSQVESGSLEDDWDFLPPKK.I \n\n        952.7977   2855.3713   2855.3800   -0.0087  1   1   18  U     R.CKDDEFTHLYTLIVRPDNTYEVK.I \n\n        1090.1683   3267.4831   3267.4884   -0.0053  0   67   3.1e-006  U     K.SGTIFDNFLITNDEAYAEEFGNETWGVTK.A \n\n        1379.6700   4135.9882   4135.9843   0.0038  0   13   0.55  U     K.GTWIHPEIDNPEYSPDANIYAYDSFAVLGLDLWQVK.S \n\n20 HSP90B1 4,72 92998 30 \n \n\ngi|210032365  0,37 377.2083   752.4020   752.4068   -0.0048  1   28   0.15  U     K.KSDYIK.L \n\n        502.7785   1003.5424   1003.5451   -0.0027  1   7   22  U     K.KTFEINPR.H \n\n        541.2781   1080.5417   1080.5352   0.0065  0   9   12  U     K.FAFQAEVNR.M \n\n        570.2937   1138.5729   1138.5731   -0.0002  0   72   6.6e-006  U     K.LGVIEDHSNR.T \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MLLSVPLLLGLLGLAAADPAIYFKEQFLDGDAWTNRWVESKHKSDFGKFVLSSGKFYGDQEKDKGLQTSQDARFYALSARFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPGGLDQKDMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDNTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDAAKPEDWDERAKIDDPTDSKPEDWDKPEHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYSPDANIYAYDSFAVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDKQDEEQRLKEEEEDKKRKEEEEAEDKEDEDDRDEDEDEEDEKEEDEEDATGQAKDEL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRVLWVLGLCCVLLTFGFVRADDEVDVDGTVEEDLGKSREGSRTDDEVVQREEEAIQLDGLNASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFLRELISNASDALDKIRLISLTDENALAGNEELTVKIKCDREKNLLHVTDTGVGMTREELVKNLGTIAKSGTSEFLNKMTEAQEDGQSTSELIGQFGVGFYSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLGRGTTITLVLKEEASDYLELDTIKNLVRKYSQFINFPIYVWSSKTETVEEPLEEDETAQEEKEEADDEAAVEEEEEEKKPKTKKVEKTVWDWELMNDIKPIWQRPSKEVEEDEYKAFYKSFSKESDDPMAYIHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVRRVFITDDFHDMMPKYLNFVKGVVDSDDLPLNVSRETLQQHKLLKVIRKKLVRKTLDMIKKIADEKYNDTFWKEFGTNIKLGVIEDHSNRTRLAKLLRFQSSHHSTDITSLDQYVERMKEKQDKIYFMAGSSRKEAESSPFVERLLKKGYEVIYLTEPVDEYCIQALPEFDGKRFQNVAKEGVKFDESEKSKESREATEKEFEPLLNWMKDKALKDKIEKAVVSQRLTESPCALVASQYGWSGNMERIMKAQAYQTGKDISTNYYASQKKTFEINPRHPLIRDMLRRVKEDEDDKTVMDLAVVLFETATLRSGYLLPDTKAYGDRIERMLRLSLNIDPEAQVEEEPEEEPEDTTEDTTDDSEQDEEETDAGAEEEEEEQETEKEPTEKDEL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRVLWVLGLCCVLLTFGFVRADDEVDVDGTVEEDLGKSREGSRTDDEVVQREEEAIQLDGLNASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFLRELISNASDALDKIRLISLTDENALAGNEELTVKIKCDREKNLLHVTDTGVGMTREELVKNLGTIAKSGTSEFLNKMTEAQEDGQSTSELIGQFGVGFYSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLGRGTTITLVLKEEASDYLELDTIKNLVRKYSQFINFPIYVWSSKTETVEEPLEEDETAQEEKEEADDEAAVEEEEEEKKPKTKKVEKTVWDWELMNDIKPIWQRPSKEVEEDEYKAFYKSFSKESDDPMAYIHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVRRVFITDDFHDMMPKYLNFVKGVVDSDDLPLNVSRETLQQHKLLKVIRKKLVRKTLDMIKKIADEKYNDTFWKEFGTNIKLGVIEDHSNRTRLAKLLRFQSSHHSTDITSLDQYVERMKEKQDKIYFMAGSSRKEAESSPFVERLLKKGYEVIYLTEPVDEYCIQALPEFDGKRFQNVAKEGVKFDESEKSKESREATEKEFEPLLNWMKDKALKDKIEKAVVSQRLTESPCALVASQYGWSGNMERIMKAQAYQTGKDISTNYYASQKKTFEINPRHPLIRDMLRRVKEDEDDKTVMDLAVVLFETATLRSGYLLPDTKAYGDRIERMLRLSLNIDPEAQVEEEPEEEPEDTTEDTTDDSEQDEEETDAGAEEEEEEQETEKEPTEKDEL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n121 \n\n \n\n        575.7732   1149.5319   1149.5302   0.0017  0   42   0.0053  U     K.EAESSPFVER.L \n\n        594.3406   1186.6667   1186.6710   -0.0043  0   35   0.028  U     K.SILFVPTSAPR.G \n\n        645.3035   1288.5924   1288.5935   -0.0012  0   40   0.007  U     K.DISTNYYASQK.K \n\n        653.8266   1305.6387   1305.6427   -0.0040  0   (25)  0.24  U     K.EFEPLLNWMK.D \n\n        661.8253   1321.6361   1321.6376   -0.0015  0   31   0.076  U     K.EFEPLLNWMK.D + Oxidation (M) \n\n        743.3795   1484.7444   1484.7471   -0.0027  0   (67)  1.6e-005  U     K.GVVDSDDLPLNVSR.E \n\n        743.3803   1484.7459   1484.7471   -0.0012  0   110   7.2e-010  U     K.GVVDSDDLPLNVSR.E \n\n        763.3632   1524.7118   1524.7195   -0.0076  0   84   2.5e-007  U     K.EEASDYLELDTIK.N \n\n        897.9820   1793.9494   1793.9597   -0.0103  0   28   0.078  U     K.TVMDLAVVLFETATLR.S + Oxidation (M) \n\n        897.9820   1793.9494   1793.9597   -0.0103  0   (6)  11  U     K.TVMDLAVVLFETATLR.S + Oxidation (M) \n\n        939.9660   1877.9174   1877.9352   -0.0178  0   86   1.7e-007  U     K.YSQFINFPIYVWSSK.T \n\n        939.9660   1877.9174   1877.9352   -0.0178  0   (23)  0.3  U     K.YSQFINFPIYVWSSK.T \n\n        939.9724   1877.9303   1877.9352   -0.0049  0   (17)  1.1  U     K.YSQFINFPIYVWSSK.T \n\n        939.9724   1877.9303   1877.9352   -0.0049  0   (28)  0.099  U     K.YSQFINFPIYVWSSK.T \n\n        1015.5322   2029.0498   2029.0579   -0.0080  0   16   1.1  U     R.LISLTDENALAGNEELTVK.I \n\n        750.6820   2249.0240   2249.0349   -0.0109  0   90   3.2e-008  U     R.FQSSHHSTDITSLDQYVER.M \n\n        1178.5362   2355.0578   2355.0623   -0.0045  0   1   20  U     R.LTESPCALVASQYGWSGNMER.I \n\n        842.7410   2525.2013   2525.2207   -0.0194  1   48   0.0005  U     K.EDEDDKTVMDLAVVLFETATLR.S + Oxidation (M) \n\n        853.4316   2557.2730   2557.2787   -0.0057  0   (13)  1.8  U     K.TVWDWELMNDIKPIWQRPSK.E + Oxidation (M) \n\n        853.4316   2557.2730   2557.2787   -0.0057  0   32   0.021  U     K.TVWDWELMNDIKPIWQRPSK.E + Oxidation (M) \n\n        1474.7009   2947.3872   2947.3837   0.0035  0   17   0.49  U     K.GYEVIYLTEPVDEYCIQALPEFDGK.R \n\n        1026.1666   3075.4780   3075.4787   -0.0007  1   27   0.038  U     K.KGYEVIYLTEPVDEYCIQALPEFDGK.R \n\n        1035.4988   3103.4746   3103.4848   -0.0103  1   (0)  20  U     K.GYEVIYLTEPVDEYCIQALPEFDGKR.F \n\n        1035.4988   3103.4746   3103.4848   -0.0103  1   5   7.2  U     K.GYEVIYLTEPVDEYCIQALPEFDGKR.F \n\n25 EEF2 6,41 96192 38 gi|8393296 0,63 475.2265   948.4385   948.4400   -0.0015  1   1   88  U     K.LDSEDKDK.E \n\n        546.2952   1090.5759   1090.5771   -0.0012  0   19   1.4  U     M.VNFTVDQIR.A \n\n        551.7667   1101.5189   1101.5165   0.0025  0   3   50  U     K.QFAEMYVAK.F + Oxidation (M) \n\n        562.2849   1122.5553   1122.5591   -0.0038  0   48   0.0015  U     K.STLTDSLVCK.A \n\n        637.8586   1273.7026   1273.7030   -0.0004  0   20   0.89  U     K.EDLYLKPIQR.T \n\n        637.8586   1273.7026   1273.7030   -0.0004  0   (18)  1.3  U     K.EDLYLKPIQR.T \n\n        654.8309   1307.6473   1307.6510   -0.0037  0   31   0.078  U     K.DSVVAGFQWATK.E \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MVNFTVDQIRAIMDKKANIRNMSVIAHVDHGKSTLTDSLVCKAGIIASARAGETRFTDTRKDEQERCITIKSTAISLFYELSENDLNFIKQSKDGSGFLINLIDSPGHVDFSSEVTAALRVTDGALVVVDCVSGVCVQTETVLRQAIAERIKPVLMMNKMDRALLELQLEPEELYQTFQRIVENVNVIISTYGEGESGPMGNIMIDPVLGTVGFGSGLHGWAFTLKQFAEMYVAKFAAKGEGQLGAAERAKKVEDMMKKLWGDRYFDPANGKFSKSANSPDGKKLPRTFCQLILDPIFKVFDAIMNFRKEETAKLIEKLDIKLDSEDKDKEGKPLLKAVMRRWLPAGDALLQMITIHLPSPVTAQKYRCELLYEGPPDDEAAMGIKSCDPKGPLMMYISKMVPTSDKGRFYAFGRVFSGVVSTGLKVRIMGPNYTPGKKEDLYLKPIQRTILMMGRYVEPIEDVPCGNIVGLVGVDQFLVKTGTITTFEHAHNMRVMKFSVSPVVRVAVEAKNPADLPKLVEGLKRLAKSDPMVQCIIEESGEHIIAGAGELHLEICLKDLEEDHACIPIKKSDPVVSYRETVSEESNVLCLSKSPNKHNRLYMKARPFPDGLAEDIDKGEVSARQELKARARYLAEKYEWDVAEARKIWCFGPDGTGPNILTDITKGVQYLNEIKDSVVAGFQWATKEGALCEENMRGVRFDVHDVTLHADAIHRGGGQIIPTARRCLYASVLTAQPRLMEPIYLVEIQCPEQVVGGIYGVLNRKRGHVFEESQVAGTPMFVVKAYLPVNESFGFTADLRSNTGGQAFPQCVFDHWQILPGDPFDNSSRPSQVVAETRKRKGLKEGIPALDNFLDKL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n122 \n\n \n\n        689.8606   1377.7067   1377.7075   -0.0007  0   (15)  2.5  U     R.CLYASVLTAQPR.L \n\n        689.8606   1377.7067   1377.7075   -0.0007  0   26   0.22  U     R.CLYASVLTAQPR.L \n\n        722.8864   1443.7583   1443.7609   -0.0027  1   (11)  6.9  U     K.EGIPALDNFLDKL.- \n\n        722.8869   1443.7593   1443.7609   -0.0017  1   49   0.0011  U     K.EGIPALDNFLDKL.- \n\n        722.8876   1443.7607   1443.7609   -0.0002  1   (8)  13  U     K.EGIPALDNFLDKL.- \n\n        722.8888   1443.7630   1443.7609   0.0021  1   (42)  0.0053  U     K.EGIPALDNFLDKL.- \n\n        722.8888   1443.7630   1443.7609   0.0021  1   (15)  2.4  U     K.EGIPALDNFLDKL.- \n\n        747.9027   1493.7908   1493.7952   -0.0044  0   67   1.2e-005  U     R.TFCQLILDPIFK.V \n\n        900.4497   1798.8848   1798.8890   -0.0042  0   91   5.1e-008  U     K.AYLPVNESFGFTADLR.S \n\n        900.4501   1798.8856   1798.8890   -0.0034  0   (39)  0.0067  U     K.AYLPVNESFGFTADLR.S \n\n        989.4881   1976.9617   1976.9666   -0.0050  0   12   3.7  U     R.GHVFEESQVAGTPMFVVK.A + Oxidation (M) \n\n        1053.0219   2104.0292   2104.0300   -0.0007  0   62   3.3e-005  U     K.IWCFGPDGTGPNILTDITK.G \n\n        715.0288   2142.0646   2142.0705   -0.0059  1   48   0.00077  U     K.ARPFPDGLAEDIDKGEVSAR.Q \n\n        715.0288   2142.0646   2142.0705   -0.0059  1   (38)  0.0069  U     K.ARPFPDGLAEDIDKGEVSAR.Q \n\n        1102.5595   2203.1044   2203.1048   -0.0004  0   5   14  U     K.STAISLFYELSENDLNFIK.Q \n\n        867.4749   2599.4030   2599.4196   -0.0166  0   (3)  9  U     R.WLPAGDALLQMITIHLPSPVTAQK.Y \n\n        867.4749   2599.4030   2599.4196   -0.0166  0   (22)  0.11  U     R.WLPAGDALLQMITIHLPSPVTAQK.Y \n\n        867.4767   2599.4082   2599.4196   -0.0114  0   54   6.9e-005  U     R.WLPAGDALLQMITIHLPSPVTAQK.Y \n\n        872.8090   2615.4051   2615.4145   -0.0095  0   (44)  0.00076  U     R.WLPAGDALLQMITIHLPSPVTAQK.Y + Oxidation (M) \n\n        920.4790   2758.4153   2758.4252   -0.0099  0   79   3.1e-007  U     R.YVEPIEDVPCGNIVGLVGVDQFLVK.T \n\n        939.8032   2816.3879   2816.3981   -0.0102  0   96   6e-009  U     K.DGSGFLINLIDSPGHVDFSSEVTAALR.V \n\n        997.1884   2988.5432   2988.5453   -0.0021  0   (15)  0.69  U     R.LMEPIYLVEIQCPEQVVGGIYGVLNR.K \n\n        1002.5195   3004.5367   3004.5402   -0.0035  0   80   2.3e-007  U     R.LMEPIYLVEIQCPEQVVGGIYGVLNR.K + Oxidation (M) \n\n        1415.6648   4243.9726   4243.9771   -0.0045  0   3   4.2  U     R.SNTGGQAFPQCVFDHWQILPGDPFDNSSRPSQVVAETR.K \n\n27 WDR1 6,15 66824 32 gi|62078997 0,87 370.1959   738.3773   738.3773   0.0001  0   14   3.9  U     K.IQDAHR.L \n\n        396.2084   790.4023   790.4007   0.0015  0   19   1.9  U     K.VCALGGSK.A \n\n        396.2084   790.4023   790.4007   0.0015  0   (18)  2.4  U     K.VCALGGSK.A \n\n        397.7004   793.3863   793.3905   -0.0042  0   26   0.27  U     R.FVNCVR.F \n\n        444.2633   886.5121   886.5124   -0.0003  0   20   1.3  U     K.VINSVDIK.Q \n\n        449.7257   897.4369   897.4417   -0.0048  0   31   0.074  U     K.GHTNQVSR.M \n\n        463.2619   924.5092   924.5141   -0.0049  0   48   0.0015  U     K.NNPSKPLR.V \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MPYEIKKVFASLPQVERGVSKILGGDPKGDNFLYTNGKCVILRNIDNPAVADIYTEHAHQVVVAKYAPSGFYIASGDISGKLRIWDTTQKEHILKYEYQPFAGKIKDIAWTEDSKRIAVVGEGREKFGAVFLWDTGSSVGEITGHNKVINSVDIKQNRPYRLATGSDDNCAAFFEGPPFKFKFTIGDHSRFVNCVRFSPDGNRFATASADGQIFIYDGKTGEKVCALGGSKAHDGGIYAISWSPDSTHLLSASGDKTSKIWDVNVNSVVSTFPMGSNVLDQQLGCLWQKDHLLSISLSGYINYLDKNNPSKPLRVIKGHSKSIQCLTVHKNGGKSYIYSGSHDGHINYWDSETGENDSFSGKGHTNQVSRMTVDESGQLVSCSMDDTVRYTNLTLRDYSGQGVVKLDVQPKCVAVGPGGYTVVVCIGQIVLLKDQKKCFSIDNPGYEPEVVAVHPGGDTVAVGGSDGNVRVYSILGATLKDEGKLLEAKGPVTDLAYSHDGAFLAVCDASKVVTVFSVADGYSENNVFYGHHAKIVCLAWSPDNEHFASGGMDMMVYVWTLSDPETKVKIQDAHRLHHVSSLAWLDEHTLVTTSHDASVKEWTITY&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n123 \n\n \n\n        532.8203   1063.6260   1063.6277   -0.0017  0   31   0.061  U     R.VYSILGATLK.D \n\n        543.2917   1084.5688   1084.5699   -0.0011  0   23   0.48  U     K.SIQCLTVHK.N \n\n        551.7634   1101.5123   1101.5131   -0.0008  0   19   1.2  U     K.YEYQPFAGK.I \n\n        573.3180   1144.6215   1144.6241   -0.0026  0   42   0.0067  U     K.VFASLPQVER.G \n\n        610.7989   1219.5832   1219.5833   -0.0001  1   50   0.0009  U     K.DIAWTEDSKR.I \n\n        747.4133   1492.8120   1492.8137   -0.0017  1   (19)  0.7  U     R.VYSILGATLKDEGK.L \n\n        747.4133   1492.8120   1492.8137   -0.0017  1   28   0.1  U     R.VYSILGATLKDEGK.L \n\n        852.4140   1702.8135   1702.8203   -0.0067  0   66   1.3e-005  U     R.FATASADGQIFIYDGK.T \n\n        1022.4557   2042.8968   2042.9044   -0.0076  0   (97)  6e-009  U     R.LATGSDDNCAAFFEGPPFK.F \n\n        1022.4574   2042.9002   2042.9044   -0.0042  0   146   8e-014  U     R.LATGSDDNCAAFFEGPPFK.F \n\n        1022.4591   2042.9036   2042.9044   -0.0008  0   (69)  3.9e-006  U     R.LATGSDDNCAAFFEGPPFK.F \n\n        1022.4591   2042.9036   2042.9044   -0.0008  0   (72)  1.9e-006  U     R.LATGSDDNCAAFFEGPPFK.F \n\n        741.3640   2221.0701   2221.0804   -0.0103  0   27   0.073  U     K.FGAVFLWDTGSSVGEITGHNK.V \n\n        1147.5382   2293.0618   2293.0685   -0.0067  0   (9)  3.8  U     K.GPVTDLAYSHDGAFLAVCDASK.V \n\n        1147.5382   2293.0618   2293.0685   -0.0067  0   (33)  0.015  U     K.GPVTDLAYSHDGAFLAVCDASK.V \n\n        765.3613   2293.0621   2293.0685   -0.0064  0   35   0.01  U     K.GPVTDLAYSHDGAFLAVCDASK.V \n\n        862.4097   2584.2073   2584.2194   -0.0121  0   16   0.77  U     K.AHDGGIYAISWSPDSTHLLSASGDK.T \n\n29 CCT6 6,63 58437 48  gi|76253725 0,93 420.7488   839.4830   839.4865   -0.0034  0   34   0.034  U     K.HTLTQIK.D \n\n        469.2633   936.5120   936.5141   -0.0021  0   34   0.041        R.GLVLDHGAR.H \n\n        469.2633   936.5120   936.5141   -0.0021  0   (27)  0.19        R.GLVLDHGAR.H \n\n        503.7667   1005.5187   1005.5165   0.0023  0   25   0.37        K.MLVSGAGDIK.L + Oxidation (M) \n\n        539.7931   1077.5716   1077.5706   0.0010  0   63   5.2e-005  U     R.IITEGFEAAK.E \n\n        596.2882   1190.5619   1190.5608   0.0011  0   (1)  69  U     K.TEVNSGFFYK.S \n\n        596.2882   1190.5619   1190.5608   0.0011  0   9   10  U     K.TEVNSGFFYK.S \n\n        623.8356   1245.6567   1245.6605   -0.0038  0   63   4.5e-005  U     K.GIDPFSLDALAK.E \n\n        628.3588   1254.7030   1254.7044   -0.0013  0   71   5.1e-006  U     R.AQAALAVNISAAR.G \n\n        429.5601   1285.6584   1285.6626   -0.0042  1   19   1.2  U     K.HKSETDTSLIR.G \n\n        833.4176   1664.8207   1664.8192   0.0015  1   1   49  U     K.VCGDSDKGFVVINQK.G \n\n        881.4679   1760.9212   1760.9309   -0.0096  0   72   4.2e-006  U     K.VLAQNSGFDLQETLVK.V \n\n        884.5183   1767.0221   1767.0294   -0.0073  0   34   0.0078  U     R.AQLGVQAFADALLIIPK.V \n\n        884.5183   1767.0221   1767.0294   -0.0073  0   (13)  1.1  U     R.AQLGVQAFADALLIIPK.V \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAAVKTLNPKAEVARAQAALAVNISAARGLQDVLRTNLGPKGTMKMLVSGAGDIKLTKDGNVLLHEMQIQHPTASLIAKVATAQDDITGDGTTSNVLIIGELLKQADLYISEGLHPRIITEGFEAAKEKALQFLEQVKVSKEMDRETLIDVARTSLRTKVHAELADVLTEAVVDSILAIRKKDEPIDLFMVEIMEMKHKSETDTSLIRGLVLDHGARHPDMKKRVENAYILTCNVSLEYEKTEVNSGFFYKSAEEREKLVKAERKFIEDRVKKIVELKKKVCGDSDKGFVVINQKGIDPFSLDALAKEGIVALRRAKRRNMERLTLACGGIALNSFDDLNPDCLGHAGLVYEYTLGEEKFTFIEKCNNPRSVTLLVKGPNKHTLTQIKDAIRDGLRAVKNAIDDGCVVPGAGAVEVALAEALIKYKPSVKGRAQLGVQAFADALLIIPKVLAQNSGFDLQETLVKVQAEHSESGQLVGVDLNTGEPMVAAEMGVWDNYCVKKQLLHSCTVIATNILLVDEIMRAGMSSLKG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n124 \n\n \n\n        772.4075   2314.2006   2314.2103   -0.0097  0   (6)  9.9  U     K.DGNVLLHEMQIQHPTASLIAK.V \n\n        777.7385   2330.1936   2330.2052   -0.0117  0   33   0.022  U     K.DGNVLLHEMQIQHPTASLIAK.V + Oxidation (M) \n\n        818.0909   2451.2509   2451.2679   -0.0170  0   17   0.59  U     K.NAIDDGCVVPGAGAVEVALAEALIK.Y \n\n        1226.6387   2451.2628   2451.2679   -0.0051  0   (10)  3.2  U     K.NAIDDGCVVPGAGAVEVALAEALIK.Y \n\n        819.1024   2454.2854   2454.2974   -0.0121  0   12   1.9  U     K.QLLHSCTVIATNILLVDEIMR.A + Oxidation (M) \n\n        819.1024   2454.2854   2454.2974   -0.0121  0   (3)  15  U     K.QLLHSCTVIATNILLVDEIMR.A + Oxidation (M) \n\n        848.7821   2543.3244   2543.3330   -0.0087  0   (68)  4.7e-006  U     K.VATAQDDITGDGTTSNVLIIGELLK.Q \n\n        1272.6733   2543.3320   2543.3330   -0.0010  0   141   2.1e-013  U     K.VATAQDDITGDGTTSNVLIIGELLK.Q \n\n        1309.2958   3924.8656   3924.8550   0.0106  0   39   0.0012  U     R.LTLACGGIALNSFDDLNPDCLGHAGLVYEYTLGEEK.F \n\n29 ATIC 6,69 64681 41 gi|48675845 0,81 504.7890   1007.5634   1007.5651   -0.0018  0   18   1.3  U     K.SLFSNIVTK.N \n\n        609.7759   1217.5373   1217.5346   0.0027  0   48   0.0011  U     R.NIPEDAADMAR.L + Oxidation (M) \n\n        660.7968   1319.5790   1319.5816   -0.0026  0   48   0.00095  U     K.YTQSNSVCYAK.D \n\n        669.3653   1336.7160   1336.7213   -0.0053  0   66   1.7e-005  U     R.VVVCNLYPFVK.T \n\n        693.3587   1384.7028   1384.7059   -0.0031  0   52   0.00055  U     K.DGQVIGIGAGQQSR.I \n\n        779.9420   1557.8694   1557.8726   -0.0032  0   121   3.9e-011  U     R.NLASLGLSLVASGGTAK.A \n\n        779.9430   1557.8714   1557.8726   -0.0012  0   (78)  7.3e-007  U     R.NLASLGLSLVASGGTAK.A \n\n        804.3931   1606.7717   1606.7661   0.0056  0   (20)  0.69  U     R.DVSELTGFPEMLGGR.V \n\n        804.3931   1606.7717   1606.7661   0.0056  0   (3)  30  U     R.DVSELTGFPEMLGGR.V \n\n        808.4045   1614.7944   1614.8042   -0.0098  0   127   1.5e-011  U     K.LSGVSVSSDAFFPFR.D \n\n        808.4084   1614.8021   1614.8042   -0.0021  0   (56)  0.00017  U     K.LSGVSVSSDAFFPFR.D \n\n        808.4084   1614.8021   1614.8042   -0.0021  0   (30)  0.067  U     K.LSGVSVSSDAFFPFR.D \n\n        812.3861   1622.7577   1622.7610   -0.0033  0   55   0.00022  U     R.DVSELTGFPEMLGGR.V + Oxidation (M) \n\n        859.4471   1716.8797   1716.8821   -0.0024  0   15   2  U     K.ALFEEVPELLTEAEK.K \n\n        615.9995   1844.9767   1844.9771   -0.0004  1   66   1.3e-005  U     K.ALFEEVPELLTEAEKK.E \n\n        615.9995   1844.9767   1844.9771   -0.0004  1   (65)  1.7e-005  U     K.ALFEEVPELLTEAEKK.E \n\n        615.9997   1844.9774   1844.9771   0.0003  1   (9)  6.3  U     K.ALFEEVPELLTEAEKK.E \n\n        1017.9598   2033.9050   2033.9119   -0.0069  0   19   0.38  U     K.AFTHTAQYDEAISDYFR.R \n\n        678.9766   2033.9079   2033.9119   -0.0041  0   (10)  3.3  U     K.AFTHTAQYDEAISDYFR.R \n\n        708.3767   2122.1084   2122.1092   -0.0008  0   11   3  U     K.VVIEACDELGIVLAHTDLR.L \n\n        1081.4904   2160.9662   2160.9708   -0.0045  0   123   1.9e-011  U     R.MSSFGDFVALSDVCDVPTAK.I + Oxidation (M) \n\n        777.4004   2329.1795   2329.1850   -0.0055  0   (1)  32  U     R.VCMVYDLYPTLTPLAIAYAR.A \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MASSQLALFSVSDKTGLVEFARNLASLGLSLVASGGTAKAIRDAGLAVRDVSELTGFPEMLGGRVKTLHPAVHAGILARNIPEDAADMARLDFNLIRVVVCNLYPFVKTVASPDVTVEAAVEQIDIGGVTLLRAAAKNHARVTVVCEPEDYGAVAAEMQGSGNKDTSLETRRHLALKAFTHTAQYDEAISDYFRRQYSKGISQMPLRYGMNPHQTPAQLYTLKPKLPITVLNGAPGFINLCDALNAWQLVTELRGAVDIPAAASFKHVSPAGAAVGVPLSEDEARVCMVYDLYPTLTPLAIAYARARGADRMSSFGDFVALSDVCDVPTAKIISREVSDGIVAPGYEEEALKILSKKKNGSYCVLQMDQSYKPDENEVRTLFGLRLSQKRNNGVVDKSLFSNIVTKNKDLPESALRDLIVATIAVKYTQSNSVCYAKDGQVIGIGAGQQSRIHCTRLAGDKANSWWLRHHPRVLSMKFKAGVKRAEVSNAIDQYVTGTIGEGEDLVKWKALFEEVPELLTEAEKKEWVDKLSGVSVSSDAFFPFRDNVDRAKRSGVAYIVAPSGSTADKVVIEACDELGIVLAHTDLRLFHH&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n125 \n\n \n\n        1165.6014   2329.1882   2329.1850   0.0032  0   54   0.00014  U     R.VCMVYDLYPTLTPLAIAYAR.A \n\n        1204.5963   2407.1780   2407.1755   0.0026  0   18   0.48  U     R.AEVSNAIDQYVTGTIGEGEDLVK.W \n\n        1204.5963   2407.1780   2407.1755   0.0026  0   (12)  2.1  U     R.AEVSNAIDQYVTGTIGEGEDLVK.W \n\n        851.7937   2552.3592   2552.3698   -0.0106  0   135   8.5e-013  U     K.TVASPDVTVEAAVEQIDIGGVTLLR.A \n\n        851.7955   2552.3646   2552.3698   -0.0052  0   (9)  3.1  U     K.TVASPDVTVEAAVEQIDIGGVTLLR.A \n\n        851.7955   2552.3646   2552.3698   -0.0052  0   (8)  3.5  U     K.TVASPDVTVEAAVEQIDIGGVTLLR.A \n\n        1277.1926   2552.3706   2552.3698   0.0009  0   (73)  1.2e-006  U     K.TVASPDVTVEAAVEQIDIGGVTLLR.A \n\n30 TKT 7,54 71940 39 gi|12018252 1,12 375.2001   748.3857   748.3868   -0.0011  0   23   0.74        R.AFDQIR.M \n\n        378.1925   754.3705   754.3722   -0.0016  0   49   0.001        K.LGHASDR.I \n\n        482.2322   962.4499   962.4531   -0.0033  0   28   0.18        R.MPTPPNYK.V + Oxidation (M) \n\n        489.7848   977.5550   977.5658   -0.0108  0   33   0.044        K.HQPTAIIAK.T \n\n        494.7818   987.5490   987.5535   -0.0045  1   44   0.0054        K.KLILDCAR.A \n\n        462.6026   1384.7859   1384.7966   -0.0107  0   (15)  1.9        R.VLDPFTIKPLDK.K \n\n        693.4014   1384.7882   1384.7966   -0.0084  0   59   7.1e-005        R.VLDPFTIKPLDK.K \n\n        701.8821   1401.7496   1401.7616   -0.0120  0   (44)  0.0028        K.LDNLVAIFDINR.L \n\n        701.8833   1401.7521   1401.7616   -0.0095  0   89   9.5e-008        K.LDNLVAIFDINR.L \n\n        701.8833   1401.7521   1401.7616   -0.0095  0   (86)  2e-007        K.LDNLVAIFDINR.L \n\n        767.9130   1533.8114   1533.8225   -0.0111  1   (14)  2.5        K.MFGIDKDAIVQAVK.G \n\n        775.9119   1549.8093   1549.8174   -0.0081  1   56   0.00018        K.MFGIDKDAIVQAVK.G + Oxidation (M) \n\n        826.3910   1650.7674   1650.7865   -0.0191  0   85   2e-007        R.TVPFCSTFAAFFTR.A \n\n        826.3981   1650.7816   1650.7865   -0.0049  0   (15)  2        R.TVPFCSTFAAFFTR.A \n\n        826.3981   1650.7816   1650.7865   -0.0049  0   (19)  0.71        R.TVPFCSTFAAFFTR.A \n\n        957.9539   1913.8933   1913.9081   -0.0148  0   (17)  0.96        R.SVPMSTVFYPSDGVATEK.A \n\n        965.9537   1929.8928   1929.9030   -0.0102  0   80   4.3e-007        R.SVPMSTVFYPSDGVATEK.A + Oxidation (M) \n\n        965.9543   1929.8941   1929.9030   -0.0089  0   (23)  0.21        R.SVPMSTVFYPSDGVATEK.A + Oxidation (M) \n\n        670.3354   2007.9845   2007.9935   -0.0090  0   (11)  4.2        K.NMAEQIIQEIYSQVQSK.K \n\n        1005.0006   2007.9866   2007.9935   -0.0069  0   (38)  0.0075        K.NMAEQIIQEIYSQVQSK.K \n\n        1010.5234   2019.0322   2019.0636   -0.0314  0   93   2.3e-008        K.ILATPPQEDAPSVDIANIR.M \n\n        1012.9932   2023.9718   2023.9884   -0.0166  0   61   3.9e-005        K.NMAEQIIQEIYSQVQSK.K + Oxidation (M) \n\n        675.6646   2023.9721   2023.9884   -0.0163  0   (18)  0.83        K.NMAEQIIQEIYSQVQSK.K + Oxidation (M) \n\n        675.6666   2023.9781   2023.9884   -0.0103  0   (45)  0.0016        K.NMAEQIIQEIYSQVQSK.K + Oxidation (M) \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDPVRQIQCDREGKRFPFLSAPPASTSSPDRAMEGYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKALDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLPEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCMLGDGEVSEGSVWEAMAFAGIYKLDNLVAIFDINRLGQSDPAPLQHQVDVYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIAKTFKGRGITGIEDKEAWHGKPLPKNMAEQIIQEIYSQVQSKKKILATPPQEDAPSVDIANIRMPTPPNYKVGDKIATRKAYGLALAKLGHASDRIIALDGDTKNSTFSELFKKEHPDRFIECYIAEQNMVSIAVGCATRDRTVPFCSTFAAFFTRAFDQIRMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPMSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAIIYSNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAEMLKKEKIGVRVLDPFTIKPLDKKLILDCARATKGRILTVEDHYYEGGIGEAVSAVVVGEPGVTVTRLAVSQVPRSGKPAELLKMFGIDKDAIVQAVKGLVTKG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n126 \n\n \n\n        827.7318   2480.1736   2480.1931   -0.0196  0   35   0.01        R.TSRPENAIIYSNNEDFQVGQAK.V \n\n        1241.0976   2480.1806   2480.1931   -0.0125  0   (20)  0.33        R.TSRPENAIIYSNNEDFQVGQAK.V \n\n        895.1294   2682.3664   2682.3898   -0.0234  1   38   0.0045        K.SKDDQVTVIGAGVTLHEALAAAEMLK.K + Oxidation (M) \n\n        895.1294   2682.3664   2682.3898   -0.0234  1   (8)  4.5        K.SKDDQVTVIGAGVTLHEALAAAEMLK.K + Oxidation (M) \n\n        1072.8780   3215.6122   3215.6351   -0.0229  0   (7)  4.2  U     R.ILTVEDHYYEGGIGEAVSAVVVGEPGVTVTR.L \n\n        1072.8780   3215.6122   3215.6351   -0.0229  0   28   0.034  U     R.ILTVEDHYYEGGIGEAVSAVVVGEPGVTVTR.L \n\n        1209.5630   3625.6672   3625.6786   -0.0114  0   0   10        R.ISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMR.Y + Oxidation (M) \n\n31 PKM2 7,15 58314 61 gi|206205  2 353.2171   704.4196   704.4221   -0.0025  0   19   1.8  U     K.VFLAQK.M \n\n        377.7340   753.4534   753.4609   -0.0075  0   21   0.46  U     K.KPRPTR.A \n\n        377.7340   753.4534   753.4609   -0.0075  0   (15)  2.1  U     K.KPRPTR.A \n\n        384.7059   767.3972   767.4038   -0.0066  0   (7)  16  U     R.SAHQVAR.Y \n\n        384.7059   767.3972   767.4038   -0.0066  0   (16)  2  U     R.SAHQVAR.Y \n\n        384.7076   767.4007   767.4038   -0.0032  0   28   0.13  U     R.SAHQVAR.Y \n\n        442.7390   883.4634   883.4698   -0.0064  0   33   0.046  U     R.MQHLIAR.E + Oxidation (M) \n\n        467.2643   932.5141   932.5154   -0.0013  0   26   0.32  U     R.GIFPVLCK.D \n\n        477.2420   952.4695   952.4726   -0.0031  0   37   0.02  U     K.IENHEGVR.R \n\n        510.2600   1018.5055   1018.5083   -0.0028  0   6   29  U     K.GDYPLEAVR.M \n\n        510.2600   1018.5055   1018.5083   -0.0028  0   (1)  81  U     K.GDYPLEAVR.M \n\n        512.7766   1023.5387   1023.5461   -0.0074  1   45   0.0032  U     R.KAADVHEVR.K \n\n        512.7766   1023.5387   1023.5461   -0.0074  1   (32)  0.062  U     R.KAADVHEVR.K \n\n        571.3067   1140.5988   1140.6026   -0.0038  0   37   0.018  U     R.GDLGIEIPAEK.V \n\n        586.3188   1170.6229   1170.6244   -0.0015  0   77   2e-006  U     R.LDIDSAPITAR.N \n\n        599.2922   1196.5698   1196.5747   -0.0049  0   57   0.00015  U     K.ITLDNAYMEK.C \n\n        611.3157   1220.6167   1220.6257   -0.0090  0   99   1.2e-008  U     K.CCSGAIIVLTK.S \n\n        680.3516   1358.6887   1358.6976   -0.0089  0   48   0.0015  U     R.NTGIICTIGPASR.S \n\n        731.9062   1461.7979   1461.8079   -0.0100  0   (80)  6.1e-007  U     K.IYVDDGLISLQVK.E \n\n        731.9062   1461.7979   1461.8079   -0.0100  0   102   3.9e-009  U     K.IYVDDGLISLQVK.E \n\n        731.9080   1461.8015   1461.8079   -0.0064  0   (47)  0.0014  U     K.IYVDDGLISLQVK.E \n\n        734.8385   1467.6625   1467.6704   -0.0079  0   92   3.6e-008  U     K.CDENILWLDYK.N \n\n        794.3795   1586.7444   1586.7576   -0.0132  0   77   1.3e-006  U     K.DAVLDAWAEDVDLR.V \n\n        794.3806   1586.7466   1586.7576   -0.0111  0   (7)  14  U     K.DAVLDAWAEDVDLR.V \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MPKPDSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSAPITARNTGIICTIGPASRSVEMLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRAATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKEKGADYLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKAADVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEAAAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDAVLDAWAEDVDLRVNLAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPVP&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n127 \n\n \n\n        794.3806   1586.7466   1586.7576   -0.0111  0   (19)  0.82  U     K.DAVLDAWAEDVDLR.V \n\n        833.4126   1664.8107   1664.8080   0.0028  0   4   27  U     R.FDEILEASDGIMVAR.G \n\n        882.9904   1763.9662   1763.9781   -0.0119  1   36   0.011  U     K.KGVNLPGAAVDLPAVSEK.D \n\n        930.4481   1858.8816   1858.8924   -0.0108  0   (109)  6.6e-010  U     K.FGVEQDVDMVFASFIR.K \n\n        938.4415   1874.8685   1874.8873   -0.0188  0   (114)  2.2e-010  U     K.FGVEQDVDMVFASFIR.K + Oxidation (M) \n\n        938.4415   1874.8685   1874.8873   -0.0188  0   (82)  3.3e-007  U     K.FGVEQDVDMVFASFIR.K + Oxidation (M) \n\n        938.4448   1874.8750   1874.8873   -0.0123  0   (103)  2.3e-009  U     K.FGVEQDVDMVFASFIR.K + Oxidation (M) \n\n        938.4448   1874.8750   1874.8873   -0.0123  0   125   1.6e-011  U     K.FGVEQDVDMVFASFIR.K + Oxidation (M) \n\n        625.9675   1874.8808   1874.8873   -0.0065  0   (15)  1.7  U     K.FGVEQDVDMVFASFIR.K + Oxidation (M) \n\n        625.9675   1874.8808   1874.8873   -0.0065  0   (12)  3.7  U     K.FGVEQDVDMVFASFIR.K + Oxidation (M) \n\n        942.4462   1882.8778   1882.8962   -0.0184  0   (28)  0.071  U     R.LNFSHGTHEYHAETIK.N \n\n        628.6347   1882.8824   1882.8962   -0.0138  0   97   8.5e-009  U     R.LNFSHGTHEYHAETIK.N \n\n        644.6622   1930.9647   1930.9788   -0.0141  0   (7)  10  U     R.EAEAAIYHLQLFEELR.R \n\n        644.6622   1930.9647   1930.9788   -0.0141  0   (21)  0.42  U     R.EAEAAIYHLQLFEELR.R \n\n        966.4911   1930.9677   1930.9788   -0.0111  0   53   0.00025  U     R.EAEAAIYHLQLFEELR.R \n\n        1073.0475   2144.0804   2144.1001   -0.0197  0   162   2.9e-015  U     R.LAPITSDPTEAAAVGAVEASFK.C \n\n        1073.0529   2144.0912   2144.1001   -0.0089  0   (72)  2.4e-006  U     R.LAPITSDPTEAAAVGAVEASFK.C \n\n        1073.0529   2144.0912   2144.1001   -0.0089  0   (31)  0.032  U     R.LAPITSDPTEAAAVGAVEASFK.C \n\n        760.3867   2278.1382   2278.1529   -0.0147  0   7   11  U     K.GDVVIVLTGWRPGSGFTNTMR.V + Oxidation (M) \n\n        812.4176   2434.2309   2434.2744   -0.0435  0   53   0.00019  U     R.AATESFASDPILYRPVAVALDTK.G \n\n        1255.5648   2509.1150   2509.1312   -0.0162  0   52   0.00011  U     R.AEGSDVANAVLDGADCIMLSGETAK.G + Oxidation (M) \n\n33 DLD 7,96 54574 28 gi|40786469 0,60 749.3873   748.3800   748.3789   0.0011  0   30   0.17  U     K.TVCIEK.N \n\n        455.2328   908.4510   908.4504   0.0006  0   28   0.18  U     K.FPFAANSR.A \n\n        534.2354   1066.4562   1066.4601   -0.0039  0   33   0.031  U     K.TNADTDGMVK.I + Oxidation (M) \n\n        564.3313   1126.6480   1126.6499   -0.0019  0   58   0.00012  U     K.ALTGGIAHLFK.Q \n\n        762.8713   1523.7281   1523.7303   -0.0022  0   8   11  U     R.VCHAHPTLSEAFR.E \n\n        896.4527   1790.8909   1790.9010   -0.0101  0   61   5.3e-005  U     K.NQVTATTADGSTQVIGTK.N \n\n        910.4369   1818.8592   1818.8604   -0.0012  0   137   1.2e-012  U     K.NETLGGTCLNVGCIPSK.A \n\n        655.0296   1962.0669   1962.0761   -0.0092  0   (29)  0.039  U     K.IPNIFAIGDVVAGPMLAHK.A \n\n        655.0296   1962.0669   1962.0761   -0.0092  0   (42)  0.0019  U     K.IPNIFAIGDVVAGPMLAHK.A \n\n        655.0308   1962.0705   1962.0761   -0.0056  0   (41)  0.0023  U     K.IPNIFAIGDVVAGPMLAHK.A \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MQSWSRVYCSLAKKGHFNRLSHGLQGASSVPLRTYSDQPIDADVTVIGSGPGGYVAAIKAAQLGFKTVCIEKNETLGGTCLNVGCIPSKALLNNSHYYHLAHGKDFASRGIEIPEVRLNLEKMMEQKRSAVKALTGGIAHLFKQNKVVHVNGFGKITGKNQVTATTADGSTQVIGTKNILIATGSEVTPFPGITIDEDTIVSSTGALSLKKVPEKLVVIGAGVIGVELGSVWQRLGADVTAVEFLGHVGGIGIDMEISKNFQRILQKQGFKFKLNTKVTGATKKSDGKIDVSVEAASGGKAEVITCDVLLVCIGRRPFTQNLGLEELGIELDPKGRIPVNTRFQTKIPNIFAIGDVVAGPMLAHKAEDEGIICVEGMAGGAVHIDYNCVPSVIYTHPEVAWVGKSEEQLKEEGVEFKVGKFPFAANSRAKTNADTDGMVKILGHKSTDRILGAHILGPGAGEMVNEAALALEYGASCEDVARVCHAHPTLSEAFREANLAASFGKPINF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n128 \n\n \n\n        655.0308   1962.0705   1962.0761   -0.0056  0   (30)  0.03  U     K.IPNIFAIGDVVAGPMLAHK.A \n\n        660.3621   1978.0644   1978.0710   -0.0066  0   (48)  0.00058  U     K.IPNIFAIGDVVAGPMLAHK.A + Oxidation (M) \n\n        660.3621   1978.0644   1978.0710   -0.0066  0   (61)  2.9e-005  U     K.IPNIFAIGDVVAGPMLAHK.A + Oxidation (M) \n\n        660.3623   1978.0651   1978.0710   -0.0059  0   (8)  4.9  U     K.IPNIFAIGDVVAGPMLAHK.A + Oxidation (M) \n\n        660.3623   1978.0652   1978.0710   -0.0058  0   77   7.5e-007  U     K.IPNIFAIGDVVAGPMLAHK.A + Oxidation (M) \n\n        660.3623   1978.0652   1978.0710   -0.0058  0   (64)  1.5e-005  U     K.IPNIFAIGDVVAGPMLAHK.A + Oxidation (M) \n\n        723.7206   2168.1400   2168.1477   -0.0077  0   (33)  0.017  U     R.RPFTQNLGLEELGIELDPK.G \n\n        1085.0802   2168.1458   2168.1477   -0.0019  0   51   0.00025  U     R.RPFTQNLGLEELGIELDPK.G \n\n        848.7679   2543.2818   2543.2942   -0.0124  0   21   0.27  U     R.LGADVTAVEFLGHVGGIGIDMEISK.N + Oxidation (M) \n\n36 PRDX1 8,27 22323 77 gi|16923958 7,16 376.2006   750.3867   750.3912   -0.0045  1   15   4.5  U     R.AEEFKK.L \n\n        831.4591   830.4519   830.4498   0.0021  0   25   0.47        R.SVDEILR.L \n\n        831.4591   830.4519   830.4498   0.0021  0   (15)  4.4        R.SVDEILR.L \n\n        444.7255   887.4364   887.4389   -0.0024  1   50   0.0013        K.SKEYFSK.Q \n\n        447.7201   893.4255   893.4243   0.0013  0   48   0.0016  U     K.ADEGISFR.G \n\n        460.7576   919.5007   919.5015   -0.0008  0   47   0.0023        R.GLFIIDDK.G \n\n        477.2629   952.5112   952.5130   -0.0018  0   33   0.042  U     K.IGHPAPSFK.A \n\n        554.3020   1106.5894   1106.5972   -0.0077  0   50   0.0012  U     R.TIAQDYGVLK.A \n\n        590.7882   1179.5618   1179.5594   0.0024  0   56   0.00022  U     K.ATAVMPDGQFK.D + Oxidation (M) \n\n        598.8184   1195.6222   1195.6237   -0.0015  0   35   0.025        R.LVQAFQFTDK.H \n\n        613.3470   1224.6794   1224.6826   -0.0032  0   (34)  0.028  U     R.QITINDLPVGR.S \n\n        613.3470   1224.6794   1224.6826   -0.0032  0   44   0.0027  U     R.QITINDLPVGR.S \n\n        680.4025   1358.7904   1358.7922   -0.0018  1   52   0.00035  U     R.GLFIIDDKGILR.Q \n\n        811.9309   1621.8473   1621.8498   -0.0025  0   (62)  3.7e-005  U     K.QGGLGPMNIPLVSDPK.R \n\n        819.9282   1637.8419   1637.8447   -0.0028  0   (21)  0.51  U     K.QGGLGPMNIPLVSDPK.R + Oxidation (M) \n\n        819.9282   1637.8419   1637.8447   -0.0028  0   (15)  1.9  U     K.QGGLGPMNIPLVSDPK.R + Oxidation (M) \n\n        819.9329   1637.8512   1637.8447   0.0065  0   81   4.4e-007  U     K.QGGLGPMNIPLVSDPK.R + Oxidation (M) \n\n        819.9329   1637.8512   1637.8447   0.0065  0   (77)  1.3e-006  U     K.QGGLGPMNIPLVSDPK.R + Oxidation (M) \n\n        883.9745   1765.9345   1765.9397   -0.0051  1   23   0.26  U     K.KQGGLGPMNIPLVSDPK.R + Oxidation (M) \n\n        798.0522   2391.1348   2391.1641   -0.0293  0   53   0.00017        K.HGEVCPAGWKPGSDTIKPDVNK.S \n\n        1196.5863   2391.1580   2391.1641   -0.0061  0   (2)  23        K.HGEVCPAGWKPGSDTIKPDVNK.S \n\n        1196.5863   2391.1580   2391.1641   -0.0061  0   (2)  24        K.HGEVCPAGWKPGSDTIKPDVNK.S \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSSGNAKIGHPAPSFKATAVMPDGQFKDISLSDYKGKYVVFFFYPLDFTFVCPTEIIAFSDRAEEFKKLNCQVIGASVDSHFCHLAWINTPKKQGGLGPMNIPLVSDPKRTIAQDYGVLKADEGISFRGLFIIDDKGILRQITINDLPVGRSVDEILRLVQAFQFTDKHGEVCPAGWKPGSDTIKPDVNKSKEYFSKQK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n129 \n\n \n\n        923.1147   2766.3222   2766.3370   -0.0148  0   21   0.22  U     K.LNCQVIGASVDSHFCHLAWINTPK.K \n\n38 ADH 8,52 40532 69 gi|202727 2,80 372.7165   743.4183   743.4177   0.0006  1   23   0.77        K.SKDAVPK.L \n\n        447.2195   892.4245   892.4259   -0.0014  0   47   0.0023        K.MVATGVCR.S \n\n        447.7402   893.4658   893.4681   -0.0022  0   39   0.013        K.LVADFMAK.K \n\n        455.2180   908.4214   908.4208   0.0006  0   (18)  1.7        K.MVATGVCR.S + Oxidation (M) \n\n        457.2520   912.4895   912.4916   -0.0022  0   (16)  2.1        K.IDAAAPLDK.V \n\n        457.2520   912.4895   912.4916   -0.0022  0   40   0.0085        K.IDAAAPLDK.V \n\n        545.7912   1089.5679   1089.5818   -0.0139  0   80   1.3e-006        K.INEAFDLLR.A \n\n        545.7912   1089.5679   1089.5818   -0.0139  0   (6)  32        K.INEAFDLLR.A \n\n        545.7912   1089.5679   1089.5818   -0.0139  0   (10)  11        K.INEAFDLLR.A \n\n        564.8306   1127.6466   1127.6550   -0.0084  1   55   0.0003        K.IIAVDINKDK.F \n\n        623.3352   1244.6558   1244.6587   -0.0030  0   48   0.0015        K.VIPLFSPQCGK.C \n\n        687.2961   1372.5777   1372.5864   -0.0087  0   (6)  10        K.HPESNLCCQTK.N \n\n        687.2984   1372.5822   1372.5864   -0.0042  0   75   1.5e-006        K.HPESNLCCQTK.N \n\n        594.0042   1778.9907   1778.9971   -0.0064  0   57   6.2e-005        K.FPLEPLITHVLPFEK.I \n\n        594.0049   1778.9930   1778.9971   -0.0041  0   (21)  0.25        K.FPLEPLITHVLPFEK.I \n\n        636.6996   1907.0770   1907.0920   -0.0151  1   (84)  8.8e-008        K.KFPLEPLITHVLPFEK.I \n\n        636.6998   1907.0776   1907.0920   -0.0144  1   (64)  9e-006        K.KFPLEPLITHVLPFEK.I \n\n        636.6998   1907.0776   1907.0920   -0.0144  1   (70)  2.3e-006        K.KFPLEPLITHVLPFEK.I \n\n        636.7000   1907.0782   1907.0920   -0.0139  1   (70)  1.9e-006        K.KFPLEPLITHVLPFEK.I \n\n        636.7000   1907.0782   1907.0920   -0.0139  1   (67)  4.5e-006        K.KFPLEPLITHVLPFEK.I \n\n        954.5480   1907.0815   1907.0920   -0.0105  1   98   3.5e-009        K.KFPLEPLITHVLPFEK.I \n\n        954.5480   1907.0815   1907.0920   -0.0105  1   (74)  8.6e-007        K.KFPLEPLITHVLPFEK.I \n\n        636.7017   1907.0832   1907.0920   -0.0088  1   (82)  1.3e-007        K.KFPLEPLITHVLPFEK.I \n\n        636.7017   1907.0834   1907.0920   -0.0087  1   (30)  0.019        K.KFPLEPLITHVLPFEK.I \n\n        636.7017   1907.0834   1907.0920   -0.0087  1   (21)  0.16        K.KFPLEPLITHVLPFEK.I \n\n        954.5495   1907.0845   1907.0920   -0.0076  1   (60)  2.1e-005        K.KFPLEPLITHVLPFEK.I \n\n        954.5499   1907.0852   1907.0920   -0.0068  1   (52)  0.00013        K.KFPLEPLITHVLPFEK.I \n\n        636.7034   1907.0884   1907.0920   -0.0036  1   (70)  1.7e-006        K.KFPLEPLITHVLPFEK.I \n\n        636.7034   1907.0884   1907.0920   -0.0036  1   (66)  4.3e-006        K.KFPLEPLITHVLPFEK.I \n\n        636.7042   1907.0909   1907.0920   -0.0011  1   (39)  0.0024        K.KFPLEPLITHVLPFEK.I \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSTAGKVIKCKAAVLWEPHKPFTIEDIEVAPPKAHEVRIKMVATGVCRSDDHAVSGSLFTPLPAVLGHEGAGIVESIGEGVTCVKPGDKVIPLFSPQCGKCRICKHPESNLCCQTKNLTQPKGALLDGTSRFSCRGKPIHHFLSTSTFSQYTVVDDIAVAKIDAAAPLDKVCLIGCGFSTGYGSAVQVAKVTPGSTCAVFGLGGVGLSVVIGCKTAGAAKIIAVDINKDKFAKAKELGATDCINPQDYTKPIQEVLQEMTDGGVDFSFEVIGRLDTMTSALLSCHSACGVSVIVGVPPSAQSLSVNPMSLLLGRTWKGAIFGGFKSKDAVPKLVADFMAKKFPLEPLITHVLPFEKINEAFDLLRAGKSIRTVLTF&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n130 \n\n \n\n        636.7042   1907.0909   1907.0920   -0.0011  1   (65)  5.1e-006        K.KFPLEPLITHVLPFEK.I \n\n        1037.5033   2072.9920   2073.0024   -0.0103  0   (146)  1.1e-013        K.VCLIGCGFSTGYGSAVQVAK.V \n\n        1037.5033   2072.9920   2073.0024   -0.0103  0   180   4.2e-017        K.VCLIGCGFSTGYGSAVQVAK.V \n\n        1037.5061   2072.9976   2073.0024   -0.0047  0   (50)  0.00044        K.VCLIGCGFSTGYGSAVQVAK.V \n\n        779.0695   2334.1868   2334.2076   -0.0209  0   (86)  9.2e-008        K.VTPGSTCAVFGLGGVGLSVVIGCK.T \n\n        1168.1031   2334.1916   2334.2076   -0.0160  0   136   8.1e-013        K.VTPGSTCAVFGLGGVGLSVVIGCK.T \n\n        829.7741   2486.3006   2486.3209   -0.0203  0   61   2.6e-005        K.AAVLWEPHKPFTIEDIEVAPPK.A \n\n        1244.1660   2486.3174   2486.3209   -0.0035  0   (13)  1.4        K.AAVLWEPHKPFTIEDIEVAPPK.A \n\n        954.4936   2860.4591   2860.4760   -0.0169  0   (17)  0.48  U     R.GKPIHHFLSTSTFSQYTVVDDIAVAK.I \n\n        954.4945   2860.4616   2860.4760   -0.0144  0   81   2.2e-007  U     R.GKPIHHFLSTSTFSQYTVVDDIAVAK.I \n\n        1368.3499   4102.0279   4102.0318   -0.0039  0   (23)  0.056        R.SDDHAVSGSLFTPLPAVLGHEGAGIVESIGEGVTCVKPGDK.V \n\n        1368.3499   4102.0279   4102.0318   -0.0039  0   24   0.042        R.SDDHAVSGSLFTPLPAVLGHEGAGIVESIGEGVTCVKPGDK.V \n\n        1419.7131   4256.1175   4256.1313   -0.0139  0   (5)  2.7       \n R.LDTMTSALLSCHSACGVSVIVGVPPSAQSLSVNPMSLLLGR.T + 2 \n\nOxidation (M) \n\n        1419.7131   4256.1175   4256.1313   -0.0139  0   (6)  2.2       \n R.LDTMTSALLSCHSACGVSVIVGVPPSAQSLSVNPMSLLLGR.T + 2 \n\nOxidation (M) \n\n        1419.7131   4256.1175   4256.1313   -0.0139  0   (8)  1.3       \n R.LDTMTSALLSCHSACGVSVIVGVPPSAQSLSVNPMSLLLGR.T + 2 \n\nOxidation (M) \n\n        1419.7158   4256.1256   4256.1313   -0.0058  0   25   0.024       \n R.LDTMTSALLSCHSACGVSVIVGVPPSAQSLSVNPMSLLLGR.T + 2 \n\nOxidation (M) \n\n39 ALDOA 8,31 39691 60 gi|202837 2,06 462.7451   923.4756   923.4825   -0.0069  0   45   0.0032        K.ELADIAHR.I \n\n        464.2148   926.4150   926.4168   -0.0018  0   2   42        R.CQYVTEK.V \n\n        522.7861   1043.5576   1043.5611   -0.0035  0   46   0.0025        R.QLLLTADDR.V \n\n        671.8531   1341.6916   1341.7041   -0.0125  0   36   0.025        K.ADDGRPFPQVIK.S \n\n        823.9015   1645.7885   1645.8019   -0.0135  1   21   0.53        R.LQSIGTENTEENRR.F \n\n        549.6054   1645.7943   1645.8019   -0.0077  1   (2)  40        R.LQSIGTENTEENRR.F \n\n        549.6054   1645.7943   1645.8019   -0.0077  1   (0)  70        R.LQSIGTENTEENRR.F \n\n        826.9132   1651.8118   1651.8239   -0.0121  0   (100)  7.1e-009        K.FSNEEIAMATVTALR.R \n\n        834.9062   1667.7978   1667.8188   -0.0211  0   100   6.2e-009        K.FSNEEIAMATVTALR.R + Oxidation (M) \n\n        603.6506   1807.9299   1807.9443   -0.0145  0   44   0.0023        K.CPLLKPWALTFSYGR.A \n\n        904.9727   1807.9308   1807.9443   -0.0135  0   (25)  0.21        K.CPLLKPWALTFSYGR.A \n\n        696.6955   2087.0646   2087.0874   -0.0228  0   99   6.9e-009        R.VNPCIGGVILFHETLYQK.A \n\n        1044.5422   2087.0698   2087.0874   -0.0175  0   (35)  0.015        R.VNPCIGGVILFHETLYQK.A \n\n        697.7048   2090.0925   2090.1120   -0.0195  0   88   5.9e-008  U     K.IGEHTPSSLAIVENANVLAR.Y \n\n        1046.0555   2090.0964   2090.1120   -0.0155  0   (1)  27  U     K.IGEHTPSSLAIVENANVLAR.Y \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MPHPYPALTPEQKKELADIAHRIVAPGKGILAADESTGSIAKRLQSIGTENTEENRRFYRQLLLTADDRVNPCIGGVILFHETLYQKADDGRPFPQVIKSKGGVVGIKVDKGVVPLAGTNGETTTQGLDGLSERCAQYKKDGADSAKWRCVLKIGEHTPSSLAIVENANVLARYASICQQNGIVPIVEPEILPDGDHDLKRCQYVTEKVLAAVYKALSDHHVYLEGTLLKPNMVTPGHACTQKFSNEEIAMATVTALRRTVPPAVPGVTFLSGGQSEEEASINLNAINKCPLLKPWALTFSYGRALQASALKAWGGKKENLKAAQEEYIKRALANSLACQGKYTPSGQSGAAASESLFISNHAY&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n131 \n\n \n\n        1046.0555   2090.0964   2090.1120   -0.0155  0   (1)  31  U     K.IGEHTPSSLAIVENANVLAR.Y \n\n        1129.5122   2257.0098   2257.0287   -0.0189  0   115   1.1e-010        K.YTPSGQSGAAASESLFISNHAY.- \n\n        1136.5637   2271.1128   2271.1343   -0.0214  0   85   1.5e-007        K.GVVPLAGTNGETTTQGLDGLSER.C \n\n        1013.8507   3038.5303   3038.5560   -0.0258  0   91   1.8e-008        R.TVPPAVPGVTFLSGGQSEEEASINLNAINK.C \n\n        1013.8512   3038.5318   3038.5560   -0.0243  0   (80)  2.5e-007        R.TVPPAVPGVTFLSGGQSEEEASINLNAINK.C \n\n        1013.8512   3038.5318   3038.5560   -0.0243  0   (86)  5.5e-008        R.TVPPAVPGVTFLSGGQSEEEASINLNAINK.C \n\n        1013.8528   3038.5366   3038.5560   -0.0195  0   (65)  7.8e-006        R.TVPPAVPGVTFLSGGQSEEEASINLNAINK.C \n\n        1013.8528   3038.5366   3038.5560   -0.0195  0   (30)  0.022        R.TVPPAVPGVTFLSGGQSEEEASINLNAINK.C \n\n        1059.5349   3175.5829   3175.5972   -0.0143  1   61   1.9e-005        R.YASICQQNGIVPIVEPEILPDGDHDLKR.C \n\n41 GAPDH 8,14 36090 62  gi|8393418 4,31 391.2005   780.3865   780.4017   -0.0153  1   18   2        K.YDDIKK.V \n\n        406.2096   810.4046   810.4058   -0.0012  0   33   0.039        K.LTGMAFR.V + Oxidation (M) \n\n        407.2270   812.4394   812.4392   0.0002  0   51   0.00076        K.QAAEGPLK.G \n\n        614.3069   1226.5992   1226.6039   -0.0047  0   78   1.4e-006        R.VVDLMAYMASK.E \n\n        622.3042   1242.5939   1242.5988   -0.0049  0   (69)  9.9e-006        R.VVDLMAYMASK.E + Oxidation (M) \n\n        622.3084   1242.6022   1242.5988   0.0034  0   (62)  4.8e-005        R.VVDLMAYMASK.E + Oxidation (M) \n\n        622.3084   1242.6022   1242.5988   0.0034  0   (77)  1.5e-006        R.VVDLMAYMASK.E + Oxidation (M) \n\n        630.3043   1258.5939   1258.5937   0.0002  0   (43)  0.0037        R.VVDLMAYMASK.E + 2 Oxidation (M) \n\n        678.8300   1355.6454   1355.6465   -0.0011  1   (26)  0.2        R.VVDLMAYMASKE.- \n\n        685.3564   1368.6982   1368.7361   -0.0379  0   75   2.5e-006        R.GAAQNIIPASTGAAK.A \n\n        694.8259   1387.6373   1387.6363   0.0009  1   58   0.0001        R.VVDLMAYMASKE.- + 2 Oxidation (M) \n\n        778.8924   1555.7702   1555.8029   -0.0326  0   (36)  0.017        R.VPTPNVSVVDLTCR.L \n\n        778.8924   1555.7702   1555.8029   -0.0326  0   (45)  0.0027        R.VPTPNVSVVDLTCR.L \n\n        778.9049   1555.7952   1555.8029   -0.0077  0   84   2.8e-007        R.VPTPNVSVVDLTCR.L \n\n        778.9075   1555.8004   1555.8029   -0.0025  0   (73)  3.6e-006        R.VPTPNVSVVDLTCR.L \n\n        890.3998   1778.7851   1778.7900   -0.0049  0   71   3.6e-006        K.LISWYDNEYGYSNR.V \n\n        738.3636   2212.0690   2212.1020   -0.0330  0   97   8.8e-009        R.VIISAPSADAPMFVMGVNHEK.Y \n\n        1107.0531   2212.0916   2212.1020   -0.0104  0   (29)  0.069        R.VIISAPSADAPMFVMGVNHEK.Y \n\n        743.6953   2228.0640   2228.0970   -0.0330  0   (81)  3.2e-007        R.VIISAPSADAPMFVMGVNHEK.Y + Oxidation (M) \n\n        749.0348   2244.0825   2244.0919   -0.0094  0   (47)  0.0009        R.VIISAPSADAPMFVMGVNHEK.Y + 2 Oxidation (M) \n\n        1123.0528   2244.0910   2244.0919   -0.0008  0   (6)  11        R.VIISAPSADAPMFVMGVNHEK.Y + 2 Oxidation (M) \n\n        1139.0201   2276.0256   2276.0307   -0.0051  0   104   1.1e-009  U     K.WGDAGAEYVVESTGVFTTMEK.A \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MVKVGVNGFGRIGRLVTRAAFSCDKVDIVAINDPFIDLNYMVYMFQYDSTHGKFNGTVKAENGKLVINGKPITIFQERDPANIKWGDAGAEYVVESTGVFTTMEKAGAHLKGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIVSNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGAAQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTPNVSVVDLTCRLEKPAKYDDIKKVVKQAAEGPLKGILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNFVKLISWYDNEYGYSNRVVDLMAYMASKE&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n132 \n\n \n\n        795.7347   2384.1824   2384.1981   -0.0157  1   21   0.3        K.RVIISAPSADAPMFVMGVNHEK.Y + Oxidation (M) \n\n        801.0709   2400.1908   2400.1930   -0.0022  1   (1)  27        K.RVIISAPSADAPMFVMGVNHEK.Y + 2 Oxidation (M) \n\n        865.7849   2594.3327   2594.3527   -0.0200  0   (117)  6.6e-011        K.VIHDNFGIVEGLMTTVHAITATQK.T \n\n        865.7849   2594.3327   2594.3527   -0.0200  0   (107)  5.8e-010        K.VIHDNFGIVEGLMTTVHAITATQK.T \n\n        865.7849   2594.3330   2594.3527   -0.0197  0   (9)  4.5        K.VIHDNFGIVEGLMTTVHAITATQK.T \n\n        865.7850   2594.3333   2594.3527   -0.0194  0   (143)  1.6e-013        K.VIHDNFGIVEGLMTTVHAITATQK.T \n\n        865.7882   2594.3428   2594.3527   -0.0098  0   (40)  0.0032        K.VIHDNFGIVEGLMTTVHAITATQK.T \n\n        871.1054   2610.2942   2610.3476   -0.0534  0   152   2.4e-014        K.VIHDNFGIVEGLMTTVHAITATQK.T + Oxidation (M) \n\n        871.1162   2610.3267   2610.3476   -0.0209  0   (126)  8.3e-012        K.VIHDNFGIVEGLMTTVHAITATQK.T + Oxidation (M) \n\n        871.1170   2610.3292   2610.3476   -0.0184  0   (100)  3.6e-009        K.VIHDNFGIVEGLMTTVHAITATQK.T + Oxidation (M) \n\n        871.1198   2610.3375   2610.3476   -0.0101  0   (22)  0.19        K.VIHDNFGIVEGLMTTVHAITATQK.T + Oxidation (M) \n\n        1108.8552   3323.5438   3323.5519   -0.0081  0   (12)  1        K.VDIVAINDPFIDLNYMVYMFQYDSTHGK.F + Oxidation (M) \n\n        1114.1878   3339.5416   3339.5468   -0.0052  0   (39)  0.0019        K.VDIVAINDPFIDLNYMVYMFQYDSTHGK.F + 2 Oxidation (M) \n\n        1114.1878   3339.5416   3339.5468   -0.0052  0   54   5.2e-005        K.VDIVAINDPFIDLNYMVYMFQYDSTHGK.F + 2 Oxidation (M) \n\n        1350.6143   4048.8211   4048.8385   -0.0175  0   (44)  0.00029        K.GILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNFVK.L \n\n        1350.6150   4048.8232   4048.8385   -0.0154  0   (91)  6.9e-009        K.GILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNFVK.L \n\n        1350.6150   4048.8232   4048.8385   -0.0154  0   (102)  4.9e-010        K.GILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNFVK.L \n\n        1350.6159   4048.8259   4048.8385   -0.0127  0   (115)  2.6e-011        K.GILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNFVK.L \n\n        1350.6159   4048.8259   4048.8385   -0.0127  0   127   1.4e-012        K.GILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNFVK.L \n\n        1350.6174   4048.8304   4048.8385   -0.0082  0   (10)  0.74        K.GILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNFVK.L \n\n        1350.6174   4048.8304   4048.8385   -0.0082  0   (8)  1.3        K.GILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNFVK.L \n\n42 ANXA2 7,55 38939 75  gi|9845234 6,08 364.2568   726.4990   726.5003   -0.0013  0   (37)  0.0096  U     K.LLVALAK.G \n\n        364.2568   726.4990   726.5003   -0.0013  0   52   0.00035  U     K.LLVALAK.G \n\n        372.7158   743.4171   743.4178   -0.0006  1   22   0.92  U     R.KGTDVPK.W \n\n        386.6806   771.3467   771.3473   -0.0006  0   25   0.27  U     R.LYDSMK.G + Oxidation (M) \n\n        411.2080   820.4014   820.4000   0.0014  0   (6)  34  U     R.SEVDMLK.I \n\n        419.2046   836.3947   836.3950   -0.0003  0   24   0.45  U     R.SEVDMLK.I + Oxidation (M) \n\n        436.2246   870.4345   870.4382   -0.0036  0   21   0.87  U     R.SVCHLQK.V \n\n        488.7477   975.4809   975.4735   0.0074  1   14   5.2  U     R.VYKEMYK.T + Oxidation (M) \n\n        488.7477   975.4809   975.4735   0.0074  1   (3)  59  U     R.VYKEMYK.T + Oxidation (M) \n\n        525.7803   1049.5460   1049.5505   -0.0046  1   31   0.096  U     R.ELYDAGVKR.K \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSTVHEILCKLSLEGDHSTPPSAYGSVKPYTNFDAERDALNIETAIKTKGVDEVTIVNILTNRSNAQRQDIAFAYQRRTKKELPSAMKSALSGHLETVMLGLLKTPAQYDASELKASMKGLGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGEFRKLLVALAKGKRAEDGSVIDYELIDQDARELYDAGVKRKGTDVPKWISIMTERSVCHLQKVFERYKSYSPYDMLESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDMLKIRSEFKRKYGKSLYYFIQQDTKGDYQKALLYLCGGDD&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n133 \n\n \n\n        526.2664   1050.5183   1050.5168   0.0015  0   22   0.63  U     K.WISIMTER.S + Oxidation (M) \n\n        544.3036   1086.5927   1086.5921   0.0006  0   53   0.00059  U     R.DALNIETAIK.T \n\n        544.3036   1086.5927   1086.5921   0.0006  0   (39)  0.015  U     R.DALNIETAIK.T \n\n        556.2791   1110.5436   1110.5458   -0.0022  0   66   2.2e-005  U     R.QDIAFAYQR.R \n\n        556.2791   1110.5436   1110.5458   -0.0022  0   (54)  0.00031  U     R.QDIAFAYQR.R \n\n        611.7996   1221.5846   1221.5877   -0.0031  0   (55)  0.00027  U     K.TPAQYDASELK.A \n\n        611.8002   1221.5859   1221.5877   -0.0018  0   (55)  0.00026  U     K.TPAQYDASELK.A \n\n        611.8002   1221.5859   1221.5877   -0.0018  0   73   4.6e-006  U     K.TPAQYDASELK.A \n\n        622.8040   1243.5934   1243.6156   -0.0222  0   64   3.5e-005  U     R.TNQELQEINR.V \n\n        622.8144   1243.6143   1243.6156   -0.0014  0   (26)  0.21  U     R.TNQELQEINR.V \n\n        684.3417   1366.6689   1366.6729   -0.0040  1   42   0.0049  U     K.DIISDTSGEFRK.L \n\n        703.3467   1404.6788   1404.6925   -0.0137  0   (54)  0.00032  U     K.SLYYFIQQDTK.G \n\n        703.3508   1404.6870   1404.6925   -0.0055  0   63   4.1e-005  U     K.SLYYFIQQDTK.G \n\n        730.8267   1459.6389   1459.6653   -0.0263  0   (24)  0.21  U     K.SYSPYDMLESIR.K \n\n        730.8267   1459.6389   1459.6653   -0.0263  0   62   3e-005  U     K.SYSPYDMLESIR.K \n\n        730.8383   1459.6620   1459.6653   -0.0033  0   (41)  0.0052  U     K.SYSPYDMLESIR.K \n\n        738.8346   1475.6546   1475.6602   -0.0056  0   (24)  0.24  U     K.SYSPYDMLESIR.K + Oxidation (M) \n\n        771.9227   1541.8309   1541.8413   -0.0104  0   110   5.9e-010  U     K.GVDEVTIVNILTNR.S \n\n        771.9230   1541.8314   1541.8413   -0.0099  0   (75)  2.3e-006  U     K.GVDEVTIVNILTNR.S \n\n        771.9257   1541.8368   1541.8413   -0.0046  0   (54)  0.00025  U     K.GVDEVTIVNILTNR.S \n\n        834.9610   1667.9075   1667.9280   -0.0205  0   (104)  2e-009  U     K.SALSGHLETVMLGLLK.T \n\n        556.9800   1667.9180   1667.9280   -0.0100  0   (68)  6.7e-006  U     K.SALSGHLETVMLGLLK.T \n\n        834.9669   1667.9192   1667.9280   -0.0088  0   (124)  1.6e-011  U     K.SALSGHLETVMLGLLK.T \n\n        834.9669   1667.9192   1667.9280   -0.0088  0   126   1e-011  U     K.SALSGHLETVMLGLLK.T \n\n        834.9680   1667.9215   1667.9280   -0.0065  0   (52)  0.00026  U     K.SALSGHLETVMLGLLK.T \n\n        834.9680   1667.9215   1667.9280   -0.0065  0   (44)  0.0017  U     K.SALSGHLETVMLGLLK.T \n\n        842.9589   1683.9033   1683.9229   -0.0196  0   (85)  1.8e-007  U     K.SALSGHLETVMLGLLK.T + Oxidation (M) \n\n        562.3127   1683.9164   1683.9229   -0.0066  0   (57)  0.0001  U     K.SALSGHLETVMLGLLK.T + Oxidation (M) \n\n        562.3127   1683.9164   1683.9229   -0.0066  0   (19)  0.61  U     K.SALSGHLETVMLGLLK.T + Oxidation (M) \n\n        842.9660   1683.9175   1683.9229   -0.0054  0   (3)  26  U     K.SALSGHLETVMLGLLK.T + Oxidation (M) \n\n        842.9660   1683.9175   1683.9229   -0.0054  0   (12)  3.1  U     K.SALSGHLETVMLGLLK.T + Oxidation (M) \n\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n134 \n\n \n\n        886.4948   1770.9750   1770.9840   -0.0089  1   126   1.1e-011  U     K.TKGVDEVTIVNILTNR.S \n\n        591.3344   1770.9813   1770.9840   -0.0027  1   (58)  6.9e-005  U     K.TKGVDEVTIVNILTNR.S \n\n        889.4324   1776.8503   1776.8564   -0.0060  0   (79)  8e-007  U     K.GLGTDEDSLIEIICSR.T \n\n        889.4324   1776.8503   1776.8564   -0.0060  0   (18)  0.81  U     K.GLGTDEDSLIEIICSR.T \n\n        889.4330   1776.8515   1776.8564   -0.0048  0   110   6.3e-010  U     K.GLGTDEDSLIEIICSR.T \n\n        889.4330   1776.8515   1776.8564   -0.0048  0   (83)  2.6e-007  U     K.GLGTDEDSLIEIICSR.T \n\n        889.4342   1776.8539   1776.8564   -0.0025  0   (71)  4.5e-006  U     K.GLGTDEDSLIEIICSR.T \n\n        889.4352   1776.8559   1776.8564   -0.0004  0   (95)  1.7e-008  U     K.GLGTDEDSLIEIICSR.T \n\n        913.4381   1824.8616   1824.8741   -0.0125  1   70   4.5e-006  U     K.TDLEKDIISDTSGEFR.K \n\n        609.2995   1824.8768   1824.8741   0.0027  1   (7)  11  U     K.TDLEKDIISDTSGEFR.K \n\n        609.2995   1824.8768   1824.8741   0.0027  1   (7)  11  U     K.TDLEKDIISDTSGEFR.K \n\n        954.9329   1907.8512   1907.8748   -0.0237  0   114   1.2e-010  U     R.AEDGSVIDYELIDQDAR.E \n\n        954.9329   1907.8512   1907.8748   -0.0237  0   (16)  0.88  U     R.AEDGSVIDYELIDQDAR.E \n\n        954.9329   1907.8512   1907.8748   -0.0237  0   (21)  0.25  U     R.AEDGSVIDYELIDQDAR.E \n\n        946.7966   2837.3679   2837.4170   -0.0492  0   (63)  1.4e-005  U     K.GDLENAFLNLVQCIQNKPLYFADR.L \n\n        946.7966   2837.3679   2837.4170   -0.0492  0   88   4.1e-008  U     K.GDLENAFLNLVQCIQNKPLYFADR.L \n\n        946.7966   2837.3679   2837.4170   -0.0492  0   (47)  0.00051  U     K.GDLENAFLNLVQCIQNKPLYFADR.L \n\n        946.8069   2837.3988   2837.4170   -0.0182  0   (33)  0.015  U     K.GDLENAFLNLVQCIQNKPLYFADR.L \n\n        946.8069   2837.3988   2837.4170   -0.0182  0   (10)  2.9  U     K.GDLENAFLNLVQCIQNKPLYFADR.L \n\n        1419.7116   2837.4086   2837.4170   -0.0084  0   (55)  8.5e-005  U     K.GDLENAFLNLVQCIQNKPLYFADR.L \n\n        980.1291   2937.3656   2937.3781   -0.0124  0   34   0.0085  U     K.LSLEGDHSTPPSAYGSVKPYTNFDAER.D \n\n        1065.5442   3193.6108   3193.6230   -0.0122  1   (36)  0.0044  U     K.EVKGDLENAFLNLVQCIQNKPLYFADR.L \n\n        1065.5442   3193.6108   3193.6230   -0.0122  1   105   5.6e-010  U     K.EVKGDLENAFLNLVQCIQNKPLYFADR.L \n\n        1065.5442   3193.6108   3193.6230   -0.0122  1   (27)  0.038  U     K.EVKGDLENAFLNLVQCIQNKPLYFADR.L \n\n43 VDAC2 7,44 32353 51 gi|13786202 1,93 409.1988   816.3831   816.3878   -0.0047  0   46   0.0037  U     K.SFNAGGHK.L \n\n        417.7309   833.4472   833.4494   -0.0022  0   49   0.002  U     K.VSGTLETK.Y \n\n        457.2275   912.4405   912.4454   -0.0048  0   25   0.26  U     R.SNFAVGYR.T \n\n        508.8012   1015.5878   1015.5914   -0.0036  0   58   0.00015  U     K.LTLSALVDGK.S \n\n        508.8022   1015.5899   1015.5914   -0.0015  0   (24)  0.38  U     K.LTLSALVDGK.S \n\n        508.8022   1015.5899   1015.5914   -0.0015  0   (40)  0.011  U     K.LTLSALVDGK.S \n\n        647.3336   1292.6527   1292.6612   -0.0085  0   (20)  0.81  U     K.YQLDPTASISAK.V \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAECCVPVCQRPICIPPPYADLGKAARDIFNKGFGFGLVKLDVKTKSCSGVEFSTSGSSNTDTGKVSGTLETKYKWCEYGLTFTEKWNTDNTLGTEIAIEDQICQGLKLTFDTTFSPNTGKKSGKIKSAYKRECINLGCDVDFDFAGPAIHGSAVFGYEGWLAGYQMTFDSAKSKLTRSNFAVGYRTGDFQLHTNVNNGTEFGGSIYQKVCEDFDTSVNLAWTSGTNCTRFGIAAKYQLDPTASISAKVNNSSLIGVGYTQTLRPGVKLTLSALVDGKSFNAGGHKLGLALELEA&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n135 \n\n \n\n        647.3336   1292.6527   1292.6612   -0.0085  0   (45)  0.0026  U     K.YQLDPTASISAK.V \n\n        647.3336   1292.6527   1292.6612   -0.0085  0   (28)  0.13  U     K.YQLDPTASISAK.V \n\n        647.3350   1292.6555   1292.6612   -0.0057  0   84   3.5e-007  U     K.YQLDPTASISAK.V \n\n        714.8458   1427.6771   1427.6933   -0.0162  0   (59)  8.5e-005  U     K.LTFDTTFSPNTGK.K \n\n        714.8458   1427.6771   1427.6933   -0.0162  0   98   1.1e-008  U     K.LTFDTTFSPNTGK.K \n\n        714.8547   1427.6948   1427.6933   0.0015  0   (95)  2.4e-008  U     K.LTFDTTFSPNTGK.K \n\n        714.8547   1427.6948   1427.6933   0.0015  0   (87)  1.6e-007  U     K.LTFDTTFSPNTGK.K \n\n        717.3220   1432.6295   1432.6333   -0.0038  0   45   0.0017  U     K.WCEYGLTFTEK.W \n\n        954.3928   1906.7710   1906.7851   -0.0140  0   138   1.5e-013  U     K.SCSGVEFSTSGSSNTDTGK.V \n\n        954.3980   1906.7815   1906.7851   -0.0036  0   (3)  5.7  U     K.SCSGVEFSTSGSSNTDTGK.V \n\n        701.7186   2102.1341   2102.1484   -0.0143  0   (68)  4.8e-006  U     K.VNNSSLIGVGYTQTLRPGVK.L \n\n        701.7186   2102.1341   2102.1484   -0.0143  0   73   1.7e-006  U     K.VNNSSLIGVGYTQTLRPGVK.L \n\n        1217.0223   2432.0300   2432.0373   -0.0073  0   66   3.2e-006  U     K.VCEDFDTSVNLAWTSGTNCTR.F \n\n        1260.1061   2518.1976   2518.2010   -0.0033  0   35   0.011  U     K.WNTDNTLGTEIAIEDQICQGLK.L \n\n44 SOD 8,96 24887 42  gi|8394331  0,88 415.1902   828.3658   828.3654   0.0004  0   28   0.13  U     R.DFGSFEK.F \n\n        416.2120   830.4093   830.4286   -0.0193  0   33   0.073  U     K.YHEALAK.G \n\n        493.2410   984.4674   984.4665   0.0009  1   24   0.37  U     K.RDFGSFEK.F \n\n        502.7751   1003.5356   1003.5451   -0.0094  0   33   0.053  U     K.NVRPDYLK.A \n\n        514.8078   1027.6011   1027.6026   -0.0014  1   31   0.069  U     K.GELLEAIKR.D \n\n        720.8957   1439.7768   1439.7984   -0.0216  0   (26)  0.17  U     K.GDVTTQVALQPALK.F \n\n        720.8957   1439.7768   1439.7984   -0.0216  0   108   1.1e-009  U     K.GDVTTQVALQPALK.F \n\n        720.9030   1439.7915   1439.7984   -0.0069  0   (74)  2.3e-006  U     K.GDVTTQVALQPALK.F \n\n        864.9261   1727.8376   1727.8743   -0.0367  0   (40)  0.0054  U     K.AIWNVINWENVSQR.Y \n\n        864.9261   1727.8376   1727.8743   -0.0367  0   (39)  0.0079  U     K.AIWNVINWENVSQR.Y \n\n        864.9261   1727.8376   1727.8743   -0.0367  0   85   1.8e-007  U     K.AIWNVINWENVSQR.Y \n\n        864.9384   1727.8623   1727.8743   -0.0120  0   (47)  0.0013  U     K.AIWNVINWENVSQR.Y \n\n        864.9410   1727.8674   1727.8743   -0.0069  0   (50)  0.00068  U     K.AIWNVINWENVSQR.Y \n\n        864.9410   1727.8674   1727.8743   -0.0069  0   (52)  0.00037  U     K.AIWNVINWENVSQR.Y \n\n        884.9281   1767.8416   1767.8540   -0.0123  0   101   5e-009  U     K.HHATYVNNLNVTEEK.Y \n\n        590.2908   1767.8504   1767.8540   -0.0036  0   (48)  0.001  U     K.HHATYVNNLNVTEEK.Y \n\n        590.2908   1767.8504   1767.8540   -0.0036  0   (41)  0.0045  U     K.HHATYVNNLNVTEEK.Y \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MLCRAACSAGRRLGPAASTAGSRHKHSLPDLPYDYGALEPHINAQIMQLHHSKHHATYVNNLNVTEEKYHEALAKGDVTTQVALQPALKFNGGGHINHSIFWTNLSPKGGGEPKGELLEAIKRDFGSFEKFKEKLTAVSVGVQGSGWGWLGFNKEQGRLQIAACSNQDPLQGTTGLIPLLGIDVWEHAYYLQYKNVRPDYLKAIWNVINWENVSQRYIVCKK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n136 \n\n \n\n        1032.0341   2062.0536   2062.0636   -0.0100  0   104   1.9e-009  U     K.LTAVSVGVQGSGWGWLGFNK.E \n\n        1032.0341   2062.0536   2062.0636   -0.0100  0   (34)  0.018  U     K.LTAVSVGVQGSGWGWLGFNK.E \n\n        1032.0341   2062.0536   2062.0636   -0.0100  0   (82)  3.1e-007  U     K.LTAVSVGVQGSGWGWLGFNK.E \n\n        1032.0341   2062.0536   2062.0636   -0.0100  0   (23)  0.25  U     K.LTAVSVGVQGSGWGWLGFNK.E \n\n45 TPM5 4,72 29158 51 gi|9653293 1,37 388.1993   774.3840   774.3871   -0.0032  0   51   0.0013        R.AELAESR.C \n\n        423.7356   845.4566   845.4606   -0.0041  1   15   5.7        K.LKEAETR.A \n\n        437.7216   873.4286   873.4304   -0.0018  1   14   5.1  U     R.EVEGERR.A \n\n        447.7344   893.4542   893.4606   -0.0065  1   (34)  0.047        R.KYEEVAR.K \n\n        447.7353   893.4561   893.4606   -0.0045  1   36   0.026        R.KYEEVAR.K \n\n        470.7254   939.4363   939.4410   -0.0047  0   22   0.59        K.HIAEEADR.K \n\n        534.7739   1067.5332   1067.5359   -0.0027  1   6   22        K.HIAEEADRK.Y \n\n        536.7418   1071.4690   1071.4767   -0.0077  0   51   0.00051        K.EEHLCTQR.M \n\n        536.7441   1071.4736   1071.4767   -0.0032  0   (15)  2.7        K.EEHLCTQR.M \n\n        566.3029   1130.5913   1130.6005   -0.0092  0   41   0.0073        K.MELQEIQLK.E \n\n        595.3139   1188.6133   1188.6238   -0.0105  1   34   0.043        K.TIDDLEDKLK.C \n\n        622.3268   1242.6390   1242.6456   -0.0066  0   50   0.001        R.IQLVEEELDR.A \n\n        642.8757   1283.7368   1283.7449   -0.0081  1   70   5.5e-006        R.KLVIIEGDLER.T \n\n        658.8166   1315.6186   1315.6368   -0.0182  0   63   4.1e-005  U     R.EQAEAEVASLNR.R \n\n        700.3756   1398.7367   1398.7467   -0.0099  1   0   70        R.RIQLVEEELDR.A \n\n        718.3401   1434.6656   1434.6734   -0.0078  0   22   0.43        R.MLDQTLLDLNEM.- \n\n        731.3295   1460.6444   1460.6500   -0.0056  1   (3)  22        K.CTKEEHLCTQR.M \n\n        731.3295   1460.6444   1460.6500   -0.0056  1   46   0.0012        K.CTKEEHLCTQR.M \n\n        821.8998   1641.7851   1641.7958   -0.0107  0   31   0.053  U     K.IQVLQQQADDAEER.A \n\n        885.9455   1769.8765   1769.8908   -0.0143  1   (14)  2.7  U     R.KIQVLQQQADDAEER.A \n\n        885.9455   1769.8765   1769.8908   -0.0143  1   16   1.6  U     R.KIQVLQQQADDAEER.A \n\n50 IGG2A 8,15 52243 30 gi|1220486  1,66 536.2912   1070.5678   1070.5720   -0.0042  0   (3)  53  U     K.SISKPEGTPR.G \n\n        536.2912   1070.5678   1070.5720   -0.0042  0   22   0.66  U     K.SISKPEGTPR.G \n\n        536.2912   1070.5678   1070.5720   -0.0042  0   (14)  4  U     K.SISKPEGTPR.G \n\n        594.8048   1187.5950   1187.6009   -0.0059  0   23   0.5  U     R.GPQVYTMAPPK.E \n\n        604.7661   1207.5177   1207.5291   -0.0114  0   36   0.015  U     K.MNGQPQENYK.N \n\n        654.8328   1307.6510   1307.6577   -0.0068  0   (53)  0.00047  U     K.SNSMVTLGCLVK.G \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAGSTTIEAVKRKIQVLQQQADDAEERAERLQREVEGERRAREQAEAEVASLNRRIQLVEEELDRAQEPLATALQKLEEAEKAADESERGMKVIENRALKDEEKMELQEIQLKEAKHIAEEADRKYEEVARKLVIIEGDLERTEERAELAESRCREMDEQIRLMDQNLKCLSAAEEKYSQKEDKYEEEIKILTDKLKEAETRAEFAERSVAKLEKTIDDLEDKLKCTKEEHLCTQRMLDQTLLDLNEM&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MKLWLNWIFLLTLLNGIQCEVKLLESGGGLVQPGGSMRLSCAASGFTFTDFYMNWIRQPAGKAPEWLGFIRNKANGYTTEYNPSVKGRFTISRDNTQNMLYLQMNTLRAEDTATYYCARGDYFNNYMFPYVMDAWGQGGSVTVSSAETTAPSVYPLAPGTALKSNSMVTLGCLVKGYFPEPVTVTWNSGALSSGVHTFPAVLQSGLYTLTSSVTVPSSTWSSQAVTCNVAHPASSTKVDKKIVPRECNPCGCTGSEVSSVFIFPPKTKDVLTITLTPKVTCVVVDISQNDPEVRFSWFIDDVEVHTAQTHAPEKQSNSTLRSVSELPIVHRDWLNGKTFKCKVNSGAFPAPIEKSISKPEGTPRGPQVYTMAPPKEEMTQSQVSITCMVKGFYPPDIYTEWKMNGQPQENYKNTPPTMDTDGSYFLYSKLNVKKETWQQGNTFTCSVLHEGLHNHHTEKSLSHSPGK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n137 \n\n \n\n        662.8310   1323.6474   1323.6527   -0.0053  0   60   7.9e-005  U     K.SNSMVTLGCLVK.G + Oxidation (M) \n\n        665.3979   1328.7813   1328.7915   -0.0102  1   78   8.2e-007  U     K.TKDVLTITLTPK.V \n\n        758.3563   1514.6981   1514.7082   -0.0101  0   57   0.00013  U     K.GFYPPDIYTEWK.M \n\n        758.3563   1514.6981   1514.7082   -0.0101  0   (27)  0.12  U     K.GFYPPDIYTEWK.M \n\n        758.3596   1514.7045   1514.7082   -0.0036  0   (38)  0.0093  U     K.GFYPPDIYTEWK.M \n\n        915.4479   1828.8813   1828.8989   -0.0176  0   115   1.9e-010  U     K.VTCVVVDISQNDPEVR.F \n\n        915.4479   1828.8813   1828.8989   -0.0176  0   (14)  2.4  U     K.VTCVVVDISQNDPEVR.F \n\n        968.9272   1935.8399   1935.8560   -0.0161  0   87   5.2e-008  U     K.NTPPTMDTDGSYFLYSK.L \n\n        976.9283   1951.8421   1951.8510   -0.0089  0   (9)  3.6  U     K.NTPPTMDTDGSYFLYSK.L + Oxidation (M) \n\n        786.3709   2356.0910   2356.1124   -0.0215  0   69   3.7e-006  U     R.FSWFIDDVEVHTAQTHAPEK.Q \n\n        1186.5161   2371.0176   2371.0283   -0.0107  0   (109)  2e-010  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n        1186.5168   2371.0190   2371.0283   -0.0093  0   (89)  1.8e-008  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n        1186.5168   2371.0190   2371.0283   -0.0093  0   129   2.1e-012  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n        1186.5168   2371.0190   2371.0283   -0.0093  0   (83)  7.4e-008  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n        1186.5180   2371.0214   2371.0283   -0.0069  0   (46)  0.00043  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n        1186.5180   2371.0214   2371.0283   -0.0069  0   (45)  0.00054  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n        1186.5184   2371.0222   2371.0283   -0.0061  0   (89)  1.8e-008  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n        1186.5184   2371.0222   2371.0283   -0.0061  0   (30)  0.014  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n        1186.5184   2371.0222   2371.0283   -0.0061  0   (17)  0.33  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n        1186.5186   2371.0226   2371.0283   -0.0057  0   (114)  6.4e-011  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n        1186.5186   2371.0226   2371.0283   -0.0057  0   (99)  2.1e-009  U     R.ECNPCGCTGSEVSSVFIFPPK.T \n\n54 GAPDH 8,43 36098 21 gi|56188 0,3 455.2450   908.4755   908.5192   -0.0436  1   (28)  0.16  U     K.AGAHLKGGAK.R \n\n        455.2450   908.4755   908.5192   -0.0436  1   54   0.00041  U     K.AGAHLKGGAK.R \n\n        890.3974   1778.7802   1778.7900   -0.0098  0   23   0.19  U     K.LISWYDNEYGYSNR.V \n\n        910.4499   1818.8853   1818.8968   -0.0115  0   51   0.00048  U     K.IVSNASCTTNCLAPLAK.V \n\n        865.7851   2594.3335   2594.3527   -0.0191  0   (15)  1  U     K.VIHDNFGIVEGLMTTVHAITATQK.T \n\n        871.1190   2610.3352   2610.3476   -0.0124  0   44   0.0012  U     K.VIHDNFGIVEGLMTTVHAITATQK.T + Oxidation (M) \n\n55 ENO1 6,7 51736 23 gi|38649320 0,36 405.7256   809.4366   809.4395   -0.0029  0   12   5.1        K.AVEHINK.T \n\n        452.7328   903.4511   903.4549   -0.0037  0   19   1.6  U     R.IEEELGSK.A \n\n        504.2531   1006.4916   1006.4940   -0.0023  0   19   1.4  U     K.SCNCLLLK.V \n\n        703.8609   1405.7073   1405.7089   -0.0016  0   58   0.00014  U     R.GNPTVEVDLYTAK.G \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MVKVGVNGFGRIGRLVTRAAFSCDKVDIVAINDPFIDLNYMVYMFQYDSTHGKFNGTVKAENGKLVINGKPITIFQERDPVKIKWGDAGAEYVVESTGVFTTMEKAGAHLKGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIVSNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGAAQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTPNVSVVDLTCRLEKPAKYDDIKKVVKQAAEGPLKGILGYTEDQVVSCDFNSNSHSSTFDAGAGIALNDNIVKLISWYDNEYGYSNRVVDLMAYMASKE&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=GECCSGTESRSRLSLRLPSVSPGPSFLPPQRSYCQNFTMSILKIHAREIFDSRGNPTVEVDLYTAKGLFRAAVPSGASTGIYEALELRDNDKTRFMGKGVSKAVEHINKTIAPALVSKKLNVVEQEKIDQLMIEMDGTENKSKFGANAILGVSLAVCKAGAVEKGVPLYRHIADLAGNPEVILPVPAFNVINGGSHAGNKLAMQEFMILPVGASSFREAMRIGAEVYHNLKNVIKEKYGKDATNVGDEGGFAPNILENKEALELLKSAIAKAGYTDQVVIGMDVAASEFYRAGKYDLDFKSPDDASRYITPDQLADLYKSFIKDYPVVSIEDPFDQDDWDAWQKFTATAGIQVVGDDLTVTNPKRIAKAAGEKSCNCLLLKVNQIGSVTESLQACKLAQSNGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQILRIEEELGSKAKFAGRSFRNPLAK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n138 \n\n \n\n        817.4066   1632.7986   1632.8141   -0.0155  0   104   2.7e-009  U     K.VNQIGSVTESLQACK.L \n\n        817.4066   1632.7986   1632.8141   -0.0155  0   (16)  1.7  U     K.VNQIGSVTESLQACK.L \n\n        817.4089   1632.8032   1632.8141   -0.0109  0   (51)  0.00051  U     K.VNQIGSVTESLQACK.L \n\n        817.4089   1632.8032   1632.8141   -0.0109  0   (23)  0.37  U     K.VNQIGSVTESLQACK.L \n\n        902.9590   1803.9034   1803.9366   -0.0332  0   (44)  0.0027        R.AAVPSGASTGIYEALELR.D \n\n        902.9590   1803.9034   1803.9366   -0.0332  0   107   1.1e-009        R.AAVPSGASTGIYEALELR.D \n\n        902.9736   1803.9326   1803.9366   -0.0041  0   (2)  32        R.AAVPSGASTGIYEALELR.D \n\n        980.9535   1959.8925   1959.9174   -0.0249  0   (26)  0.092  U     K.DATNVGDEGGFAPNILENK.E \n\n        980.9535   1959.8925   1959.9174   -0.0249  0   117   8.5e-011  U     K.DATNVGDEGGFAPNILENK.E \n\n        980.9627   1959.9109   1959.9174   -0.0065  0   (2)  28  U     K.DATNVGDEGGFAPNILENK.E \n\n        980.9627   1959.9109   1959.9174   -0.0065  0   (29)  0.06  U     K.DATNVGDEGGFAPNILENK.E \n\n        1177.0784   2352.1422   2352.1519   -0.0097  0   (0)  39        R.SGETEDTFIADLVVGLCTGQIK.T \n\n        1177.0784   2352.1422   2352.1519   -0.0097  0   (1)  30        R.SGETEDTFIADLVVGLCTGQIK.T \n\n        1177.0786   2352.1426   2352.1519   -0.0093  0   158   6.4e-015        R.SGETEDTFIADLVVGLCTGQIK.T \n\n57 MCPT1 6,55 27603 68 gi|8393764 2,92 452.7229   903.4313   903.4298   0.0015  0   62   8.2e-005  U     K.DPTSDTLR.E \n\n        476.7459   951.4772   951.4774   -0.0001  1   23   0.5  U     K.REYTQQK.I \n\n        476.7459   951.4772   951.4774   -0.0001  1   (20)  1.1  U     K.REYTQQK.I \n\n        563.2695   1124.5245   1124.5285   -0.0040  0   61   6.2e-005  U     K.DSCGGFLITR.Q \n\n        601.7977   1201.5809   1201.6026   -0.0217  0   70   9.1e-006  U     R.QFVLTAAHCR.G \n\n        645.3394   1288.6642   1288.6623   0.0019  1   43   0.0051  U     R.TGVKDPTSDTLR.E \n\n        771.4398   1540.8649   1540.8766   -0.0116  0   (54)  0.00017  U     R.IAPYVPWINTVLR.E \n\n        771.4425   1540.8704   1540.8766   -0.0062  0   62   2.7e-005  U     R.IAPYVPWINTVLR.E \n\n        771.4425   1540.8704   1540.8766   -0.0062  0   (60)  4.7e-005  U     R.IAPYVPWINTVLR.E \n\n        528.2871   1581.8395   1581.8475   -0.0079  1   40   0.0055  U     R.GREITVTLGAHDVSK.R \n\n        905.4159   1808.8173   1808.8264   -0.0091  0   38   0.0059  U     R.HYDNNFQVCVGLSTR.L \n\n        922.9821   1843.9496   1843.9654   -0.0158  0   (32)  0.042  U     K.NYNFLPNLHDIMLLK.L \n\n        615.6601   1843.9584   1843.9654   -0.0070  0   (24)  0.25  U     K.NYNFLPNLHDIMLLK.L \n\n        615.6618   1843.9636   1843.9654   -0.0018  0   (46)  0.0015  U     K.NYNFLPNLHDIMLLK.L \n\n        615.6618   1843.9636   1843.9654   -0.0018  0   (46)  0.0015  U     K.NYNFLPNLHDIMLLK.L \n\n        922.9896   1843.9647   1843.9654   -0.0007  0   69   6.6e-006  U     K.NYNFLPNLHDIMLLK.L \n\n        930.9823   1859.9500   1859.9604   -0.0103  0   (37)  0.013  U     K.NYNFLPNLHDIMLLK.L + Oxidation (M) \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MQALLFLMALLLPSGAGAEEIIGGVESIPHSRPYMAHLDIITERGLKDSCGGFLITRQFVLTAAHCRGREITVTLGAHDVSKREYTQQKIKVEKQFIHKNYNFLPNLHDIMLLKLEKQVELTPAVDVVPLPSPSDFIHPGTLCWTAGWGRTGVKDPTSDTLREVALRIMDEEACKIYRHYDNNFQVCVGLSTRLQTAYTGDSGGPLLCAGVVHGIVSYGHPDATPPAVFTRIAPYVPWINTVLRESS&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n139 \n\n \n\n        620.9913   1859.9520   1859.9604   -0.0084  0   (43)  0.0031  U     K.NYNFLPNLHDIMLLK.L + Oxidation (M) \n\n        1201.5993   3601.7761   3601.8028   -0.0268  0   (76)  5e-007  U     K.QVELTPAVDVVPLPSPSDFIHPGTLCWTAGWGR.T \n\n        1201.5993   3601.7761   3601.8028   -0.0268  0   92   1.2e-008  U     K.QVELTPAVDVVPLPSPSDFIHPGTLCWTAGWGR.T \n\n        1201.6038   3601.7896   3601.8028   -0.0133  0   (2)  12  U     K.QVELTPAVDVVPLPSPSDFIHPGTLCWTAGWGR.T \n\n        1201.6038   3601.7896   3601.8028   -0.0133  0   (6)  4.7  U     K.QVELTPAVDVVPLPSPSDFIHPGTLCWTAGWGR.T \n\n        1201.6047   3601.7923   3601.8028   -0.0106  0   (32)  0.01  U     K.QVELTPAVDVVPLPSPSDFIHPGTLCWTAGWGR.T \n\n        1294.6430   3880.9072   3880.9207   -0.0135  0   124   4.6e-012  U     R.LQTAYTGDSGGPLLCAGVVHGIVSYGHPDATPPAVFTR.I \n\n60 DPP7 4,87 55649 22  gi|14010871 0,33 584.3106   1166.6067   1166.6084   -0.0017  0   (11)  6.4  U     K.DLTQLFGFAR.N \n\n        584.3106   1166.6067   1166.6084   -0.0017  0   29   0.097  U     K.DLTQLFGFAR.N \n\n        1130.0544   2258.0942   2258.1080   -0.0137  0   46   0.00094  U     K.AASNIIFSNGDLDPWAGGGIQR.N \n\n        926.4395   2776.2966   2776.3014   -0.0048  0   58   4.8e-005  U     K.DLFLQGAYDTISQNFGTCQSLSSPK.D \n\n        1389.1619   2776.3092   2776.3014   0.0078  0   (51)  0.00024  U     K.DLFLQGAYDTISQNFGTCQSLSSPK.D \n\n        1389.1619   2776.3092   2776.3014   0.0078  0   (7)  5.5  U     K.DLFLQGAYDTISQNFGTCQSLSSPK.D \n\n        974.8522   2921.5349   2921.5552   -0.0203  0   58   3.5e-005  U     K.YPHLVAGALAASAPVIAVAGLGNPDQFFR.D \n\n        974.8522   2921.5349   2921.5552   -0.0203  0   (47)  0.00045  U     K.YPHLVAGALAASAPVIAVAGLGNPDQFFR.D \n\n        994.4981   2980.4725   2980.4867   -0.0142  0   1   19  U     R.NAFTVLAMMDYPYPTNFLGPLPANPVK.V \n\n  TRA1 5,02 74390 23 gi|51858886 0,47 377.2113   752.4080   752.4068   0.0012  1   35   0.034  U     K.KSDYIK.L \n\n        541.2767   1080.5389   1080.5352   0.0037  0   (2)  59  U     K.FAFQAEVNR.M \n\n        541.2767   1080.5389   1080.5352   0.0037  0   17   1.8  U     K.FAFQAEVNR.M \n\n        594.3420   1186.6694   1186.6710   -0.0016  0   60   7.3e-005  U     K.SILFVPTSAPR.G \n\n        743.3757   1484.7368   1484.7471   -0.0103  0   75   2.6e-006  U     K.GVVDSDDLPLNVSR.E \n\n        893.4493   1784.8841   1784.8904   -0.0063  0   18   1  U     R.EEEAIQLDGLNASQIR.E \n\n        939.9692   1877.9238   1877.9352   -0.0114  0   58   9.4e-005  U     K.YSQFINFPIYVWSSK.T \n\n        1015.5318   2029.0490   2029.0579   -0.0088  0   21   0.32  U     R.LISLTDENALAGNEELTVK.I \n\n        848.0983   2541.2730   2541.2838   -0.0108  0   10   3.3  U     K.TVWDWELMNDIKPIWQRPSK.E \n\n        910.1118   2727.3136   2727.3311   -0.0175  1   18   0.42  U     R.TDDEVVQREEEAIQLDGLNASQIR.E \n\n        1109.1886   3324.5440   3324.5497   -0.0057  0   41   0.0014  U     K.MTEAQEDGQSTSELIGQFGVGFYSAFLVADK.V \n\n61 LUM 6 38654 21 gi|13591983 0,51 613.2940   1224.5734   1224.5735   -0.0000  0   52   0.00052  U     R.NNQIDHIDEK.A \n\n        613.2940   1224.5734   1224.5735   -0.0000  0   (23)  0.39  U     R.NNQIDHIDEK.A \n\n        691.3438   1380.6729   1380.6674   0.0056  0   57   0.00017  U     K.ITNIPDEYFNR.F \n\n        837.9032   1673.7919   1673.7970   -0.0052  0   66   1.5e-005  U     K.SLEYLDLSFNQMSK.L \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MGLHPCSPVDHGVPSWVLVLLLTLGLCSLQATADSVLDPDFRENYFEQYMDHFNFESFSNKTFGQRFLVSDKFWKMGEGPIFFYTGNEGDIWSLANNSGFIVELAAQQEALLVFAEHRYYGKSLPFGVQSTQRGYTQLLTVEQALADFAVLLQALRHNLGVQDAPTIAFGGSYGGMLSAYMRMKYPHLVAGALAASAPVIAVAGLGNPDQFFRDVTADFYGQSPKCAQAVRDAFQQIKDLFLQGAYDTISQNFGTCQSLSSPKDLTQLFGFARNAFTVLAMMDYPYPTNFLGPLPANPVKVGCERLLSEGQRIMGLRALAGLVYNSSGMEPCFDIYQMYQSCADPTGCGTGSNARAWDYQACTEINLTFDSNNVTDMFPEIPFSDELRQQYCLDTWGVWPRPDWLQTSFWGGDLKAASNIIFSNGDLDPWAGGGIQRNLSTSIIAVTIQGGAHHLDLRASNSEDPPSVVEVRKLEATLIREWVAAARLKQPAEAQWPGPK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRVLWVLGLCCVLLTFGFVRADDEVDVDGTVEEDLGKSREGSRTDDEVVQREEEAIQLDGLNASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFLRELISNASDALDKIRLISLTDENALAGNEELTVKIKCDREKNLLHVTDTGVGMTREELVKNLGTIAKSGTSEFLNKMTEAQEDGQSTSELIGQFGVGFYSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLGRGTTITLVLKEEASDYLELDTIKNLVRKYSQFINFPIYVWSSKTETVEEPLEEDETAQEEKEEADDEAAVEEEEEEKKPKTKKVEKTVWDWELMNDIKPIWQRPSKEVEEDEYKAFYKSFSKESDDPMAYIHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVRRVFITDDFHDMMPKYLNFVKGVVDSDDLPLNVSRETLQQHKLLKVIRKKLVRKTLDMIKKIADEKYNDTFWKEFGTNIKLGVIEDHSNRTRLAKLLRFQSSHHSTDITSLDQYVERMKEKQDKIYFMAGSSRKEAESSPFVERLLKKGYEVIYLTEPVDEYCIQALPEFDGKRFQNVAKEGVKFDESEKSKESREATEKEFEPLLNWMKDKALKDKVFGPQTVVSPHRN&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MNVCTFTLVLALVGSVSGQYYDYDAPLFMYGELSPNCAPECNCPHSYPTAMYCDDLKLKSVPMVPPGIKYLYLRNNQIDHIDEKAFENVTDLQWLILDHNLLENSKIKGKVFSKLKQLKKLHINYNNLTESVGPLPKSLQDLQLANNKISKLGSFDGLVNLTFIYLQHNQLKEEAVSASLKGLKSLEYLDLSFNQMSKLPAGLPTSLLTLYLDNNKITNIPDEYFNRFTGLQYLRLSHNELADSGVPGNSFNISSLLELDLSYNKLKSIPTVNENLENYYLEVNKLEKFDVKSFCKILGPLSYSKIKHLRLDGNPLTQSSLPPDMYECLRVANEITVN&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n140 \n\n \n\n        845.8993   1689.7841   1689.7920   -0.0079  0   (1)  52  U     K.SLEYLDLSFNQMSK.L + Oxidation (M) \n\n        972.0414   1942.0682   1942.0775   -0.0093  0   77   7.7e-007  U     K.LPAGLPTSLLTLYLDNNK.I \n\n        972.0414   1942.0683   1942.0775   -0.0092  0   (7)  7.6  U     K.LPAGLPTSLLTLYLDNNK.I \n\n        972.0414   1942.0683   1942.0775   -0.0092  0   (10)  3.9  U     K.LPAGLPTSLLTLYLDNNK.I \n\n        972.0439   1942.0733   1942.0775   -0.0042  0   (8)  5.6  U     K.LPAGLPTSLLTLYLDNNK.I \n\n        972.0439   1942.0733   1942.0775   -0.0042  0   (15)  0.95  U     K.LPAGLPTSLLTLYLDNNK.I \n\n        1153.5395   2305.0644   2305.0719   -0.0074  0   (2)  23  U     R.LDGNPLTQSSLPPDMYECLR.V \n\n        1153.5428   2305.0710   2305.0719   -0.0008  0   35   0.012  U     R.LDGNPLTQSSLPPDMYECLR.V \n\n        1153.5428   2305.0710   2305.0719   -0.0008  0   (18)  0.6  U     R.LDGNPLTQSSLPPDMYECLR.V \n\n  RBBP4 4,74 47911 30 gi|5032027 0,30 387.6975   773.3804   773.3820   -0.0016  0   22   0.99  U     K.DFSIHR.L \n\n        447.7344   893.4543   893.4494   0.0049  0   (5)  31  U     R.VINEEYK.I \n\n        447.7344   893.4543   893.4494   0.0049  0   9   13  U     R.VINEEYK.I \n\n        487.2765   972.5384   972.5393   -0.0008  0   (8)  19  U     K.TVALWDLR.N \n\n        487.2765   972.5384   972.5393   -0.0008  0   18   1.8  U     K.TVALWDLR.N \n\n        534.2635   1066.5125   1066.5155   -0.0031  0   48   0.0013  U     K.INHEGEVNR.A \n\n        564.7704   1127.5262   1127.5248   0.0014  0   14   3.2  U     K.GEFGGFGSVSGK.I \n\n        736.3668   1470.7191   1470.7242   -0.0051  0   81   5.4e-007  U     K.TPSSDVLVFDYTK.H \n\n        903.4134   1804.8122   1804.8162   -0.0040  0   (11)  3.3  U     K.HPSKPDPSGECNPDLR.L \n\n        903.4134   1804.8122   1804.8162   -0.0040  0   (18)  0.7  U     K.HPSKPDPSGECNPDLR.L \n\n        602.6128   1804.8165   1804.8162   0.0002  0   79   5.2e-007  U     K.HPSKPDPSGECNPDLR.L \n\n        958.4527   2872.3363   2872.3515   -0.0152  0   24   0.078  U     K.IGEEQSPEDAEDGPPELLFIHGGHTAK.I \n\n        1275.9778   3824.9116   3824.9236   -0.0120  0   2   11  U     K.NTPFLYDLVMTHALEWPSLTAQWLPDVTRPEGK.D \n\n63 YWHAE 4,63 29326 58  gi|5803225 1,93 453.7169   905.4192   905.4178   0.0014  1   (22)  0.7  U     K.MKGDYHR.Y \n\n        453.7169   905.4192   905.4178   0.0014  1   (20)  1.2  U     K.MKGDYHR.Y \n\n        454.2636   906.5126   906.5174   -0.0049  0   48   0.0016  U     R.NLLSVAYK.N \n\n        459.2676   916.5207   916.5229   -0.0023  0   27   0.28  U     R.IISSIEQK.E \n\n        459.2676   916.5207   916.5229   -0.0023  0   (5)  46  U     R.IISSIEQK.E \n\n        461.7091   921.4037   921.4127   -0.0090  1   26   0.23  U     K.MKGDYHR.Y + Oxidation (M) \n\n        461.7091   921.4037   921.4127   -0.0090  1   (25)  0.26  U     K.MKGDYHR.Y + Oxidation (M) \n\n        489.2509   976.4872   976.4899   -0.0027  0   11   9.9  U     R.QMVETELK.L \n\n        595.3293   1188.6440   1188.6536   -0.0096  0   (61)  7.3e-005  U     K.DSTLIMQLLR.D \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MADKEAAFDDAVEERVINEEYKIWKKNTPFLYDLVMTHALEWPSLTAQWLPDVTRPEGKDFSIHRLVLGTHTSDEQNHLVIASVQLPNDDAQFDASHYDSEKGEFGGFGSVSGKIEIEIKINHEGEVNRARYMPQNPCIIATKTPSSDVLVFDYTKHPSKPDPSGECNPDLRLRGHQKEGYGLSWNPNLSGHLLSASDDHTICLWDISAVPKEGKVVDAKTIFTGHTAVVEDVSWHLLHESLFGSVADDQKLMIWDTRSNNTSKPSHSVDAHTAEVNCLSFNPYSEFILATGSADKTVALWDLRNLKLKLHSFESHKDEIFQVQWSPHNETILASSGTDRRLNVWDLSKIGEEQSPEDAEDGPPELLFIHGGHTAKISDFSWNPNEPWVICSVSEDNIMQVWQMAENIYNDEDPEGSVDPEGQGS&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDDREDLVYQAKLAEQAERYDEMVESMKKVAGMDVELTVEERNLLSVAYKNVIGARRASWRIISSIEQKEENKGGEDKLKMIREYRQMVETELKLICCDILDVLDKHLIPAANTGESKVFYYKMKGDYHRYLAEFATGNDRKEAAENSLVAYKAASDIAMTELPPTHPIRLGLALNFSVFYYEILNSPDRACRLAKAAFDDAIAELDTLSEESYKDSTLIMQLLRDNLTLWTSDMQGDGEEQNKEALQDVEDENQ&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n141 \n\n \n\n        595.3296   1188.6446   1188.6536   -0.0090  0   (20)  1.1  U     K.DSTLIMQLLR.D \n\n        595.3296   1188.6446   1188.6536   -0.0090  0   (57)  0.00019  U     K.DSTLIMQLLR.D \n\n        595.3312   1188.6478   1188.6536   -0.0059  0   (30)  0.11  U     K.DSTLIMQLLR.D \n\n        595.3312   1188.6478   1188.6536   -0.0059  0   (27)  0.21  U     K.DSTLIMQLLR.D \n\n        603.3304   1204.6463   1204.6485   -0.0023  0   79   1.3e-006  U     K.DSTLIMQLLR.D + Oxidation (M) \n\n        603.3309   1204.6473   1204.6485   -0.0012  0   (57)  0.00018  U     K.DSTLIMQLLR.D + Oxidation (M) \n\n        603.3309   1204.6473   1204.6485   -0.0012  0   (51)  0.00076  U     K.DSTLIMQLLR.D + Oxidation (M) \n\n        619.3262   1236.6378   1236.6462   -0.0085  0   73   4e-006  U     K.HLIPAANTGESK.V \n\n        692.8375   1383.6605   1383.6783   -0.0177  1   15   2.5  U     R.YLAEFATGNDRK.E \n\n        709.3769   1416.7392   1416.7460   -0.0067  1   32   0.055  U     R.IISSIEQKEENK.G \n\n        724.3541   1446.6935   1446.7024   -0.0089  0   70   7.3e-006  U     K.VAGMDVELTVEER.N \n\n        738.8568   1475.6990   1475.7364   -0.0374  0   (87)  1.6e-007  U     K.LICCDILDVLDK.H \n\n        738.8568   1475.6990   1475.7364   -0.0374  0   (28)  0.12  U     K.LICCDILDVLDK.H \n\n        738.8722   1475.7299   1475.7364   -0.0065  0   (48)  0.0015  U     K.LICCDILDVLDK.H \n\n        738.8722   1475.7299   1475.7364   -0.0065  0   (65)  2.5e-005  U     K.LICCDILDVLDK.H \n\n        738.8727   1475.7309   1475.7364   -0.0055  0   95   2.7e-008  U     K.LICCDILDVLDK.H \n\n        738.8727   1475.7309   1475.7364   -0.0055  0   (82)  5.9e-007  U     K.LICCDILDVLDK.H \n\n        738.8734   1475.7322   1475.7364   -0.0042  0   (26)  0.22  U     K.LICCDILDVLDK.H \n\n        738.8734   1475.7322   1475.7364   -0.0042  0   (53)  0.00042  U     K.LICCDILDVLDK.H \n\n        910.4619   1818.9091   1818.9298   -0.0206  0   87   1.3e-007  U     K.AASDIAMTELPPTHPIR.L \n\n        607.3137   1818.9191   1818.9298   -0.0107  0   (37)  0.013  U     K.AASDIAMTELPPTHPIR.L \n\n        607.3137   1818.9191   1818.9298   -0.0107  0   (51)  0.0005  U     K.AASDIAMTELPPTHPIR.L \n\n        910.4671   1818.9197   1818.9298   -0.0100  0   (83)  3.2e-007  U     K.AASDIAMTELPPTHPIR.L \n\n        607.3144   1818.9213   1818.9298   -0.0085  0   (26)  0.16  U     K.AASDIAMTELPPTHPIR.L \n\n        607.3144   1818.9213   1818.9298   -0.0085  0   (31)  0.052  U     K.AASDIAMTELPPTHPIR.L \n\n        1044.4782   2086.9418   2086.9582   -0.0164  0   (61)  2.9e-005  U     K.AAFDDAIAELDTLSEESYK.D \n\n        1044.4782   2086.9418   2086.9582   -0.0164  0   (10)  3.8  U     K.AAFDDAIAELDTLSEESYK.D \n\n        1044.4782   2086.9418   2086.9582   -0.0164  0   (30)  0.04  U     K.AAFDDAIAELDTLSEESYK.D \n\n        1044.4812   2086.9478   2086.9582   -0.0104  0   (111)  3.2e-010  U     K.AAFDDAIAELDTLSEESYK.D \n\n        1044.4812   2086.9478   2086.9582   -0.0104  0   (122)  2.6e-011  U     K.AAFDDAIAELDTLSEESYK.D \n\n        1044.4812   2086.9478   2086.9582   -0.0104  0   132   2.3e-012  U     K.AAFDDAIAELDTLSEESYK.D \n\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n142 \n\n \n\n        1090.9677   2179.9208   2179.9328   -0.0119  0   (9)  2  U     R.DNLTLWTSDMQGDGEEQNK.E \n\n        1090.9677   2179.9208   2179.9328   -0.0119  0   11   1.3  U     R.DNLTLWTSDMQGDGEEQNK.E \n\n        899.1254   2694.3542   2694.3721   -0.0178  1   35   0.01  U     K.LICCDILDVLDKHLIPAANTGESK.V \n\n70 MYL 4,67 19940 66 gi|71037403 3,09 400.7271   799.4397   799.4439   -0.0043  1   (21)  0.87  U     R.EAPIDKK.G \n\n        400.7271   799.4397   799.4439   -0.0043  1   26   0.3  U     R.EAPIDKK.G \n\n        518.2604   1034.5062   1034.5066   -0.0004  0   46   0.0025  U     R.ELLTTMGDR.F \n\n        614.8114   1227.6082   1227.6095   -0.0013  0   58   0.00014  U     K.LNGTDPEDVIR.N \n\n        619.2841   1236.5537   1236.5557   -0.0020  0   (57)  0.00012  U     K.EAFNMIDQNR.D \n\n        619.2854   1236.5563   1236.5557   0.0006  0   (26)  0.16  U     K.EAFNMIDQNR.D \n\n        619.2854   1236.5563   1236.5557   0.0006  0   (6)  17  U     K.EAFNMIDQNR.D \n\n        627.2826   1252.5506   1252.5506   0.0000  0   58   9.7e-005  U     K.EAFNMIDQNR.D + Oxidation (M) \n\n        630.8025   1259.5904   1259.5935   -0.0031  0   32   0.048  U     K.GNFNYIEFTR.I \n\n        708.3180   1414.6214   1414.6252   -0.0038  0   72   2.7e-006  U     R.FTDEEVDELYR.E \n\n        708.3182   1414.6218   1414.6252   -0.0034  0   (45)  0.0014  U     R.FTDEEVDELYR.E \n\n        679.9789   2036.9149   2036.9183   -0.0034  1   5   12  U     R.DGFIDKEDLHDMLASMGK.N + Oxidation (M) \n\n        1045.9845   2089.9544   2089.9779   -0.0234  0   93   2e-008  U     R.ATSNVFAMFDQSQIQEFK.E \n\n        1045.9943   2089.9740   2089.9779   -0.0038  0   (10)  3.9  U     R.ATSNVFAMFDQSQIQEFK.E \n\n        1053.9902   2105.9658   2105.9728   -0.0070  0   (6)  9.3  U     R.ATSNVFAMFDQSQIQEFK.E + Oxidation (M) \n\n        1053.9902   2105.9658   2105.9728   -0.0070  0   (16)  0.92  U     R.ATSNVFAMFDQSQIQEFK.E + Oxidation (M) \n\n        1181.5344   2361.0542   2361.0583   -0.0041  0   (95)  8.3e-009  U     R.NAFACFDEEAIGTIQEDYLR.E \n\n        1181.5344   2361.0542   2361.0583   -0.0041  0   (55)  8.4e-005  U     R.NAFACFDEEAIGTIQEDYLR.E \n\n        1181.5345   2361.0544   2361.0583   -0.0039  0   161   1.8e-015  U     R.NAFACFDEEAIGTIQEDYLR.E \n\n72 ARHGDIA 5,12 23450 57 gi|31982030 3,97 475.2748   948.5351   948.5392   -0.0041  1   3   59  U     K.YKEALLGR.V \n\n        490.7500   979.4854   979.4875   -0.0021  0   31   0.072  U     K.YIQHTYR.K \n\n        490.7536   979.4927   979.4875   0.0052  0   (1)  83  U     K.YIQHTYR.K \n\n        490.7536   979.4927   979.4875   0.0052  0   (13)  4.5  U     K.YIQHTYR.K \n\n        623.2823   1244.5501   1244.5496   0.0005  0   33   0.036  U     K.TDYMVGSYGPR.A \n\n        825.9578   1649.9010   1649.9101   -0.0091  0   94   2e-008  U     R.VAVSADPNVPNVIVTR.L \n\n        892.4036   1782.7927   1782.8022   -0.0094  0   (44)  0.0016  U     R.AEEYEFLTPMEEAPK.G \n\n        892.4036   1782.7927   1782.8022   -0.0094  0   (28)  0.059  U     R.AEEYEFLTPMEEAPK.G \n\n        892.4045   1782.7944   1782.8022   -0.0078  0   66   1.1e-005  U     R.AEEYEFLTPMEEAPK.G \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSSKRAKTKTTKKRPQRATSNVFAMFDQSQIQEFKEAFNMIDQNRDGFIDKEDLHDMLASMGKNPTDEYLDAMMNEAPGPINFTMFLTMFGEKLNGTDPEDVIRNAFACFDEEAIGTIQEDYLRELLTTMGDRFTDEEVDELYREAPIDKKGNFNYIEFTRILKHGAKDKDD&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRKYKEALLGRVAVSADPNVPNVIVTRLTLVCSTAPGPLELDLTGDLESFKKQSFVLKEGVEYRIKISFRVNREIVSGMKYIQHTYRKGVKIDKTDYMVGSYGPRAEEYEFLTPMEEAPKGMLARGSYNIKSRFTDDDKTDHLSWEWNLTIKKEWKD&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n143 \n\n \n\n        900.3989   1798.7833   1798.7971   -0.0138  0   (36)  0.0081  U     R.AEEYEFLTPMEEAPK.G + Oxidation (M) \n\n        959.4658   1916.9170   1916.9327   -0.0157  1   111   4.6e-010  U     K.SIQEIQELDKDDESLR.K \n\n        639.9828   1916.9267   1916.9327   -0.0060  1   (36)  0.013  U     K.SIQEIQELDKDDESLR.K \n\n        788.7036   2363.0891   2363.1070   -0.0179  1   73   1.5e-006  U     R.FTDDDKTDHLSWEWNLTIK.K \n\n        1182.5588   2363.1030   2363.1070   -0.0039  1   (5)  9.5  U     R.FTDDDKTDHLSWEWNLTIK.K \n\n        859.4392   2575.2958   2575.3091   -0.0134  0   (34)  0.013  U     R.LTLVCSTAPGPLELDLTGDLESFK.K \n\n        1288.6589   2575.3032   2575.3091   -0.0059  0   40   0.003  U     R.LTLVCSTAPGPLELDLTGDLESFK.K \n\n        902.1254   2703.3545   2703.4041   -0.0496  1   105   9.6e-010  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        902.1373   2703.3900   2703.4041   -0.0140  1   (71)  1.9e-006  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        902.1373   2703.3900   2703.4041   -0.0140  1   (32)  0.015  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        902.1375   2703.3906   2703.4041   -0.0135  1   (35)  0.008  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        902.1375   2703.3908   2703.4041   -0.0133  1   (26)  0.057  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        902.1375   2703.3908   2703.4041   -0.0133  1   (33)  0.013  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        902.1375   2703.3908   2703.4041   -0.0133  1   (28)  0.042  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        902.1395   2703.3966   2703.4041   -0.0075  1   (0)  21  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        902.1399   2703.3979   2703.4041   -0.0062  1   (100)  2.2e-009  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        902.1399   2703.3979   2703.4041   -0.0062  1   (101)  1.7e-009  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        902.1399   2703.3979   2703.4041   -0.0062  1   (103)  1.3e-009  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n        1352.7074   2703.4002   2703.4041   -0.0038  1   (37)  0.0042  U     R.LTLVCSTAPGPLELDLTGDLESFKK.Q \n\n75 KRT8 5,49 52678 63 gi|203734 1,64 368.1749   734.3352   734.3381   -0.0029  0   36   0.033  U     -.MSTSGPR.A \n\n        368.1749   734.3352   734.3381   -0.0029  0   (17)  2.8  U     -.MSTSGPR.A \n\n        434.7206   867.4266   867.4311   -0.0045  1   (15)  3  U     K.HGDDLRR.S \n\n        434.7206   867.4266   867.4311   -0.0045  1   20   0.83  U     K.HGDDLRR.S \n\n        435.7196   869.4247   869.4243   0.0004  0   11   6.4  U     R.ISSSSFSR.V \n\n        435.7196   869.4247   869.4243   0.0004  0   (10)  7.9  U     R.ISSSSFSR.V \n\n        440.2189   878.4233   878.4246   -0.0013  0   11   10  U     R.SFTSGPGAR.I \n\n        457.2215   912.4284   912.4301   -0.0017  0   77   1.6e-006  U     R.VGSSSSSFR.G \n\n        508.2750   1014.5355   1014.5345   0.0009  0   14   5.1  U     R.QLEALGQEK.L \n\n        508.2750   1014.5355   1014.5345   0.0009  0   (11)  8.8  U     R.QLEALGQEK.L \n\n        527.2678   1052.5211   1052.5250   -0.0039  0   20   0.92  U     R.QIHEEEIR.E \n\n        533.7593   1065.5040   1065.5090   -0.0050  1   17   2.1        K.YEDEINKR.T \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSTSGPRAFSSRSFTSGPGARISSSSFSRVGSSSSSFRGSLGGFGGAGVGGITAVTVNQSLLNPLKLEVDPNIQAVRTQEKEQIKTLNNKFASFIDKVRFLEQQNKMLETKWSLLQQQKTSRSNMDNMFESYINNLRRQLEALGQEKLKLEVELGNMQGLVEDFKNKYEDEINKRTEMENEFVLIKKDVDEAYMNKVELESRLEGLTDEINFLRQIHEEEIRELQSQISDTSVVLSMDNSRSLDMDSIIAEVRAQYEEIANRSRAEAETMYQIKYEELQTLAGKHGDDLRRSKTEISEMNRNISRLQAEIDALKGQRATLEAAIADAEQRGELAVKDANAKLEDLKNALQKAKQDMARQLREYQELMNVKLALDIEIATYRKLLEGEESRLESGMQNMSIHTKTTSGYAGGLSSSYGGLTSPGFSYGMSSFQPGFGSVGGSSTYSRTKAVVVKKIETRDGKLVSESSDIMSK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n144 \n\n \n\n        547.2652   1092.5159   1092.5199   -0.0040  0   44   0.0046  U     R.AQYEEIANR.S \n\n        558.7981   1115.5817   1115.5822   -0.0005  1   21   0.88  U     K.DANAKLEDLK.N \n\n        592.2887   1182.5628   1182.5590   0.0037  0   6   19  U     R.AEAETMYQIK.Y \n\n        598.2950   1194.5754   1194.5802   -0.0048  0   80   8.2e-007  U     K.LVSESSDIMSK.- \n\n        627.3431   1252.6717   1252.6775   -0.0058  0   43   0.0042  U     K.LEVDPNIQAVR.T \n\n        639.3552   1276.6959   1276.7027   -0.0067  0   79   1.1e-006        K.LALDIEIATYR.K \n\n        674.8364   1347.6583   1347.6704   -0.0121  0   88   1.5e-007  U     R.SLDMDSIIAEVR.A \n\n        676.8372   1351.6598   1351.6693   -0.0095  0   (81)  6.4e-007  U     R.TEMENEFVLIK.K \n\n        676.8372   1351.6598   1351.6693   -0.0095  0   89   1e-007  U     R.TEMENEFVLIK.K \n\n        676.8397   1351.6647   1351.6693   -0.0046  0   (3)  46  U     R.TEMENEFVLIK.K \n\n        679.8431   1357.6716   1357.6837   -0.0121  0   105   2.7e-009  U     R.ATLEAAIADAEQR.G \n\n        682.8386   1363.6627   1363.6653   -0.0026  0   (13)  3.9  U     R.SLDMDSIIAEVR.A + Oxidation (M) \n\n        710.3687   1418.7229   1418.7405   -0.0176  0   90   7.2e-008  U     R.LEGLTDEINFLR.Q \n\n        710.3687   1418.7229   1418.7405   -0.0176  0   (69)  9.4e-006  U     R.LEGLTDEINFLR.Q \n\n        710.3687   1418.7229   1418.7405   -0.0176  0   (72)  4.9e-006  U     R.LEGLTDEINFLR.Q \n\n        710.3687   1418.7229   1418.7405   -0.0176  0   (51)  0.00059  U     R.LEGLTDEINFLR.Q \n\n        713.8530   1425.6914   1425.6922   -0.0008  1   18   1.1  U     R.SRAEAETMYQIK.Y \n\n        910.9514   1819.8883   1819.9026   -0.0143  0   145   1.8e-013  U     K.LEVELGNMQGLVEDFK.N \n\n        924.3975   1846.7804   1846.7978   -0.0174  0   89   2.5e-008  U     R.SNMDNMFESYINNLR.R \n\n        940.3966   1878.7786   1878.7876   -0.0090  0   (78)  3e-007  U     R.SNMDNMFESYINNLR.R + 2 Oxidation (M) \n\n        668.6363   2002.8872   2002.8989   -0.0117  1   35   0.01  U     R.SNMDNMFESYINNLRR.Q \n\n        688.0287   2061.0644   2061.0816   -0.0172  1   20   0.5  U     K.LKLEVELGNMQGLVEDFK.N \n\n        1055.0050   2107.9954   2108.0056   -0.0101  0   22   0.29  U     R.ELQSQISDTSVVLSMDNSR.S \n\n        862.1333   2583.3781   2583.4021   -0.0240  0   119   2.3e-011  U     R.GSLGGFGGAGVGGITAVTVNQSLLNPLK.L \n\n        1292.7013   2583.3880   2583.4021   -0.0140  0   (61)  1.2e-005  U     R.GSLGGFGGAGVGGITAVTVNQSLLNPLK.L \n\n        1273.6896   3818.0470   3818.0691   -0.0221  1   2   3.2  U     R.GSLGGFGGAGVGGITAVTVNQSLLNPLKLEVDPNIQAVR.T \n\n        1403.9512   4208.8318   4208.8546   -0.0228  0   17   0.077  U    \n K.TTSGYAGGLSSSYGGLTSPGFSYGMSSFQPGFGSVGGSSTYSR.T \n\n+ Oxidation (M) \n\n        1403.9512   4208.8318   4208.8546   -0.0228  0   (10)  0.37  U    \n K.TTSGYAGGLSSSYGGLTSPGFSYGMSSFQPGFGSVGGSSTYSR.T \n\n+ Oxidation (M) \n\n76 EZR 5,83 69477 29 gi|40804381 0,59 545.2825   1088.5505   1088.5462   0.0043  1   6   33  U     R.ITEAEKNER.V \n\n        552.7913   1103.5680   1103.5764   -0.0084  0   56   0.00026        K.IGFPWSEIR.N \n\n        552.7948   1103.5751   1103.5764   -0.0012  0   (35)  0.033        K.IGFPWSEIR.N \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MPKPINVRVTTMDAELEFAIQPNTTGKQLFDQVVKTIGLREVWYFGLQYVDNKGFPTWLKLDKKVSAQEVRKENPVQFKFRAKFYPEDVADELIQDITQKLFFLQVKEGILSDEIYCPPETAVLLGSYAVQAKFGDYNKEMHKSGYLSSERLIPQRVMDQHKLSRDQWEDRIQVWHAEHRGMLKDSAMLEYLKIAQDLEMYGINYFEIKNKKGTDLWLGVDALGLNIYEKDDKLTPKIGFPWSEIRNISFNDKKFVIKPIDKKAPDFVFYAPRLRINKRILQLCMGNHELYMRRRKPDTIEVQQMKAQAREEKHQKQLERQQLETEKKRRETVEREKEQMLREKEELMLRLQDFEQKTKRAEKELSEQIEKALQLEEERRRAQEEAERLEADRMAALRAKEELERQAQDQIKSQEQLAAELAEYTAKIALLEEARRRKEDEVEEWQHRAKEAQDDLVKTKEELHLVMTAPPPPPPPVYEPVNYHVQEGLQDEGAEPMGYSAELSSEGILDDRNEEKRITEAEKNERVQRQLQTLSNELSQARDENKRTHNDIIHNENMRQGRDKYKTLRQIRQGNTKQRIDEFEAM&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n145 \n\n \n\n        558.7989   1115.5833   1115.5822   0.0011  1   69   1.4e-005  U     R.AKEAQDDLVK.T \n\n        588.3086   1174.6026   1174.5996   0.0031  0   38   0.015  U     R.IQVWHAEHR.G \n\n        591.7983   1181.5820   1181.5869   -0.0049  0   60   9.2e-005        K.APDFVFYAPR.L \n\n        591.7995   1181.5844   1181.5869   -0.0026  0   (51)  0.00073        K.APDFVFYAPR.L \n\n        496.9324   1487.7755   1487.7766   -0.0011  1   10   7.7        R.RKPDTIEVQQMK.A + Oxidation (M) \n\n        830.8983   1659.7821   1659.7933   -0.0112  0   72   3.7e-006  U     R.EVWYFGLQYVDNK.G \n\n        973.9730   1945.9315   1945.9495   -0.0180  0   82   3e-007  U     K.IAQDLEMYGINYFEIK.N \n\n        989.0173   1976.0201   1976.0255   -0.0054  0   3   29  U     K.GTDLWLGVDALGLNIYEK.D \n\n        1012.4932   2022.9718   2022.9786   -0.0067  0   (34)  0.023  U     K.FYPEDVADELIQDITQK.L \n\n        1012.4957   2022.9768   2022.9786   -0.0017  0   58   9.2e-005  U     K.FYPEDVADELIQDITQK.L \n\n        1012.4957   2022.9768   2022.9786   -0.0017  0   (30)  0.048  U     K.FYPEDVADELIQDITQK.L \n\n        675.3329   2022.9769   2022.9786   -0.0017  0   (23)  0.25  U     K.FYPEDVADELIQDITQK.L \n\n        1033.5052   2064.9958   2065.0038   -0.0079  0   92   2.9e-008        R.VTTMDAELEFAIQPNTTGK.Q \n\n        779.0619   2334.1637   2334.1743   -0.0106  1   14   1.4  U     K.GTDLWLGVDALGLNIYEKDDK.L \n\n        941.8051   2822.3936   2822.4048   -0.0112  0   81   2.5e-007  U     K.EGILSDEIYCPPETAVLLGSYAVQAK.F \n\n        1412.2064   2822.3982   2822.4048   -0.0065  0   (21)  0.25  U     K.EGILSDEIYCPPETAVLLGSYAVQAK.F \n\n        1412.2064   2822.3982   2822.4048   -0.0065  0   (7)  5.7  U     K.EGILSDEIYCPPETAVLLGSYAVQAK.F \n\n        941.8068   2822.3987   2822.4048   -0.0061  0   (5)  9.6  U     K.EGILSDEIYCPPETAVLLGSYAVQAK.F \n\n80 CMPK 5,66 22383 62 \n \n\ngi|150383503 3,03 354.6788   707.3430   707.3490   -0.0060  1   1   1.1e+002  U     K.IFDKEG.- \n\n        482.7647   963.5149   963.5178   -0.0029  0   37   0.025  U     K.FLIDGFPR.N \n\n        608.7867   1215.5589   1215.5632   -0.0043  0   (40)  0.0081  U     R.NQDNLQGWNK.T \n\n        608.7891   1215.5637   1215.5632   0.0005  0   58   0.00013  U     R.NQDNLQGWNK.T \n\n        613.2913   1224.5680   1224.5697   -0.0017  0   45   0.0024  U     K.SVDEVFGDVMK.I \n\n        621.2891   1240.5636   1240.5646   -0.0010  0   (13)  2.8  U     K.SVDEVFGDVMK.I + Oxidation (M) \n\n        662.9206   1323.8266   1323.8377   -0.0111  0   72   1.1e-006  U     K.IVPVEITISLLK.R \n\n        662.9246   1323.8346   1323.8377   -0.0032  0   (45)  0.00046  U     K.IVPVEITISLLK.R \n\n        662.9246   1323.8346   1323.8377   -0.0032  0   (50)  0.00013  U     K.IVPVEITISLLK.R \n\n        669.2916   1336.5687   1336.5751   -0.0064  0   (0)  40  U     R.EMDQTMAANAQK.N \n\n        677.2925   1352.5704   1352.5700   0.0004  0   43   0.002  U     R.EMDQTMAANAQK.N + Oxidation (M) \n\n        685.2865   1368.5585   1368.5649   -0.0064  0   (34)  0.011  U     R.EMDQTMAANAQK.N + 2 Oxidation (M) \n\n        493.9230   1478.7472   1478.7518   -0.0046  0   28   0.12  U     K.YGYTHLSAGELLR.D \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MKPLVVFVLGGPGAGKGTQCARIVEKYGYTHLSAGELLRDERKNPDSQYGELIEKYIKEGKIVPVEITISLLKREMDQTMAANAQKNKFLIDGFPRNQDNLQGWNKTMDGKADVSFVLFFDCNNEICIDRCLERGKSSGRSDDNRESLEKRIQTYLESTKPIIDLYEEMGKVKKIDASKSVDEVFGDVMKIFDKEG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MKPLVVFVLGGPGAGKGTQCARIVEKYGYTHLSAGELLRDERKNPDSQYGELIEKYIKEGKIVPVEITISLLKREMDQTMAANAQKNKFLIDGFPRNQDNLQGWNKTMDGKADVSFVLFFDCNNEICIDRCLERGKSSGRSDDNRESLEKRIQTYLESTKPIIDLYEEMGKVKKIDASKSVDEVFGDVMKIFDKEG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n146 \n\n \n\n        740.3818   1478.7491   1478.7518   -0.0026  0   (3)  36  U     K.YGYTHLSAGELLR.D \n\n        740.9764   1479.9381   1479.9388   -0.0007  1   10   0.65  U     K.IVPVEITISLLKR.E \n\n        760.8803   1519.7460   1519.7518   -0.0058  1   10   7.1  U     R.KNPDSQYGELIEK.Y \n\n        785.4580   1568.9015   1568.9113   -0.0098  0   (39)  0.0049  U     -.MKPLVVFVLGGPGAGK.G \n\n        785.4610   1568.9073   1568.9113   -0.0039  0   76   9.3e-007  U     -.MKPLVVFVLGGPGAGK.G \n\n        791.0707   2370.1902   2370.2028   -0.0126  0   (41)  0.0028  U     R.IQTYLESTKPIIDLYEEMGK.V \n\n        796.4023   2386.1852   2386.1977   -0.0125  0   49   0.00045  U     R.IQTYLESTKPIIDLYEEMGK.V + Oxidation (M) \n\n        796.4023   2386.1852   2386.1977   -0.0125  0   (10)  3.8  U     R.IQTYLESTKPIIDLYEEMGK.V + Oxidation (M) \n\n83 PGK1 8,02 44909 64 gi|40254752 5,78 460.7394   919.4643   919.4685   -0.0042  0   43   0.0062  U     K.SLMDEVVK.A \n\n        468.7379   935.4613   935.4634   -0.0021  0   (28)  0.17  U     K.SLMDEVVK.A + Oxidation (M) \n\n        483.2414   964.4682   964.4688   -0.0006  0   44   0.0041        R.VDFNVPMK.N + Oxidation (M) \n\n        487.7282   973.4418   973.4505   -0.0087  0   52   0.00061        R.FHVEEEGK.G \n\n        487.7331   973.4517   973.4505   0.0012  0   (31)  0.09        R.FHVEEEGK.G \n\n        487.7331   973.4517   973.4505   0.0012  0   (16)  3        R.FHVEEEGK.G \n\n        522.8146   1043.6146   1043.6227   -0.0081  1   66   2.2e-005  U     K.LTLDKLDVK.G \n\n        551.2713   1100.5280   1100.5323   -0.0043  0   51   0.00085        K.NNQITNNQR.I \n\n        387.1911   1158.5514   1158.5669   -0.0156  1   (12)  6.5        R.FHVEEEGKGK.D \n\n        580.2841   1158.5536   1158.5669   -0.0133  1   50   0.0011        R.FHVEEEGKGK.D \n\n        601.3310   1200.6473   1200.6536   -0.0063  0   70   9.5e-006  U     K.IQLINNMLDK.V \n\n        601.3311   1200.6476   1200.6536   -0.0060  0   (19)  1.1  U     K.IQLINNMLDK.V \n\n        610.3160   1218.6174   1218.6496   -0.0321  0   58   0.00016  U     K.YSLEPVAAELK.S \n\n        610.3324   1218.6502   1218.6496   0.0006  0   (37)  0.018  U     K.YSLEPVAAELK.S \n\n        610.3324   1218.6502   1218.6496   0.0006  0   (35)  0.027  U     K.YSLEPVAAELK.S \n\n        659.8625   1317.7105   1317.7180   -0.0075  0   62   4.8e-005  U     K.ITLPVDFVTADK.F \n\n        692.3537   1382.6928   1382.6976   -0.0049  0   16   1.9  U     R.AHSSMVGVNLPQK.A + Oxidation (M) \n\n        817.8944   1633.7742   1633.7849   -0.0107  0   (54)  0.0003        K.LGDVYVNDAFGTAHR.A \n\n        817.8944   1633.7742   1633.7849   -0.0107  0   (59)  8.5e-005        K.LGDVYVNDAFGTAHR.A \n\n        545.5989   1633.7748   1633.7849   -0.0101  0   68   1e-005        K.LGDVYVNDAFGTAHR.A \n\n        864.4420   1726.8695   1726.8786   -0.0091  0   103   2.8e-009  U     K.VNEMIIGGGMAFTFLK.V \n\n        864.4437   1726.8727   1726.8786   -0.0059  0   (41)  0.0044  U     K.VNEMIIGGGMAFTFLK.V \n\n        870.9564   1739.8982   1739.9054   -0.0072  0   53   0.00033        K.VSHVSTGGGASLELLEGK.V \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQRIKAAVPSIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAAELKSLLGKDVLFLKDCVGSEVENACANPAAGTVILLENLRFHVEEEGKGKDASGNKVKAEPAKIDAFRASLSKLGDVYVNDAFGTAHRAHSSMVGVNLPQKAGGFLMKKELNYFAKALESPERPFLAILGGAKVADKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLYDEEGAKIVKDLMAKAEKNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGTESSKKYAEAVARAKQIVWNGPVGVFEWEAFARGTKSLMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGKVLPGVDALSNV&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n147 \n\n \n\n        870.9564   1739.8982   1739.9054   -0.0072  0   (50)  0.00054        K.VSHVSTGGGASLELLEGK.V \n\n        872.4370   1742.8594   1742.8736   -0.0141  0   (102)  4.3e-009  U     K.VNEMIIGGGMAFTFLK.V + Oxidation (M) \n\n        872.4438   1742.8731   1742.8736   -0.0005  0   (92)  4.2e-008  U     K.VNEMIIGGGMAFTFLK.V + Oxidation (M) \n\n        884.9849   1767.9552   1767.9883   -0.0331  0   (90)  4.1e-008  U     K.ALESPERPFLAILGGAK.V \n\n        884.9849   1767.9552   1767.9883   -0.0331  0   93   2.4e-008  U     K.ALESPERPFLAILGGAK.V \n\n        590.3284   1767.9634   1767.9883   -0.0248  0   (53)  0.00021  U     K.ALESPERPFLAILGGAK.V \n\n        590.3316   1767.9729   1767.9883   -0.0154  0   (70)  3.6e-006  U     K.ALESPERPFLAILGGAK.V \n\n        590.3334   1767.9785   1767.9883   -0.0098  0   (28)  0.066  U     K.ALESPERPFLAILGGAK.V \n\n        590.3334   1767.9785   1767.9883   -0.0098  0   (27)  0.07  U     K.ALESPERPFLAILGGAK.V \n\n        590.3342   1767.9807   1767.9883   -0.0075  0   (14)  1.5  U     K.ALESPERPFLAILGGAK.V \n\n        590.3342   1767.9807   1767.9883   -0.0075  0   (15)  1.2  U     K.ALESPERPFLAILGGAK.V \n\n        590.3344   1767.9814   1767.9883   -0.0069  0   (56)  8.3e-005  U     K.ALESPERPFLAILGGAK.V \n\n        884.9994   1767.9843   1767.9883   -0.0040  0   (64)  1.4e-005  U     K.ALESPERPFLAILGGAK.V \n\n        884.9994   1767.9843   1767.9883   -0.0040  0   (39)  0.0043  U     K.ALESPERPFLAILGGAK.V \n\n        991.9617   1981.9089   1981.9302   -0.0213  0   (109)  5.4e-010  U     K.VLNNMEIGTSLYDEEGAK.I \n\n        991.9617   1981.9089   1981.9302   -0.0213  0   120   3.8e-011  U     K.VLNNMEIGTSLYDEEGAK.I \n\n        991.9658   1981.9171   1981.9302   -0.0131  0   (102)  2.6e-009  U     K.VLNNMEIGTSLYDEEGAK.I \n\n        1012.0066   2021.9986   2022.0310   -0.0323  1   98   8.6e-009  U     K.ITLPVDFVTADKFDENAK.T \n\n        675.0145   2022.0217   2022.0310   -0.0092  1   (65)  1.6e-005  U     K.ITLPVDFVTADKFDENAK.T \n\n        675.0148   2022.0224   2022.0310   -0.0086  1   (9)  6.7  U     K.ITLPVDFVTADKFDENAK.T \n\n        675.0151   2022.0235   2022.0310   -0.0075  1   (70)  6.2e-006  U     K.ITLPVDFVTADKFDENAK.T \n\n        679.0152   2034.0238   2034.0391   -0.0153  0   55   0.00016  U     K.SVVLMSHLGRPDGVPMPDK.Y \n\n        684.3480   2050.0222   2050.0340   -0.0118  0   (9)  7  U     K.SVVLMSHLGRPDGVPMPDK.Y + Oxidation (M) \n\n        1053.0153   2104.0160   2104.0531   -0.0370  0   (75)  1.5e-006  U     K.QIVWNGPVGVFEWEAFAR.G \n\n        1053.0153   2104.0160   2104.0531   -0.0370  0   125   1.8e-011  U     K.QIVWNGPVGVFEWEAFAR.G \n\n        1053.0221   2104.0296   2104.0531   -0.0234  0   (8)  8.2  U     K.QIVWNGPVGVFEWEAFAR.G \n\n        1241.0654   2480.1162   2480.1312   -0.0149  0   (19)  0.3  U     K.TGQATVASGIPAGWMGLDCGTESSK.K \n\n        1241.0654   2480.1162   2480.1312   -0.0149  0   (11)  2.1  U     K.TGQATVASGIPAGWMGLDCGTESSK.K \n\n        1241.0654   2480.1162   2480.1312   -0.0149  0   130   2.7e-012  U     K.TGQATVASGIPAGWMGLDCGTESSK.K \n\n        827.7132   2480.1178   2480.1312   -0.0134  0   (99)  2.9e-009  U     K.TGQATVASGIPAGWMGLDCGTESSK.K \n\n        1241.0710   2480.1274   2480.1312   -0.0037  0   (32)  0.016  U     K.TGQATVASGIPAGWMGLDCGTESSK.K \n\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n148 \n\n \n\n        1241.0710   2480.1274   2480.1312   -0.0037  0   (19)  0.36  U     K.TGQATVASGIPAGWMGLDCGTESSK.K \n\n        1241.0710   2480.1274   2480.1312   -0.0037  0   (28)  0.044  U     K.TGQATVASGIPAGWMGLDCGTESSK.K \n\n        870.4095   2608.2068   2608.2262   -0.0194  1   (36)  0.0079  U     K.TGQATVASGIPAGWMGLDCGTESSKK.Y \n\n        870.4095   2608.2068   2608.2262   -0.0194  1   48   0.00046  U     K.TGQATVASGIPAGWMGLDCGTESSKK.Y \n\n        875.7429   2624.2068   2624.2211   -0.0143  1   (17)  0.61  U     K.TGQATVASGIPAGWMGLDCGTESSKK.Y + Oxidation (M) \n\n        924.7743   2771.3012   2771.3218   -0.0206  0   (87)  5.3e-008  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        924.7743   2771.3012   2771.3218   -0.0206  0   (92)  1.7e-008  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        924.7743   2771.3012   2771.3218   -0.0206  0   (75)  1e-006  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        924.7756   2771.3051   2771.3218   -0.0167  0   (56)  7.9e-005  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        924.7756   2771.3051   2771.3218   -0.0167  0   (17)  0.56  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        924.7756   2771.3051   2771.3218   -0.0167  0   (94)  1.2e-008  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        924.7763   2771.3070   2771.3218   -0.0148  0   (147)  5.1e-014  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        1386.6615   2771.3084   2771.3218   -0.0134  0   180   3.1e-017  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        924.7768   2771.3087   2771.3218   -0.0131  0   (28)  0.048  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        924.7790   2771.3153   2771.3218   -0.0065  0   (41)  0.0021  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        924.7790   2771.3153   2771.3218   -0.0065  0   (75)  9.2e-007  U     K.DCVGSEVENACANPAAGTVILLENLR.F \n\n        981.5071   2941.4994   2941.5115   -0.0121  1   49   0.00028  U     K.IQLINNMLDKVNEMIIGGGMAFTFLK.V + 2 Oxidation (M) \n\n        1079.2326   3234.6760   3234.6781   -0.0021  1   4   6.1  U     K.SVVLMSHLGRPDGVPMPDKYSLEPVAAELK.S \n\n88 LGALS3 8,93 27269 37 gi|13929190 4,78 417.2276   832.4406   832.4477   -0.0070  0   24   0.48  U     R.VIVCNTK.Q \n\n        445.1950   888.3755   888.3838   -0.0084  0   (9)  12  U     K.QDNNWGR.E \n\n        445.1950   888.3755   888.3838   -0.0084  0   9   10  U     K.QDNNWGR.E \n\n        475.2256   948.4367   948.4525   -0.0158  1   8   17  U     R.FNENNRR.V \n\n        644.3113   1286.6080   1286.6156   -0.0076  0   71   5.9e-006  U     K.GNDIAFHFNPR.F \n\n        433.5722   1297.6948   1297.7030   -0.0083  0   (37)  0.014  U     K.IQVLVEADHFK.V \n\n        433.5722   1297.6948   1297.7030   -0.0083  0   (32)  0.052  U     K.IQVLVEADHFK.V \n\n        649.8562   1297.6978   1297.7030   -0.0052  0   49   0.0009  U     K.IQVLVEADHFK.V \n\n        649.8562   1297.6978   1297.7030   -0.0052  0   (45)  0.0023  U     K.IQVLVEADHFK.V \n\n        735.3671   1468.7196   1468.7351   -0.0155  0   79   9.5e-007  U     R.QSAFPFESGKPFK.I \n\n        1085.5595   2169.1044   2169.1351   -0.0307  0   (83)  2e-007  U     R.EISQLGIIGDITLTSASHAMI.- \n\n        1085.5595   2169.1044   2169.1351   -0.0307  0   (86)  1.1e-007  U     R.EISQLGIIGDITLTSASHAMI.- \n\n        1085.5703   2169.1260   2169.1351   -0.0091  0   (90)  3.9e-008  U     R.EISQLGIIGDITLTSASHAMI.- \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MADGFSLNDALAGSGNPNPRGWPGAWGNQPGAGGYPGASYPGAYPGQAPPGGYPGQAPPSAYPGPTGPSAYPGPTAPGAYPGPTAPGAFPGQPGGPGAYPSAPGAYPSAPGAYPATGPFGAPTGPLTVPYDMPLPGGVMPRMLITIIGTVKPNANSITLNFKKGNDIAFHFNPRFNENNRRVIVCNTKQDNNWGREERQSAFPFESGKPFKIQVLVEADHFKVAVNDVHLLQYNHRMKNLREISQLGIIGDITLTSASHAMI&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n149 \n\n \n\n        1085.5703   2169.1260   2169.1351   -0.0091  0   (100)  4e-009  U     R.EISQLGIIGDITLTSASHAMI.- \n\n        1093.5639   2185.1132   2185.1300   -0.0168  0   111   3.3e-010  U     R.EISQLGIIGDITLTSASHAMI.- + Oxidation (M) \n\n        729.3799   2185.1179   2185.1300   -0.0121  0   (79)  5.4e-007  U     R.EISQLGIIGDITLTSASHAMI.- + Oxidation (M) \n\n        1093.5676   2185.1206   2185.1300   -0.0094  0   (22)  0.23  U     R.EISQLGIIGDITLTSASHAMI.- + Oxidation (M) \n\n        1093.5676   2185.1206   2185.1300   -0.0094  0   (17)  0.85  U     R.EISQLGIIGDITLTSASHAMI.- + Oxidation (M) \n\n        763.4295   2287.2667   2287.2973   -0.0306  0   (88)  2.9e-008  U     R.MLITIIGTVKPNANSITLNFK.K \n\n        1144.6518   2287.2890   2287.2973   -0.0083  0   (2)  8.1  U     R.MLITIIGTVKPNANSITLNFK.K \n\n        768.7652   2303.2739   2303.2923   -0.0184  0   (42)  0.0011  U     R.MLITIIGTVKPNANSITLNFK.K + Oxidation (M) \n\n        768.7652   2303.2739   2303.2923   -0.0184  0   (30)  0.016  U     R.MLITIIGTVKPNANSITLNFK.K + Oxidation (M) \n\n        768.7657   2303.2752   2303.2923   -0.0170  0   102   1.2e-009  U     R.MLITIIGTVKPNANSITLNFK.K + Oxidation (M) \n\n              768.7657   2303.2752   2303.2923   -0.0170  0   (101)  1.3e-009  U     R.MLITIIGTVKPNANSITLNFK.K + Oxidation (M) \n\n \n\n \n\nTabela 03.D: Pept\u00eddeos sequenciados por prote\u00edna identificada atrav\u00e9s de espectrometria de massas para as bandas isoladas por cromatografia de afinidade e selecionadas em \n\n1D SDS-PAGE. \nSPOT Identidade pI kDa Cobertura Acesso emPAI (M+H) obs (M+H) exp (M+H) calc delta (ppm) miss score expect Unique Sequ\u00eancia de Pept\u00eddeo \n\nA 1 Tropomiosina 4,63 32995 47 gi|66730475 1,87 585.8379   1169.6612   1169.6656   -0.0044  0   (35)  0.022        K.LVILEGELER.S \n\n        585.8379   1169.6613   1169.6656   -0.0043  0   (34)  0.028        K.LVILEGELER.S \n\n        585.8383   1169.6621   1169.6656   -0.0035  0   37   0.013        K.LVILEGELER.S \n\n        622.3158   1242.6170   1242.6456   -0.0286  0   75   2.9e-006        R.IQLVEEELDR.A \n\n        622.3249   1242.6353   1242.6456   -0.0103  0   (64)  3.6e-005        R.IQLVEEELDR.A \n\n        622.3269   1242.6393   1242.6456   -0.0063  0   (69)  1.1e-005        R.IQLVEEELDR.A \n\n        649.8854   1297.7563   1297.7605   -0.0042  1   62   3e-005        R.KLVILEGELER.S \n\n        666.8143   1331.6141   1331.6317   -0.0176  0   111   6.1e-010        K.ATDAEADVASLNR.R \n\n        672.3400   1342.6655   1342.6728   -0.0073  0   40   0.0082  U     K.QLEEEQQALQK.K \n\n        678.8245   1355.6344   1355.6456   -0.0112  0   83   3.4e-007  U     K.SLIASEEEYSTK.E \n\n        678.8245   1355.6344   1355.6456   -0.0112  0   (69)  9.4e-006  U     K.SLIASEEEYSTK.E \n\n        700.3783   1398.7421   1398.7467   -0.0045  1   (33)  0.037        R.RIQLVEEELDR.A \n\n        700.3794   1398.7442   1398.7467   -0.0025  1   59   0.00011        R.RIQLVEEELDR.A \n\n        703.3428   1404.6711   1404.6984   -0.0273  0   103   3.7e-009  U     K.TIDDLEETLASAK.E \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDAIKKKMQMLKLDKENAIDRAEQAEADKKQAEDRCKQLEEEQQALQKKLKGTEDEVEKYSESVKDAQEKLEQAEKKATDAEADVASLNRRIQLVEEELDRAQERLATALQKLEEAEKAADESERGMKVIENRAMKDEEKMELQEMQLKEAKHIAEDSDRKYEEVARKLVILEGELERSEERAEVAESRARQLEEELRTMDQALKSLIASEEEYSTKEDKYEEEIKLLEEKLKEAETRAEFAERSVAKLEKTIDDLEETLASAKEENVEIHQTLDQTLLELNNL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n150 \n\n \n\n        703.3510   1404.6874   1404.6984   -0.0110  0   (75)  2.6e-006  U     K.TIDDLEETLASAK.E \n\n        703.3510   1404.6874   1404.6984   -0.0110  0   (54)  0.00037  U     K.TIDDLEETLASAK.E \n\n        730.8693   1459.7241   1459.7267   -0.0025  1   (37)  0.016        K.KATDAEADVASLNR.R \n\n        730.8693   1459.7241   1459.7267   -0.0025  1   43   0.0041        K.KATDAEADVASLNR.R \n\n        1183.0906   2364.1666   2364.1808   -0.0142  0   (78)  5.2e-007  U     K.EENVEIHQTLDQTLLELNNL.- \n\n        1183.0906   2364.1666   2364.1808   -0.0142  0   110   3.7e-010  U     K.EENVEIHQTLDQTLLELNNL.- \n\n        1183.0972   2364.1798   2364.1808   -0.0010  0   (74)  1.4e-006  U     K.EENVEIHQTLDQTLLELNNL.- \n\n                                \n\nA 2 \nProte\u00edna \nribossomal \n60S L10a \n\n9,94 24987 52 gi|13592009 2,04 408.7065   815.3983   815.4038   -0.0055  0   1   1.3e+002  U     K.NWQNVR.A \n\n        633.3719   1264.7293   1264.7326   -0.0033  0   52   0.00032  U     K.VLCLAVAVGHVK.M \n\n        678.8443   1355.6740   1355.6972   -0.0233  0   66   1.9e-005  U     K.YDAFLASESLIK.Q \n\n        678.8545   1355.6945   1355.6972   -0.0028  0   (61)  7e-005  U     K.YDAFLASESLIK.Q \n\n        726.3774   1450.7403   1450.7490   -0.0087  0   (43)  0.0041  U     K.AVDIPHMDIEALK.K \n\n        726.3774   1450.7403   1450.7490   -0.0087  0   61   6.4e-005  U     K.AVDIPHMDIEALK.K \n\n        726.3787   1450.7428   1450.7490   -0.0062  0   (35)  0.027  U     K.AVDIPHMDIEALK.K \n\n        734.3771   1466.7397   1466.7439   -0.0042  0   (44)  0.0026  U     K.AVDIPHMDIEALK.K + Oxidation (M) \n\n        742.8977   1483.7808   1483.7922   -0.0114  1   120   6.6e-011  U     K.KYDAFLASESLIK.Q \n\n        742.9050   1483.7955   1483.7922   0.0033  1   (106)  1.7e-009  U     K.KYDAFLASESLIK.Q \n\n        790.4233   1578.8320   1578.8439   -0.0119  1   (59)  7.8e-005  U     K.AVDIPHMDIEALKK.L \n\n        790.4273   1578.8400   1578.8439   -0.0039  1   70   6.5e-006  U     K.AVDIPHMDIEALKK.L \n\n        790.4273   1578.8400   1578.8439   -0.0039  1   (56)  0.00015  U     K.AVDIPHMDIEALKK.L \n\n        800.9078   1599.8010   1599.8079   -0.0068  0   (38)  0.011  U     K.FPSLLTHNENMVAK.V \n\n        800.9089   1599.8032   1599.8079   -0.0047  0   65   2.4e-005  U     K.FPSLLTHNENMVAK.V \n\n        808.9052   1615.7959   1615.8028   -0.0069  0   (59)  9.6e-005  U     K.FPSLLTHNENMVAK.V + Oxidation (M) \n\n        808.9064   1615.7983   1615.8028   -0.0045  0   (49)  0.001  U     K.FPSLLTHNENMVAK.V + Oxidation (M) \n\n        631.6011   1891.7814   1891.8193   -0.0379  0   (31)  0.013  U     K.FSVCVLGDQQHCDEAK.A \n\n        631.6049   1891.7929   1891.8193   -0.0264  0   (38)  0.0032  U     K.FSVCVLGDQQHCDEAK.A \n\n        946.9152   1891.8157   1891.8193   -0.0036  0   (72)  1.7e-006  U     K.FSVCVLGDQQHCDEAK.A \n\n        946.9152   1891.8157   1891.8193   -0.0036  0   (30)  0.028  U     K.FSVCVLGDQQHCDEAK.A \n\n        946.9161   1891.8176   1891.8193   -0.0017  0   (85)  8.4e-008  U     K.FSVCVLGDQQHCDEAK.A \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSSKVSRDTLYEAVREVLHGNQRKRRKFLETVELQISLKNYDPQKDKRFSGTVRLKSTPRPKFSVCVLGDQQHCDEAKAVDIPHMDIEALKKLNKNKKLVKKLAKKYDAFLASESLIKQIPRILGPGLNKAGKFPSLLTHNENMVAKVDEVKSTIKFQMKKVLCLAVAVGHVKMTDDELVYNIHLAVNFLVSLLKKNWQNVRALYIKSTMGKPQRLY&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n151 \n\n \n\n        946.9161   1891.8176   1891.8193   -0.0017  0   99   3.5e-009  U     K.FSVCVLGDQQHCDEAK.A \n\n                                \n\nA 3 SET 4,21 33419 29 gi|60499029 0,61 604.7978   1207.5811   1207.5972   -0.0161  0   60   0.0001  U     R.VEVTEFEDIK.S \n\n        637.3293   1272.6440   1272.6561   -0.0121  0   (31)  0.085  U     R.LNEQASEEILK.V \n\n        637.3339   1272.6532   1272.6561   -0.0029  0   93   4.9e-008  U     R.LNEQASEEILK.V \n\n        723.8250   1445.6355   1445.6423   -0.0068  0   64   1.9e-005        K.EFHLNESGDPSSK.S \n\n        920.8943   1839.7741   1839.7992   -0.0250  0   96   5.1e-009        R.IDFYFDENPYFENK.V \n\n        920.9027   1839.7908   1839.7992   -0.0083  0   (45)  0.00082        R.IDFYFDENPYFENK.V \n\n        920.9063   1839.7981   1839.7992   -0.0011  0   (91)  2.4e-008        R.IDFYFDENPYFENK.V \n\n        732.3346   2193.9820   2194.0138   -0.0318  0   (97)  5.6e-009  U     K.EQQEAIEHIDEVQNEIDR.L \n\n        732.3346   2193.9820   2194.0138   -0.0318  0   102   1.8e-009  U     K.EQQEAIEHIDEVQNEIDR.L \n\n        732.3410   2194.0011   2194.0138   -0.0127  0   (81)  2.8e-007  U     K.EQQEAIEHIDEVQNEIDR.L \n\n                                \n\nA 4 Tropomiosina 4,63 32995 47 gi|66730475  2,16 537.2719   1072.5293   1072.5513   -0.0219  1   55   0.00038  U     K.LDKENAIDR.A \n\n        537.2728   1072.5311   1072.5513   -0.0202  1   (52)  0.00083  U     K.LDKENAIDR.A \n\n        574.2936   1146.5726   1146.5768   -0.0042  1   54   0.0004  U     K.LKGTEDEVEK.Y \n\n        585.8330   1169.6515   1169.6656   -0.0141  0   67   1.4e-005        K.LVILEGELER.S \n\n        585.8383   1169.6621   1169.6656   -0.0035  0   (31)  0.058        K.LVILEGELER.S \n\n        585.8383   1169.6621   1169.6656   -0.0035  0   (33)  0.036        K.LVILEGELER.S \n\n        585.8397   1169.6649   1169.6656   -0.0006  0   (54)  0.00027        K.LVILEGELER.S \n\n        585.8397   1169.6649   1169.6656   -0.0006  0   (65)  2.3e-005        K.LVILEGELER.S \n\n        622.3038   1242.5930   1242.6456   -0.0525  0   (34)  0.031        R.IQLVEEELDR.A \n\n        622.3038   1242.5930   1242.6456   -0.0525  0   (75)  2.7e-006        R.IQLVEEELDR.A \n\n        622.3205   1242.6265   1242.6456   -0.0191  0   (68)  1.5e-005        R.IQLVEEELDR.A \n\n        622.3205   1242.6265   1242.6456   -0.0191  0   75   3.1e-006        R.IQLVEEELDR.A \n\n        622.3269   1242.6392   1242.6456   -0.0063  0   (63)  4.8e-005        R.IQLVEEELDR.A \n\n        649.8818   1297.7491   1297.7605   -0.0114  1   (60)  4.9e-005        R.KLVILEGELER.S \n\n        649.8856   1297.7567   1297.7605   -0.0038  1   (65)  1.5e-005        R.KLVILEGELER.S \n\n        649.8856   1297.7567   1297.7605   -0.0038  1   70   4.5e-006        R.KLVILEGELER.S \n\n        666.8023   1331.5901   1331.6317   -0.0416  0   (85)  1.7e-007        K.ATDAEADVASLNR.R \n\n        666.8193   1331.6241   1331.6317   -0.0076  0   (79)  9e-007        K.ATDAEADVASLNR.R \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MAPKRQSAILPQPKKPRPVAAPKLEDKSASPGLPKGEKEQQEAIEHIDEVQNEIDRLNEQASEEILKVEQKYNKLRQPFFQKRSELITKIPNFWVTTFVNHPQVSALLGEEDEEALHYLTRVEVTEFEDIKSGYRIDFYFDENPYFENKVLSKEFHLNESGDPSSKSTEIKWKSGKDLTKCSSQTQNKASRKRQHEEPESFFTWFTDHSDAGADELGEVIKDDIWPNPLQYYLVPDMDDEEGEAEDDDDDDEEEEGLEDIDEEGDEDEGEEDNDEDEGEEGEEDEGEDD&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MDAIKKKMQMLKLDKENAIDRAEQAEADKKQAEDRCKQLEEEQQALQKKLKGTEDEVEKYSESVKDAQEKLEQAEKKATDAEADVASLNRRIQLVEEELDRAQERLATALQKLEEAEKAADESERGMKVIENRAMKDEEKMELQEMQLKEAKHIAEDSDRKYEEVARKLVILEGELERSEERAEVAESRARQLEEELRTMDQALKSLIASEEEYSTKEDKYEEEIKLLEEKLKEAETRAEFAERSVAKLEKTIDDLEETLASAKEENVEIHQTLDQTLLELNNL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n152 \n\n \n\n        666.8205   1331.6265   1331.6317   -0.0052  0   121   6.4e-011        K.ATDAEADVASLNR.R \n\n        666.8205   1331.6265   1331.6317   -0.0052  0   (106)  2.1e-009        K.ATDAEADVASLNR.R \n\n        666.8222   1331.6298   1331.6317   -0.0019  0   (35)  0.024        K.ATDAEADVASLNR.R \n\n        666.8222   1331.6298   1331.6317   -0.0019  0   (42)  0.0046        K.ATDAEADVASLNR.R \n\n        672.3338   1342.6530   1342.6728   -0.0198  0   52   0.00052  U     K.QLEEEQQALQK.K \n\n        678.8146   1355.6146   1355.6456   -0.0310  0   (74)  2.4e-006  U     K.SLIASEEEYSTK.E \n\n        678.8302   1355.6458   1355.6456   0.0002  0   83   3.8e-007  U     K.SLIASEEEYSTK.E \n\n        700.3769   1398.7392   1398.7467   -0.0075  1   (46)  0.0021        R.RIQLVEEELDR.A \n\n        700.3787   1398.7428   1398.7467   -0.0038  1   70   7e-006        R.RIQLVEEELDR.A \n\n        703.3343   1404.6540   1404.6984   -0.0444  0   (65)  2.6e-005  U     K.TIDDLEETLASAK.E \n\n        703.3349   1404.6552   1404.6984   -0.0432  0   (89)  9.9e-008  U     K.TIDDLEETLASAK.E \n\n        703.3349   1404.6552   1404.6984   -0.0432  0   (92)  4.4e-008  U     K.TIDDLEETLASAK.E \n\n        703.3349   1404.6552   1404.6984   -0.0432  0   107   1.5e-009  U     K.TIDDLEETLASAK.E \n\n        703.3533   1404.6921   1404.6984   -0.0063  0   (63)  4.9e-005  U     K.TIDDLEETLASAK.E \n\n        703.3541   1404.6937   1404.6984   -0.0047  0   (70)  8.1e-006  U     K.TIDDLEETLASAK.E \n\n        730.8680   1459.7215   1459.7267   -0.0051  1   (51)  0.00067        K.KATDAEADVASLNR.R \n\n        730.8684   1459.7223   1459.7267   -0.0043  1   100   8.3e-009        K.KATDAEADVASLNR.R \n\n        1183.0624   2364.1102   2364.1808   -0.0706  0   (96)  7.5e-009  U     K.EENVEIHQTLDQTLLELNNL.- \n\n        1183.0624   2364.1102   2364.1808   -0.0706  0   114   1.3e-010  U     K.EENVEIHQTLDQTLLELNNL.- \n\n        1183.0825   2364.1504   2364.1808   -0.0304  0   (82)  2.5e-007  U     K.EENVEIHQTLDQTLLELNNL.- \n\n        1183.0825   2364.1504   2364.1808   -0.0304  0   (42)  0.0021  U     K.EENVEIHQTLDQTLLELNNL.- \n\n        1183.0892   2364.1638   2364.1808   -0.0170  0   (75)  1.2e-006  U     K.EENVEIHQTLDQTLLELNNL.- \n\n                                \n\nA 5 \nProte\u00edna \nribossomal \n60S L10a \n\n9,94 24987 42 gi|13592009 2,51 633.3723   1264.7300   1264.7326   -0.0026  0   57   0.00011  U     K.VLCLAVAVGHVK.M \n\n        678.8466   1355.6786   1355.6972   -0.0186  0   67   1.9e-005  U     K.YDAFLASESLIK.Q \n\n        726.3787   1450.7428   1450.7490   -0.0062  0   51   0.00065  U     K.AVDIPHMDIEALK.K \n\n        726.3787   1450.7428   1450.7490   -0.0062  0   (39)  0.0099  U     K.AVDIPHMDIEALK.K \n\n        734.3757   1466.7368   1466.7439   -0.0071  0   (36)  0.019  U     K.AVDIPHMDIEALK.K + Oxidation (M) \n\n        742.8994   1483.7842   1483.7922   -0.0080  1   94   2.7e-008  U     K.KYDAFLASESLIK.Q \n\n        742.9022   1483.7899   1483.7922   -0.0023  1   (59)  9.2e-005  U     K.KYDAFLASESLIK.Q \n\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n153 \n\n \n\n        790.4269   1578.8393   1578.8439   -0.0047  1   52   0.00038  U     K.AVDIPHMDIEALKK.L \n\n        800.9078   1599.8010   1599.8079   -0.0069  0   (45)  0.0023  U     K.FPSLLTHNENMVAK.V \n\n        800.9078   1599.8010   1599.8079   -0.0069  0   (33)  0.033  U     K.FPSLLTHNENMVAK.V \n\n        800.9078   1599.8011   1599.8079   -0.0068  0   70   6.7e-006  U     K.FPSLLTHNENMVAK.V \n\n        800.9078   1599.8011   1599.8079   -0.0068  0   (63)  3.3e-005  U     K.FPSLLTHNENMVAK.V \n\n        808.9057   1615.7969   1615.8028   -0.0059  0   (31)  0.064  U     K.FPSLLTHNENMVAK.V + Oxidation (M) \n\n        808.9072   1615.7998   1615.8028   -0.0030  0   (35)  0.027  U     K.FPSLLTHNENMVAK.V + Oxidation (M) \n\n        808.9072   1615.7998   1615.8028   -0.0030  0   (21)  0.58  U     K.FPSLLTHNENMVAK.V + Oxidation (M) \n\n        631.6020   1891.7843   1891.8193   -0.0350  0   (37)  0.0033  U     K.FSVCVLGDQQHCDEAK.A \n\n        946.9141   1891.8137   1891.8193   -0.0056  0   71   2e-006  U     K.FSVCVLGDQQHCDEAK.A \n\n                                \n\nB 1 Dermicidina 6,08 11391 10 gi|16751921  0,30 564.7658   1127.5171   1127.5207   -0.0036  0   26   0.2  U     K.ENAGEDPGLAR.Q \n\n                                \n\nB 2 Dermicidina 6,08 11391 10 gi|16751921  0,30 564.7658   1127.5171   1127.5207   -0.0036  0   26   0.2  U     K.ENAGEDPGLAR.Q \n\n                                \n\nB 3 \nHistona H2A \ntype 1-C \n\n11,05 14097 21  gi|4504245 0,24 966.0853   1930.1561   1930.1615   -0.0054  0   (25)  0.021  U     R.VTIAQGGVLPNIQAVLLPK.K \n\n        966.0853   1930.1561   1930.1615   -0.0054  0   (32)  0.0044  U     R.VTIAQGGVLPNIQAVLLPK.K \n\n        966.0870   1930.1595   1930.1615   -0.0020  0   82   4.1e-008  U     R.VTIAQGGVLPNIQAVLLPK.K \n\n  Histona H4 11,36 11360 9 gi|4504301 0,30 590.8129   1179.6111   1179.6135   -0.0024  0   50   0.00092  U     R.ISGLIYEETR.G \n\n                                \n\nC 1 \nProte\u00edna \nribossomal \n60S P0  \n\n5,91 34365 25 gi|11693176 0,74 609.3381   1216.6616   1216.6703   -0.0088  0   44   0.0034  U     K.IIQLLDDYPK.C \n\n        611.3118   1220.6091   1220.6149   -0.0058  0   40   0.01  U     R.GHLENNPALEK.L \n\n        633.8085   1265.6025   1265.6074   -0.0049  0   53   0.00039  U     K.CFIVGADNVGSK.Q \n\n        657.3534   1312.6922   1312.7027   -0.0105  0   71   6.7e-006  U     K.TSFFQALGITTK.I \n\n        714.9151   1427.8156   1427.8235   -0.0079  0   (40)  0.0054  U     R.GTIEILSDVQLIK.T \n\n        714.9154   1427.8162   1427.8235   -0.0073  0   58   8e-005  U     R.GTIEILSDVQLIK.T \n\n        1090.5537   2179.0928   2179.0943   -0.0015  0   48   0.00076  U     R.AGAIAPCEVTVPAQNTGLGPEK.T \n\n                                \n\nC 2 \nProte\u00edna \nribossomal \n60S L10a \n\n9,94 24987 42 gi|13592009 1,4 678.8520   1355.6895   1355.6972   -0.0078  0   61   7.7e-005  U     K.YDAFLASESLIK.Q \n\n        726.3789   1450.7431   1450.7490   -0.0058  0   38   0.011  U     K.AVDIPHMDIEALK.K \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRFMTLLFLTALAGALVCAYDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQRSSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MRFMTLLFLTALAGALVCAYDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQRSSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSGRGKQGGKARAKAKSRSSRAGLQFPVGRVHRLLRKGNYAERVGAGAPVYLAAVLEYLTAEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGRVTIAQGGVLPNIQAVLLPKKTESHHKAKGK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=LLLLLALKTLWAVGNRFEAQIIGGREAVPHSRPYMVSLQNTKSHMCGGVLVHQKWVLTAAHCLSEPLQQLKLVFGLHSLHDPQDPGLTFYIKQAIKHPGYNLKYENDLALLKLDGRVKPSKNVKPLALPRKPRDKPAEGSRCSTAGWGITHQRGQLAKSLQELDLRLLDTRMCNNSRFWNGVLTDSMLCLKAGAKGQAPCKGDSGGPLVCGKGKVDGILSFSSKNCTDIFKPTVATAVAPYSSWIRKVIGRWSPQPLT&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSSKVSRDTLYEAVREVLHGNQRKRRKFLETVELQISLKNYDPQKDKRFSGTVRLKSTPRPKFSVCVLGDQQHCDEAKAVDIPHMDIEALKKLNKNKKLVKKLAKKYDAFLASESLIKQIPRILGPGLNKAGKFPSLLTHNENMVAKVDEVKSTIKFQMKKVLCLAVAVGHVKMTDDELVYNIHLAVNFLVSLLKKNWQNVRALYIKSTMGKPQRLY&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                     Ap\u00eandice \n\n154 \n\n \n\n        742.9014   1483.7882   1483.7922   -0.0040  1   99   9e-009  U     K.KYDAFLASESLIK.Q \n\n        800.9090   1599.8035   1599.8079   -0.0043  0   57   0.00015  U     K.FPSLLTHNENMVAK.V \n\n        800.9090   1599.8035   1599.8079   -0.0043  0   (46)  0.0018  U     K.FPSLLTHNENMVAK.V \n\n        631.6070   1891.7991   1891.8193   -0.0203  0   33   0.0097  U     K.FSVCVLGDQQHCDEAK.A \n\n                                \n\nD 1 Asporina 8,51 43139 22 gi|62078745 0,25 655.8281   1309.6417   1309.6455   -0.0038  0   33   0.042  U     K.YWEIQPATFR.C \n\n        767.4305   1532.8465   1532.8562   -0.0097  0   49   0.00081  U     K.GLTSLYALILNNNK.L \n\n        772.0505   2313.1296   2313.1424   -0.0127  0   32   0.022  U     R.VVHCSDLGLTSVPSNIPFDTR.M \n\n                                \n\nD 2 \nCase\u00edna \nquinase 2 \n\n7,29 45159 30 gi|16758674 0,33 764.8819   1527.7493   1527.7569   -0.0076  0   51   0.00053  U     K.QLYQTLTDYDIR.F \n\n        866.4364   1730.8583   1730.8628   -0.0045  0   35   0.018  U     R.TPALVFEHVNNTDFK.Q \n\n        885.9264   1769.8383   1769.8472   -0.0089  0   84   2.6e-007  U     K.YSEVFEAINITNNEK.V \n\n              848.7479   2543.2218   2543.2431   -0.0214  1   48   0.00057  U     K.VLGTEDLYDYIDKYNIELDPR.F \n\n \n\n \n\n \n\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MKEYMMLLLLAVCSAKPFFSPSHTALKTMMLKDMEDTDDEDNDDDDDDNSLFPTKEPVNPFFPFDLFPTCPFGCQCYSRVVHCSDLGLTSVPSNIPFDTRMVDLQNNKIKEIKENDFKGLTSLYALILNNNKLTKIHPKTFLTTKKLRRLYLSHNQLSEIPLNLPRSLAELRIHDNKVKKIQKDTFKGMNALHVLEMSANPLDNNGIEPGAFEGVTVFHIRIAEAKLTSIPKGLPPTLLELHLDFNKISTVELEDFKRYKELQRLGLGNNKITDIENGTFANIPRVREIHLEHNKLKKIPSGLQELKYLQIIFLHNNSITKVGVNDFCPTVPKMKKSLYSAISLFNNPMKYWEIQPATFRCVVGRMSVQLGNVGK&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\nhttp://www.ncbi.nlm.nih.gov/blast/Blast.cgi?ALIGNMENTS=50&amp;ALIGNMENT_VIEW=Pairwise&amp;AUTO_FORMAT=Semiauto&amp;CDD_SEARCH=on&amp;CLIENT=web&amp;COMPOSITION_BASED_STATISTICS=on&amp;DATABASE=nr&amp;DESCRIPTIONS=100&amp;ENTREZ_QUERY=(none)&amp;EXPECT=10&amp;FILTER=L&amp;FORMAT_BLOCK_ON_RESPAGE=None&amp;FORMAT_OBJECT=Alignment&amp;FORMAT_TYPE=HTML&amp;GAPCOSTS=11+1&amp;I_THRESH=0.001&amp;LAYOUT=TwoWindows&amp;MATRIX_NAME=BLOSUM62&amp;NCBI_GI=on&amp;PAGE=Proteins&amp;PROGRAM=blastp&amp;QUERY=MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMSSAGMAGGSTPVSSANMMSGISSVPTPSPLGPLAGSPVIAAANSLGIPVPAAAGAQQ&amp;SERVICE=plain&amp;SET_DEFAULTS.x=9&amp;SET_DEFAULTS.y=5&amp;SHOW_OVERVIEW=on&amp;WORD_SIZE=3&amp;END_OF_HTTPGET=Yes\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n155 \n\n \n\nAp\u00eandice E \n\n \n\n \n\nFigura 01.E: Valida\u00e7\u00e3o dos experimentos de imunohistoqu\u00edmica e an\u00e1lise prote\u00f4mica. A) SDS-PAGE 1D \n\nde extratos de prote\u00edna total de intestino delgado dos animais pertencentes aos grupos III, IV e V. B) \n\nWestern bloting para detec\u00e7\u00e3o de CEA, Calnexina e ?-actina. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                   Ap\u00eandice \n\n156 \n\n \n\nAp\u00eandice F \n\nTabela 01. F: Rela\u00e7\u00e3o de prote\u00ednas que apresentaram regi\u00e3o de similaridade com os pept\u00eddeos selecionados por Phage display atrav\u00e9s do alinhamento de sequ\u00eancias realizado \n\npor BLASTp. \nPept\u00eddeo \n(Grupo) \n\nSimilaridade prot\u00e9ica \n(BLASTp) \n\nFun\u00e7\u00e3o Bibliografia \n\nQPHKVFFPNLPR \n(DMHg1) \n\nNME5  \n(Nucleoside diphosphate kinase homolog 5) \n\nMet\u00e1stase tumoral, atenua\u00e7\u00e3o de apoptose. \n(Desvignes et al., 2009) \n(Li et al., 2012)  \n\nMYO7A  \n(Unconventional myosin-VIIa) \n\nMaior susceptibilidade \u00e0 mielomas malignos. (Fernandez et al., 2009) \n\nSPATA22  Sem rela\u00e7\u00e3o com c\u00e2ncer. - \n\nSCAND3  Sem rela\u00e7\u00e3o com c\u00e2ncer. - \n\nLAAQQYTSALKS \n(DBTd1) \n\nMUC4 \n(Mucin-4 precursor) \n\nPotencializa progress\u00e3o e met\u00e1stase tumoral, reprime apoptose. (Rachagani et al., 2012) \n\nLIM FHL1B \n(Four and a half LIM domains protein 1) \n\nProto-oncogene, diferencia\u00e7\u00e3o celular, inibi\u00e7\u00e3o de Notch. (Surendran et al., 2010) \n\nUBR2 \n(E3 ubiquitin-protein ligase UBR2) \n\nDegrada\u00e7\u00e3o de prote\u00ednas. (Sultana et al., 2012) \n\nENOX 1 e 2 \n(Ecto-ENOX disulfide-thiol exchanger 1 e 2) \n\nRelacionadas \u00e0 oxida\u00e7\u00e3o e trocas de ti\u00f3is dissulfetos em \nprote\u00ednas. \n\n(Morre et al., 2008) \n\nSIAH1 \n(E3 ubiquitin-protein ligase SIAH1) \n\nSupressora de tumores e ativadora de apoptose. (Wen et al., 2010) \n\nTTC21A Sem rela\u00e7\u00e3o com c\u00e2ncer. - \n\nTNTPPSQRVHLS \n(DBTd2) \n\nGPR50 \n(Probable G-protein coupled receptor 150) \n\n  \n\nSTAT4 \n(Signal transducer and activator of transcription 4) \n\nProlifera\u00e7\u00e3o e migra\u00e7\u00e3o tumoral. \n(Liu et al., 2012) \n(Uluer et al., 2012) \n\nVGLL1 \n(Transcription cofactor vestigial-like protein 1) \n\nProlifera\u00e7\u00e3o celular independente de ancoragem. (Pobbati et al., 2012) \n\nLIPE Sem rela\u00e7\u00e3o com c\u00e2ncer. - \n\nMICAL1 \n(NEDD9-interacting protein with calponin and LIM) \n\nFavorecimento de apoptose e prolifera\u00e7\u00e3o celular. \n(Ashida et al., 2006) \n(Zhou et al., 2011) \n\nFERM \nFavorecimento de migra\u00e7\u00e3o e invas\u00e3o dependentes de ades\u00e3o \ncelular. \n\n(Song et al., 2012) \n(Wang et al., 2012) \n\nANK1 \n(Ankyrin-1) \n\nResist\u00eancia \u00e0 apoptose. (Liao et al., 2011) \n\n \n\n\n\nSilva, K.T.S.                                                                                                                                                                                                                                   Ap\u00eandice \n\n157 \n\n \n\nFDTKAGLTSLVA \n(DBTg1) \n\nWIZ Sem rela\u00e7\u00e3o com c\u00e2ncer. - \n\nABCD1 \n(ATP-binding cassette sub-family D member \n\n1) \n\nRedu\u00e7\u00e3o da toxicidade de quimioter\u00e1picos com consequente \nresist\u00eancia. \n\n(Chen et al., 2009) \n(Hour et al., 2009) \n\nAGRN \n(Agrin precursor) \n\nSuper expressa em diversos tipos de c\u00e2ncer. \n(Fernebro et al., 2006) \n(Rajkumar et al., 2011) \n\nHDC \n(Histidine decarboxylase) \n\nEst\u00edmulo de s\u00edntese de histamina. (Francis et al., 2012) \n\nCYP2T1 \n(Cytochrome P450, fam. 2, subfam.T, \n\npolypeptide 1) \nMetabolismo de xenobi\u00f3ticos. (Wang et al., 2009) \n\nKIAA1598 Sem rela\u00e7\u00e3o com c\u00e2ncer. - \n\nKDPTQFKPMSLW \n(DBTg2) \n\nFAM129B \n(Niban-like protein 1) \n\nPromo\u00e7\u00e3o de invas\u00e3o celular. (Chen et al., 2011) \n\nFOXO1 \n(Forkhead Box protein O1) \n\nControle de prolifera\u00e7\u00e3o celular e apoptose. \n(Sangodkar et al., 2012) \n(Xie et al., 2012) \n\nCOMMD5 \n(COMM domain-containing protein 5 ) \n\nControle de prolifera\u00e7\u00e3o celular. (Solban et al., 2000) \n\nPOLR2A \n(RNA polymerase II subunit RPB1) \n\nSuper expresso em c\u00e9lulas tumorais. (Markaverich et al., 2011) \n\nPOMT2 Sem rela\u00e7\u00e3o com c\u00e2ncer. - \n\nEYQLPSRTVPRD \n(DBTg3) \n\nSKIV2L Sem rela\u00e7\u00e3o com c\u00e2ncer. - \n\nPKD1L3 Sem rela\u00e7\u00e3o com cancer. - \n\nDOK3 \n(Docking protein 3) \n\nAtiva\u00e7\u00e3o celular mediada por imunoreceptores e supressora de \ntumor. \n\n(Lemay et al., 2000) \n(Berger et al., 2010) \n\nCLK2 \n(Dual specificity protein kinase) \n\nRelacionada ao ciclo celular, apoptose e replica\u00e7\u00e3o do DNA. (Jiang et al., 2003) \n\nTWF1 \n(Twinfilin-1) \n\nSuper expressa em diversos tipos de c\u00e2ncer, moduladora de \ncitoesqueleto. \n\n(Baniwal et al., 2010) \n\nPER2 \n (Period circadian protein homolog 2) \n\nDesenvolvimento, invas\u00e3o e met\u00e1stase. (Wang et al., 2011) \n\nDLC1 \n(Rho GTPase-activating protein 7) \n\nProlifera\u00e7\u00e3o, polariza\u00e7\u00e3o e remodelamento de citoesqueleto \ncelular. \n\n(Lukasik et al., 2011) \n\nLMNA \n(Pre-lamin A/C precursor) \n\nSuper expressa em c\u00e2ncer gastro intestinal. Ades\u00e3o Celular. \n(Belt et al., 2011) \n(Lee et al., 2012) \n\nMSX2 \n(Homeobox protein MSX2) \n\nInvas\u00e3o e sobreviv\u00eancia celular tumoral. \n(Gremel et al., 2011) \n(Zhai et al., 2011) \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n158 \n\n \n\nRefer\u00eancias bibliogr\u00e1ficas \u2013 Ap\u00eandice F \n\n \n\nAshida, S. et al., 2006. Expression of novel molecules, MICAL2-PV (MICAL2 prostate \n\ncancer variants), increases with high Gleason score and prostate cancer \n\nprogression. Clinical cancer research : an official journal of the American \n\nAssociation for Cancer Research, 12(9): 2767-73. \n\nBaniwal, S.K. et al., 2010. Runx2 transcriptome of prostate cancer cells: insights into \n\ninvasiveness and bone metastasis. Molecular cancer, 9: 258. \n\nBelt, E.J. et al., 2011. Loss of lamin A/C expression in stage II and III colon cancer is \n\nassociated with disease recurrence. European journal of cancer, 47(12): 1837-45. \n\nBerger, A.H. et al., 2010. Identification of DOK genes as lung tumor suppressors. Nature \n\ngenetics, 42(3): 216-23. \n\nChen, K.G., Valencia, J.C., Gillet, J.P., Hearing, V.J. and Gottesman, M.M., 2009. \n\nInvolvement of ABC transporters in melanogenesis and the development of \n\nmultidrug resistance of melanoma. Pigment cell &amp; melanoma research, 22(6): \n\n740-9. \n\nChen, S., Evans, H.G. and Evans, D.R., 2011. FAM129B/MINERVA, a novel adherens \n\njunction-associated protein, suppresses apoptosis in HeLa cells. The Journal of \n\nbiological chemistry, 286(12): 10201-9. \n\nDesvignes, T., Pontarotti, P., Fauvel, C. and Bobe, J., 2009. Nme protein family \n\nevolutionary history, a vertebrate perspective. BMC evolutionary biology, 9: 256. \n\nFernebro, J. et al., 2006. Gene expression profiles relate to SS18/SSX fusion type in \n\nsynovial sarcoma. International journal of cancer. Journal international du cancer, \n\n118(5): 1165-72. \n\nFrancis, H. et al., 2012. Inhibition of histidine decarboxylase ablates the autocrine \n\ntumorigenic effects of histamine in human cholangiocarcinoma. Gut, 61(5): 753-\n\n64. \n\nGremel, G. et al., 2011. Functional and prognostic relevance of the homeobox protein \n\nMSX2 in malignant melanoma. British journal of cancer, 105(4): 565-74. \n\nHour, T.C. et al., 2009. Downregulation of ABCD1 in human renal cell carcinoma. The \n\nInternational journal of biological markers, 24(3): 171-8. \n\nJiang, N., Benard, C.Y., Kebir, H., Shoubridge, E.A. and Hekimi, S., 2003. Human CLK2 \n\nlinks cell cycle progression, apoptosis, and telomere length regulation. The \n\nJournal of biological chemistry, 278(24): 21678-84. \n\nLee, W.S. et al., 2012. Methylation status of lamin A/C in gastric cancer cell lines. \n\nHepato-gastroenterology, 59(116): 1313-8. \n\nLemay, S., Davidson, D., Latour, S. and Veillette, A., 2000. Dok-3, a novel adapter \n\nmolecule involved in the negative regulation of immunoreceptor signaling. \n\nMolecular and cellular biology, 20(8): 2743-54. \n\nLi, F. et al., 2012. Identification of NME5 as a contributor to innate resistance to \n\ngemcitabine in pancreatic cancer cells. The FEBS journal, 279(7): 1261-73. \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n159 \n\n \n\nLiao, Y.H., Hsu, S.M., Yang, H.L., Tsai, M.S. and Huang, P.H., 2011. Upregulated \n\nankyrin repeat-rich membrane spanning protein contributes to tumour progression \n\nin cutaneous melanoma. British journal of cancer, 104(6): 982-8. \n\nLiu, S. et al., 2012. The oncoprotein HBXIP uses two pathways to up-regulate S100A4 \n\nin promotion of growth and migration of breast cancer cells. The Journal of \n\nbiological chemistry, 287(36): 30228-39. \n\nLukasik, D., Wilczek, E., Wasiutynski, A. and Gornicka, B., 2011. Deleted in liver cancer \n\nprotein family in human malignancies (Review). Oncology letters, 2(5): 763-768. \n\nMarkaverich, B.M., Shoulars, K. and Rodriguez, M.A., 2011. Luteolin Regulation of \n\nEstrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast \n\nCancer Cells. International journal of biomedical science : IJBS, 7(2): 101-111. \n\nMorre, D.J., Hostetler, B., Weston, N., Kim, C. and Morre, D.M., 2008. Cancer type-\n\nspecific tNOX isoforms: A putative family of redox protein splice variants with \n\ncancer diagnostic and prognostic potential. BioFactors, 34(3): 201-7. \n\nPobbati, A.V., Chan, S.W., Lee, I., Song, H. and Hong, W., 2012. Structural and \n\nfunctional similarity between the Vgll1-TEAD and the YAP-TEAD complexes. \n\nStructure, 20(7): 1135-40. \n\nRachagani, S. et al., 2012. MUC4 potentiates invasion and metastasis of pancreatic cancer \n\ncells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis, \n\n33(10): 1953-64. \n\nRajkumar, T. et al., 2011. Identification and validation of genes involved in cervical \n\ntumourigenesis. BMC cancer, 11: 80. \n\nSangodkar, J. et al., 2012. Targeting the FOXO1/KLF6 axis regulates EGFR signaling \n\nand treatment response. The Journal of clinical investigation, 122(7): 2637-51. \n\nSolban, N. et al., 2000. HCaRG, a novel calcium-regulated gene coding for a nuclear \n\nprotein, is potentially involved in the regulation of cell proliferation. The Journal \n\nof biological chemistry, 275(41): 32234-43. \n\nSong, X. et al., 2012. A novel membrane-dependent on/off switch mechanism of talin \n\nFERM domain at sites of cell adhesion. Cell research, 22(11): 1533-45. \n\nSultana, R., Theodoraki, M.A. and Caplan, A.J., 2012. UBR1 promotes protein kinase \n\nquality control and sensitizes cells to Hsp90 inhibition. Experimental cell \n\nresearch, 318(1): 53-60. \n\nSurendran, K., Selassie, M., Liapis, H., Krigman, H. and Kopan, R., 2010. Reduced Notch \n\nsignaling leads to renal cysts and papillary microadenomas. Journal of the \n\nAmerican Society of Nephrology : JASN, 21(5): 819-32. \n\nUluer, E.T., Aydemir, I., Inan, S., Ozbilgin, K. and Vatansever, H.S., 2012. Effects of 5-\n\nfluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the \n\nJAK/STAT pathway. Acta histochemica, 114(7): 641-6. \n\nWang, S.J., Wong, G., de Heer, A.M., Xia, W. and Bourguignon, L.Y., 2009. CD44 \n\nvariant isoforms in head and neck squamous cell carcinoma progression. The \n\nLaryngoscope, 119(8): 1518-30. \n\nWang, T. et al., 2012. FERM-containing protein FRMD5 is a p120-catenin interacting \n\nprotein that regulates tumor progression. FEBS letters, 586(19): 3044-50. \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n160 \n\n \n\nWang, Y., Hua, L., Lu, C. and Chen, Z., 2011. Expression of circadian clock gene human \n\nPeriod2 (hPer2) in human colorectal carcinoma. World journal of surgical \n\noncology, 9: 166. \n\nWen, Y.Y. et al., 2010. SIAH1 induced apoptosis by activation of the JNK pathway and \n\ninhibited invasion by inactivation of the ERK pathway in breast cancer cells. \n\nCancer science, 101(1): 73-9. \n\nXie, L. et al., 2012. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood, \n\n119(15): 3503-11. \n\nZhai, Y. et al., 2011. MSX2 is an oncogenic downstream target of activated WNT \n\nsignaling in ovarian endometrioid adenocarcinoma. Oncogene, 30(40): 4152-62. \n\nZhou, Y. et al., 2011. MICAL-1 is a negative regulator of MST-NDR kinase signaling \n\nand apoptosis. Molecular and cellular biology, 31(17): 3603-15. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n161 \n\n \n\nAp\u00eandice G \n\nArtigo publicado \u2013 Revista: Journal of Proteome Research \n\nFator de Impacto: 5,001. Qualis CAPES \u00c1rea CBIOL I: A1 \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n162 \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n163 \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n164 \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n165 \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n166 \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n167 \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n168 \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n169 \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n170 \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n171 \n\n \n\n \n\n\n\nSilva, K.T.S.                                                                                                                        Ap\u00eandice \n\n172"}]}}}